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 I 
ABSTRACT 
 
A common feature of neurodegenerative conditions including Parkinson’s disease (PD) is 
the presence of intracytoplasmic proteinacious inclusions. In PD these inclusions are called 
Lewy bodies (LBs) and contain a number of proteins including α-synuclein, ubiquitin and 
neurofilaments (NFs). NFs, the intermediate filaments expressed in neuronal cells are 
responsible for the maintenance of axonal structure. Although NFs were the first proteins 
identified in LBs their role in PD pathogenesis has not been fully explored. The work 
presented here attempts to address some of the gaps in the current knowledge concerning 
NF turnover and the role of NFs in PD using the human SH-SY5Y neuroblastoma cell line, 
commonly used as a cellular model of neurodegeneration. Mitochondrial dysfunction, 
dopamine (DA) mediated oxidative stress and impaired protein degradation have all been 
implicated in PD pathogenesis. The complex I inhibitor MPTP and its active metabolite 
(MPP+) induce Parkinsonism in humans and other primates and have been extensively used 
as PD mimetics in both cellular and animal models.  
 
Addition of specific protease inhibitors in the presence of cycloheximide (an inhibitor of 
new protein synthesis) revealed that NF-heavy chains are degraded by macroautophagy and 
cathepsin D, possibly with some involvement of cysteine cathepsin, but not calpain or the 
ubiquitin proteasome system (UPS). This is in contrast to α-synuclein which was degraded 
by macroautophagy, the UPS and calpain. Treatment with MPP+ did not increase NF half-
life despite a reduction in the activity of the 20S proteasome, cathepsin D and 
macroautophagy. However an activation of cysteine cathepsin activity was observed with 
MPP+ treatment, suggesting a role for these cathepsins in NF turnover following complex I 
inhibition. Inhibition of cysteine cathepsins in MPP+ treated cells resulted in increased cell 
death suggesting that activation of cysteine cathepsins is protective in this context. 
Following treatment with 100 µM DA, NF turnover appeared to be reduced, accompanied 
by a reduction in 20S proteasome activity and macroautophagy but activation of calpain.  
 
To allow analysis of the effects of mitochondrial dysfunction on the distribution of NFs in 
live cells, Green Fluorescent Protein (GFP) tagged NFs were produced. Live imaging of 
cells treated with a high dose of MPP+ displayed a retraction of axonal processes which 
occurred within the first 20 - 30 minutes of treatment. Analysis of the rate of retraction of 
GFP fluorescence and the remaining axonal structure indicated that NF retraction was not 
an early event in axonal retraction, at least with this concentration of MPP+. 
 
The effect of mitochondrial dysfunction and/or proteasome inhibition on protein 
aggregation and inclusion formation was investigated in differentiated SH-SY5Y cells. 
Treatment with MPP+, epoxomicin (proteasome inhibitor, epoxo) or MPP+/epoxo resulted 
in an enrichment of NFs in a detergent insoluble fraction and accumulation of NF-H in a 
perinuclear location together with p62 and LC3, suggesting the attempted degradation of 
accumulated NF-H by macroautophagy. Further analysis of GFP-tagged NFs in MPP+ 
treated cells should assist in the elucidation of the role of NFs in the formation of 
inclusions and will allow analysis of protein partners during complex I dysfunction and 
other cellular states linked to neurodegeneration. 
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1.1. Background to Parkinson’s disease 
 
Parkinson’s disease (PD) is a progressive neurodegenerative motor disorder first described 
by James Parkinson in 1817. It mainly affects the elderly and manifests in bradykinesia, 
rigidity, resting tremour, gait dysfunction and postural instability (reviewed by Olanow et al, 
2001). Pathologically it is characterised by a selective degeneration of the dopaminergic 
neurons of the substantia nigra pars compacta (SNpc) but is only apparent once 
approximately 70 % of the nigral neurons have already been lost. A proportion of the 
remaining neurons contain intracytoplasmic inclusions called Lewy bodies (LBs, named 
after Fritz Heinrich Lewy) or Pale bodies (early forms of Lewy bodies) or may contain Lewy 
neuritis which are inclusions found in neuronal processes (Braak et al, 2003, reviewed by 
Olanow et al, 2004, and Robinson, 2008). Although most PD cases are idiopathic, genetic 
cases (Table 1.1) have provided insight into the pathways that may be involved in PD 
pathogenesis or disease progression (reviewed by Mouradian, 2002, and Robinson, 2008). 
 
There is evidence for the involvement of defective cellular respiration in post-mortem PD 
brain (Parker et al, 1989) corroborated by the effects of the complex I inhibitor, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Ballard et al, 1985, Ramsay et al, 1986) and the 
presence of oxidatively damaged mitochondrial complex I subunits in PD brain (Keeney et 
al, 2006). Furthermore, loss of function mutations (detailed in Table 1.1) in genes that play a 
role in the maintenance of mitochondrial homeostasis have been implicated in familial forms 
of PD (reviewed by Burbulla et al, 2010, and Schapira, 2009).  The ability of toxins such as 
MPTP (Ballard et al, 1985, Langston et al, 1984, Langston, 1985) and rotenone (Betarbet et 
al, 2000, Panov et al, 2005, Sherer et al, 2002) to mimic aspects of parkinsonism has led to 
the suggestion that environmental factors such as exposure to herbicides or pesticides may be 
involved in PD, but to date no epidemiological evidence has identified a single causative 
agent (reviewed by Di Monte, 2001, Jenner, 2001, and Malkus et al, 2009). The lack of the 
discovery of a single cause has led to the suggestion that PD pathogenesis is multifactoral, 
involving both genetic (which could affect individual susceptibility) and environmental 
factors (reviewed by Di Monte, 2001, Jenner, 2001, and Sulzer, 2007). Interestingly cigarette 
smoking, coffee drinking (in men particularly) and high uric acid levels are associated with 
reduced risk of PD whereas significant head injury is associated with increased risk (Di 
Monte, 2001, Schapira, 2009). The protective effect of cigarette smoking may be due to 
inhibition of monoamine oxidase (MAO) by MAO inhibitors in smoke (Fowler et al, 1996) 
whereas the protective effect of coffee drinking may be due to the activation of the 
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phosphatidyl inositol 3 kinase (PI3K)/Akt pathway by caffeine which prevents apoptosis 
(Nakaso et al, 2008). 
 
Increased oxidative stress (possibly resulting from mitochondrial dysfunction) has also been 
implicated in PD pathogenesis, evidence of which is in the form of oxidatively modified 
proteins, lipids and DNA in the substantia nigra of PD patients (Alam et al, 1997, Castellani 
et al, 1996, Lyras et al, 1998) and reduced levels of glutathione in PD brain (Riederer et al, 
1989). The vulnerability of dopaminergic neurons may be a product of their structure and 
function, their high energy requirements and their predisposition to oxidative stress resulting 
from the auto-oxidation of dopamine (Hirsch et al, 1988, Sulzer, 2007, Sulzer et al, 2000). 
 
PD is also characterised by the presence of aggregated proteins in LBs which suggests an 
accumulation of abnormal proteins modified by oxidative damage (Castellani et al, 1996, 
Dalfó & Ferrer, 2008) or aberrant phosphorylation (Chen & Feany, 2005, Forno et al, 1986, 
Hasegawa et al, 2002, Schmidt et al, 1996) and defective clearance by protein degradation 
pathways (McNaught et al, 2002, Schlossmacher et al, 2002). Since the discovery of 
mutations in UCH-L1 (deubiquitinating enzyme) and parkin (an ubiquitin ligase) resulting 
in loss of function (Table 1.1), defects in the ubiquitin proteasome system (UPS) have been 
proposed to contribute to PD pathogenesis (Kitada et al, 1998, Leroy et al, 1998, Liu et al, 
2002, Sriram et al, 2005). The bulk degradation of proteins may also occur via the 
autophagosome-lysosome pathway and since this pathway does not rely on the unfolding of 
proteins it may be a more efficient process than the UPS for the degradation of aggregated 
proteins (reviewed by Rubinsztein, 2006). Although previously thought of as a nonselective 
process, it is now known that protein complexes, aggregates and organelles can be targeted 
for degradation by macroautophagy by the interaction of p62/SQSTM1 and LC3-II in an 
ubiquitin-like reaction (discussed in more detail below, Pankiv et al, 2007). Due to the 
presence of p62 in proteinacious inclusions of numerous neurodegenerative conditions 
(Zatloukal et al, 2002) and the role of macroautophagy in the clearance of defective 
organelles including mitochondria (Geisler et al, 2010a) and protein aggregates (Lee et al, 
2004, Rideout et al, 2004) more attention has recently been given to the role of the 
autophagosome-lysosome pathway in PD pathogenesis. 
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Table 1.1 Genes identified in familial Parkinson’s disease. 
Summary of the genetic causes of Parkinson’s disease (PD) (reviewed by Burbulla et al, 2010, and Schapira, 2009). 
Gene Function Mutation Clinical Features References 
Parkin 
(PARK2) 
Ubiquitin ligase and role in 
mitophagy 
Several different types that result 
mainly in loss of function 
Autosomal recessive juvenile onset 
(<40 y), symptoms can present as early 
as 7 y. No LBs. 
(Kitada et al, 1998, 
Sriram et al, 2005) 
PINK1 
(PARK6) 
Mitochondrial kinase and role in 
mitophagy 
Loss of function, mutations usually in 
kinase domain 
Early onset parkinsonism (<40 y), early 
motor complications. 
(Valente et al, 2004) 
DJ-1 
(PARK7) 
Transcription factor, chaperone, 
modulation of basal autophagy and 
mitochondrial homeostasis 
Loss of function 
Young onset and slow progression 
(rare). 
(Bonifati et al, 2003) 
α-synuclein 
(PARK1 + 
PARK4) 
Unknown function. May play a role 
in vesicular DA uptake. 
Multiplication of WT; A53T; E46K; 
A30P 
Duplications in late-onset, triplications 
in early onset. A53T and A30P - early 
onset with dementia. E46K - early 
dementia. 
(Kruger et al, 1998, 
Polymeropoulos et al, 
1997, Ross et al, 2008, 
Singleton et al, 2003) 
LRRK2 
(PARK8) 
Structure suggests numerous 
functions; protein-protein interaction, 
ubiquitin-binding, kinase and 
GTPase activity 
several mutations, most common is 
G2019S in the kinase domain 
(increases autophosphorylation) 
Numerous mutations linked to 
autosomal-dominant PD. Exhibit 
characteristics of several 
neurodegenerative diseases. 
(Hernandez et al, 2005, 
reviewed in Mata et al, 
2006, Zimprich et al, 
2004) 
UCHL1 
(PARK5) 
ubiquitin carboxyhydrolase L1, 
deubiquitinating enzyme (DUB) 
I93M missense mutation; reduced 
enzyme activity 
Symptoms typical for PD (Leroy et al, 1998) 
NF-M Neuronal intermediate filament 
G336S mutation in the rod domain that 
results in abnormal assembly of NFs 
Early onset PD, early but temporary 
response to levodopa. 
(Lavedan et al, 2002) 
ATP13A2 Lysosomal ATPase Loss of function Early onset PD with dementia (Ramirez et al, 2006) 
 
3 
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1.2. Lewy Bodies (LBs) 
1.2.1. Background 
 
LBs, classically described as having a dense core of granular material surrounded by 
fibrillar components that radiate at the periphery, may occur in isolation or in multiples, 
they may be spherical or elongated and range in size between 8-30 µm in diameter (Braak 
et al, 2003, Katsuse et al, 2003, reviewed by Shults, 2006). Images of LBs in the SNc from 
post-mortem samples from PD patients are shown in Figure 1.1.  
 
Figure 1.1 Images of Lewy bodies (LBs) in the substantia nigra (SNc) dopaminergic neurons from post-
mortem samples of patients with sporadic PD.  
(A) Eosin staining of spherical LBs with a distinct core and peripheral halo. (B) Electron micrograph of a LB 
reveals a dense core (c) and a peripheral halo of filamentous material (h). (C) LB stained with anti-ubiquitin, 
showing ubiquitin staining concentrated in the core. (D) LB stained with anti-α-synuclein revealed that α-
synuclein staining is concentrated in the halo. (E) Immunofluorescence staining of LB for ubiquitin (red) and α-
synuclein (green) revealed that ubiquitin staining was concentrated in the core and α-synuclein staining was 
concentrated in the halo. (A-D) Images obtained from Olanow et al (2004) and (E) image obtained from 
(McNaught & Olanow (2006). 
 
LBs have been found to contain numerous proteins (some of which are listed in Table 1.2), 
the most abundant of which are α-synuclein, ubiquitin and the neurofilament (NF) subunits  
(Forno et al, 1986, Galloway et al, 1988, Galloway et al, 1992, Olanow et al, 2004, Schmidt 
et al, 1991).  
 
 
E 
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Table 1.2 List of proteins described as being components of Lewy bodies (LBs) 
Some known components of LBs discovered by immunohistochemical staining or analysis of protein components in isolated LBs 
Protein Function Reference(s) 
α-synuclein Unknown 
Presence in halo confirmed by immunohistochemistry (Katsuse et al, 2003, McNaught et al, 2002, 
Schlossmacher et al, 2002) and immuno-EM (Katsuse et al, 2003) 
ubiquitin 
Targets proteins for degradation by the  
proteasome  
Core  localisation established with immunohistochemistry (Galloway et al, 1988, Iwatsubo et al, 1996, 
McNaught et al, 2002, Schlossmacher et al, 2002, Schmidt et al, 1996, Schmidt et al, 1991) and 
immuno-EM (Galloway et al, 1992) 
Neurofilaments 
Neuronal intermediate filaments, 
cytoskeletal components 
Presence in core and halo confirmed by Immunohistochemistry  (Forno et al, 1986, Galloway et al, 1988, 
Hill et al, 1991, Iwatsubo et al, 1996, Schmidt et al, 1996, Schmidt et al, 1991)  and immuno-EM 
(Galloway et al, 1992, Hill et al, 1991) , Western blotting (Pollanen et al, 1992) 
Parkin 
E3 ubiquitin ligase, involved in 
mitophagy 
Presence in core established by immunohistochemistry (Schlossmacher et al, 2002). Western blotting of 
purified LBs immunoprecipitated the anti-α-synuclein (Schlossmacher et al, 2002) 
p62/SQSTM1 
p62 binds ubiquitinated proteins and 
LC3-II on autophagosomes 
Presence in LBs confirmed by immunohistochemistry (Zatloukal et al, 2002) 
p35 Cdk5 activator  Presence in LBs confirmed by immunohistochemistry (Nakamura et al, 1997) 
Cdk5 Ser/Thr Kinase 
Presence in halo and core established by immunohistochemistry (Brion & Couke, 1995, Nakamura et al, 
1997, Takahashi et al, 2000) and immuno-EM (Takahashi et al, 2000) 
 
 
5 
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Table 1.2 (continued) 
Protein Function Reference(s) 
Tubulin Cytoskeletal component Presence of tubulin confirmed by immunohistochemistry (Galloway et al, 1988, Katsuse et al, 2003). β-
tubulin identified by an anti-Lewy body monoclonal antibody (Iwatsubo et al 1996)  
MAP1 Microtubule associated protein 1 Immunohistochemistry (Galloway et al, 1988) 
MAP2 Microtubule associated protein 2 Halo staining observed with imunohistochemistry (Galloway et al, 1988, Iwatsubo et al, 1996) but immuno-
EM confirmed halo and core staining (Galloway et al, 1992) 
γ-Tubulin Cytoskeletal protein, component of 
centrosome 
Presence in LBs confirmed by immunohostochemistry (McNaught et al, 2002) 
Pericentrin Component of centrosome Presence in LB (more intense halo staining than core) confirmed by immunohistochemistry (McNaught et 
al, 2002) 
Components of the 
UPS (PA28, PA700) 
Degradation of proteins  
 
Presence in core of LBs confirmed by immunohistochemistry (McNaught et al, 2002) 
Heat Shock Proteins 
(HSP70) 
Chaperones, protein folding and 
targeting of proteins for degradation 
Presence in LBs confirmed by immunohistochemistry (McNaught et al, 2002) 
Tissue 
Transglutaminase 
(TG2) 
Cross-linking enzyme Evidene of TG2 catalysed isodipeptide bonds in the halo of LBs that co-localises with α-synuclein (Junn et 
al, 2003) 
6  
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It is noteworthy that unlike neurofibrillary tangles in AD, LBs do not stain with antibodies to 
tau (Brion & Couke, 1995, Galloway et al, 1988, Galloway et al, 1992, Pollanen et al, 1992), 
in addition other proteins that are abundantly expressed in neurons such as synaptophysin, β-
synuclein and γ-synuclein are not found in LBs (reviewed by Olanow et al, 2004). LBs are not 
limited to the SNpc or to PD but are also found in the brains of patients suffering from 
dementia with LBs (DLB) and Alzheimer’s disease (AD) in the cortical and brainstem regions 
and in some cases patients are diagnosed with both PD and AD (Brion & Couke, 1995, 
Iwatsubo et al, 1996, Schmidt et al, 1996, Schmidt et al, 1991, Takahashi et al, 2000).  
 
As PD progresses LB pathology develops with it. During the earlier stages LBs are weakly 
stained with antibodies to α-synuclein and are less defined than at later stages when α-
synuclein staining is more intense and LBs are well-defined (Braak et al, 2003, Katsuse et al, 
2003). Pale bodies, often found in the SNpc and locus ceruleus and poorly stained with eosin 
have been hypothesized to be early forms of LBs (Braak et al, 2003, reviewed by Olanow et al, 
2004, and Wakabayashi et al, 2006) and are usually larger in size than LBs and contain 
mitochondria (Bedford et al, 2008).  
 
NFs (the first discovered protein components of LBs) are traditionally described as being 
localised to the filamentous halo of SNpc LBs (Forno et al, 1986, Galloway et al, 1988) 
however their presence in the core of detergent-treated SNc LBs was revealed by immunogold 
labelling and electron microscopy (Galloway et al, 1992). Cortical (Schmidt et al, 1991) and 
amygdala LBs (Schmidt et al, 1996) which stain poorly with eosin readily revealed NF 
staining in the core and halo. Since poor eosin staining is associated with earlier forms of LBs 
such as pale bodies (Braak et al, 2003, reviewed by Shults, 2006), the lack of core NF staining 
in immunohistochemistry of LBs may be an artefact resulting from the masking of NF 
epitopes in the densely compacted structure of the core. In fact work by Hill et al (1991) 
suggested that antibodies directed to the tail domain of NFs preferentially labelled NFs in the 
halo whereas antibodies directed to the rod and head domains labelled NFs in the LB core, an 
effect that may have been due the masking of epitopes in the core. Interestingly, although all 
three NF subunits (both phosphorylated and nonphosphorylated) have been found to be present 
in cortical LBs, phosphorylated NF-M (medium) appears to be the most prevalent subunit 
(Iwatsubo et al, 1996, Schmidt et al, 1991).  
 
Many other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), DLB and 
AD are also associated with abnormal accumulations of NFs in the brain (reviewed by Julien, 
1999, and Petzold, 2005). Increased levels of NF-L have also been reported in the 
cerebrospinal fluid in patients with ALS and AD (Rosengren et al, 1996). 
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1.2.2. Aggresomes and Lewy bodies 
 
Aggresomes were first described by Johnston, Ward and Kopito (1998) when they 
characterised the cellular and molecular response to the aggregation of misfolded proteins. 
They suggested that when the capacity of the proteasome is exceeded by either increased 
production of a misfolded protein or the impairment of the proteasome itself, aggregated 
proteins are sequestered into an ubiquitin-rich structure at the microtubule-organising centre 
(MTOC) and surrounded by a cage of vimentin filaments. They called this structure an 
aggresome. In addition to the aggregated proteins, mitochondria and vesicular bodies were 
also described trapped in the filamentous component of aggresomes. The authors suggested 
that the formation of aggresomes is a cellular response to remove abnormal aggregated 
proteins and promote cell survival (Figure 1.2, Johnston et al, 1998). Indeed work with 
huntingtin suggested that the formation of intranuclear inclusions of mutant huntingtin may 
be a cellular response to protect against cell death (Saudou et al, 1998). 
 
Since the description of aggresomes a myriad of papers have been published describing the 
formation of aggresomes in numerous disease states and experimental models (Burnett & 
Pittman, 2005, Fu et al, 2005, Hasegawa et al, 2004, Kawaguchi et al, 2003, McNaught et al, 
2002, Rajan et al, 2001). It is now accepted that aggresomes are formed in response to the 
accumulation of misfolded or damaged proteins which may be toxic to the cell as soluble 
oligomeric forms. These oligomeric forms are actively transported to the MTOC where they 
are accumulated into an aggresome and then degraded. Aggresomes are regions of enhanced 
proteolysis due to the recruitment of mitochondria, UPS components and autophagosomes 
and lysosomes (Fu et al, 2005, Kawaguchi et al, 2003, reviewed in Kopito, 2000).  
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Figure 1.2 A diagrammatic representation of the formation of aggresomes.  
Misfolded proteins are targeted for destruction by the Ubiquitin proteasome system (UPS) by the 
attachment of ubiquitin. If the capacity of the UPS is exceeded either via the overproduction of misfolded 
proteins or the impairment of the 26S proteasome, misfolded proteins are accumulated into aggregates. 
These aggregates are then transported along the microtubules to the microtubule organising centre (MTOC) 
where they are accumulated into a structure called an aggresome and surrounded by a ‘cage’ of vimentin 
filaments. In addition mitochondria and other vesicular structures are often found embedded in the 
filamentous component suggesting transport of mitochondria towards the aggresome (adapted from 
Johnston et al, 1998) 
 
The centrosome is a natural choice as a ‘hub’ for protein degradation due to the close 
proximity of the endoplasmic reticulum (Wigley et al, 1999), lysosomes, chaperones such as 
Hsp70 and Hsp90 and the concentration in the centrosome of active proteasomal machinery 
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(Fabunmi et al, 2000, Wigley et al, 1999). Furthermore it is the MTOC from which 
microtubules, the tracks along which motor proteins move, originate. It is therefore the 
natural ‘end-of the-line’ to which a retrograde motor would take its cargo. Interestingly, the 
presence of proteasomal elements in the centrosome is not dependent on an intact 
microtubule network suggesting that the UPS is not transported to the centrosome along the 
microtubule network (Fabunmi et al, 2000).  
 
How and why LBs form remains unexplained despite extensive work in this area. The most 
promising hypothesis of LB formation suggests that LBs are originally formed as 
aggresomes for the removal of abnormal proteins that a potentially cytotoxic. However due 
to the over-production of abnormal proteins and the general failure of degradative pathways 
charged with their clearance, aggresomes are not cleared and form insoluble inclusions and 
LBs. Therefore LBs may be failed aggresomes (reviewed by McNaught et al, 2002, and 
Olanow et al, 2004). The lack of LBs in autosomal recessive juvenile parkinsonism resulting 
from loss of function mutations in the gene for parkin suggests that the ubiquitination of 
aggregated proteins is a requirement for their transport to the MTOC and aggresome 
formation (reviewed by Olanow et al, 2004).  
 
1.3. Oxidative stress and mitochondrial dysfunction 
1.3.1. Oxidative stress 
1.3.1.1. Oxidative stress in neurodegeneration and ageing 
 
Increased oxidative stress has been implicated in age-related neurodegenerative conditions 
due to the observed increase in oxidatively damaged proteins and lipids in post-mortem 
samples from patients with AD (Korolainen et al, 2006, Lyras et al, 1997, Smith et al, 1998), 
PD and DLB (Alam et al, 1997, Castellani et al, 1996, Lyras et al, 1998). Indeed the degree 
of lipid peroxidation and the levels of superoxide dismutase are increased in blood plasma 
from PD patients and accompanied by a decrease in the levels of glutathione (Sharma et al, 
2008). This result is supported by another study of anti-oxidant levels in the blood of PD 
patients which showed an increase in the levels of superoxide dismutase and a decrease in the 
levels of antioxidants such as vitamin C and E compared to age-matched controls (Nikam et 
al, 2009).  
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1.3.1.2. Dopamine and the susceptibility of dopaminergic neurons 
 
Dopamine (DA) is a neurotransmitter of dopaminergic neuronal cells which are responsible 
for the initiation of motor tasks and feedback (reviewed by Sulzer, 2007), a function which is 
evident when looking at the effects of dopaminergic neuronal loss on movement and the 
initiation of movement in patients with PD. DA is usually produced at neuronal terminals by 
the hydroxylation of tyrosine which is catalysed by tyrosine hydroxylase (TH, which is often 
used as a marker to stain dopaminergic neurons). Dopaminergic neurons are thought to be 
particularly susceptible to oxidative damage due to DA auto-oxidation in the presence of 
transition metal ions or deamination by MAO (Figure 1.3). The higher levels of MAO and 
iron in the SNpc increases the susceptibility of this region of the brain to oxidative stress 
compared to the rest of the brain (reviewed by Caudle et al, 2008, and Hom et al, 1997).   
 
Figure 1.3 The Oxidation of Dopamine (DA). 
Catalytic oxidation of DA by MAO results in the production of H2O2 and 3,4-dihydoxyphenylalanine 
which is rapidly oxidized to DOPAC by aldehyde dehydrogenase. Auto-oxidation of DA results in 
production of 6-hydroxy dopamine (6-OHDA) and H2O2. Further oxidation of H2O2  produces additional 
reactive oxygen species (ROS), .OH and O2-. A more common DA auto-oxidation reaction is the 
production of DA quinone which polymerizes to form neuromelanin. All these products of DA oxidation 
can go on to cause oxidative damage to proteins, lipids and DNA (reviewed by Blum et al, 2001, Caudle et 
al, 2008, Luo et al, 1998, and Sulzer, 2007). 
 
Dopaminergic neurons contain a number of feedback mechanisms to prevent DA toxicity 
including the inhibition of tyrosine hydroxylase, the uptake of DA into vesicles via the 
vesicular monoamine transporter-2 (VMAT-2), metabolism of DA by MAO and the 
reduction of DA quinone by glutathione. The maintenance of DA in synaptic vesicles against 
the concentration gradient is maintained by a vesicular H+-ATPase, the functioning of which 
can be undermined by a reduction in mitochondrial ATP production resulting in  the release 
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of vesicular DA into the cytosol where it can contribute to neuronal toxicity (reviewed by 
Sulzer, 2007). The presence of DA enhanced the neurotoxicity and inclusion formation 
induced by neostriatal infusion of proteasome inhibitors in rats and in PC12 cells treated with 
proteasome inhibitors (Fornai et al, 2003).  
 
Due to the preferential loss of dopaminergic neurons in PD, experimental models of PD have 
employed the use of DA, preferentially in cellular models (Hirrlinger et al, 2002, Stokes et al, 
2002, Stokes et al, 2000), or 6-hydroxy-dopamine (6-OHDA) in both cellular (Cheung et al, 
2009, Nakamura et al, 2006, Smith & Cass, 2007, Tirmenstein et al, 2005) and animal 
(Dabbeni-Sala et al, 2001, De Iuliis et al, 2005, Glinka et al, 1996) models. Due to the 
inability of 6-OHDA to cross the blood-brain barrier, the use of 6-OHDA in animal models 
of PD requires the direct injection of 6-OHDA into the striatum, SNpc or the ascending 
medial forebrain bundle (reviewed by Blum et al, 2001) 
 
1.3.2. Mitochondrial dysfunction in neurodegeneration and ageing 
 
Although the source of the increased ROS (reactive oxygen species) is uncertain, 
mitochondrial dysfunction has been implicated (reviewed by Butterfield & Kanski, 2001, 
Cassarino et al, 1997, Navarro et al, 2008), corroborated by the altered activity of complex I 
of the electron transport chain observed in the SNpc (Keeny et al, 2006) and in platelet 
mitochondria (Parker et al, 1989) of PD patients. Energy metabolism with ageing was also 
shown to be reduced by the accumulation of oxidatively damaged mitochondrial aconitase 
(an enzyme involved in the citric acid cycle) in ageing flies (Yan et al, 1997) and decreased 
mitochondrial energy production is observed in rat brain, particularly the hippocampus 
(associated with memory and cognitive abilities), with ageing (Navarro et al, 2008).  
 
Support for the role of altered complex I activity in PD came from the accidental production 
of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) as a contaminating by-product of 
synthetic heroine in Northern California in the 1980’s. Drug users who injected MPTP 
quickly developed an accelerated form of Parkinsonism (Ballard et al, 1985, Langston et al, 
1984, Langston, 1985, Snow et al, 2000).  MPTP (capable of crossing the blood-brain 
barrier) is converted to its active metabolite, 1-methyl-4-phenyl pyridinium (MPP+), by 
monoamine oxidase B in astrocytes (Glover et al, 1986, Ransom et al, 1987). Once MPTP is 
converted to MPP+ it is concentrated in the brain due to the inability of MPP+ to cross the 
blood-brain barrier (reviewed by Tetrud & Langston, 1989). MPP+ is then selectively taken 
up by dopaminergic neurons via the DA transporter due to its structural similarity to DA 
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(Gessner et al, 1985, Javitch et al, 1985, Stephans et al, 2002) where it accumulates in 
mitochondria and inhibits complex I (Ramsay et al, 1986, Stephans et al, 2002).  
 
As such MPTP treatment has been extensively used to establish experimental models of PD 
(Ahn et al, 2009, Bezard et al, 1997, Caneda-Ferron et al, 2008, Gupta et al, 1986, Langston 
et al, 1984, Shimoji et al, 2005, Stephans et al, 2002, Yazdani et al, 2006). The animal model 
that most closely resembles human PD is the MPTP treated primate model (Langston, 1985). 
It is noteworthy that the effects of MPTP were greater and more permanent in older primates 
and primates treated with small doses of MPTP over longer periods. Similarly aged mice 
were also shown to be more sensitive to MPTP treatment (Gupta et al, 1986).  
 
Extensive evidence for the production of reactive oxygen species (ROS) as a result of 
MPTP/MPP+ treatment in animal (Blanchet et al, 1998, Cassarino et al, 1997, Fallon et al, 
1997) and cellular models is available (Cassarino et al, 1997, Hom et al, 1997, Lotharius & 
O'Malley, 2000), however the toxic effects of MPTP/MPP+ are at least partly independent of 
ROS formation (Blanchet et al, 1998, Caneda-Ferron et al, 2008, Fonck & Baudry, 2001, 
Hom et al, 1997) and instead increase the vulnerability to oxidative stress (Lee et al, 2000). 
Cells capable of increasing energy production via glycolysis to compensate for decreased 
mitochondrial oxidative phosphorylation show some resistance to MPTP/MPP+ (Denton & 
Howard, 1987). Not only does MPTP result in increased ROS via complex I inhibition but  
also as a consequence of the release and intracellular accumulation of vesicular DA induced 
by the binding of acetylcholine receptors by MPTP (Lotharius & O'Malley, 2000, Song & 
Ehrich, 1997) and extracellularly as a result of DA efflux via the DAT transporter (Lotharius 
& O'Malley, 2000) and reduced DA re-uptake (Fonck & Baudry, 2001, reviewed in Obata, 
2002, and Toshio et al, 2002). Indeed the presence of DA and its auto-oxidation increases the 
vulnerability of dopaminergic neurons to the effects MPTP/MPP+ (Boada et al, 2000, 
Lotharius & O'Malley, 2000). 
 
Chapter 1: General Introduction 
 14 
1.4. The role of protein degradative pathways  
 
A number of neurodegenerative diseases including PD are characterised by an abnormal 
accumulation of proteins into inclusion bodies (reviewed by Ross & Poirier, 2004). Under 
normal conditions the cytotoxic accumulation of proteins is prevented by their rapid 
clearance, so that equilibrium exists between the production of abnormal proteins and their 
degradation. Most protein degradation in the cell is mediated by the ubiquitin proteasome 
system (UPS) and the autophagy-lysosome pathway (reviewed by Goldberg, 2003, Martinez-
Vicente & Cuervo, 2007, and Rubinsztein, 2006). However due to an age-related decline in 
proteolytic activity (Cuervo & Dice, 2000, Kapphahn et al, 2007, Keller et al, 2000, Kiffin et 
al, 2007, Sitte et al, 2000, Yu et al, 2009), the ability of cells to maintain this equilibrium is 
compromised during ageing.  
 
1.4.1. Ubiquitin Proteasome System (UPS)  
1.4.1.1. Structure and function 
 
The UPS is not only responsible for the degradation of short-lived nuclear and cytosolic 
proteins and abnormal (misfolded or oxidatively damaged) proteins but also plays a role in 
the regulation of many cellular processes. It regulates the turnover of many regulatory 
proteins such as transcription factors and cell cycle regulators (reviewed by Coux et al, 1996) 
such as cyclin B and p27Kip1, the degradation of which regulates the progression of cells 
through anaphase and triggers the G1/S transition respectively (Hattori et al, 2003, Machiels 
et al, 1997, Tsvetkov et al, 1999).  
 
The 26S proteasome is an ATP-dependent multicatalytic proteolytic complex consisting of a 
20S catalytic core and two 19S regulatory caps (PA700 or PA28, Figure 1.4), assembly of 
which requires the assistance of at least nine dedicated chaperones to ensure that the 
numerous proteins that make up the 26S proteasome are assembled correctly (reviewed by 
Bedford et al, 2010). The 20S catalytic core is a hollow barrel composed of two outer 7-
membered rings of α-subunits and two inner 7-membered rings of β-subunits (Groll et al, 
1997). Located on the β-rings and projecting into the inside of the barrel two of each of the 
three main types of catalytic active sites (trypsin-like, chymotrypsin-like and caspase-like) 
can be found (Heinemeyer et al, 1997).  
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In eukaryotes many different proteasomal subunits exist but based on their similarities all 
subunits can be classified as either α- or β-subunits. The core particle is composed of two 
identical halves in which the 7-membered α/β-rings are composed of 7 different α/β-subunits. 
The sequences of α-subunits are characterized by a high degree of conservation with all 
subunits containing a conserved motif at their N-terminus essential for the assembly of the 
proteasome (Coux et al, 1996, Yao et al, 1999). The sequences of the β-subunits on the other 
hand are not so conserved but all contain an N-terminal pro-sequence that is cleaved to reveal 
(on most β-subunits) an N-terminal threonine (Thr) residue (Coux et al, 1996) responsible for 
proteolytic activity (Jäger et al, 1999, Kisselev et al, 2000).  
 
The N-termini of the α-subunits also control access to the proteolytic active sites confined 
within the core particle by forming a gated channel (Groll et al, 2000). This channel is 
opened by the 19S regulatory subunit which is responsible for interacting with proteins 
targeted for degradation by the UPS via a process called ubiquitination (the covalent binding 
of ubiquitin to the target protein). Ubiquitin is a 76 amino acid polypeptide (reviewed in 
Glickman & Ciechanover, 2002) which covalently binds to target proteins via one of its 
seven lysine residues.  
 
The number of ubiquitin residues and the particular lysine residue linked to the target 
proteins acts as a signal targeting the proteins either for destruction (which requires at least 
four ubiquitin moieties linked via their Lys48 residues) or for any of the non-proteolytic 
signalling functions of ubiquitin. Although Lys63 chains are usually associated with non-
proteolytic functions, the 26S proteasome binds both Lys48 and Lys63 polyubiquitinated 
proteins and both are degraded by the 26S proteasome (Bedford et al, 2010). The conjugation 
of ubiquitin to a target protein as illustrated in Figure 1.4 is accomplished by three different 
enzymes; E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 
(ubiquitin ligase; Glickman & Ciechanover, 2002). 
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Figure 1.4 Scheme describing the ubiquitination and degradation of proteins by the ubiquitin 
proteasome system. E1 (ubiquitin-activating enzyme) activates ubiquitin via the hydrolysis of ATP to 
produce a high-energy thiol ester intermediate (E1-S~ubiquitin). Ubiquitin is then transferred to E2 
(ubiquitin conjugating enzyme) via ATP hydrolysis to produce of another high-energy thiol ester 
intermediate (E2-S~ubiquitin). Ubiquitin is then transferred from E2 to a cysteine residue in the active site 
of E3 (ubiquitin ligase) which is bound to the protein substrate and catalyses the conjugation of ubiquitin 
to the ε-NH2 group of a lysine residue of the protein substrate. Once the protein is ubiquitnated, further 
ubiquitin monomers are linked via their Lys48 residues to produce a polyubiquitin chain of at least 4 
ubiquitin moieties which targets it to the 19S regulatory subunit of the 26S proteasome. The 26S 
Proteasome consists of 2 seven-membered rings each of α- and β-subunits, stacked one on top of the other 
to form the barrel-shaped 20S catalytic core. Two regulator 19S caps can be found at the entrance and exit. 
Proteins to be degraded (represented here in orange) are unfolded and pass through the inside of the 20S 
catalytic core where they are broken down (Ardley et al, 2005, Glickman & Ciechanover, 2002, ves-
Rodrigues et al, 1998), resulting in fragments of 8-12 amino acids in length (Kisselev et al, 1999). 
Ubiquitin carboxy-terminal hydrolases or deubiquitinating enzymes (DUBs) which have the ability to 
break isopeptide bonds are responsible for the depolymerisation and recycling of ubiquitin chains (Coux et 
al, 1996, Glickman & Ciechanover, 2002). 
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1.4.1.2. Proteasomal deficiency during ageing and neurodegeneration 
1.4.1.2.1. Overview 
 
An age-related decline in proteasome activity has been reported in a number of tissues 
including the brain, retina and spinal cord (Kapphahn et al, 2007, Keller et al, 2000). In a 
recent proteomic analysis of oxidatively modified proteins with ageing, the deubiquitinating 
enzyme UCH-L1 was identified providing further support for the decline in UPS-directed 
protein degradation with ageing (Toda et al, 2010).  
  
As mentioned earlier (section 1.3.1.1) oxidatively damaged proteins are increased with age 
and in PD and DLB, suggesting increased oxidative stress. One of the functions of the 
proteasome is the degradation of oxidatively modified proteins, which can be degraded in an 
ATP and ubiquitin independent manner directly by the 20S proteasome (Shringarpure et al, 
2003). However, there is evidence that the proteasome itself is sensitive to oxidative damage, 
as seen in the spinal cord of aged rats (Keller et al, 2000) and in SH-SY5Y cells treated with 
dopamine (Caneda-Ferron et al, 2008). Lipofuscin/ceroid (a biological marker of ageing) 
accumulating in ageing post-mitotic fibroblasts has also been shown to directly inhibit 
proteasome activity (Sitte et al, 2000). The loss of proteasome function and increased 
oxidative damage with age has a cumulative effect resulting in increased vulnerability of cells 
to oxidative damage and the accumulation of oxidatively damaged proteins that are not 
cleared. Indeed inhibition of the proteasome with lactacystin in SH-SY5Y neuroblastoma 
cells increases the vulnerability of these cells to oxidative damage (Lev et al, 2006). 
 
It has been reported that all three proteolytic activities [chymotrypsin-like (CLA), trypsin-like 
(TLA) and caspase-like (PLA)] of the proteasome are reduced in PD nigral tissues compared 
to age-matched controls (McNaught & Jenner, 2001, McNaught et al, 2003), a result 
supported in a further study by Tofaris et al (2003) who compared chymotrypsin-like activity 
in various brain regions of PD patients. The reduction in proteasome activity may be the 
result of an observed selective loss of the 20S α-subunits in the SNpc, the loss of which 
would prevent the normal assembly of proteasomes (McNaught et al, 2002, McNaught et al, 
2003). Furthermore, a reduction in the levels PA700 and PA28 regulatory subunits was also 
observed in PD SNpc (McNaught et al, 2003). Support for the role of proteasome dysfunction 
in PD comes from early onset forms of the disease which arise due to mutations in 
components of the UPS; parkin (an ubiquitin ligase) and ubiquitin C-terminal hydrolase L1 
(UCH-L1) (reviewed by Betarbet et al, 2005, Kitada et al, 1998, Leroy et al, 1998) and the 
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reduced expression of UCH-L1 mRNA and protein in the medulla oblongata and SNpc of PD 
patients with LB pathology (Barrachina et al, 2006).  
 
Lys63 polyubiquitinated proteins are accumulated in characteristic inclusions of 
neurodegenerative conditions such as Huntington’s disease (HD), AD and PD (reviewed by 
Bedford et al, 2010). In addition, immunohistochemical studies of LBs have revealed the 
presence of UPS components such as the ubiquitin activating enzyme E1, the regulatory 
subunits PA700 and PA28, the chaperone HSP70 (McNaught et al, 2002, reviewed in 
Olanow et al, 2004), 26S proteasome ATPase, ubiquitin conjugating enzyme UbcH7 (E2) 
and UCH-L1 (reviewed by Licker et al, 2009). 
 
1.4.1.2.2. The effects of mitochondrial dysfunction on proteasome activity 
 
The treatment of human SH-SY5Y neuroblastoma cells with the PD mimetic MPP+ also 
resulted in decreased activity of CLA and PLA of the proteasome, however since anti-
oxidants were not protective in these cells, the effect of MPP+ on the proteasome in this case 
was reported not to be dependent on oxidative damage but rather through limited ATP 
availability (Caneda-Ferron et al, 2008). Furthermore, treatment of marmosets with MPTP 
resulted in a reduction in the activity of all three proteolytic activities of the 20S proteasome 
(CLA, TLA and PLA) and in the expression of the regulatory and structural subunits of the 
26S proteasome (Zeng et al, 2006). Continuous infusion of rats with MPTP was also reported 
to result in a reduction proteasome activity (Fornai et al, 2005). 
 
A role for the UPS in the clearance of aggregated proteins induced by chronic MPP+ 
treatment of rat mesencephalic neuronal cells was suggested by Sawada et al (2004) due to 
the increase in protein aggregation and inclusion formation following proteasome inhibition. 
In this case proteasome inhibition and aggregate formation was also accompanied by 
neuroprotection. Similarly, intranigral injection of rats with MPP+ and proteasome inhibitors 
revealed dopaminergic neuronal loss with MPP+ treatment which was blocked by 
proteasome inhibition (Sawada et al, 2004), suggesting again that the proteasome is involved 
in MPP+ induced cell death and that inclusions are protective. A role for the proteasome in 
cell death was also shown in HT22 cells and rat primary neuron cultures as a result of 
oxidative glutamate toxicity (van Leyen et al, 2005). However in rat cortical neurons 
proteasome inhibition induced apoptotic cell death (Rideout & Stefanis, 2002), suggesting 
that the role of the proteasome in cell survival and cell death is more complex. Increased 
levels of ubiquitinated proteins were also observed in human SK-N-MC neuroblastoma cells 
treated chronically with a rotenone (Sherer et al, 2002).  
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There is evidence of the involvement of other proteolytic pathways in the clearance of 
aggregated proteins. The clearance of aggregated proteins during washout and recovery of 
rotenone treated cells was only partially blocked by proteasome inhibition suggesting that 
other pathways are also involved in the clearance of aggregated proteins and aggresomes 
(Lee et al, 2002). One of the other pathways may be macroautophagy which is discussed in 
more detail in section 1.4.2. 
 
1.4.1.2.3. The use of proteasome inhibitors as models for neurodegeneration 
 
Since the suggestion of a role for defects in proteasome activity in neurodegenerative 
conditions characterized by protein aggregates, proteasome inhibition has been extensively 
used to induce inclusion formation in experimental models (Ardley et al, 2003, Bedford et al, 
2008, Fornai et al, 2003, Ito et al, 2002, Junn et al, 2002, Rideout et al, 2001, Rideout & 
Stefanis, 2002, Sullivan et al, 2004). Evidence that inclusion formation is an active process is 
the requirement of transcription, which verifies that inclusions are not simply formed due to 
the passive build-up of ubiquitinated proteins that are not degraded. In addition ubiquitination 
is a requirement for the formation of inclusions (Rideout et al, 2005, Rideout & Stefanis, 
2002). In HEK293 cells, proteasome inhibition and/or expression of a mutant aggregate-
prone protein resulted in the expansion of the centrosome and recruitment of proteasomal 
elements from the cytosol (Wigley et al, 1999). 
 
In cellular models, proteasome inhibition resulted in the formation of protein aggregates and 
inclusions (Fornai et al, 2003, Ito et al, 2002, Rideout et al, 2005, Rideout et al, 2001, 
Rideout & Stefanis, 2002) that preceded apoptotic cell death at later time-points (Rideout et 
al, 2005, Rideout & Stefanis, 2002). These aggregates contained proteins such as α-
synuclein, ubiquitin (Fornai et al, 2003, Rideout et al, 2001, Rideout & Stefanis, 2002), 
chaperones such as Hsp70 and Hsp27, proteasomal subunits (Ito et al, 2002, Rideout & 
Stefanis, 2002), parkin, the ubiquitin-activating enzyme E1 (Fornai et al, 2003), and 
intermediate filaments such as α-internexin (Rideout & Stefanis, 2002) and vimentin (Ito et 
al, 2002). Similar inclusions were formed following proteasome inhibition in cellular models 
overexpressing parkin (Ardley et al, 2003, Junn et al, 2002).  
 
Chronic low level proteasome inhibition in SH-SY5Y cells resulted in increased 
mitochondrial oxidative stress, reduced oxygen consumption at maximum respiration, 
reduced mitochondrial protein synthesis and increased association of mitochondria with 
lysosomal structures indicating increased mitochondrial turnover. In addition these cells also 
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contained the products of partial mitochondrial degradation and high concentrations of 
Lipofuscin indicating reduced macroautophagy (Sullivan et al, 2004). Therefore deficiencies 
in proteasome activity as observed during ageing and in age-related neurodegenerative 
conditions are likely to have an effect on the maintenance of mitochondrial homeostasis. 
 
Intragastric injection of proteasome inhibitors in rats resulted in the formation of α-synuclein-
positive inclusions in the dorsal motor nucleus of the vagus (DMV) but this was not 
accompanied by degeneration and no effect on the dopaminergic neurons of the substantia 
nigra was observed, the lack of which was attributed by the authors to the short treatment 
regime used (Miwa et al, 2006). Another study which employed microinfusion of proteasome 
inhibitors into the neostriatum of rats, revealed selective loss of dopaminergic neurons of the 
SNpc and the formation of inclusions immunoreactive for α-synuclein, ubiquitin, parkin and 
the ubiquitin activating enzyme E1 (Fornai et al, 2003).  
 
Further evidence for the role of the proteasome in aberrant protein aggregation was obtained 
from a transgenic mouse model of 26S proteasome depletion resulting from the targeted 
conditional knockout of PSMC1 (a proteasome ATPase which is an essential subunit of the 
19S regulator cap). In these mice, PSMC1 knockout was targeted to the catecholaminergic 
neurons and resulted in neurodegeneration and LB-like inclusions resembling pale bodies 
that contained proteins such as ubiquitin, α-synuclein, p62, γ-tubulin, NF, αB crystallin and 
numerous mitochondria and spherical structures (Bedford et al, 2008).  
 
1.4.2. Autophagy-Lysosome Pathway  
1.4.2.1. Background 
 
Autophagy is traditionally described as a cellular adaptation to starvation (particularly in 
single cell organisms) which allows cells to provide for their energy and amino acid needs by 
self-digestion or catabolism until the situation improves. In humans autophagy can be 
upregulated in cells of organs such as the liver between meal times. Basal levels of autophagy 
are essential for the maintenance of cellular homeostasis allowing for the turnover of long-
lived proteins and it is the only pathway available for the turnover of organelles and large 
protein complexes (reviewed by Ichimura et al, 2008b, and Nixon, 2006).  
 
Autophagy can be divided into three main categories, represented in Figure 1.5:  
1) Macroautophagy: a portion of the cytoplasm is engulfed by a newly formed 
autophagosome or phagophore. The outer membrane of the mature 
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autophagosome fuses with a lysosome which is followed by the degradation of its 
inner membrane and contents by the lysosomal proteases (reviewed by 
Bandhyopadhyay & Cuervo, 2007, Ichimura et al, 2008a, Luzio et al, 2007, 
Martinez-Vicente & Cuervo, 2007, and Mizushima et al, 2008). 
2) Microautophagy: the lysosomal membrane invaginates and engulfs a small 
portion of the cytoplasm (Martinez-Vicente & Cuervo, 2007, Mizushima et al, 
2008). 
3) Chaperone mediated autophagy (CMA): CMA is a more selective form of 
autophagy in which proteins are targeted for degradation by chaperone proteins 
such as Hsc70 which interacts with the lysosomal membrane receptor LAMP-2A 
(Bandhyopadhyay & Cuervo, 2007, Martinez-Vicente & Cuervo, 2007, 
Mizushima et al, 2008). 
After degradation of proteins and lipids the resultant macromolecules are released into the 
cytosol via lysosomal permeases for recycling (reviewed by Xie & Klionsky, 2007). 
 
Figure 1.5 Diagrammatic representations of the three main types of autophagy.  
(1) Macroautophagy, in which a phagophore forms and engulfs a portion of the cytoplasm, the autophagosome matures 
and then fuses with a lysosome; (2) Microautophagy, involves the invagination of the lysosomal membrane around a 
portion of the cytoplasm; and (3) Chaperone mediated autophagy (CMA), in which proteins are targeted for degradation 
by the lysosome by the binding of chaperone proteins such as Hsc70 which in turn binds to lysosomal membrane 
receptor, LAMP-2A (adapted from Martinez-Vicente & Cuervo, 2007, and Mizushima et al, 2008).  
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1.4.2.2. Macroautophagy 
1.4.2.2.1. Autophagosome membrane formation  
 
The process of autophagosome synthesis has been extensively studied in yeast and as such 
many of the components are called Atg (Autophagy-related genes) proteins based on their 
nomenclature in yeast models. Autophagosome synthesis in mammalian cells can apparently 
initiate anywhere in the cytoplasm (reviewed by Simonsen & Tooze, 2009) unlike yeast in 
which all autophagosomes arise from a single phagophore assembly site (PAS) containing 
Atg components required for autophagosome synthesis (Mari et al, 2010). However the 
source of the initiating phagophore membrane in mammalian cells is still elusive (Simonsen 
& Tooze, 2009). Recently Axe et al (2008) identified phosphatidylinositol 3-phosphate (PI-
3P) rich structures called omegasomes near the endoplasmic reticulum in response to nutrient 
starvation in mammalian cells. These structures also contained Atg8 (LC3, microtubule 
associated protein 1 light chain 3) and Atg5, proteins involved in autophagosome synthesis 
(Axe et al, 2008). The initiation of the autophagophore membrane requires the presence of 
assembly components such as beclin 1, Atg14 and the class III phosphatidylinositol 3-kinase 
complex (Vps34; Itakura et al, 2008, Juhász et al, 2008). 
 
Autophagosome synthesis is controlled by an ubiquitin-like conjugation system (Figure 1.6), 
involving two ubiquitin-like proteins, Atg12 and LC3, both of which have a ubiquitin fold at 
their C-terminus. The recruitment of the ubiquitin-like conjugation system to the PAS is 
controlled by a self-assembling protein called Atg9 (ATG9L1) which is normally found in 
punctate structures and is transported to the PAS by the Atg9 transporting factors Atg23 and 
Atg27 (reviewed by Nixon, 2006, and Xie & Klionsky, 2007). In a recent report LC3 was 
shown to be phosphorylated by protein kinase A (PKA) at Ser12 and that the induction of 
macroautophagy was dependent on LC3 dephosphorylation (Cherra et al, 2010).  
 
The fusion of autophagosome and lysosome is dependent upon the presence of an intact 
microtubule network suggesting a role for microtubule motor proteins in the transport of 
autophagosomes to lysosomes (Webb et al, 2004). In fact disruption of dynein activity by the 
expression of dynein with ALS-associated mutations in PC12 cells expressing either mutant 
huntingtin or A53T α-synuclein impaired the autophagic clearance of protein aggregates 
(Ravikumar et al, 2005). 
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Figure 1.6 Autophagosome formation is controlled by an ubiquitin-like reactions. 
(A) Formation of the Atg12-Atg5-Atg16 complex is a ubiquitin-like conjugation event in which the binding of the C-
terminal Glycine residue of Atg12 to an internal Lysine residue of Atg5 is facilitated by the E1-like activating enzyme 
Atg7 and the E2-like conjugating enzyme Atg10. Atg16 then covalently binds to the Atg5 of the Atg12-Atg5 complex 
on the side opposite to Atg12. The association of the Atg12-Atg5-Atg16 complex with the expanding phagophore 
membrane is mediated by Atg5. (B) The conjugation of LC3 to phosphatidylethanolamine (PE) is another ubiquitin-
like conjugation event. LC3 is cleaved by Atg4 to reveal a Glycine residue. This processed form of LC3 (LC3-I) is 
conjugated to PE by Atg7 (E1-like activating enzyme) and Atg3 (E2-like conjugating enzyme). (C) The Atg12-Atg5-
Atg16 complex and PE bound LC3-II decorate the expanding phagophore or developing autophagome. Atg12-Atg5-
Atg16 is preferentially found associated with the cytosolic surface of the phagophore whereas LC3-II is found on the 
lumenal and cytosolic surfaces. Once the autophagosome is formed, Atg12-Atg5-Atg16 is released but LC3-II remains 
associated. Following fusion with the lysosome, the cytosolic pool of LC3-II is cleaved from PE by Atg4 and recycled 
whereas the lumenal pool is degraded by lysosomal proteases together with the inner autophagosome membrane 
(reviewed by Xie & Klionsky, 2007). 
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1.4.2.2.2. Lysosomes 
 
Lysosomes are membrane bound acidic organelles with a lumenal pH of 4.6-5.0 maintained 
by H+-pumping vacuolar ATPases (reviewed by Luzio et al, 2007). They contain a wide 
spectrum of hydrolytic enzymes, which after synthesis and tagging with mannose-6-
phosphate are delivered to endosomes which either fuse with lysosomes or mature into 
lysosomes themselves (Luzio et al, 2007). The most abundant lysosomal proteases are the 
cathepsins of which there are several types: B, L, S, V, C, F, K and X are cysteine proteases, 
whereas D is an aspartic protease and G is a serine protease (Stoka et al, 2001, reviewed by 
Turk & Stoka, 2007).  
 
1.4.2.2.2.1. The role of cathepsins in ageing and neurodegeneration 
 
The cysteine cathepsins have been suggested to also participate in both apoptosis and 
necrotic cell death depending on the degree of cysteine cathepsin leakage from lysosomes. If 
leakage from lysosomes is limited leading to the more selective release of cysteine 
cathepsins, apoptosis is triggered. Whereas if conditions are such that leakage is more 
pronounced necrotic cell death is triggered (Droga-Mazovec et al, 2008, Stoka et al, 2001, 
Turk & Stoka, 2007, reviewed by Vasiljeva & Turk, 2008, Wang et al, 2006a). Exposure of 
SH-SY5Y neuroblastoma to H2O2 resulted in oxidative damage, lysosomal membrane 
leakage followed by mitochondrial damage and the initiation of apoptotic cell death. 
However in this case it was cathepsin D and not cathepsin B activation that preceded caspase 
activation (Castino et al, 2007).  
 
However cysteine cathepsins are also associated with cell survival, especially in cancer cells 
(Gocheva et al, 2006, Stoka et al, 2001, reviewed by Vasiljeva & Turk, 2008). Indeed 
inhibition of cysteine cathepsins such as cathepsin B and L results in apoptotic cell death in 
cancer cell lines (Colella et al, 2010, Gocheva et al, 2006, Zhu & Uckun, 2000). In 
osteosarcoma cells with mutations in mitochondrial DNA, the expression and activity of 
cathepsin B is elevated (Hamer et al, 2009). 
 
Cathepsins have also been implicated in neurodegenerative conditions. A comparison of 
cathepsin activities in the frontal cortex grey and white matter of normal, AD, DLB and PD 
brain and the caudate nucleus of HD brain did not reveal changes in activities of any of the 
cathepsins other than cathepsin H in HD which was elevated. However the activity of 
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dipeptidyl aminopeptidase II (a serine protease with optimum pH of 4.5-5.5, Hui, 1988) was 
reduced in DLB and PD and elevated in HD (Mantle et al, 1995).  
 
Mice with targeted neuronal deficiency in cathepsin D displayed extensive apoptotic and 
necrotic neuronal cell death as well as the presence of accumulated α-synuclein despite a 
compensatory upregulation of the expression of cathepsin B, L, F and H. In addition these 
mice also exhibited reduced proteasome activity and defective macroautophagy (Qiao et al, 
2008). Similarly over-expression of GFP tagged human α-synuclein in C.elegans resulted in 
dopaminergic cell death and α-synuclein accumulation which was alleviated by the co-
expression of human cathepsin D. The role of cathepsin D in preventing α-synuclein toxicity 
was also shown by the co-expression of cathepsin D in SH-SY5Y cells over-expressing α-
synuclein (Qiao et al, 2008). Cathepsin D (Hamazaki, 1996) and cathepsin B may be 
involved in the degradation of β-amyloid. Decreasing the levels of the endogenous cathepsin 
B inhibitor (cystatin C) in mice expressing human amyloid precursor protein and β-amyloid 
lowers the levels of soluble β-amyloid, protecting them against early mortality and 
improving cognitive functioning (Sun et al, 2008). 
 
1.4.2.2.3. The selectivity of macroautophagy depends on p62/SQSTM1 
 
The traditional view that macroautophagy is a largely non-selective process has been 
replaced with the idea that proteins or organelles can be targeted for degradation through the 
interaction of macroautophagy targeting proteins. One such protein is p62/SQSTM1, which 
in humans has been suggested to act as a linking protein between ubiquitinated protein 
aggregates and LC3, thereby facilitating the removal of aggregates by autophagy (Bjorkoy et 
al, 2005, Pankiv et al, 2007).  
 
p62 is a 440 amino acid protein containing an N-terminal Phox and Bemlp (PBI) domain, 
followed by a ZZ-type zinc-finger domain, a PEST region containing phosphorylation sites 
and a C-terminal ubiquitin association (UBA) domain (reviewed by Geetha & Wooten, 2002, 
and Ichimura et al, 2008a). The UBA domain (for interaction with ubiquitin) and PBI domain 
(for self-oligomerization) are both required for the formation of cytoplasmic p62 bodies 
containing ubiquitinated proteins which can then be degraded by autophagy (Bjorkoy et al, 
2005). Its ability to interact with LC3-II is due to the presence of a LC3-II interacting region 
(LIR) which was mapped to a 22 amino acid stretch between the N-terminal PBI domain and 
the C-terminal UBA domain and shown to be essential for the autophagic degradation of 
ubiquitinated protein aggregates, providing evidence linking p62 to the clearance of 
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ubiquitinated protein aggregates by macroautophagy (Pankiv et al, 2007). A scheme 
illustrating the possible targeted degradation of inclusions and protein aggregates by p62 is 
given in Figure 1.7 (reviewed in Mizushima et al, 2008). 
 
 
Figure 1.7 A scheme illustrating the proposed role of macroautophagy in the clearance of inclusions 
and protein aggregates.  
Ubiquitinated protein aggregates bind p62/SQSTM1 which also interacts with LC3-II on the membrane of 
the developing autophagosome. The autophagosome engulfs the protein aggregate or inclusion. The 
autophagosome then fuses with a lysosome and aggregates and the inner autophagome membrane are 
degraded by the lysosomal proteases.  
 
1.4.2.2.4. The role of macroautophagy in neurodegeneration 
 
During ageing there is a general decline in both macroautophagy and CMA. In studies with 
mice longevity is improved by caloric restriction which induces autophagy (reviewed by 
Mizushima et al, 2008). In mice, the targeted disruption of the expression of Atg5 (involved 
in the formation of the autophagosome membrane) resulted in neurodegeneration, motor 
defects and an accumulation of inclusion bodies, highlighting the importance of basal 
autophagy in neuronal cells (Hara et al, 2006). The effect of the accumulation of toxic 
proteins or protein aggregates is largely dependent on the cell type affected; mitotic cells are 
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able to divide and distribute aggregates between daughter cells, effectively diluting the toxic 
products. Whereas terminally differentiated cells such as neurons do not have that option and 
need to be able to clear toxic proteins or aggregates. As cells age, their protein degradative 
pathways loose efficacy and the continued build-up of toxic products eventually leads to cell 
death (Martinez-Vicente & Cuervo, 2007).  
 
A role for autophagy in PD is suggested by evidence that α-synuclein, a well known marker 
of LBs, is degraded by both chaperone-mediated autophagy and the UPS (Webb et al., 2003, 
Ghee et al., 2000, Cuervo et al., 2004) and by the reported induction of autophagy in SH-
SY5Y cells by MPP+ (Zhu et al., 2007). PD-associated mutant forms of α-synuclein bind 
LAMP-2 with greater affinity than wild-type α-synuclein but are not internalized, thereby 
inhibiting CMA by blocking LAMP-2 (Cuervo et al, 2004). A recent report also showed that 
overexpression of α-synuclein in SK-H-SH, HeLa and HEK293 cells and transgenic mice 
impaired macroautophagy (Winslow et al, 2010). Protein aggregates formed in rotenone 
treated COS-7 cells expressing wild-type and PD-associated mutant forms of α-synuclein 
were cleared by macroautophagy but the efficiency of this clearance system decreased with 
longer treatment periods (Lee et al, 2004). In rat cortical neurons protein aggregates resulting 
from proteasome inhibition were also cleared by macroautophagy (Rideout et al, 2004).  
 
This suggests that in response to protein aggregation as a result of cellular stress, cells may 
upregulate macroautophagy to clear these aggregates. In fact inhibition of macroautophagy in 
SH-SY5Y cells overexpressing α-synuclein results in cell death (Lee et al, 2004). Continued 
stress however eventually results in decreased efficiency of clearance systems and ultimately 
cell death. The presence of p62 in LBs and inclusions of other neurodegenerative conditions 
characterized by protein aggregation (Nakaso et al, 2004, Zatloukal et al, 2002) supports the 
hypothesis that these inclusion bodies are the result of the failed clearance of aggresomes. 
 
In a transgenic mouse model expressing superoxide dismutase 1 (SOD1) with a familial 
amyotrophic lateral sclerosis (ALS) mutation, the levels of p62 accumulated. p62 was shown 
to directly interact with polyubiquitinated mutant SOD1 in aggregates which did not appear 
to have a negative effect on cell viability and did not form in the absence of p62 (Gal et al, 
2007). Proteasome inhibition of PC12 cells resulted in the accumulation of α-synuclein, p62 
and ubiquitin in inclusion bodies that co-localized with γ-tubulin suggesting the formation of 
an aggresome-like structure. The accumulation of p62 was accompanied by the induction of 
p62 expression which shown to be essential for aggregate formation (Nakaso et al, 2004). An 
induction of p62 expression with proteasome inhibition was also observed in HeLa cells 
(Bjorkoy et al, 2005). 
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Evidence for the role of lysosomal degradation in PD pathogenesis was supplied by the 
identification of loss of function mutations in a lysosomal ATPase (ATP13A2) in a Chilean 
family with early-onset hereditary PD and an elevation ATP13A2 mRNA in dopaminergic 
neurons of the SNpc of sporadic PD patients (Ramirez et al, 2006). In addition, the levels of 
LAMP1, Cathepsin L and Hsp73 are reduced in PD brain compared to age-matched controls 
(Chu et al, 2009). Lysosomal malfunction was suggested in a PD-mouse model resulting 
from chronic treatment with MPTP/probenecid. This model was characterised by 
dopaminergic neuron loss and the production of LB-like inclusions associated with numerous 
lipid filled vacuoles and large amounts of lipofuscin (Meredith et al, 2002). MPP+ treatment 
in SH-SY5Y neuroblastoma cells resulted in a dose-dependent increase in the levels of LC3-
II (used as a marker of autophagosomes) which the authors attributed to an induction of 
autophagosome synthesis (Zhu et al, 2007). An upregulation of LC3-II levels following 
MPP+ treatment was also found in rat PC12 cells expressing A30P α-synuclein but in this 
work the authors also found that MPP+ impaired dynein activity and decreased dynein 
proteins levels. Thus preventing the autophagic clearance of α-synuclein by preventing 
autophagome-lysosome fusion (Cai et al, 2009), which is dependent upon the activity of 
dynein (Ravikumar et al, 2005). 
 
1.4.2.2.5. The role of mitophagy in neurodegeneration 
 
Proteins involved in mitochondrial homeostasis have been identified in loss of function 
mutations observed in familial forms of PD. Parkin (an E3 ligase) and PINK1 (a 
mitochondrial Ser/Thr kinase) are involved in the targeting of dysfunctional mitochondria for 
removal by mitophagy (reviewed by Burbulla et al, 2010, Geisler et al, 2010a). PINK1 has a 
cytosolic and mitochondrial distribution and its translocation to mitochondria is dependent on 
its kinase activity. In functional mitochondria, PINK-undergoes voltage dependent cleavage 
but in dysfunctional mitochondria PINK1 is not cleaved and full-length PINK1 accumulates. 
Accumulated PINK1 results in the recruitment and activation of parkin, which in turn 
catalyses the autoubiquitination of parkin at Lys63 and the ubiquitination of VDAC1 
(voltage-dependent anion channel 1) at Lys27 which in turn recruits the adaptor p62 which 
targets the mitochondria for degradation by mitophagy. Knockdown of p62 and VDAC1 
completely prevents autophagic mitochondrial clearance and recruitment of parkin to 
dysfunctional mitochondria respectively (reviewed by Burbulla et al, 2010, Geisler et al, 
2010a).  
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In SH-SY5Y cells expressing either wild-type or PD associated PINK1 mutants together with 
wild-type GFP tagged parkin the importance of the interaction between functional PINK1 
and parkin for the clearance of damaged mitochondria was demonstrated. In fact the kinase 
activity of PINK1 (often affected in PD mutants) was shown to be essential for the physical 
interaction of PINK1 and parkin (Geisler et al, 2010b). Similarly parkin with PD-associated 
mutations did not translocate to dysfunctional mitochondria in HeLa cells expressing either 
wild-type or mutant HA-tagged parkin and treated with a mitochondrial uncoupler. The 
importance of parkin and PINK1 in mitophagy was also demonstrated in SH-SY5Y cells 
expressing either wild-type or PD associated mutant parkin and PINK1. Therefore functional 
parkin and PINK1 are required for the clearance of defective mitochondria by mitophagy 
(Geisler et al, 2010a).  
 
1.4.3. Calpain   
1.4.3.1. Background 
 
Calpain is a ubiquitously expressed calcium dependent cysteine proteases composed of an 80 
kD catalytic subunit and a 30 kD regulatory subunit which are activated following autolytic 
cleavage of N-terminal fragments of both subunits when intracellular calcium levels are 
increased. Calpain is classified into two types according to the concentration of calcium 
required for activity: m-calpain (calpain II) which requires concentrations of 200-800 µM 
calcium and µ-calpain (calpain I) which requires concentrations of 2-75 µM calcium 
(reviewed by Goll et al, 2003, and Mehdi, 1991).  The binding of calcium induces 
conformational changes in calpain that leads to the correct alignment of the catalytic active 
sites (Moldoveanu et al, 2002). 
 
1.4.3.2. Calpain in ageing and neurodegeneration 
 
In PD it has been reported that calpain-II expression is increased in nigral dopaminergic 
neurons (Mouatt-Prigent et al, 1996). In MPTP mouse models of PD calpain expression is 
increased (Chera et al, 2004) and calpain inhibition attenuates MPTP toxicity (Crocker et al, 
2003). Interestingly, under conditions of stress, such as anoxia and reoxygenation and periods 
of chronic inflammation, calpains have been implicated in NF-M, NF-H (Stys & Jiang, 2002) 
and NF-L degradation (Kunz et al, 2004, Shields et al, 1997). 
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1.5. Neurofilaments 
1.5.1. Function of neurofilaments 
 
Neurofilaments are members of the intermediate filament (IF) family that are specifically 
expressed in neuronal cells. IFs are divided into five types, four found in the cytoplasm and 
one (the lamins) found in the nucleus, with a diameter of 10-12 nm. Together with the 
microtubules (MTs, 23-25 nm) and microfilaments (MFs, 5-8 nm), IFs make up the 
cytoskeleton of eukaryotic cells (reviewed by Janmey et al, 2003, and Perrot et al, 2008, 
Petzold, 2005).  
 
Some recognised functions of NFs include the maintenance of axonal structure and the 
optimization of nerve impulse conduction velocity in myelinated neurons. The latter depends 
of myelin thickness and internodal length, which are proportional to axonal calibre, the 
thickness of which is thought to be dependent on the expression of NFs (Hoffman et al, 1987, 
Perrot et al, 2008, Zhu et al, 1997). NFs have also been proposed to act as docking sites for 
organelles in the axon (Hirokawa, 1982, Perrot et al, 2008); active mitochondria for example 
have been shown to interact with the side-arms of phosphorylated NFs (Hirokawa, 1982, 
Wagner et al, 2003), which may allow mitochondria to be spaced at intervals in long axons to 
provide energy for metabolic processes.  
 
Another function of NFs is in the determination of dendritic architecture which is generally 
more dynamic in both developing and mature neurons and reflects the role of dendrites in 
neuronal plasticity (Kong et al, 1998). Neurofilaments have also been proposed to play a role 
in the regeneration of myelinated axons after peripheral nerve injury which is delayed in the 
absence of NFs (Zhu et al, 1997). 
 
1.5.2. Composition and assembly of neurofilaments 
 
Neurofilaments are composed of three separate protein subunits; NF-L (light, 68 kDa), NF-M 
(medium, 145-160 kDa) and NF-H (heavy, 190-210 kDa) which all have the same basic 
structure: an N-terminal head domain, a conserved alpha-helical rod domain of 310 amino 
acids and a variable length C-terminal domain (Perrot et al, 2008, Petzold, 2005). NFs are 
considered to be obligate heteropolymers because although NF-L can form homopolymers in 
vitro, these homopolymers are less mechanically stable and rely the inclusion of NF-M or 
NF-H to provide NFs with mechanical stability (Brown et al, 1998, Kim et al, 2007). NF-H 
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and NF-M are not capable of self-assembly and rely on the presence of NF-L (Chen et al, 
2000). Some redundancy in the functioning of NF-H and NF-M is suggested by the 
compensatory upregulation of NF-M and α-tubulin expression in mice lacking NF-H (Rao et 
al, 1998). 
 
The assembly of NFs occurs in five stages (figure 1.8): the central core domains of NF-L and 
either NF-H or NF-M are wound around each other to form heterodimers, which are then sorted 
in an anti-parallel fashion to form heterotetramers, two heterotetramers then come together to 
form protofibrils which are finally arranged in staggered, overlapping fashion to form the 
neurofilament (Janmey et al, 2003, Petzold, 2005).   
 
Figure 1.8 A schematic of the assembly of neurofilament subunits into neurofilaments.  
The NF subunits come together as Heterodimers. Heterodimers then associate with each other in an anti-
parallel fashion as heterotetramers. Heterotetramers associate to form protofibrils and then 4 protofibrils 
come together as neurofilaments. Figure adapted from Petzold et al (2005) and Janmey et al (2003).  
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Each NF is composed of four protofilaments which are intertwined helically to form the four-
stranded structure (Wen & Wisniewski, 1984). The C-terminal tails of NF-H and NF-M form 
side-arm projections that project from the core filament and form interconnections with other 
NFs (resulting in a parallel arrangement of NF filaments in the axon), MTs and organelles 
(Bocquet et al, 2009, Chen et al, 2000, Hirokawa, 1982, Nakagawa et al, 1995), the length of 
which increases with phosphorylation (Janmey et al, 2003). 
 
In mature neurons the stoichiometric ratio of NF-L:NF-M:NF-H is 7:3:2, suggesting that 
there are on average three NF-M/NF-L dimers to two NF-H/NF-L dimers and one NF-
L/NF-L dimer in a fully differentiated NF (reviewed by Janmey et al, 2003, and Perrot et 
al, 2008).  The importance of subunit stoichiometry for the maintenance of the NF 
network is highlighted by the decrease in NF-M and NF-H protein levels following the 
targeted disruption of NF-L gene expression (Zhu et al, 1997) and by the reduction in 
axonal calibre following the over-expression of each of the NF subunits individually, or 
co-expression NF-M and NF-H, in transgenic mice, which was only prevented by co-
expression of either NF-M or NF-H with NF-L (Xu et al, 1996). It is now accepted that 
other intermediate filaments such as α-internexin and peripherin co-assemble with NFs 
(Yan et al, 2007, Yuan et al, 2006), although which intermediate filaments associate often 
depends on the developmental stage (Yan et al, 2007).  
 
1.5.2. Control of neurofilament gene expression 
 
During neuronal development it has been established that neurofilament expression is 
preceded by and replaces the expression of vimentin in neuronal progenitor cells in the 
central and peripheral nervous systems (Bignami et al, 1982). However, for a time NFs and 
vimentin have been shown to coexist in radially orientated filaments of early bipolar 
neuroblasts in the mouse embryo (Cochard & Paulin, 1984) and for a limited period in the rat 
embryo (Bignami et al, 1982). In addition vimentin and NFs have also been shown to exist in 
both separate filaments and the same filament in differentiated PC12 cells and N2a cells 
(Yabe et al, 2003).  
 
NF-L is the first NF subunit expressed during neuronal development and is usually expressed 
with peripherin and α-internexin (Perrot et al, 2008). Peripherin does not polymerize with 
NF-M and NF-H and is usually downregulated in the CNS, although in the PNS it continues 
to be expressed (reviewed by Grant & Pant, 2000). Initially in developing neurons NF-L and 
NF-M are expressed whereas the expression of NF-H is delayed and associated with a more 
Chapter 1: General Introduction 
 33 
mature phenotype (Carden et al, 1987, Grant & Pant, 2000).  In cortical neurons the 
expression of NF-H was preceded by the expression of NF-L, NF-M and α-internexin 
providing further evidence for the delayed expression of NF-H during development (Yuan et 
al, 2009). 
 
The genes coding for NF-M and NF-L are closely linked on chromosome 8 whereas the NF-
H gene is found on chromosome 22. Several studies have suggested that the expression of 
NF-L and NF-M is mutually regulated and independent of NF-H (Grant & Pant, 2000, Perrot 
et al, 2008) providing a mechanism for the two-stage expression of NFs during development. 
 
1.5.3. Phosphorylation of neurofilament proteins 
 
The three NF subunits all contain multiple phosphorylation sites (Julien & Mushynski, 1982, 
Wong et al, 1984); up to 51 phosphorylation sites can be found on the C-terminus of NF-H. 
The head domains of NF-M and NF-L also contain protein kinase A (PKA), protein kinase C 
(PKC) and protein kinase N (PKN) phosphorylation sites (Ser44 for NF-M and Ser55 for 
NF-L) which become phosphorylated in the cell body soon after synthesis (Perrot et al, 2008, 
Sihag & Nixon, 1990) and are thought to regulate NF assembly by preventing the premature 
assembly of NFs (Manser et al, 2008).  
 
The C-terminal domains of NF-H and NF-M form side-arm projections which project from 
the filament and contain numerous KSP phosphorylation sites (repeats of Lysine-Serine-
Proline motifs) which become extensively phosphorylated in the axon (Nixon et al, 1987, 
Soussan et al, 1994). The kinases responsible for the phosphorylation of KSP sites in NF-M 
and NF-H are the proline directed kinases such as Cdk5 which is activated following the 
cleavage of p35 to p25 (Pant et al, 1997, Shea et al, 2004, Sun et al, 1996) and mitogen-
activated protein kinases (MAPK) such as Erk1/2 (extracellular signal related kinase), SAPK 
(stress activated protein kinase), GSKβ and p38 (Perrot et al, 2008). Erk1/2 and Cdk5 each 
preferentially phosphorylate NFs at different KSP motifs; the motif for which Erk1/2 has a 
higher affinity is KSPXXXK whereas Cdk5 has a higher affinity for KSPXK (Veeranna et al, 
1998). There are some species differences in the type of KSP motifs which predominate in 
NFs, for example in rat NF-H contains 41 KSPXXXK motifs which are preferentially 
phosphorylated by Erk1/2 (Veeranna et al 1998) whereas human NF-H which contains 34 
KSPXK motifs which are preferentially phosphorylated by Cdk5 (Pant et al 1997).  
 
The Ser-Thr residues of the glutamic acid region of the three NF subunits are phosphorylated 
by casein kinase I (CKI) and the Ser473 on the tail of NF-L is phosphorylated by casein 
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kinase II (CKII, reviewed by Perrot et al, 2008). Figure 1.9 is a cartoon diagram illustrating 
the general structure of the three NFs and position of phosphorylation sites and kinases 
responsible for phosphorylation. 
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Figure 1.9 A cartoon drawing illustrating the position of various phosphorylation sites on the three 
neurofilament subunits.  
The general structure of the three human neurofilament (NF) subunits with N-terminal head domain, 
conserved central core or rod domain and the variable length C-terminal tail domain. The glutamic acid 
rich regions are in green and the glutamic acid and lysine rich region in NF-H is indicated in red. The KSP 
sites are in orange and the various kinases responsible for the phosphorylation of NFs at various sites are 
indicated by the stars (Grant & Pant, 2000, Perrot et al, 2008). 
 
It has been suggested that the resulting repulsive forces of phosphorylated side-arm 
projections increases NF spacing and axon diameter (Sanchez et al, 2000). Work with mice 
lacking the tail domain of NF-H revealed that the C-terminus of NF-H is not essential for 
axonal growth, NF transport or the maintenance of axonal calibre (Rao et al, 2002, Yuan et 
al, 2006) suggesting some redundancy in the functioning of NF-H and NF-M. Redundancy in 
the functioning of NF-M and NF-H in radial growth was also suggested in mice lacking NF-
H in which increased NF-M phosphorylation compensated for the lack of NF-H (Sanchez et 
al, 2000). 
 
It is noteworthy that the NF population is not homogenously phosphorylated, instead a 
mixture of phosphorylation states from non-phosphorylated NFs to extensively 
phosphorylated NFs can be found in axonal structures (Brown, 1998). The phosphorylation 
of NFs is a dynamic process that involves both phosphorylation and dephosphorylation 
events that affect the associations and functioning of NFs as they progress along the axon 
(Nixon & Lewis, 1987, Nixon & Lewis, 1986). 
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1.5.4. Axonal transport 
 
Neurofilaments are synthesized in cell bodies and assembled into hetero-oligomers, which 
are then transported along the axon by a process called axonal transport (Nixon & Lewis, 
1986, Yabe et al, 1999, Yan et al, 2007, Yan & Brown, 2005, Yuan et al, 2003). Historically 
NFs have been described as being transported by slow axonal transport (1 mm/d) (reviewed 
in Chou & Goldman, 2000), but the current concensus is that NFs are transported rapidly (0.6 
µm/s) but intermittently, accounting for an overall transport rate consistent with slow axonal 
transport (Brown et al, 2005, Lasek et al, 1993, Roy et al, 2000, Trivedi et al, 2007, Yuan et 
al, 2003). The vast majority of NF subunits are associated with the stationary NF network 
with only a small proportion (as little as 8 %) of NFs at any one time being associated with 
the more motile NF population (Brown et al, 2005, Nixon & Logvinenko, 1986). 
Ultrastructural studies of mouse N2a cells revealed a core of triton-insoluble NFs that are 
more closely bundled together than peripheral populations and exhibited increased reactivity 
to RT97 (which recognises developmentally delayed pNF-H). Newly synthesized and motile 
NFs were associated with the peripheral populations which were not as closely bundled 
(Yabe et al, 2001).  
 
Several studies have provided evidence for the involvement of motor proteins in the axonal 
transport of NFs. The actin-based motor protein myosin (Jung et al, 2004) and the 
microtubule motor protein kinesin (most likely kinesin 5a) have been implicated in the 
anterograde transport of NFs (Jung et al, 2005, Theiss et al, 2005, Xia et al, 2003, Yabe et al, 
1999). The motor protein dynein has been implicated in the retrograde transport of NFs 
within the axon and the initial anterograde transport of NFs just as they enter the axon from 
the cell body (He et al, 2005, Motil et al, 2006, Motil et al, 2007, Theiss et al, 2005, Wagner 
et al, 2004).  
 
Work with GFP tagged NFs has also shown that when NFs enter the growth cone they 
immediately change direction and quickly move back in the retrograde direction into the 
axon often at rates faster than their entry into the growth cone (Uchida & Brown, 2004) and 
that NFs entering the growth cone are more dynamic, soluble and less phosphorylated and 
participate in the remodelling of the cytoskeleton during axonal elongation (Chan et al, 
2003). 
 
Phosphorylation plays an important role in this transport process although the exact 
mechanism is still not fully resolved. The phosphorylation status of the C-terminal domain of 
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NF-H and NF-M appears to affect NF transport rate. This is most likely due to the 
dissociation of phosphorylated NFs from the anterograde motor protein (Jung et al, 2005, 
Yabe et al, 2000), resulting in a greater association with the stationary axonal cytoskeleton 
(Ackerley et al, 2003). The kinase implicated in the regulation of axonal transport is Cdk5 
since inhibition of Cdk5 in cortical neurons increased the transport rate of NFs (Ackerley et 
al, 2003, Moran et al, 2005, Shea et al, 2004). Further evidence of the effect of 
phosphorylation on NF transport is the decrease in NF-H transport in retinas following in situ 
phosphatase inhibition (Shea et al, 2003). 
 
1.5.5. Neurofilaments in ageing and neurodegeneration 
 
Age-related biochemical changes in NFs include the increased appearance of 
hyperphosphorylated NFs with ageing (Gou et al, 1995), which may be due to a decline in 
the activity of protein phosphatase 2A (PP2A; Veeranna et al, article in press). Furthermore 
NFs from aged rats were shown to contain more NF-H/NF-L than NF-M/NF-L and 
ultrastructural studies of NFs revealed that in the sciatic nerves and spinal cord of aged rats, 
NFs are more densely packed than in young rats (Uchida et al, 1999).  
 
Abnormal accumulations of NFs have been reported in other neurodegenerative conditions 
and as a result of toxin treatment. As mentioned earlier NFs are major components of LBs 
(Forno et al, 1986) and aberrant NF phosphorylation and accumulation has been reported in 
AD (Anderton et al, 1982, Sternberger et al, 1985, Su et al, 1996). Most familial AD cases 
are the result of mutations in presenilin-1 which when expressed in N2a cells prevented the 
formation of a filamentous NF network and instead resulted in accumulations of NFs in the 
cell body (Dowjat et al, 2001). 
 
Charcot-Marie-Tooth disease is characterised by mutations in NF-L which have been shown 
to result not only in the defective axonal transport of NFs and their accumulation in 
inclusions in the cell body but also in the accumulation of mitochondria in the cell body co-
localizing with the mutant NF-L inclusions (Brownlees et al, 2002, Pérez-Ollé et al, 2005). In 
mouse primary cultured motor neurons the expression of CMT-associated mutant NF-L 
resulted in a reduction in cell viability and an aggregation of NF-L in the cell body (Zhai et 
al, 2007). 
 
Abnormal accumulations of NFs are also a prominent pathological feature of amyotrophic 
lateral sclerosis (ALS or motor neuron disease). Disease progression in transgenic mice 
expressing an ALS-associated mutation in Cu2+/Zn2+ superoxide dismutase (SOD1) was 
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slower in mice also lacking NF-L suggesting a role for NFs in the pathogenesis of ALS 
(Williamson et al, 1998). Aberrant phosphorylation of neurofilaments in ALS may be 
induced by the stress activated protein kinase p38α, the active form of which closely 
associates with NF accumulations in ALS (Ackerley et al, 2004). In addition, a role for Cdk5 
in the aberrant phosphorylation of NFs in ALS was also suggested by immunostaining which 
revealed higher levels of Cdk5 in the spinal motor neurons of SOD1 mutant mice than in 
wild-type mice, accompanied by elevated levels of p25 compared to p35 (suggesting Cdk5 
activation) and NF hyperphosphorylation (Nguyen et al, 2001). 
 
In Neuronal Intermediate Filament Inclusion disease (NIFID), a fairly newly described 
condition with frontotemporal dementia and gliosis. Neuronal loss is characterised 
pathologically by severe anterior lope and caudate atrophy and the presence of inclusion 
bodies containing NFs and α-internexin (Josephs et al, 2003, Molina-Porcel et al, 2008).   
 
Exposure to environmental toxins has also been implicated in neurodegenerative conditions 
associated with NF abnormal phosphorylation and aggregation. NF accumulations induced 
by arsenic treatment may be due to its inhibitory effect on NF transport and activation of 
Cdk5 and JNK-1 (DeFuria & Shea, 2007). The accumulation of NFs has also been reported 
in rabbit spinal motor neurons (Kimura et al, 2007) and N2a cells following treatment with 
aluminium (Shea et al, 1997) and in SH-SY5Y cells treated with 2,5-hexadione (a neurotoxic 
metabolite of hexane) and acrylamide (Hartley et al, 1997). Aberrant activation of Cdk5 
(Wang et al, 2006b) and an accumulation of NFs (Gupta et al, 2000) were observed in 
organophosphate-induced delayed neuropathy (OPIDN) in hens. In differentiating mouse 
N2a cells, subcytotoxic MPTP treatment resulted in an inhibition of axonal outgrowth and an 
increase in NF-H phosphorylation mediated by c-Jun-NH2-terminal kinase (JNK) activation 
which when inhibited attenuated the MPTP-induced reduction in axonal outgrowth (De 
Girolamo & Billett, 2006). 
 
1.6. SH-SY5Y cells 
 
SH-SY5Y neuroblastoma cells are the thrice cloned derivative of the SK-N-SH cell line 
(Biedler et al, 1978), originally established in 1970 from a bone marrow biopsy of a 4 year 
old female patient with neuroblastoma (Biedler et al, 1973). The SK-N-SH parental cell line 
is composed of at least two distinct subclones that differ morphologically and biochemically 
from each other. One is a neuroblastic cell type (N-type) with a small amount of cytoplasm 
and delicate cell processes of variable length while the other is a larger epithelioid cell type 
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(S-type) (Biedler et al, 1973). The relative composition of the N and S cell types in the SK-
N-SH cell line is largely dependent on culture conditions which favour one cell type over 
another (Sadée et al, 1987). Three subclones of the original parental cell line have been 
established; the SH-SY5Y cell line composed predominantly of the N-type cells, the SH-EP 
cell line composed predominantly of S-type cells and the SH-IP cell line composed of an 
intermediate cell type (Biedler et al, 1978).  
 
The SH-SY5Y neuroblastoma cell line expresses the muscarinic cholinergic receptor, the µ 
and δ opioid receptors, dopamine-β-hydroxylase, tyrosine hydroxylase (Biedler et al, 1973, 
Biedler et al, 1978, Sadée et al, 1987) and MAOA (Fitzgerald et al, 2007) and are able to 
take up and produce DA (Sadée et al, 1987). These attributes have contributed to the use of 
both differentiated and undifferentiated SH-SY5Y neuroblastoma cells as models for 
dopaminergic neurons.  
 
Differentiation of SH-SY5Y cells (discussed in more detail in chapter 5) is most often 
accomplished by either treating cells with retinoic acid (RA) alone or treating cells 
sequentially with RA and brain derived neurotrophic factor (BDNF).  Arguments supporting 
the use of differentiated cells as a PD model include (a) the more mature homogeneous 
phenotype exhibited by the cells, (b) higher levels of DAT, TH and dopamine-β-hydroxylase 
(Xie et al, 2010) and (c) the inability of cells to divide prevents cells from diluting out 
protein aggregates between daughter cells (Hasegawa et al, 2004). The validity of the use of 
undifferentiated cells as a PD model is argued by the observed increased tolerance of RA 
differentiated cells to PD mimetics due to the upregulation of survival signalling (Cheung et 
al, 2009). 
 
1.7. Aims 
 
Although NFs were the first protein components identified in LBs (Forno et al, 1986, 
Galloway et al, 1988, Galloway et al, 1992), their role in PD pathogenesis and LB formation 
is still not fully understood. Altered NF expression was dismissed as a contributory factor in 
LB formation by Bergeron et al (1996) due to a lack of changes in NF-L mRNA levels in 
patients with PD or DLB compared to controls. However, this work did not look at changes 
in protein levels which may be affected by decreased or increased proteolysis or at post-
translational modifications which may alter NF functioning and distribution. Since the 
discovery of mutations in α-synuclein in familial PD (Kruger et al, 1998, Polymeropoulos et 
al, 1997) and the presence of α-synuclein in LBs of idiopathic PD (McNaught et al, 2002) 
focus in PD research switched from NFs to α-synuclein.  
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Since then research has also concentrated on mitochondrial dysfunction and oxidative stress 
(reviewed by Schapira, 2009), protein aggregation and defects in protein degradative 
pathways (reviewed in Bedford et al, 2008, Robinson, 2008, and Schneider & Zhang, 2010) 
and axonal transport (Ittner et al, 2008, Morfini et al, 2007, Saha et al, 2004) and how all 
these pathways interact in disease pathogenesis (reviewed in Keller et al, 2004, Malkus et al, 
2009). The identification of a rare mutation in the rod domain of NF-M in familial PD in a 
French/Canadian family which resulted in abnormal NF assembly (Lavedan et al, 2002) 
renewed interest in NFs in PD. However since three relatives heterozygous for the same 
mutation failed to develop PD, the mutation in NF-M may increase disease susceptibility 
rather than being a primary cause.  Aberrant accumulations of NFs have been reported in 
several other neurodegenerative conditions including ALS, CMT disease, AD, NIFID and 
OPIDN. Several unanswered questions remain concerning the role of NFs in PD and LB 
pathology and the aims of this project were to address some of these questions. 
 
Very little is known about the degradative pathways involved in NF turnover in healthy cells 
and whether defects in these pathways could contribute to the accumulation of NFs in LBs. 
To address this question, the effects of PD mimetics (MPP+ and DA) on degradative 
pathways and their involvement in NF degradation was investigated in proliferating SH-
SY5Y neuroblastoma cells.  
 
Secondly, to establish a model in which the effects of PD mimetics on NF distribution could 
be investigated in live cultures in real-time, green fluorescent protein (GFP) tagged human 
NF subunits were produced. Preliminary work using this model concentrated on investigating 
the effects of acute MPP+ toxicity on NF distribution. In addition, the feasibility of using the 
GFP tag in co-immunoprecipitation experiments to identify NF associating proteins was 
investigated. 
 
Thirdly, to investigate the role of NFs in aggresome and inclusion formation it was necessary 
to develop a cellular model of inclusion formation. Since differentiated SH-SY5Y 
neuroblastoma cells develop inclusions more readily than undifferentiated cells (Hasegawa et 
al, 2004, reviewed in Robinson, 2008), SH-SY5Y cells were differentiated with retinoic acid 
(RA) and brain derived neurotrophic factor (BDNF). To induce inclusion formation, 
RA/BDNF differentiated cells were treated with MPP+, epoxomicin (proteasome inhibitor) 
or MPP+/epoxomicin and the effects of these treatments on the levels and distribution of NFs 
and the ability to produce inclusions was compared. 
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2.1. Materials 
2.1.1. Cell culture  
2.1.1.1. Reagents 
Dulbecco’s Modified Eagles Medium/F12 Ham, DMEM/F12 (12-719F); Penicillin-
Streptomycin (17-603E); Foetal bovine serum (14-801F); L-glutamine (17-605E), Trypsin-
EDTA (02-007E) purchased from Lonza, Berkshire, UK 
DMEM/F12 (D6421); DMEM/F12 without phenol red (D6434); MEM non-essential amino 
acid solution (M7145); Hybri-max sterile filtered dimethyl sulfoxide, DMSO (D2650); 
trypan blue solution (0.4 %, T8154) purchased from Sigma-Aldrich, Poole, UK  
Gibco Opti-MEM® I Reduced Serum Medium without phenol red purchased from 
Invitrogen Ltd (11058-021) 
Dulbecco’s Phosphate Buffered Saline (DPBS) from PAA Laboratories Ltd (H15-002) 
2.1.1.2. Plastic ware 
Cell culture flasks (T25, T75 and T125), 6 well plates and 96 well plates were supplied by 
Sarstedt, Leicester, UK 
ibidi µ-dish ibiTreat tissue culture treated, sterile, 35 mm from Thistle Scientific Ltd, 
Glasgow, UK (806136) 
BD Biocoat™ Poly-D-Lysine 8-well culture slides purchased from SLS Ltd, Nottingham 
UK (354632) 
Nunc Lab-Tek 8 well sterile permanox chamber slide purchased from SLS Ltd, Nottingham 
UK (177445) 
BD tissue culture dish (100 x 200 mm) purchases from SLS Ltd, Nottingham UK 
IWAKI 35 mm glass base dish, 27 mm diameter purchased from SLS Ltd, Nottingham UK 
(TIS5450) 
2.1.2. Laboratory reagents 
Adenosine 5’-triphosphate, ATP from Sigma-Aldrich (A3377) 
Bicinchoninic Acid (BCA) Kit from Sigma-Aldrich (BCA1-1KT) 
Bio-Rad protein assay dye reagent concentrate from BioRad Laboratories Ltd, 
Hertfordshire, UK (500-0006) 
BC Assay from Cheshire Sciences UK (UP40840A) 
Bovine serum albumin, lyopholized powder, BSA from Sigma-Aldrich (A2153) 
Igepal CA-630 from Sigma-Aldrich (I3021) 
Dimethyl sulfoxide, DMSO from Sigma-Aldrich (472301) 
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Triethylamine, TEA from Sigma-Aldrich (471283) 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoulium bromide, MTT from Sigma-Aldrich 
(M2128) 
All-trans retinoic acid from Sigma-Aldrich (R2625) 
µMACS™ Epitope Tag (GFP) Protein Isolation Kits from Miltenyi Biotec Ltd (130-091-
125) 
Recombinant Human Brain Derived Neurotrophic Factor (BDNF) from Miltenyi Biotec Ltd 
(130-093-811) 
HALT™ protease inhibitor cocktail - used at 1:100 from ThemoFisher Scientific (78430) 
HALT phosphatase inhibitor cocktail - used at 1:100 from ThermoFisher Scientific (78428) 
SDS-PAGE and Western blotting reagents 
Biotinylated Protein Ladder, 9-200 kD from Cell Signaling Technology (#7727) 
Dual colour Prestained Precision Plus Protein™ Standards, 10-250 kD from BioRad 
Laboratories Ltd, Hertfordshire, UK (#161-0374) 
Pierce ECL Western blotting substrate from ThermoFisher Scientific (32106) 
Uptima Uptilight™ High sensitivity WB Chemiluminescent Substrate from Cheshire 
Sciences (UK) Ltd (98490B) 
Restore Plus Western blot stripping buffer from ThermoFisher Scientific (46430) 
Copper phthalocyanine 3, 4’, 4’’, 4’’’ tetrasulphonic acid tetrasodium salt from Sigma-
Aldrich  (245356) 
Acrogel-3-solution (40 % solution) acrylamide from BDH, Poole UK (443735T) 
Accugel 29:1 (40 % solution) acrylamide from GeneFlow Ltd UK (A20068) 
Dithiothreitol (DTT) from Melford Laboratories Ltd (MB1015) 
2D-PAGE and mass spectrometry reagents 
ReadyStrip™ IPG strips, pH 3 - 10, 7 cm from BioRad Laboratories Ltd, Hertfordshire, UK 
(163-2000) 
Unstained Protein Ladder, 10-250 kD from New England Biolabs Inc (P7703S) 
Silver staining kit from Fisher Scientific (GZ17115001) 
LC-MS Grade Acetonitrile (ACN) from Fisher Scientific (A/0600/15) 
LC-MS Grade water from Fisher Scientific (W/0112/15) 
Trifluoracetic acid (TFA) from Fisher Scientific (T/3258/04) 
Mineral Oil, Biotechnology Grade from BioRad Laboratories Ltd, Hertfordshire, UK (163-
2129) 
Fluorogenic peptide substrates 
N-Succinyl-Leu-Leu-Val-Tyr-AMC (7-amino-4-methylcoumarin) – CLA substrate used at 
50 µM - stored as 40 mM in DMSO at -20°C which are diluted to 1 mM in assay buffer 
before use purchased from Enzo Life Sciences, Exeter, UK (BML-P802). 
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Z-Phe-Arg-AMC (7-amino-4-methylcoumarin) - OmniCathepsin™ fluorogenic substrate 
cleaved by cysteine cathepsins B, C/DPP-I, F, L2/V, L, O, S, X/Z used at 200 µM - stored 
at -20°C as 50 mM stocks in DMSO which are diluted to 10 mM in assay buffer before use 
purchased from Enzo Life Sciences, Exter, UK ( BML-P139). 
Cathepsin L activity assay kit (fluorometric) purchased from abcam, Cambridge UK 
(ab65306) 
Cathepsin D activity assay kit (fluorometric) purchased from abcam, Cambridge UK 
(ab65302) 
Horse radish peroxidise (HRP) and alkaline phosphatase (AP) conjugated Secondary 
Antibodies 
Polyclonal goat anti-mouse IgG HRP conjugated antibody from DakoCytomation, 
Cambridgeshire, UK (PO447) 
Polyclonal goat anti-rabbit IgG HRP conjugated antibody from DakoCytomation, 
Cambridgeshire, UK (PO448) 
Polyclonal rabbit anti-goat IgG HRP conjugated antibody from DakoCytomation, 
Cambridgeshire, UK (PO449) 
Polyclonal bovine anti-goat IgG (H + L) HRP conjugated antibody from Stratech Scientific 
Ltd, Suffolk UK (805-035-180) 
Polyclonal horse anti-mouse IgG, AP conjugated antibody from Cell Signalling 
Technology (#7056) 
Polyclonal goat anti-rabbit IgG, AP conjugated antibody from Cell Signalling Technology 
(#7054) 
Polyclonal goat anti-mouse IgG AP conjugated antibody from DakoCytomation, 
Cambridgeshire, UK (DO486) 
Imunofluorescence secondary antibodies and nuclear and organelle stains 
VECTASHIELD anti-fade mountant containing Propidium Iodide from Vector 
Laboratories Ltd (H-1300) 
VECTASHIELD anti-fade mountant from Vector Laboratories Ltd (H-1000) 
Prolong Gold antifade with Dapi from Invitrogen Ltd (P36935) 
Alexa fluor 568 donkey anti-sheep IgG from Invitrogen Ltd (A21099) 
Alexa fluor 488 donkey anti-sheep IgG from Invitrogen Ltd (A11015)  
Alexa fluor 568 donkey anti-rabbit IgG from Invitrogen Ltd (A10042) 
Alexa fluor 488 donkey anti-mouse IgG from Invitrogen Ltd (A21202) 
Alexa fluor 568 donkey anti-goat IgG from Invitrogen Ltd (A11057) 
Alexa fluor 488 goat anti-mouse IgG from Invitrogen Ltd (A11001) 
Alexa fluor 568 Goat anti-mouse IgG from Invitrogen Ltd (A11004) 
Alexa fluor 488 goat anti-rabbit IgG from Invitrogen Ltd (A11008) 
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Molecular biology reagents 
SensiMix™Plus SYBR Kit from Quantace (QT605) 
QuikChange® XL Site-Directed Mutagenesis Kit from Stratagene 
QIAprep® Spin Miniprep Kit from QIAGEN HOUSE (27106) 
QIAquick® Plasmid Midi Kit from QIAGEN HOUSE (12143) 
QIAquick® Gel Extraction Kit from QIAGEN HOUSE (28704) 
RNAeasy mini-kit from QIAGEN HOUSE (74104) 
E.coli TOP10 competent bacteria from Invitrogen Ltd  
Kanamycin sulphate from Streptomyces kanamyceticus (K4000) from Sigma-Aldrich  
TOPO TA Cloning Kit with pCR-2.1 TOPO vector and E.coli TOP10 competent cells from 
Invitrogen Ltd (K4500-01) 
FastDigest™ EcoRI from Fermentas UK (FD0274) 
FastDigest™ KpnI from Fermentas UK (FD0524) 
FastDigest™ HindIII from Fermentas UK (FD0504) 
6 x DNA loading dye from Fermentas UK (R0611) 
PrimeSTAR™ HS DNA Polymerase 
TopVision™ LE GQ Agarose from Fermentas UK (R0491) 
AcuPrime™ Taq DNA Polymerase System from Invitrogen Ltd (12339016) 
LipofectAMINE™2000 transfection reagent from Invitrogen (11668-019) 
Superscript II reverse transcriptase from Invitrogen Ltd (18064014) 
Advantage®-GC Genomic PCR kit (Clontech, TAKARA) 
Platinum PCR SuperMix (Invitrogen) 
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Table 2.1 List of Toxins and inhibitors used 
Compound Function 
Working 
Concentration 
Purchased from 
1-methyl-4-phenylpyridinium 
(MPP+) iodide (solid), 
100mM stock solution in 
DMEM/F12 stored at -20ºC 
Inhibitor of complex I of 
electron transport chain in 
oxidative phosphorylation 
10 µM – 5 mM 
Sigma-Aldrich 
(D048) 
Epoxomicin (solid), 1 mM 
stock solution solubilised in 
DMSO and stored at -20ºC 
Irreversible specific 
inhibitor of 20S 
proteasome 
5 – 10 nM Enzo (PI-127) 
Calpain Inhibitor III, 
Carbobenzoxy-valinyl-
phenylalininal, MDL28170; 10 
mM stock solution solubilised 
in DMSO and stored at -20 ºC 
Cell permeable inhibitor of 
calpain I and II (Ki = 8 
nM). Sequence Z-Val-Phe-
CHO 
10 µM 
Merck Chemicals Ltd 
(208722) 
Bafilomycin A1 from 
Streptomyces griseus (solid), 
10 µM stock solution , 
solubilised with DMSO and 
stored at -20 ºC 
Inhibitor of autophagy, 
inhibits fusion of 
autophagosome and 
lysosome 
5 – 10 nM 
Sigma-Aldrich    (B 
1793) 
3-methyl adenine, 3-MA 
(solid), stock solution of 50 
mM, prepared in SFM by 
heating to 55 °C to solubilise 
Inhibitor of autophagy 5 mM 
Sigma-Aldrich 
(M9281) 
Rapamycin from Streptomyces 
hygrosopicus 
(2.5 mg/ml in DMSO) 
Inhibits mTOR, thereby 
activating macroautophagy 
0.2 µg/ml 
Sigma-Aldrich 
(R8781) 
InSolution™ Cyclohexmide  
(100 mg/ml in DMSO) 
Inhibitor of new protein 
synthesis 
10 µg/ml 
Merck Chemicals Ltd 
(239765) 
Pepstatin A, synthetic (solid), 
1 mM stock solution 
solubilised with DMSO and 
stored at -20 ºC 
Reversible inhibitor of 
aspartic proteases. Inhibits 
cathepsin D, pepsin and 
rennin. 
1 µM 
Merck Chemicals Ltd 
(516481) 
Cathepsin Inhibitor II  
(Z-Phe-Gly-NHO-Bz-pMe) 
(solid), 10 mM stock solution 
solubilised in DMSO and 
stored at -20 ºC 
Cysteine protease inhibitor. 
Selectively inhibits 
cathepsin B, L, S and 
papain 
10 µM 
Merck Chemicals Ltd  
(219417) 
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Table 2.2  List of antibodies detailing their use, characteristics, the applications for which and concentration at which they were used and company they were 
purchased from 
Concentration used in each application 
Name 
Specificity 
(immunogen) 
Host species 
WB IF IP 
Purchased 
from 
Anti-γ-
tubulin 
γ-tubulin,48 kDa; 
reacts with human and mouse (synthetic peptide 
EEFATEGTDRKDVFFY-K, corresponding to amino acids 38-53 of 
human γ-tubulin) 
Rabbit, 
polyclonal 
antiserum 
1:2000  ND Sigma (T3559) 
B512 
α-tubulin, 50 kDa; reacts  with a variety of organisms including human, 
mouse and rat; recognises an epitope at C-terminal end (sarkosyl-
resistant filaments from sea urchin) 
Mouse, 
monoclonal 
1:2000 1:200 ND Sigma (T6074) 
Anti-actin 
Actin, 42 kDa; reacts with a variety of organisms including human (C-
terminal actin fragment with sequence SGPSIVHRKCF) 
Rabbit, affinity 
isolated antigen 
specific 
1:1000 1:100 ND 
Sigma 
(A2066) 
RV202 
Vimentin, 57 kDa; reacts with human, mouse, rat, chicken, dog, goat, 
hamster, monkey and cow (vimentin extract of calf lens) 
mouse, 
monoclonal 
1:5000 1:500 ND 
abcam 
(ab8978) 
N52 
NF-H, phosphorylated and non-phosphorylated, 200 kDa; reacts with 
human, mouse; recognises an epitope at the caboxyterminal tail segment 
Mouse, 
monoclonal 
1:2000 1:200 ND 
Sigma          
(N0142) 
smi32 
non-phosphorylated NF-H, 200 kDa; reacts with mouse and rat,  
(hypothalamus from Fischer 344 rats) 
Mouse, 
monoclonal 
1:1000 1:200 ND 
abcam 
(ab28029) 
 
RMO270 
NF-M, phosphorylated and non-phosphorylated, 160 kDa; reacts with 
phosphate independent epitope in C-terminal domain. Reacts with 
human; (Rat neurofilaments) 
Mouse, 
monoclonal 
(ascites) 
1:500 1:50 ND 
Invitrogen 
(13-0700) 
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Table 2.2. (continued) 
Concentration used in each application 
Name 
Specificity 
(immunogen) 
Host species 
WB IF IP 
Purchased 
from 
smi31 
pNF-H and pNF-M, 200 kDa and 160 kDa; reacts with mammalian, 
Xenopus, chicken (homogenisized hypothalami from Fischer 344 rats) 
Mouse, 
monoclonal, 
ascites 
1:1000 1:200 ND 
abcam 
(ab24573) 
RT97 
pNF-H, 200 kDa, developmentally delayed; reacts with human and rat 
(Triton X-100 insoluble rat brain protein) 
Mouse, 
monoclonal 
1:50 ND ND 
abcam 
(ab17126) 
RNF403 
pNF-M, 160 kDa; reacts with human and rat, reacts exclusively with 
pNF-M (NF preparation from calf brain tissue) 
Mouse, 
monoclonal 
1:500 1:50 ND 
abcam 
(ab9271) 
DA2 
NF-L, 68 kDa; reacts with human NF-L (purified and dephosphorylated 
pig NF-L) 
Mouse, 
monoclonal, 
ascites 
1:2000 1:200 ND 
Invitrogen  
(13-0400) 
Anti-Kinesin 
5A 
Kinesin 5A, 110 kDa; reacts with human, mouse, rat, cow (the synthetic 
peptide CGYEAEDQAKLFPLHQETAAS corresponding to amino acids 
1007-1027 of mouse Kinesin 5A) 
Rabbit, 
polyclonal 
1:1000 1:100 ND 
abcam 
(ab5628) 
Anti-Kinesin 
5C 
Kinesin 5C, 110 kDa; reacts human and rat (Synthetic peptide 
AVHAIRGGGGSSSNSTHYQK corresponding to amino acids 938-957 
of human kinesin 5C) 
Rabbit, 
polyclonal 
1:1000 1:100 ND 
abcam 
(ab5630) 
Dynein 70.1 
Dynein, 70 kDa; reacts with a variety of species including human and 
rat, (cytoplasmic full length native protein purified from chick brain) 
Mouse, 
monoclonal 
1:2000 1:200 ND 
abcam 
(ab6304) 
anti-GFP GFP, 27-30 kD; reactive against all variants of Aequorea victoria GFP 
(highly purified recombinant GFP) 
Rabbit, 
polyclonal 
1:5000 - 
1:10 000 
ND ND Abcam 
(ab6556) 
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Table 2.2. (continued) 
Concentration used in each application 
Name 
Specificity 
(immunogen) 
Host species 
WB IF IP 
Purchased 
from 
anti-α-
synuclein  
(C-20) 
α-synuclein, 19 kDa; reacts with human 
Rabbit, 
polyclonal 
1:1000 1:100 ND 
Santa Cruz 
(sc-7011-R) 
anti-Cdk5  
(C-8) 
Cdk5, 30 kDa; reacts with mouse, rat and human (recombinant peptide 
found in C-terminus of human Cdk5) 
Rabbit, 
polyclonal 
1:100 ND ND 
Santa Cruz 
(sc-173) 
Bcl-2-100 
Human Bcl-2, 26 kDa 
(synthetic peptide corresponding to amino acids 41-54 of Bcl-2 
conjugated to thyroglobulin) 
Mouse, 
monoclonal 
ascites fluid 
1:1000 ND ND 
Sigma (B 
3170) 
anti-pAkt 
Phosphorylated Akt (Ser473), 60 kDa; reacts with human, mouse and 
rat (synthetic phosphopeptide corresponding to residues around Ser473 
of mouse Akt) 
Rabbit, 
monoclonal 
1:1000 ND ND 
Cell Signalling 
Technology 
(193H12) 
Anti-NTRK2 NTrk2/NTrkB, 90-100 kDa; reacts with human 
Rabbit, affinity 
isolated 
1:200 ND ND 
Sigma Prestige 
Antibodies 
(HPA007637) 
CTD19 
Cathepsin D, 52 and 34 kDa; reacts with human (native protein purified 
from human liver) 
Mouse, 
monoclonal 
1:1000 1:200 ND 
abcam 
(ab6313) 
Anti-LC3B 
LC3B, 16-18 kDa; reacts with human, rat and mouse (synthetic peptide 
corresponding to amino acids 2-15 of human LC3B) 
Rabbit, affinity 
isolated 
1:1000 1:100 ND Sigma (L7543) 
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Table 2.2. (continued) 
Concentration used in each application 
Name 
Specificity 
(immunogen) 
Host species 
WB IF IP 
Purchased 
from 
Anti-PSMC1 
PSMC1, 50 kDa; 26S protease regulatory subunit 4, reacts with 
human 
Rabbit, affinity 
isolated 
1:2000 1:100 ND 
Sigma Prestige 
Antibodies 
(HPA000872) 
anti-p62 
SQSTM1 
p62 (SQSTM1),  62 kDa, recognises human p62, (peptide derived from 
residues 387-436 in the UBA domain)  
Rabbit, 
polyclonal 
1:1000 1:100 ND 
Enzo (BML-
PW9860 
anti-Hsc70 
(HSP70), 
clone BRM-
22 
Hsp70, 70 kD; bovine, human, rat, rabbit, chicken, guinea pig, 
drosophila, nematode and plant (bovine brain Hsp70) 
Mouse 
monoclonal, 
ascites 
1:5000 ND ND 
Sigma 
(H5147) 
anti-α-Fodrin 
(clone AA6) 
α-Fodrin or αII-spectrin,  240 - 280 kDa and cleavage products  120 – 
145 kDa; reacts with a variety of species including human (chicken 
blood cell membranes following hypotonic lysis and mechanical 
enucleation) 
Mouse, 
monoclonal 
1:5000 ND ND BIOMOL 
(FG 6090) 
CUB 7402 Transglutaminase 2 (TG2), 77-85 kDa, reacts with guinea pig, dog, 
rabbit and human (purified guinea pig TG2) 
Mouse, 
monoclonal 
1:1000 1:100 ND abcam 
(ab2386) 
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2.1.3. Specialist laboratory consumables 
Black 96 well microplates purchased from Greiner Bio-One Ltd UK (655076) 
µ Columns for µMACs protein isolation kits from Miltenyi Biotec Ltd (130-042-701) 
Chromatography paper (3 mm) purchased from Fisher Scientific (CJF240090) 
Sterilin inoculation loops (10 µl) purchased from Fisher Scientific (DIS-101-026V) 
Fisherbrand immersion oil purchased from Fisher Scientific (FB69193) 
0.22 µm pore nitro-pure nitrocelluose purchased from Genetic Research Instrumentation 
(WP2HY00010) 
Sterilin sero 96 well microtitre plates purchased from SLS (MIC9008) 
2.1.4. Specialist equipment 
Aida image Analyser v 4.03 software (Raytek Scientific Ltd, Germany) 
ATTO HorizBlot semi-dry blotter (ATTO corporation, Japan) 
Beckman Coulter DU 530 Life Science UV/VIS Spectrophotometer (Beckman, UK) 
Bio-Rad Spectrophotometer – Model 680 Microtitre plate reader 
CBS Isothermal liquid nitrogen storage system 2300 series (Sanyo Biomedical Division, 
UK) 
Consort mini power supply (GeneFlow, UK) 
Power Pac mini power supply (Bio-Rad Laboratories Ltd, UK) 
Mini-wet blotter (GeneFlow, UK) 
FLUOstar OPTIMA (BMG LABTECH, UK) 
FujiFilm FLA-5100 gel scanner (FujiFilm Life Sciences Products, UK) 
FujiFilm Intellegent dark box (FujiFilm Life Sciences Products, UK) 
Mini-Protean III (Bio-Rad Laboratories, UK) 
Mini-Protean tetra (Bio-Rad Laboratories, UK) 
Ohaus Scout Pro Balance (Fisher Scientific UK) 
MIKRO 22R microfuge (Hettich, Germany) 
Ultraflex III TOF/TOF (Brucker Daltonics Ltd UK) 
iBlot (Invitrogen) 
Sanyo CO2 incubator MCO-17AIC (Sanyo Gallencamp PLC, UK) 
Stuart orbital incubator S150 
Leica CLSM Laser Confocal Scanning Microscope (Leica, Germany) 
Leica Inverted CLSM laser confocal microscope (Leica, Germany) 
Leica IRE2 time-lapse fluorescence microscope with full-stage incubation (Leica, 
Germany) 
Olympus BX51 Fluorescence Microscope (Olympus, Japan) 
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Olympus Mercury lamp U-RFL-T (Olympus, Japan) 
Nikon Digital Net camera DN100 (Nikon, Japan) 
Nikon Eclipse TS 100 inverted microscope (Nikon, Japan) 
Rotor-gene 3000 Thermal cycler (Corbett Research, Germany) 
Soniprep 150 (MSE scientific instruments, UK) 
Walker class II microbiological safety cabinet (Walker safety cabinets, UK) 
Quartz Cuvette, ultra micro absorbtion cell, path length10 mm, 50 µl volume purchased 
from Hellma (105.202-QS) 
Philips pH meter - PW9409 (Pye-Unicam, UK) 
Olympus CK2 ULWCD light microscope (Olympus, Japan) 
MACS multistand from Miltenyi Biotec, Germany (016708) 
µMACS™ Seperator from Miltenyi Biotec, Germany (130-042-602) 
 
2.2. Methods 
2.2.1. Cell culture 
2.2.1.1. Maintenance of SH-SY5Y neuroblastoma cells 
Cells were maintained at 37ºC in a humidified atmosphere of 95 % air, 5 % CO2. 
Proliferating Human SH-SY5Y neuroblastoma cells were maintained in normal growth 
medium containing 10 % (v/v) heat inactivated foetal bovine serum, DMEM/F12, 1 % (v/v) 
MEM non-essential amino acids, 2 mM L-glutamine, 200 units/ml penicillin and 200 µg/ml 
streptomycin. Cells were maintained until they reached 85-90 % confluency before 
subculture. For maintenance and expansion, cells were grown in either T75 or T175 flasks. 
2.2.1.2. Subculture of SH-SY5Y neuroblastoma cells 
Once cells reached around 85-90 % confluency they were detached by trypsinization using 
1 x Trypsin in Dulbecco’s Phosphate Buffered Saline (DPBS). The cell monolayer was 
washed twice with DPBS to remove all traces of serum and detached with 1 x 
Trypsin/DPBS solution at 37ºC for 3-5 minutes. Trypsin was quenched by the addition of 
growth medium. Cells were harvested by centrifugation at 300 x g for 5 minutes. Cell was 
determined number as described in section 2.2.1.3 and seeded at the required cell densities 
for different experiments. 
2.2.1.3. Determination of cell number 
Viable cell number was determined using a hemacytometer slide. The cell pellet was 
resuspended in 1 ml of growth medium by pipetting up and down at least 30 times to ensure 
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that the cells are not clumped together. Typically, a small aliquot of the cell suspension was 
then diluted 1 in 10 with growth medium in a 0.5 ml eppendorf tube. An equal volume of 
trypan blue solution (0.4 % (v/v)) was then added to the diluted cell suspension. Non-viable 
cells take up the dye and are stained while viable cells remain unstained. Cells were counted 
on the hemocytometer slide and an average number per square was determined. To 
calculate the number of cells per ml equation 1 was used. To calculate the percentage viable 
cells equation 2 was used. The number of cells per ml was used to determine the volume of 
cell suspension required to seed cells at the required cell density for experiments. 
 
2.2.1.4. Cryopreservation and resuscitation of SH-SY5Y neuroblastoma cells  
Cell pellets were resuspended in freezing mix (25 % (v/v) Heat inactivated foetal bovine 
serum, 10 % (v/v) DMSO, 200 units/ml Penicillin and 200 µg/ml streptomycin, 2 mM L-
glutamine in DMEM/F12) at a cell density of 2 x 106 cells/ml. Cryovials were frozen at -
80ºC overnight and then transferred to liquid nitrogen storage. 
2.2.1.5. Differentiation of SH-SY5Y cells 
Cells were seeded at a density of 500 000 cells/flask in T25 flasks or at a density of 8000 
cells/well in 8-well chamber slides. Cells were incubated overnight at 37ºC in a humidified 
atmosphere of 5 % CO2, 95 % air in full growth medium. Following overnight recovery the 
medium was replaced with differentiation medium (1 % (v/v) heat inactivated foetal bovine 
serum, DMEM/F12, 1 % (v/v) MEM non-essential amino acids, 2 mM L-glutamine, 200 
units/ml penicillin and 200 µg/ml streptomycin) containing 10 µM all-trans retinoic acid 
(RA, Sigma). RA differentiation medium was replaced with fresh RA differentiation 
medium every three days. For cells differentiated using RA alone, cells were treated with 
RA for a period of eight days. For cells differentiated using a combination of RA and brain 
derived neurotrophic factor (BDNF), treatment with RA lasted for a period of five days. 
Cells were then washed twice with serum free medium (SFM; DMEM/F12, 2 mM L-
glutamine, 200 units/ml penicillin and 200 µg/ml streptomycin, MEM non-essential amino 
acids) to remove all traces of serum and treated with 50 ng/ml BDNF in SFM. After three 
Cells/ml = Average cells per square x dilution factor x 104 
    
Where the dilution factor = dilution factor for cell suspension x dilution factor 
for trypan blue (typically 10 x 2) 
Each square is 0.25 mm x 0.25 mm 
(1) 
% Viable cells = [ (Number of stained cells)/(total number of cells)] x 100 
    
(2) 
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days treatment with BDNF, cells were ready to be used in experiments. SFM containing 
BDNF was replaced every three to four days with fresh SFM containing BDNF. 
2.2.1.6. Quantification of axon outgrowth 
To quantify axon outgrowth to assess the differentiation of SH-SY5Y neuroblastoma cells 
with Retinoic acid (RA) or RA followed by BDNF, mitotic and RA or RA/BDNF 
differentiated SH-SY5Y cells cultured in T25 flasks and viewed by phase contrast 
microscopy using the 10 x objective. Images were analysed using Leica QWin software, in 
which axon length were measured and the number of cells with axon-like processes that are 
greater than 2.5 x the width of the cell body were counted and expressed as a percentage of 
the total number of cells.   
2.2.1.7. Transfection of SH-SY5Y neuroblastoma cells with GFP tagged 
neurofilament proteins using LipofectAMINE™   
SH-SY5Y cells were seeded at a cell density of 250 000 cells per 35mm diameter dishes 
(ibidi µdish or Iwaki) or at a density of 1.5 x 106 cells in 100 mm culture dishes (BD) 
depending on the application. A LipofectAMINE™ 2000 to DNA ratio of 1 µg DNA to 2 µl 
LipofectAMINE™ 2000 was used. Following overnight recovery, the medium was 
removed, the monolayer rinsed twice with DPBS, and incubated with 1 x Gibco Opti-
MEM® I Reduced Serum Medium. For transfection of cells in 35 mm dishes, 1 µl of 
LipofectAMINE™ 2000 was added directly to 99 µl of Opti-MEM® I in sterile 1.5 ml 
tubes. For transfection of cells in 100 mm dishes, 5 µl of LipofectAMINE™ 2000 was 
added directly to 495 µl of Opti-MEM® I in 1.5 ml tubes. After adding LipofectAMINE™ 
2000, tubes were vortexed gently, briefly centrifuged and then incubated at room 
temperature for 5 minutes. Plasmid DNA (1 µg for transfections in 35 mm dishes and 5 µg 
for transfections in 100 mm dishes) was added to the Opti-MEM® I/LipofectAMINE™ 
2000 mix, tubes were vortexed gently, briefly centrifuged and incubated for 30 minutes at 
room temperature. After the 30 minute incubation, the Opti-MEM® 
I/LipofectAMINE™2000/DNA mix was added directly the cells in a drop-wise fashion and 
plates were swirled to ensure equal dispersion. Cells were returned to the incubator for 4 h 
before media was replaced with growth medium without antibiotics. Following overnight 
recovery, the growth medium was replaced again with growth medium containing 
antibiotics. 
2.2.1.8. Assessment of cell viability using the MTT reduction assay 
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoulium 
bromide) reduction which in anchorage dependent cells is based on the principle that viable 
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cells will accumulate MTT intracellularly. The MTT is then reduced by mitochondrial 
enzymes and enzymes of the endoplasmic reticulum to produce a formazan product which 
is membrane impermeable and therefore accumulates in viable cells. The product can be 
solubilised in DMSO and detected using a spectrophotometer.  
Undifferentiated cells were seeded at a density of 5000 cells/well while RA/BDNF 
differentiated cells were seeded at a density of 10 000 cells/wells in 96 well plates. 
Following overnight recovery cells were treated with a variety of different compounds in 
100 µl of medium (see Table 2.1 for a comprehensive list) for a specified time course. 1 
hour before the end of the time-point, MTT was added to each well to give a final 
concentration of 0.5 mg/ml and plates were re-incubated at 37ºC in a humidified 
atmosphere of 95 % air, 5 % CO2 for 1 hour. The medium was then aspirated from the wells 
and the formazan product was solubilised with 100 µl DMSO per well. Plates were agitated 
for 2 minutes on a plate shaker before measured using a microplate reader at 570 nm. 
2.2.2. Preparation of cell lysates 
2.2.2.1. Preparation of total cell extracts 
To prepare total cell extracts following treatment spent media was transferred to a 15 ml 
tube. The monolayer was then washed twice with Dulbecco’s PBS and the washes were 
added to the spent media. Floating cells were harvested by centrifugation at 300 x g for 5 
minutes and washed twice with Dulbecco’s PBS to remove any serum. In the meantime 300 
µl of ice-cold total extraction buffer (50 mM Tris, pH 6.8; 5 mM EDTA; 1 % (w/v) SDS; 1 
mM Sodium orthovanadate; 1 % (v/v) Halt Protease Inhibitor Cocktail; 1 % (v/v) Halt 
Phosphatase Inhibitor Cocktail) was added directly to the monolayer. The monolayer of 
cells in the flask was extracted into the total extraction buffer using a cell scraper and then 
transferred into a 1.5 ml tube on ice. Harvested and washed floating cells were combined to 
produce the total cell extract. Samples were then placed in a heating block at 100 ºC for 5 
minutes. Samples were sonicated on ice (3 x 3 sec bursts on 6-10 power setting) and then 
stored at -80 ºC until required. The protein concentration of samples was determined using 
the BC Assay (see section 2.2.6.1.) and total cell extracts were analysed by SDS-PAGE as 
described in section 2.2.7. 
2.2.2.2. Preparation of cell lysates for proteasome activity determination 
Cells were seeded at a density of 250,000 cells per well in 6-well tissue culture plates. 
Following treatment, cells were detached using a cell scraper and transferred to 2 ml tubes 
and placed on ice. Cells were harvested by centrifugation at 300 x g for 7 minutes at 4 ºC. 
To prepare cell  lysates 100 µl ice-cold homogenisation buffer (20mM Tris/HCl, pH 7.0, 
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0.1mM EDTA, 1nM 2-mercaptoethanol, 5mM ATP, 20% (v/v) glycerol, 0.4% (v/v) Igepal 
CA-630) was added to the harvested cell pellets, samples were then vortex mixed 
vigorously for 1 minute followed by centrifugation at 17380 x g at 4 ºC for 2 min. The 
resultant supernatant was transferred to a 0.5 ml microfuge tube and kept on ice to be used 
in the fluorogenic peptide assay for proteasome activity described in section 2.2.4.  
2.2.2.3. Preparation of cell lysates for cathepsin activity determination 
Cells were seeded at a density of 250 000 cells/well in 6-well tissue culture plates. 
Following treatment, cells were detached by mechanical detachment using a cell scraper 
and the cell suspension was transferred to 2 ml tubes and placed on ice. Cells were 
harvested by centrifugation at 300 x g for 7 minutes at 4 ºC. Cells were lysed in 150 µl of 
ice-cold cell lysis buffer (provided with cathepsin L and cathepsin D assay kits, abcam) and 
incubated on ice for 10 min. The lysate was then centrifuged for 5 min at 20160 x g and the 
cleared supernatant was transferred to a 0.5 ml tube and kept on ice to be used in the 
fluorogenic peptide assays described in section 2.2.5. 
2.2.2.4. Preparation of cell lysates for immunoprecipitation 
Cells were seeded in 100 mm culture dishes (BD) at a cell density of 1.5 x 106 cells/dish. 
Cells were transfected with 5 µg of plasmid DNA using LipofectAMINE™2000 as 
described in section 2.2.1.6. Cells were allowed to recover for 48 hours before being 
extracted into a Low Salt Lysis Buffer (1% (v/v) Igepal CA-630, 50 mM Tris HCl, pH 8.0). 
Spent media was discarded and the monolayer was washed twice with DPBS to remove all 
traces of serum. 1 ml of ice-cold Low Salt Lysis Buffer was added directly to the monolayer 
and the lysate was collected using a cell scraper. The cell lysate was immediately mixed, 
placed on ice and incubated on ice for 30 minutes with occasional mixing. The cell lysate 
was then centrifuged for 10 minutes at 10,000 x g at 4ºC. The supernatant was harvested 
and transferred to a fresh 1.5 ml tube and either kept on ice for immediate 
immunoprecipitation as described in section 2.2.5 or stored at -80ºC until required. The cell 
debris pellet was dissolved in 1 ml of total extraction buffer (see section 2.2.2.1.), boiled for 
5 min and stored at -80ºC. 
2.2.3. Assessment of proteasome activity using a fluorogenic peptide 
assay 
20-30 µl of lysates (prepared as described in section 2.2.2.2.) were incubated at 37 ºC with 
10 µl of 1 mM N-Succinyl-Leu-Leu-Val-Tyr-AMC (the fluorogenic substrate for 
chymotryosin-like activity, CLA of the 20S proteasome) in assay buffer (50nM HEPES pH 
8.0, 0.5mM EGTA) in a total reaction volume of 200 µl in black microtitre plates to give a 
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final working concentration of 50 µM for the CLA substrate. Using a FLUORstar OPTIMA 
fluorometer (BMG LABTECH), readings were taken every 5 minutes at excitation and 
emission wavelengths of 355 nm and 460 nm respectively for 1 hour. The rate of substrate 
cleavage is directly proportional to proteasome CLA activity. Protein estimation on each 
sample was carried out using the BioRad protein assay as described in section 2.2.6.2. 
Results were expressed as change in fluorescence units/min/µg protein. An example of a 
typical plot showing change in fluorescence over time is given in Figure 2.1. 
 
Figure 2.1 A Typical plot of fluorescence units versus time (minutes) from which proteasome 
activity was determined. 
The rate of the reaction (protease activity) was determined from the slope of the ‘line of best fit’ on the 
linear portion of the curve for the fluorescence recordings taken every 5 minutes over a 1 hour period. 
The rate of the reaction was expressed as change in fluorescence over time per µg protein determined 
separately using the BioRad protein assay kit (section 2.2.6.2).  
 
2.2.4. Assessment of cathepsin activity using a fluorogenic peptide assay 
2.2.4.1. Cathepsin D activity assay 
20 µl of cell lysates (prepared as described in section 2.2.2.3.) were incubated at 37°C with 
20 µM (final concentration) cathepsin D substrate - (7-methoxycoumarin-4-yl)acetyl (Mca)-
Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2, provided with the cathepsin 
D assay kit (abcam) - in cathepsin assay buffer (1 M NaOAc pH 5.5, 1.2 M NaCl, 100 mM 
DTT) in a total reaction volume of 100 µl in black 96 well microtitre plates. Using a 
FLUORstar OPTIMA fluorometer (BMG LABTECH), readings were taken every 5 minutes 
at excitation and emission wavelengths of 355 nm and 460 nm respectively over an hour. 
The resultant fluorescence is a measure of the hydrolysis of the peptide substrate and by 
inference the protease activity. Protein estimation on each sample was carried out using the 
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BioRad protein assay as described in section 2.2.6.2. Results were expressed as change in 
fluorescence units/min/µg protein. 
2.2.4.2. Cysteine cathepsin activity assay 
20 µl of cell lysates (prepared as described in section 2.2.2.3.), were incubated at 37°C with 
200 µM (final concentration) OmniCathepsin™ substrate [Z-Phe-Arg-AMC (7-amino-4-
methylcoumarin)] in cathepsin assay buffer (1 M NaOAc pH 5.5, 1.2 M NaCl, 100 mM 
DTT) in a total reaction volume of 100 µl in black 96 well microtitre plates. Using a 
FLUORstar OPTIMA fluorometer (BMG LABTECH), readings were taken every 5 minutes 
at excitation and emission wavelengths of 355 nm and 460 nm respectively over an hour. 
The resultant fluorescence is a measure of the hydrolysis of the peptide substrate and by 
inference the protease activity. Protein estimation on each sample was carried out using the 
BioRad protein assay as described in section 2.2.6.2. Results were expressed as change in 
fluorescence units/min/µg protein. 
2.2.5. Co-immunoprecipitation of GFP tagged fusion proteins  and their 
associated proteins using the µMACS™ Epitope Tag Protein 
Isolation Kit 
GFP tagged neurofilament proteins and their associated proteins were co-
immunoprecipitated using the µMACS™ GFP Tag Protein Isolation Kit (Miltenyi) from 
lysates prepared in section 2.2.2.4. To magnetically label the GFP-tagged neurofilament 
subunits, 50 µl of anti-GFP MicroBeads were added to the lysate. After mixing the labelling 
reaction was incubated on ice for 30 minutes. The µ column was placed in the magnetic 
field of the µMACS separator and equilibrated by applying 200 µl of lysis buffer (1% (v/v) 
Igepal CA-630, 50 mM Tris HCl, pH 8.0). After the labelling reaction, the lysate was 
applied to the column and the excluded supernatant was collected. The column was then 
washed four times with Wash Buffer 1 (150 mM NaCl, 1 % (v/v) Igepal CA-630, 0.5 % 
sodium deoxycholate, 0.1 % (w/v) SDS, 50 mM Tris-HCl, pH 8.0). The column was then 
rinsed with 100 µl Wash Buffer 2 (20 mM Tris-HCl, pH 7.5) to remove residual salt and 
detergent from the immune complex before elution. 20 µl of Triethylamine (TEA) elution 
buffer (0.1 M Triethylamine pH 11.8, 0.1 % (v/v) Triton X-100) was applied to the column 
and incubated for 5 minutes at room temperature. The bound antigen was eluted from the 
column (E1, eluate 1) by the application of 50 µl of Triethylamine (TEA) elution buffer and 
collected in a 1.5 ml tube containing 3 µl 1 M MES, pH 3 for neutralisation. Eluate 2 (E2) 
was collected in a fresh 1.5 ml tube containing 3 µl 1 M MES, pH 3 by applying another 50 
µl Triethylamine elution buffer. Eluates and excluded supernatants were stored at -80ºC 
until required.   
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2.2.6. Determination of protein content 
2.2.6.1. BC Assay 
A microtitre plate version of the BC Assay was used to assay the protein content in all 
samples that are in buffers compatible with this assay. A standard curve was prepared by 
diluting 2-20 µg of 1 mg/ml BSA in a total volume of 20 µl directly into the microtitre 
plate. 5 µl of sample buffer was added to each standard whilst samples were diluted 
appropriately, typically 5 µl of sample was diluted in 20 µl water. 200 µl of BC reagent 
(Bicinchoninic Acid solution containing 0.08 % (w/v) copper (II) sulphate) was then added 
to each well. Plates were incubated at 37 ºC for 30 minutes to allow for colour development. 
Absorbance was measured at 570 nm. Protein content of each sample was determined from 
the equation of the ‘line of best fit’ for the standard curve, an example of which is given in 
Figure 2.2.  
 
Figure 2.2 Standard calibration curve for BSA (0 - 20 µg) obtained using the BC Assay kit and  
measured at 570 nm.  
Protein content of samples (unknowns) was determined using the equation of the ‘line of best fit’.  
2.2.6.2. Bio-Rad protein assay 
The Bio-Rad microassay procedure was used as per manufacturer’s instructions to assay the 
protein content of cell lysates used to assay proteasome activity. A standard curve was 
prepared using several dilutions of 1 mg/ml BSA from 5 to 50 µg/ml in a volume of 800 µl. 
For the samples (unknowns), 10 µl of each sample was prepared in a volume of 800 µl. 200 
µl of Bio-Rad dye reagent concentrate (Coomassie Brilliant Blue G-250, phosphoric acid, 
methanol) was added to each tube and mixed by vortex mixing. 200 µl of each sample and 
standard solution was transferred to a 96 well microtitre plate. Absorbance was measured at 
570 nm. Protein content of each sample was determined from the equation of the ‘line of 
best fit’. 
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2.2.7. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
For SDS-PAGE, the resolving gel mix was prepared as described in Table 2.3 depending on 
which concentration of resolving gel was required. After the addition of the required 
quantity of APS and TEMED, the resolving gel mix was poured between glass plates with 
1.5 mm spacers that were assembled in the gel mould apparatus for the Bio-Rad Protean III 
or Tetra gel kit (Bio-Rad) as per manufacturer’s instructions. The resolving gel mix was 
overlaid with 1 ml of water and allowed to set for at least 45 minutes at room temperature. 
 
Table 2.3 Recipes for the preparation of resolving gel mix at various concentrations 
Resolving Gel Concentration 7.5% (v/v) 10% (v/v) 12% (v/v) 15% (v/v) 
40 % (v/v) acrylamide 1.9 ml 2.5 ml 3.0 ml 3.75 ml 
1.5 M Tris buffer, pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10 % (w/v) SDS 100 µl 100 µl 100 µl 100 µl 
water 5.5 ml 4.9 ml 4.4 ml 3.65 ml 
TEMED 5 µl 5 µl 5 µl 5 µl 
APS 50 µl 50 µl 50 µl 50 µl 
 
Once the resolving gel was set, the overlaying water was removed and the required volume 
of stacking gel (3-5 ml per gel) was transferred from the working stock solution (Table 2.4) 
and polymerised with the required volume of APS and TEMED.  
 
Table 2.4 Stacking Gel Mix (working stack kept at 
4°C and used as required): 
 
To polymerize 10 ml stacking gel: 
TEMED 20 µl 
10 % (w/v) APS 50 µl 
 
The stacking gel was allowed to polymerise in the presence of 10 or 15 well combs for at 
least 30 minutes after which the comb was removed. 
 
Stacking gel concentration 4 % (v/v) 
40 % (v/v) acrylamide 10 ml 
0.5 M Tris buffer, pH 6.8 25 ml 
10 % (w/v) SDS 1 ml 
water 64 ml 
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The gels were then fixed into the gel tank according to manufacturer’s instructions and the 
inner and outer reservoirs were then filled with Tris-glycine SDS-PAGE running buffer 
(0.0256 M Tris base, 0.192 M Glycine, 0.1 % (w/v) SDS, pH 8.3). 
Samples were mixed with an equal volume of 2 x reducing sample buffer (40 ml of 10 % 
(w/v) SDS; 20 ml glycerol; 20 ml 0.5 M Tris-HCl, pH 6.8; 1.54 g DTT, 0.01 g 
Bromophenol blue). Samples and molecular weight standards were then incubated at 100 °C 
for 5 minutes in a heating block, followed by centrifugation at high speed for 10 seconds. 
Samples and standards were then applied into the wells and separated at 200 V until the 
dye-front approached the bottom of the gel (45 minutes to 1 hour). 
2.2.8. Western blotting and immunoprobing 
2.2.8.1. Western blotting 
2.2.8.1.1. Wet-blotting 
A wet blotting apparatus from GeneFlow was used for wet blotting. Following 
electrophoresis, gels were rinsed in Tris-glycine electroblotting buffer (39 mM Glycine, 48 
mM Tris base, 0.0375 % (w/v) SDS, 20 % (v/v) methanol) to partially remove 
electrophoresis buffer salts. The nitrocellulose membranes and filter papers (4 pieces per 
gel) were cut to the gel dimensions (6 cm x 9 cm) and soaked with Tris-glycine 
electroblotting buffer. The immunoblot sandwich was prepared as follows: a sponge was 
placed on the red panel, followed by two pieces of filter paper and then the nitrocellulose 
membrane. The electrophoresis gel was then carefully placed onto the nitrocellulose taking 
care to avoid trapping air bubbles. The sandwich was then completed by placing the 
remaining two pieces of filter paper on top of the gel, followed by a sponge. The cassette 
was then closed and returned to the tank of the wet-blotting apparatus so that the red panel 
faced the anode and run at a constant 30 V overnight (16 h). Protein transfer was assessed 
by reversibly staining the nitrocellulose membranes with 0.05 % (w/v) Copper 
phthalocyanine 3, 4’, 4’’, 4’’’ tetrasulphonic acid tetrasodium salt in 12 mM HCl. The 
copperstained nitrocellulose membranes were then photographed with a FujiFilm CCD 
camera after which they were destained in 12 mM NaOH. 
2.2.8.2. Semi-dry electroblotting 
For lower molecular weight proteins such as α-synuclein and LC3B Proteins separated by 
elctrophoresis were transferred to nitrocellulose membranes using either a semi-dry blotting 
technique using an iblot (Invitrogen). Following electrophoresis, gels were rinsed in 
deionised water to partially remove electrophoresis buffer salts. The piece of filter paper 
provided with the iBlot transfer stacks was soaked in deionised water. The lower stack 
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containing the nitrocellulose membrane was placed into position on the iBlot apparatus, 
followed by the electrophoresis gel that was rinsed in water to remove electrophoresis 
buffer salts, taking care not to trap air bubbles. The piece of filter paper was then placed 
on top of the gel, followed by the upper stack. The provided sponge was put into 
position in the lid of the apparatus which was secured into place and proteins were 
transferred for 7 minutes. Protein transfer was assessed by reversibly staining the 
nitrocellulose membranes with 0.05 % (w/v) Copper phthalocyanine 3, 4’, 4’’, 4’’’ 
tetrasulphonic acid tetrasodium salt in 12 mM HCl. The copperstained nitrocellulose 
membranes were then photographed with a FujiFilm CCD camera after which they 
destained in 12 mM NaOH. 
2.2.8.2. Immunoprobing 
Nitrocellulose membranes were blocked with 3 % (w/v) marvel/TBS-Tween for 1 hour at 
room temperature. Membranes were probed with primary antibodies at the concentrations 
listed in Table 2.2 overnight at 4 ºC diluted in 3 % (w/v) marvel/TBS-Tween. Following 
overnight incubation in primary antibody, nitrocellulose membranes were washed three 
times with TBS - 0.1 % (v/v) Tween. Membranes were then incubated in appropriate HRP 
(Horse Radish Peroxidase) conjugated secondary antibodies (1:1000) or in some cases AP 
(Alkaline Phosphatase) conjugated secondary antibodies (1:1000) for 1 ½ hours at room 
temperature diluted in 3 % (w/v) BSA/TBS-Tween. Membranes were then washed again 
three times with TBS- 0.1 % (v/v) Tween.  
2.2.8.3. Secondary antibody detection of Western blots 
2.2.8.3.1. Enhanced Chemiluminescence (ECL) detection 
 
Membranes probed with HRP conjugated secondary antibodies were developed by 
Enhanced Chemiluminescence (ECL) using a FujiFilm CCD camera imaging device. 
Briefly, a 1:1 solution of detection reagent 1 and detection reagent 2 was pipetted directly 
onto the membrane. After 1 minute incubation, excess substrate was removed and the 
membrane transferred to the dark box of the FujiFilm CCD camera in which it was 
developed.  
2.2.8.3.2. Alkaline phosphatase (AP) detection 
Membranes probed with AP conjugated secondary antibodies were developed by a 
colorometric method using 0.75 M Tris, pH 9.5 buffer containing 0.08 mg/ml BCIP (5-
Bromo-4-Chloro-3 Indolyl Phosphate, 33 µl of 50 mg/ml stock in 20 ml of substrate buffer) 
and 0.165 mg/ml NBT (Nitro Blue Tetrazolium, 44 µl of 75 mg/ml stock in 20 ml of 
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substrate buffer). Membranes were developed in the dark until bands are visible, whereupon 
development was stopped by extensive washing in deionised water. 
2.2.9. Peptide mass fingerprinting of proteins co-immunoprecipitated with 
GFP tagged NF subunits 
For 1-dimensional and 2-dimensional SDS-PAGE all solutions were prepared in ultra-pure 
water. For 1-dimensional SDS-PAGE (described in section 2.2.7) samples prepared in 
section 2.2.5 from 100 mm culture dishes were mixed with 5 x sample buffer so that a 
maximum volume of the sample could be loaded. Proteins were separated by SDS-PAGE as 
described in section 2.2.7. 
2.2.9.1. 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
For 2D-PAGE, the cell lysates were prepared from 5 x 100 mm culture dishes to increase 
protein concentration in eluates (see section 2.2.5.). 50 µl of the eluate was acetone 
precipitated by the addition of 4 volumes of ice-cold acetone overnight at -20 ºC. 
Precipitated protein was harvested by centrifugation at full speed for 10 minutes at 4 ºC. 
Protein pellets were dried at room temperature for 30 minutes, resuspended in 130 µl of 
sample rehydration buffer (8 M urea, 4 % (v/v) CHAPS, 0.2 % carrier ampholytes, 0.0002 
% (w/v) bromophenol blue, 50 mM DTT) and 125 µl was applied to one of the IEF tray 
channels. A 7 cm pH 3-10 IPG strip was laid on the sample and passively hydrated for 1 
hour at room temperature. The strip was covered with 700 µl mineral oil and focused using 
a Protean IEF cell programmed with the following focusing protocol: active hydration for 
13 h and 40 min at 20 ºC at 50 µA/strip, 250 V for 20 min (linear), 4000 V for 2 h and 30 
min (linear) and 4000 V, rapid for 10000 Vhours.  
The resolving gel was prepared with ultra-pure water as described in section 2.2.7 and 
allowed to set. The resolving gel was then topped with a layer of 4 % (v/v) polyacrylamide 
stacking gel prepared as described in section 2.2.7 using ultra-pure water. Strips were 
removed from the IEF tray and placed into a rehydration tray. Strips were equilibrated with 
DTT rehydration buffer (20 mg/ml DTT, 6 M urea, 2 % (w/v) SDS, 20 % (v/v) glycerol, 50 
mM Tris-HCl, pH 8.8) for 15 minutes with gentle agitation to reduce sulphydryl groups. 
The DTT rehydration buffer was then replaced with Iodoacetamide equilibration buffer (25 
mg/ml iodoacetamide, 6 M urea, 2 % (w/v) SDS, 20 % (v/v) glycerol, 50 mM Tris-HCl, pH 
8.8) and strips were incubated for 15 minutes with gentle agitation to alkylate the sulfhydryl 
groups to prevent sulfhydryl cross-bridges from reforming. The stacking gel was overlaid 
with 0.5 % (w/v) agarose in Tris-glycine SDS-PAGE running buffer containing 0.1 % (w/v) 
bromophenol blue and the IPG strip was slid in place between the two glass plates so that it 
rested on the top of the stacking gel. A piece of filter onto which 1 µl of protein standards 
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was applied was inserted at the acidic end of the IPG strip. Gels were assembled in the gel 
tank apparatus as described in section 2.2.7 and run at 200 V.  
2.2.9.2. Silver staining of gels for mass spectrometry  
All solutions used for silver staining were prepared using ultra-pure water. After SDS-
PAGE, polyacrylamide gels were fixed for 1 hour with two changes of fixation solution (50 
% (v/v) ethanol, 12 % (v/v) acetic acid). Gels were then washed three times for 20 minutes 
with 20 % (v/v) ethanol. Gels were sensitized by incubating for 2 minutes in 0.02 % (v/v) 
sodium thiosulphate and washed three times for 5 minutes ultra-pure water. Incubated gels 
with silver stain solution (0.2 % (w/v) silver nitrate, 0.076 % (v/v) formalin) for 20 minutes. 
Gels were washed twice with ultra-pure water for 20 seconds each and developed by adding 
developing solution (6 % (w/v) sodium carbonate, 0.0004 % sodium thiosulphate, 0.05 % 
(v/v) formalin). Development was stopped by adding a stop solution (12 % (v/v) acetic 
acid). Gels were kept in the fridge in ultra-pure water. 
2.2.9.3. In-gel trypsin digestion of excised protein bands or spots 
Silver stained polyacrylamide gels from which spots/bands were excised and trypsinized the 
day after they were silver stained. The excised spots/bands were dehydrated with the 
addition of 50 µl of 2:1 acetonitrile (ACN): 25 mM NH4HCO3 for 15 minutes. The 
supernatant was removed and spots/bands were rehydrated with the addition of 50 µl 25 
mM NH4HCO3 for 10 minutes. The supernatant was removed and the 
dehydration/rehydration cycle was repeated. The spots/bands were then dehydrated with 50 
µl 2:1 ACN: 25 mM NH4HCO3 for 15 minutes and allowed to air-dry for 15 minutes. Dried 
spots/bands were resuspended in 12.5 ng/µl Promega sequencing grade trypsin (V5113) in 
25 mM NH4HCO3 on ice (10 µl of trypsin for bands and 4 µl of trypsin for gel spots) and 
allowed to hydrate for 20-30 minutes. Excess trypsin was removed and spots were covered 
with 10-30 µl 25 mM NH4HCO3 (enough to cover the gel) and incubated at 37ºC for 4 
hours prior to shaking for 20 minutes. The supernatant was removed and transferred to 0.5 
ml tubes. An additional 20 µl 80/20 ACN/water was added to the trypsinized gel 
spots/bands for a further 15 minutes, supernatant was removed and combined with the 
previous supernatant. Samples were stored at -80ºC.  
To perform mass spectrometry, 1 µl of 1 % (v/v) Trifluoracetic acid (TFA) was added, 
mixed and 1 µl of samples were spotted directly onto the MALDI target plate with 1 µl of 
10 mg/ml CHCA matrix in 50:50 ACN:water containing 0.1 % TFA. Peptide mass spectra 
were processed using an Ultraflex III TOF/TOF Brucker Daltonik Ltd). 
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2.2.10. Immunofluorescence imaging 
2.2.10.1. Methanol fixation 
Cells in 8-well chamber slides were fixed with ice-cold 90 % (v/v) methanol/TBS for 20 
minutes at -20 ºC. For cytoskeletal staining, cells were then permeabilzed for 10 minutes 
using 1 % (v/v) Triton X-100 in TBS at room temperature. In an alternative method when 
staining for smaller soluble proteins, cells were permeabilized using 0.2 % (v/v) Triton X-
100. Wells were rinsed with PBS before staining. 
2.2.10.2. Immunofluorescence staining 
Fixed and permeabilised slides were blocked for 1 hour with 3 % (w/v) BSA/TBS-Tween 
(0.1%) at room temperature before incubating with primary antibodies (see Table 2.2 for a 
list of antibodies used and the dilutions at which they were used) diluted in 3 % (w/v) 
BSA/TBS-Tween (0.1 %) overnight at 4 ºC in a humidified chamber. Cells were washed 
extensively with TBS/ 0.1 % (v/v) Tween 20. Cells were incubated with anti-IgG alexa-
fluor conjugated secondary antibodies (1:200) for 2 hours at room temperature. Cells were 
then washed extensively with TBS/ 0.1 % (v/v) Tween 20 to remove all unbound secondary 
antibody. The chambers were removed and slides were mounted with anti-fade mountant 
and a glass coverslip (thickness size 0). The coverslip was sealed in place with clear nail 
varnish.  
Slides were viewed by laser confocal microscopy using a Leica CLSM Laser confocal 
microscope. Cells were viewed using the 40 x and 63 x objective. AlexaFluor 488 and GFP 
were excited with the Argon laser (emission wavelength of 488 nm) and the AlexaFluor 568 
and propidium iodide nuclear stain was excited with the Krypton laser (emission 
wavelength of 568 nm). Gain and offset were set against the control and kept constant for 
all treatments so that the fluorescence intensity between control and treatments were 
comparable.   
Slides were also visualised using an Olympus Fluorescence microscope, AlexaFluor 488 
was visualised using a blue filter for FITC visualisation, AlexaFluor 568 and Propidium 
Iodide were visualised using a green filter for TRITC visualization and DAPI was 
visualised using the UV filter. In addition cells were also visualized by phase contrast which 
allowed the overlaying of fluorescence signals on phase contrast images. 
2.2.11. Live cell imaging 
Cells were seeded at a density of 250 000 cells in 35 mm glass bottomed dishes (ibidi µdish 
or Iwaki) and transfected with GFP/NFs as described in section 2.2.1.7. Cells were imaged 
Chapter 2 Materials and Methods 
 64 
live using a Leica inverted confocal microscope. GFP fluorescence was excited with the 
Argon laser (emission wavelength of 488 nm). 
For time-lapse imaging cells expressing GFP-tagged NF-M or NF-H were viewed live using 
a Leica IRE2 time-lapse fluorescence microscope with full-stage incubation. The 
fluorescence from GFP-tagged neurofilaments was excited using the filter for FITC/GFP 
image acquisition. Fluorescence and DiC images were taken concurrently every 5 minutes 
over the course of an hour with shutters closing after each acquisition. Images were saved 
using Openlab image acquisition software and processed using ImageJ imaging software to 
produce overlaid images, time-lapse movies and to measure axonal process length.  
2.2.12. General molecular biology techniques 
2.2.12.1. Amplification of neurofilament subunits by Polymerase Chain Reaction 
(PCR) 
Neurofilament subunit DNA was amplified cDNA preparations from SH-SY5Y 
neuroblastoma cells (kindly donated by Dr Julia Fitzgerald). A list of the primers used to 
amplify NF cDNA is given in Table 2.5. NF-M and NF-L cDNA were amplified by 
Advantage® 2 PCR in a 25 µl total reaction volume containing 1 µl of template DNA 
according to manufacturer’s instructions. Initial attempts to amplify the entire sequence of 
NF-H using Advantage 2 PCR or PrimeSTAR™ HS DNA Polymerase, did not yield a full-
length NF-H cDNA sequence. Due to the high GC content of the first 1000 bp of NF-H it 
was decided to clone NF-H in two separate parts; the so-called N-terminal part containing 
this GC-rich region and the C-terminal part. The N-terminal part was amplified using the 
Advantage®-GC Genomic PCR according to manufacturer’s instructions with reactions 
containing 0, 2.5, 5.0 and 7.5 µl of 5 M GC melt to optimize the amount of GC melt in the 
reaction in a 25 µl reaction volume. The C-terminus part of NF-H was amplified using 
Platinum PCR SuperMix according to manufacturer’s instructions.  
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Table 2.5 List of primers used for the amplification of neurofilament subunits  
Name Sequence 
hNF-M_fwd 5’-GAATTCAGATGAGCTACACGTTGGACTC-3’ (blue, EcoRI site; green, start codon; underlined, homologous to hNF-M cDNA) 
hNF-M_rev 5’-TTTCCTTCAGTGGGTCTCACTGATTCAGCTG-3’ (yellow, SalI site; red, stop codon; underlined, homologous to hNF-M cDNA) 
hNF-L_fwd 5’-GAATTCCCATGAGTTCCTTCAGCTACGAG-3’ (blue, EcoRI site; green, start codon; underlined, homologous to hNF-L cDNA) 
hNF-L_rev 5’-CGATTCTTCTTTCTAACTTGGGGGCAGCTG-3’ (yellow, SalI site; red, stop codon; underlined, homologous to hNF-L cDNA) 
hNF-H_fwd 5’-GAATTCCCATGATGAGCTTCGGCGGCG-3’ (blue, EcoRI site; green, start codon; underlined, homologous to hNF-H cDNA) 
hNF-H_rev 5’-TGTTCCGGCGGTTCCCCTTCATTCAGCTG-3’ (yellow, SalI site; red, stop codon; underlined, homologous to hNF-H cDNA) 
hNF-H_N_fwd 5’-TGCTCAGGCCATGATGAGCTTCG-3’ green, translational start; underlined, homologous to hNF-H cDNA 
hNF-H_N_rev 5’-TGGTCCTTCGGTAAGTCGTCGAC-3’ pink, XmnI recognition site; underlined, homologous to hNF-H cDNA 
hNF-H_C_fwd 5’-ACCAGGAAGCCATTCAGCAGCTG-3’ pink, XmnI recognition site; underlined, homologous to hNF-H cDNA 
hNF-H_C_rev 5’-TGTTCCGGCGGTTCCCCTTCATT-3’ red, translational stop; underlined, homologous to hNF-H cDNA 
2.2.12.2. Agarose gel electrophoresis of DNA 
The products of PCR reactions or DNA fragments produced by restriction endonuclease 
digestion were evaluated by agarose gel electrophoresis. 0.8-1.5 % (w/v) agarose in 1 x 
TAE buffer (40 mM Tris, 2 mM EDTA, pH 8.5) and containing 0.0002 mg/ml Ethidium 
Bromide was prepared. DNA samples were mixed with 10 x DNA loading dye (0.025 % 
(w/v) bromophenol blue, 20 % ficoll, 1 % (w/v) SDS, 0.1 M EDTA, pH 8.0) or 5 x DNA 
loading dye (Fermentas) and applied to the wells. A DNA ladder (either the 1 kbp or the 
100 bp) was also applied. Gels were electrophoresed in 1 x TAE buffer and run at 80 mA. 
2.2.12.3. Purification of DNA from agarose gels 
The desired band was cut out of the gel by viewing the gel on a UV light box. DNA was 
purified from the agarose gel using the QIAquick® gel extraction kit (QIAGEN) according 
to manufacturer’s instructions. DNA was eluted by applying 25 µl sterile water to the 
QIAquick® spin column and incubating for 10 minutes at room temperature before 
centrifuging at 10,000 x g for 1 minute. Purified DNA was vortex mixed and centrifuge 
shortly. DNA concentration was determined using the method described in section 2.2.12.6. 
2.2.12.4. Cloning of DNA fragments into pCR-2.1 TOPO and pCR-XL TOPO and 
transformation of E.coli competent cells 
4 µl of purified DNA was transferred to a sterile 0.5 ml tube to which 1 µl of salt solution 
(provided with the cloning kit) and 1 µl of the pCR TOPO vector (Clontech, TAKARA) 
was added. The cloning reaction was incubated for 30 minutes at room temperature and 
then transferred to ice. 
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E.coli TOP10 competent bacteria (Invitrogen) were thawed quickly on ice. The cloning 
reaction was added to cells which were mixed gently by tapping. The cells were incubated 
on ice for 30 minutes and then subjected to heat shock treatment at 42ºC for 30 seconds and 
placed on ice for 2 minutes. 250 µl of S.O.C. medium was added to the transformed cells 
which were incubated with shaking at 37ºC for 1 hour. The bacteria were spread on pre-
warmed LB agar plates containing 50 µg/ml kanamycin. Cells were incubated overnight at 
37ºC. 
2.2.12.5. Purification of plasmid DNA from bacterial cells 
2.2.12.5.1. Mini-Prep 
To prepare mini-prep plasmid DNA, 2.5 ml LB broth containing 50 µg/ml kanamycin was 
inoculated with bacterial clones. Inoculated media were incubated overnight at 220 rpm at 
37ºC. Overnight cultures were poured into sterile 2 ml tubes and centrifuged for 5 minutes 
at 6,800 x g at room temperature to harvest the bacterial cell pellet. DNA was prepared 
using the QIAGEN® Plasmid Mini Kit (QIAGEN) as per manufacturer’s instructions. To 
elute plasmid DNA from the QIAprep spin column, 30 to 50 µl of sterile water was applied 
directly onto the matrix of the column and incubated for 5 minutes at room temperature. 
The solution of plasmid DNA was collected by centrifugation at 17,900 x g for 1 minute in 
a fresh sterile 1.5 ml tube. The DNA solution was vortex mixed and centrifuged shortly. 
DNA concentration was determined using the method described in section 2.2.12.6 
2.2.12.5.2. Midi-Prep 
To prepare midi-prep plasmid DNA bacterial clones containing the desired plasmid were 
cultured over-night in 200 ml of LB broth containing 50 µg/ml kanamycin or 100 µg/ml 
ampicillin depending on the antibiotics resistance genes on the plasmid being purified. 
Following overnight culture, bacterial cells were harvested by centrifugation at 2500 x g for 
15 minutes at 4ºC. Plasmid DNA was prepared using the QIAGEN® Plasmid Midi Kit 
(QIAGEN) according to manufacturer’s instructions. DNA pellets were air-dried at room 
temperature and resuspended in a total of 100 µl water. The average DNA midi-prep 
produced around 200 µg of plasmid DNA. DNA concentration was determined using the 
method described in section 2.2.12.6 
2.2.12.6. Determination of DNA and RNA concentration 
For Mini-Prep DNA preparations, the plasmid DNA solution was diluted 70 fold in 70 µl 
water. For midi-prep plasmid DNA solutions two dilutions of the plasmid DNA solutions 
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were prepared (1:100 and 1:200). Absorbance at 260 and 280 nm was measured using a UV 
spectrometer. DNA concentration was calculated using the equation below:  
  OD260 x 50 x dilution factor = [DNA; ng/µl]. 
For RNA preparations, RNA preparations were diluted 25 fold in 75 µl water. Absorbance 
at 260 and 280 nm was measured using a UV spectrometer. DNA concentration was 
calculated using the following equation: 
  OD260 x 40 x 25 = [RNA; ng/ul] 
2.2.12.7. Restriction endonuclease digestion 
2.2.12.7.1. Limited digests 
To confirm the insertion of cloned DNA fragments into plasmid vectors, limited digests of 
Mini-prep DNA using restriction endonuclease were prepared. For limited digests 2.5 units 
of restriction endonuclease were used per reaction which consists of 2 µl of mini-prep DNA 
(approximately 0.1 µg) in a total reaction volume of 10 µl according to manufacturers 
instructions for the restriction endonuclease used. The reactions were then incubated at 37 
ºC for 1-2 hours and analysed by agarose gel electrophoresis. 
2.2.12.7.2. Quantitative digests 
To clone the neurofilaments into pEGFP-C3, quantitative digests were performed to cut the 
neurofilament DNA out of the cloning vector and to clone it into pEGFP-C3. The pEGFP-
C3 used in this work contained rNF-M, so to replace the rNF-M with the human 
neurofilament DNA a quantitative digest of this plasmid was also performed. Typically 3 
µg of plasmid DNA was digested with 30 units of restriction endonuclease in a total 
reaction volume of 100 µl. The reactions were incubated in a thermal cycler at 37 ºC for 8-
12 hours; enzymes were then deactivated at 65 ºC for 20 minutes and held at 10 ºC. 
2.2.12.8. Site-directed mutagenesis 
PCR-derived mutations were corrected using the QuikChange® XL Site-Directed 
Mutagenesis Kit from Stratagene according to manufacturer’s instructions. Mutagenic 
primers (listed in Table 2.6) were designed to be between 25 and 45 bases in length with the 
correction in the middle of the sequence and have a minimum GC content of 40% and a 
melting temperature (Tm) of ≥ 78ºC calculated using the equation for Tm below: 
  Tm = 81.5 + 0.45(%GC) – 675/N - % mismatch 
  Where N is the primer length in bases 
To insert a base into a sequence the following equation for the calculation of Tm was used:
  Tm = 81.5 + 0.41(%GC)-675/N 
  Where N does not include the base being inserted 
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The mutagenesis reaction uses PfuTurbo® DNA Polymerase which replicates both plasmid 
strands with high fidelity and without displacing the mutant oligonucleotide primers. The 
set of mutagenesis primers bind to the complementary strands of the plasmid and each of 
these strands is extended during temperature cycling by PfuTurbo® DNA Polymerase 
resulting in a mutated plasmid with staggered nicks. Following temperature cycling the 
PCR product was treated with the endonuclease Dpn I which digests methylated and 
hemimethylated DNA and is used to digest the parental DNA template. The nicked plasmid 
DNA was transformed into E.coli XL10-Gold ultracompetent cells as per manufacturer’s 
instructions. 500 µl of pre-warmed SOC medium (Invitrogen) was added to the transformed 
cells and they were incubated for 1 hour at 37ºC with shaking at 220 rpm. The 
transformation reaction was then plated onto LB agar containing 50 µg/ml kanamycin and 
incubated overnight at 37ºC. The following day, colonies were picked and plasmid DNA 
was purified using the mini-prep procedure described above. The sequences were confirmed 
to contain the corrections by sequencing. 
 
Table 2.6 List of primers used for the amplification of neurofilament subunits  
Name Sequence 
hNF-M_ 
Lys_Glu-fwd 
5’-GAGAAGGTGCACTACCTGGAGCAGCAGAATAAG-3’  
Purple, base change to correct mutation (Tm 75.3°C) 
hNF-M_ 
Lys_Glu-rev 
5’-CTTATTCTGCTGCTCCAGGTAGTGCACCTTCTC-3’  
Purple, base change to correct mutation(Tm 75.3°C) 
hNF-L_ 
Lys_Arg-fwd 
5’-GAGTCTGAAGAAGCAAAAGAAGAAGAAGAAGGAGGTG-3’  
Purple, base change to correct mutation (Tm 74.7°C) 
hNF-L_ 
Lys_Arg-rev 
5’-CACCTCCTTCTTCTTCTTCTTTTGCTTCTTCAGACTC-3’ 
Purple, base change to correct mutation (Tm 74.7°C) 
hNF-H_N_ 
Phe_Ser-fwd 
5’- GCTGGCTCCTCCAGCGGCTTCCACT -3’ 
Purple, base change to correct mutation (Tm 79.7°C) 
hNF-H_N_ 
Phe_Ser-rev 
5’- AGTGGAAGCCGCTGGAGGAGCCAGC -3’ 
Purple, base change to correct mutation (Tm 79.7°C) 
2.2.12.9. Bacterial cell culture 
2.2.12.9.1. Subculture of bacterial clones 
Bacterial colonies were picked from existing LB-agar plates containing either 50 µg/ml 
kanamycin or 100 µg/ml ampicillin plates onto fresh LB-agar containing either  50 µg/ml 
kanamycin or 100 µg/ml ampicillin. Plates were incubated overnight at 37 ºC. 
2.2.12.9.2. Cryopreservation and resuscitation of bacterial cells 
To prepare glycerol stocks of bacterial cultures, cultures were picked into a bibby sterilin 
with 1 ml of LB broth containing 50 µg/ml kanamycin and incubated overnight at 37ºC at 
220 rpm. An equal volume of glycerol freezing mix was added to the bacterial culture. 
Glycerol stocks were aliquoted into cryovials and stored at -80ºC.  
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To resuscitate glycerol stocks of bacterial cells, a small amount of bacterial cells were 
picked from the surface of the tube using a sterile toothpick and cultured overnight in a 
bibby sterilin with 2 ml of LB broth containing 50 µg/ml kanamycin at 37ºC at 220 rpm. To 
obtain single cultures a loop full of bacteria from the overnight culture was streaked on an 
LB agar plate containing 50 µg/ml kanamycin. Plates were incubated overnight at 37ºC. 
2.2.13. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
2.2.13.1. Preparation of standard DNA for qRT-PCR 
2.2.13.1.1. Amplification and cloning of standard DNA 
Primers (Table 2.8) designed for quantitative real-time PCR were used to amplify the TG2, 
dynein light intermediate chain, kinesin 5C, NTrkB, PSMC1, α1-tubulin, GAPDH and Bcl-
2 for standard DNA using the AcuPrime™ Taq DNA Polymerase System according to 
manufacturer’s instructions (Invitrogen). Typically the total reaction volume was 25 µl; 
containing 1 µl of template DNA, 0.5 µl AcuPrime™ Taq DNA polymerase, 10 µM each of 
the forward and reverse primers and 2.5 µl 10 x AcuPrime™ PCR Buffer I. The PCR 
products were analysed by agarose gel electrophoresis using 1.5 % (w/v) agarose gels as 
described in section 2.2.12.2. The PCR products were excised from the gel and purified as 
described in section 2.2.12.3. 
DNA segments were cloned into pCR-2.1 TOPO (Invitrogen) according to manufacturer’s 
instructions and transformed into E.coli TOP10 competent bacteria (Invitrogen) as 
described in section 2.2.12.4. Six to 10 colonies were picked for sequencing. Plasmid DNA 
from selected clones was purified using the Qiagen Mini-Prep procedure as described in 
section 2.2.12.5.1. Plasmid DNA from the selected clones was analysed by restriction 
enzyme digestion using EcoRI as described in section 2.2.12.7. Clones for sequencing were 
then selected and 3000ng/20 µl DNA was sent to MWG for sequencing. Plasmid DNA 
midi-preps from selected clones were prepared as described in section 2.2.12.5.2. 
2.2.13.1.2. Preparation of standard solutions 
2.2.13.1.2.1. Linearization of plasmid midi-prep DNA 
To relax the super-coiled DNA structure of the plasmid enough to allow DNA polymerase 
to gain access to the molecule, the plasmid midi-preps of standard DNA were linearized by 
restriction endonuclease digestion. The restriction endonuclease chosen for this task 
depended on the presence of its recognition sequence in the multiple cloning of the plasmid 
vector and the absence of this sequence from the DNA insert. Plasmid DNA was linearized 
using a FastDigest™ system (Fermentas). Briefly in a total volume of 100 µl, 10 µg of 
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DNA was digested by 10 µl Restriction Endonuclease in the presence of 10 µl 10 x 
FastDigest™ Buffer for 5 minutes at 37ºC. The Restriction endonucleases used for the 
linearization of standard DNA are listed in Table 2.7. 
 
 
Table 2.7 The linearization of standard plasmid DNA for each gene to relax the supercoiled DNA 
structure.  
The linearization was accomplished by restriction endonuclease digestion using restriction endonucleases 
for which the recognition sequence is found in the multiple cloning site of the plasmid vector but is absent 
from the DNA insert. 
Gene Plasmid Restriction Endonuclease 
NF-H pEGFP-C3 HindIII 
NF-M pEGFP-C3 KpnI 
NF-L pEGFP-C3 HindIII 
α-tubulin pCR-2.1 TOPO HindIII 
PSMC1 pCR-2.1 TOPO HindIII 
NTrkB pCR-2.1 TOPO HindIII 
Bcl-2 pCR-2.1 TOPO HindIII 
TG2 pCR-2.1 TOPO HindIII 
Dynein Light Intermediate Chain pCR-2.1 TOPO HindIII 
KIF5C pCR-2.1 TOPO HindIII 
GAPDH pC-2.1 TOPO HindIII 
 
95 µl of the linearized plasmid DNA was transferred to a fresh 1.5 ml tube for purification 
using the QIAquick PCR Purification Kit (QIAGEN). The remaining 5 µl of linearized 
plasmid DNA was run on an agarose gel to check that the DNA was linearized. 
2.2.13.1.2.2. Purification of linearized plasmid DNA  
Linearized plasmid DNA was purified using the QIAquick® PCR Purification Kit from 
QIAGEN according to manufacturer’s instructions. DNA was eluted from the QIAprep 
column with 30 µl of water. The DNA concentration of the purified linearized plasmid 
DNA was measured using a nanodrop UV spectrometer and was between 100-300 ng/µl.    
2.2.13.1.2.3. Preparation of standard DNA solutions for qRT-PCR 
The number of double-stranded DNA molecules/µl in the original solution (purified 
linearized plasmid DNA prepared in section 2.2.13.1.2.2) was calculated using equation 1. 
  c(DNA[ng/µl])/1x109 
   
 vector length [bp] x 660   
 
x 6.022x1023 = dsDNA molecules/µl……..(1) 
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The volume of the original solution required to prepare 100 µl of standard solution 1 (SL1) 
in RT Buffer (10 mM Tris, pH 8, 15 mM KCl, 0.6 mM MgCl2.6H2O) containing 1x1010 
single-stranded DNA molecules was calculated using equation 2.  
 
           100 µl x 1x1010 dsDNA molecules/µl 
 
        c(dsDNA molecules/µl in original solution) 
 
                                       2 
 
Standard solution 2 (SL2) containing 1x108 ssDNA molecules/µl was prepared by diluting 
10 µl of SL1 in 990 µl RT Buffer. Standard solution 3 (SL3) containing 1x107 ssDNA 
molecules was prepared by making a ten-fold dilution of SL2.  
2.2.13.2. Preparation of sample cDNA preparations 
2.2.13.2.1. RNA preparation 
To ensure that all surfaces and equipment used during the RNA extraction procedure were 
ribonuclease-free, all surfaces and equipment were cleaned with water, RNaseZap spray and 
70 % (v/v) ethanol.  Cells were seeded at a density of 500 000 cells per flask in T25 flasks 
and either maintained as proliferating cells or differentiated with RA or RA/BDNF as 
described in section 2.2.1.5. Toxin treated cells (MPP+ and/or epoxomicin) were 
predifferentiated with RA/BDNF before being treated.  
Cells were detached by trypsinization and cell pellets were harvested as described in section 
2.2.1.2. For the differentiation experiments, spent media was discarded and only attached 
cells were harvested. For experiments involving toxin treatment, spent media also was 
collected. Cell pellets were washed with DPBS and transferred to 1.5 ml tubes and collected 
by centrifugation at 300 x g for 5 min. The supernatant was discarded and cell pellets were 
resuspended in freshly prepared RLT buffer (300 μl RLT + 3 μl β-mercaptoethanol) and 
applied to Qia-Shredder columns and centrifuged for 2 minutes at 10000 x g for efficient 
cell lysis. The columns were discarded and RNA in the flow-through was precipitated by 
adding 300 µl of 70 % (v/v) ethanol. After mixing by pipetting, the flow-through/ethanol 
mix was applied to the RNeasy columns and centrifuged at 10000 x g for 15 sec allowing 
the RNA to bind to the matrix of the RNeasy column. Contaminating proteins were washed 
off by adding 700 µl RW1 wash buffer and centrifuging at 10000 x g for 15 sec. Salts and 
other contaminants were washed off by washing columns twice with 500 µl RPE wash 
buffer and centrifuging at 10000 x g for 15 sec between each wash. To dry the matrix and 
remove all traces of ethanol columns were centrifuged again at 10000 x g for 2 min. 
= µl original solution required….(2) 
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Columns were then transferred to fresh tubes and 30 µl of water was added to each column 
and incubated for a further 5 min. To collect RNA, columns were then centrifuged for 2 min 
at 10000 x g. RNA concentration was determined as described in section 2.2.12.6. 
2.2.13.2.2. Reverse transcription PCR 
All the different temperature steps in this reaction were performed in a thermal cycler. 1-3 
µg RNA was diluted to a maximum volume of 10 µl with sterile deionized water. Two 
master mix solutions were prepared: Master Mix 1 contained 1 µl oligodT18 and 1 µl dNTPs 
per reaction; Master Mix 2 contained 4 µl 5 x first-strand buffer, 2 µl 0.1 M DTT and 1 µl 
water per reaction. Master Mix 1 was added to the RNA dilution and incubated at 65 °C for 
5 min. The reaction was then transferred immediately to ice and Master Mix 2 was added, 
followed by incubation at 42 °C for 2 min.  After which 1 µl of SuperScript II reverse 
transcriptase (Invitrogen) was added to each reactions and reactions were incubated at 42 °C 
for 70 minutes, followed by 70 °C for 15 min and reactions were then held at 4 °C until 
storage at -20 °C. 
2.2.13.3. Quantitative Real-Time PCR 
Quantitative Real-Time PCR (qRT-PCR) reactions for each gene were run with a set of 
standards in which the numbers of DNA molecules are known. Standards used were; SL3 
(107) → 106 → 105 → 104 → 103 → 102 → 10 → 1 molecules/µl. Briefly, seven 1.5 ml 
tubes for the standard curve, one for the PCR master mix (MM) and one tube for the primer 
dilution were placed into a rack. 90 µl of RT Buffer (10 mM Tris, pH 8, 15 mM KCl, 0.6 
mM MgCl2.6H2O) was pipetted into the seven tubes for the standard curve. 90 µl of water 
was added to the tube for the primer dilution and the required amount of water (depending 
on the number of reactions) was added to the tube for the PCR master mix. The primer mix 
containing 5 µM of each primer (forward and reverse) was prepared by adding 5 µl of each 
primer (100 µM stock) to the 90 µl of water in the primer mix tube. According to the 
suggested protocol for the SensiMix™Plus SYBR Kit each 10 µl reaction requires 5 µl of 
SensiMix™Plus SYBR, 0.4 µl 5µM forward primer (200nM), 0.4 µl 5µM reverse primer 
(200nM), 1 µl DNA template and water to 10 µl. A PCR master mix containing all the 
components except the template DNA (namely the 5 µl SensiMix™Plus SYBR, 0.4 µl 
primer mix and 3.5 µl water per reaction) was prepared. Standards were prepared by serial 
dilution; each dilution was mixed thoroughly by pipetting up and down 20 times. 9 µl of the 
PCR master mix was pipetted into the PCR tubes for the rotorgene added 1 µl of template 
DNA.  
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The reaction profile was as follows: 
  Enzyme Activation Step 95ºC 10 minutes 
 
      95ºC  15 sec not acquiring 
      65ºC  30 sec not acquiring 
      72ºC  30 sec acquiring on SYBR 
       
  Melting curve 60-99ºC ramp up, rising by 0.5ºC for each step 
  Wait 60 sec on 1st step, then 5 sec for each step afterwards 
  Acquired melt on SYBR 
Data was analysed with the Rotor-gene 6000 series software. When samples and standards 
were selected an automatic threshold was calculated. The cycle number at which a reaction 
reaches the threshold is called the Ct value. The Ct values of the standards were used to 
produce a standard calibration curve from which the RNA copy number in the samples 
could be determined.  
 
45 cycles 
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Table 2.8 Primers used to target sequences for amplification by Quantitative real-time PCR, melting 
temperature (Tm) was calculated using the formula: Tm = 2(A+T) + 4(G + C) 
Gene Primers Tm, ºC 
Size of 
amplified 
sequence 
NF-H 
fwd: 5’-TCCTACCAGGAAGCCATTCAG-3’ 
rev: 5’-CCTTCTGGAAGCGAGAAAGGAA-3’ 
66 ºC 
66 ºC 
201 bp 
NF-M 
fwd: 5’-CAGCTACCAGGACACCATCCA-3’ 
rev: 5’- GGAGCTTCCACCTTGGGTTTC-3’ 
66 ºC 
66 ºC 
265 bp 
NF-L 
fwd: 5’-GCAGCTTACAGGAAACTCTTGG-3’ 
rev: 5’-GTTTCCTCCACTTCGATCTGCT-3’ 
66 ºC 
66 ºC 
214 bp 
α-tubulin 1b 
fwd: 5’-CTAATCCCTAGCCACTATGCGT-3’ 
rev: 5’-GCGAACTTCATCAATGACTGTGG-3’ 
66 ºC 
66 ºC 
263 bp 
PSMC1 
fwd: 5’-TTGAGAGTGGTTGGCTCTGAAC-3’ 
rev: 5’-TCAATGCGGCCTGGTCTGATAA-3’ 
66 ºC 
66 ºC 
306 bp 
NTrkB 
fwd: 5’-TGGCAGTGAAGACCCTGAAGG-3’ 
rev: 5’-TTGCCCTCAGCCATCAGCAC-3’ 
66 ºC 223 bp 
Bcl-2 
fwd: 5’-TAACGGAGGCTGGGATGCCTT-3’ 
rev: 5’-AGCCTGCAGCTTTGTTTCATGG-3’ 
66 ºC 
66 ºC 
248 bp 
TG2 
fwd: 5’-GTCGTGACCAACTACAACTC-3’ 
rev: 5’-AGCAGTACGTCCCTTCGCTCT-3’ 
66 ºC 
66 ºC 
223 bp 
Dynein Light 
Intermediate 
Chain 
fwd: 5’-CGGTACCTCTGGTCATAATTGG-3’ 
rev: 5’-AGGAGGAGATCCTATTTGACCG-3’ 
66 ºC 
66 ºC 
281 bp 
KIF5C 
fwd: 5’-GAGCAGCTCACCAAAGTTCACA-3’ 
rev: 5’-CTTGGCGATCTGGGCTGAATG-3’ 
66 ºC 
66 ºC 
253 bp 
GAPDH 
fwd: 5’-CCATCACCATCTTCCAGGAGCGA-3’ 
rev: 5’-GGATGACCTTGCCCACAGCCTTG-3’ 
66 ºC 
66 ºC 
447 bp 
 
2.2.14. Statistical analysis 
Statistical analyses were performed using minitab15 and GraphPad Prism5. A variety of 
statistical tests for significance were used depending on the application. Tests used include 
the one- and two-tailed T-Tests and one-way and two-way ANOVA with Bonferroni’s post-
hoc tests. 
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3.1. Introduction 
3.1.1. Neurofilament degradation 
3.1.1.1. Background 
 
The major protein degradative pathways in the cell are the ubiquitin proteasome system, the 
autophagy-lysosome system (which includes the cathepsins) and the calpain system. A role 
for calpain in NF degradation has been extensively documented. All three NF subunits have 
been shown to be degraded by both µ- and m-calpain in in vitro experiments (Heijink et al, 
2000, Kamakura et al, 1985, Shields et al, 1997), with NF-M being the most susceptible, 
followed by NF-L and NF-H respectively. Additionally in vitro experiments revealed that 
NFs were also degraded by cathepsin B but the order of susceptibility to degradation was 
altered to NF-M > NF-H > NF-L (Kamakura et al 1985). The cleavage of NF-L in protein 
homogenates from rat optic nerves incubated with calcium was inhibited by E-64 (Shields 
et al 1997), a cysteine protease inhibitor which in the past was frequently used to inhibit 
calpain (Iwasaki et al, 1987). However E-64 is a general cysteine protease inhibitor that 
also inhibits cathepsins B, H and L and is therefore not a specific calpain inhibitor (Barrett 
et al, 1982, Gour-Salin et al, 1994, reviewed by Rubinsztein et al, 2009). 
 
Calpain has also been implicated in neurofilament degradation following cellular stress. NF 
degradation during anoxia and reoxygenation of transected rat optic nerves was abolished 
following calcium removal and reduced in the presence of two different calpain inhibitors 
(Stys & Jiang, 2002). In an animal model of spinal cord injury, NF degradation was 
prevented by leupeptin and E-64 suggesting a role for calcium activated neutral proteases 
in spinal cord injury (Iwasaki et al, 1987). In zymosan-induced model of inflammation 
calpain activation and the breakdown of NF-L was prevented by the calpain inhibitor 
MDL28170, suggesting that calpain is involved in NF-L degradation (Kunz et al, 2004). 
Further support of the role of calpain in neurofilament degradation comes from the 
similarity of the breakdown products in rat transected nerves with the products resulting 
from an experimental model of calpain-induced proteolysis by Western blotting (Schlaepfer 
et al, 1985).  
 
Fasani et al (2004) investigated the role of trypsin and α-chymotrypsin in neurofilament 
degradation because in their hands the proteolysis of isolated neurofilaments by calpain and 
other cysteine activated proteases was very low. They found that trypsin and α-
chymotrypsin could degrade all three neurofilament subunits but that NF-M exhibited the 
most resistance to proteolysis. 
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Another candidate protease for neurofilament turnover is the lysosomal enzyme cathepsin 
D. Its role in neurofilament degradation has previously been investigated using an in vitro 
approach in which neurofilament proteins prepared from post-mortem human brain were 
incubated with cathepsin D (also purified from post-mortem human brain). All three 
neurofilament subunits were degraded by cathepsin D but the higher molecular weight 
subunits exhibited a greater degree of proteolysis than NF-L (Nixon & Marotta, 1984). A 
role for cathepsin D was also suggested by Suzuki et al (1988) who showed that purified 
bovine brain cathepsin D degraded neurofilaments in a crude neurofilament fraction from 
bovine brain. 
 
3.1.1.2. Determination of half-life of proteins  
 
Pulse chase analysis, which involves the pre-incubation of cells with radiolabelled amino 
acid precursors such as 35S-labelled methionine or cysteine to label proteins, is among the 
most widely used methods to determine protein half-lives because of the minimum impact 
this method has on cellular metabolism. During the chase period an excess of non-
radiolabelled precursor molecules is added to prevent cells from incorporating any more 
radiolabel into proteins. During the chase period cell extracts are prepared at a number of 
time-points and the protein of interest is isolated by immunoprecipitation and the eluate is 
then analysed by SDS-PAGE (Zhou, 2004).  
 
Pulse chase analysis is technically demanding and requires immunoprecipitation of the 
target protein out of the mix of radio-labelled proteins. Immunoprecipitation is best suited 
to work with soluble proteins and may not be appropriate for the isolation of 
neurofilaments (which are mainly insoluble) for half-life determination experiments. To 
avoid immunoprecipitation, the radio-labelled target protein could be added directly to cells 
but this requires microinjection which is itself technically demanding. Due to health and 
safety concerns there is also a move to move away from techniques requiring radioactive 
labelling when an alternative technique is available.   
 
Another method often used to determine protein half-life is the interruption of new protein 
synthesis by compounds such as cycloheximide (CHX), combined with inhibition of 
different proteolytic pathways. Cycloheximide (CHX) is an antibiotic produced by 
Streptomyces griseus which inhibits protein synthesis in eukaryotes, by interrupting peptide 
chain elongation (Baliga et al, 1969) via binding to the 60S ribosomal subunit of the 80S 
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ribosome (Figure 3.1, Stocklein & Piepersberg, 1980). CHX has been used in SH-SY5Y 
cells over-expressing α-synuclein to assess the effect of proteasome inhibition on the levels 
of α-synuclein (Tofaris et al, 2001). Ren et al (2003) used puromycin (another protein 
synthesis inhibitor) to investigate the role of the proteasome in the degradation of α-tubulin 
in HEK293 cells.  
 
Figure 3.1 Schematic diagram illustrating the inhibition of translational elongation by cycloheximide 
(CHX).  
During translational elongation eEF2 facilitates the translocation of deacylated-tRNA from the P-site on the 
60S ribosome to the E-site after peptide bond formation and the translocation of the peptidyl-tRNA from the 
A-site to the P-site. The A-site is now free to accept the next aminoacyl-tRNA, the binding of which requires 
the action of eEF1A. Cycloheximide binds to the E-site on the 60S ribosomal subunit. The binding of 
cycloheximide interferes with the release of the deacylated-tRNA which stalls the ribosome and blocks 
translational elongation. The ability of Cycloheximide to bind to the E-site even when occupied by deacylated 
tRNA allows cycloheximide to interrupt translational elongation at any time (Schneider-Poetsch et al, 2010). 
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A comparison of different approaches to the determination of cytoskeletal protein half-life 
can be found in Table 3.1. Neurofilament turnover in mice using pulse-chase analysis has 
been reported to be biphasic, with a fast turnover rate and a slow turnover rate. The 
different turnover rates have been attributed to two different NF populations, the fast rate 
belonging to the more motile element while the slow turnover rate belonged to the more 
stationary element, which was most likely incorporated into the axonal cytoskeleton (Nixon 
& Logvinenko, 1986). The biphasic turnover of cytoskeletal proteins has also been reported 
by Safaei and Fischer (1990) in rats in which slower turnover rates were observed in the 
Triton X-100 insoluble fractions. Neither of these studies employed immunoprecipitation 
techniques to isolate NFs and other cytoskeletal proteins from the protein fractions 
analysed. Instead they used Coomassie blue staining of SDS-polyacrylamide gels (SDS-
PAG) and immunoblotting to identify the bands corresponding to the NF subunits and the 
other cytoskeletal proteins investigated. 
 
Table 3.1 Summary of half-life data of cytoskeletal proteins determined in vivo from animal models 
or in vitro using cultured cells. 
Cytoskeletal 
Element 
in vivo or 
in vitro 
Method T(1/2) Reference 
NF-H, NF-L and 
NF-M 
in vivo, 
mice 
Pulse-chase 
[3H]-proline injected 
intracranially 
20 d 
and  
55 d 
Nixon and Logvinenko 
(1986) 
NF-H, NF-L and 
NF-M 
in vivo, 
rats 
Pulse-chase [35S]-methionine 
injected intracranially 
18 d Safaei and Fischer (1990) 
NF-L 
in vivo, 
mouse 
Inducible expression of hNF-
L. Turned off the expression 
of hNF-L then analysed 
samples by Immunblotting 
21 d Millecamps et al (2007)  
α-tubulin 
in vivo, 
rats 
Pulse-chase [35S]-methionine 
injected intracranially 
4.8 d  
and 
15 d  
Safaei and Fischer (1990) 
α-tubulin 
in vitro, 
HEK293 
cells 
Inhibition of protein synthesis 
by puramycin. Monitored NF 
by immunobloting 
22.5 h Ren et al (2003) 
 
In the transgenic mouse model (mNF-L-/-) with inducible human NF-L expression, NF-L 
expression was controlled using a Tet-off tetracycline-regulated system. Half-life was 
determined by switching-off hNF-L expression with doxycycline treatment and cerebellum 
extracts from animals treated over an 8 week time-course were analysed by SDS-PAGE and 
Western blotting with an anti-NF-L antibody (Millecamps et al, 2007). 
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There is a difference in the estimation of half-lives of proteins in cultured cells compared to 
half-life estimates in animal models. An example of this is the estimate of half-life of α-
tubulin: in rats it was in the order of 5-15 days (Safaei and Fisher 1990) whereas in 
HEK293 cells, half-life was estimated at 22.5 h (Ren et al 2003). Therefore, estimates of 
half-life for neurofilament proteins in proliferating SH-SY5Y neuroblastoma cells can be 
expected to be considerably less than 18-22 days. 
 
3.1.2. Degradative pathways involved in cytoskeletal protein turnover 
 
All three degradative pathways (UPS, the autophagy-lysosome systems and the calpain 
system) have been suggested to play a role in the turnover of cytoskeletal proteins 
(Kamakura et al, 1985, Nixon & Marotta, 1984, Ren et al, 2003, Stys & Jiang, 2002, Suzuki 
et al, 1988). The following section will consider the use of specific inhibitors in an analysis 
of the roles of various proteases in protein degradation, together with a limited review of 
different approaches used to monitor protease activities. 
 
3.1.2.1. The Ubiquitin Proteasome System 
 
The discovery and development of proteasome inhibitors has enabled researchers to 
investigate the role of this multi-enzyme complex, containing trypsin-like, chymotrypsin-
like and caspase-like activities, in many cellular processes. There are a number proteasome 
inhibitors available that differ in their specificity to the proteasome among the most 
frequently used are MG132, lactacystin and epoxomicin (reviewed in Groll & Huber, 
2004). Epoxomicin is the most specific proteasome inhibitor available at this time which 
even at concentrations as high as 50 µM does not inhibit papain, chymotrypsin, trypsin, 
cathepsin B or calpain (Sin et al, 1999).  
 
Epoxomicin was originally identified for its anti-tumour and anti-inflammatory properties 
which were discovered to be due to its ability to irreversibly inhibit the chymotrypsin-like, 
trypsin-like and caspase-like activities of the 20S proteasome by binding to the 20S catalytic 
subunits LMP2, LMP7, Z and MECL1 (Sin et al 1999). The unique specificity of 
Epoxomicin for the proteasome was explained when the crystal structure of the 
epoxomicin:20S proteasome complex was revealed. The binding of epoxomicin to the 20S 
proteasome results in the formation of a morpholino ring (6-atom ring) between the 
nucleophilic amino terminal threonine (Thr1) of the β5 (chymotrypsin-like activity) subunit 
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and the pharmacophore of Epoxomicin (Figure 3.2). A requirement for the formation of the 
morpholino ring is the presence of a nucleophilic amino terminal residue which is absent in 
most other proteases with the exception of other members of the Ntn (N-terminal 
nucleophile) family of hydrolases (Groll et al, 2000, reviewed in Groll & Huber, 2004). 
Epoxomicin most potently inhibits chymotrypsin-like activity, followed by trypsin-like 
activity and caspase-like activity (Kim et al, 1999). Proteasomes belong to the family of Ntn 
hydrolases since it is the hydroxyl group on the amino-terminal threonine which acts as a 
catalytic nucleophile which hydrolyses peptide bonds (Kisselev et al, 2000). 
 
Figure 3.2 A scheme describing the possible mechanism for the formation of the morpholino ring 
structure between the pharmacophore of Epoxomicin and the amino terminal threonine residue of 
the β5 subunit of the 20S proteasome (adapted from Groll et al, 2000). 
 
3.1.2.1. Calpain 
 
E-64 and leupeptin have frequently been used in the past as inhibitors for calpain; however 
these inhibitors are not specific for calpain since they also inhibit other cysteine proteases 
such as papain and cathepsin B. Another limitation to their use is that they are not 
membrane permeable making them unsuitable for the inhibition of calpain in situations 
where cell penetration is required. MDL28170 is a cell permeable calpain inhibitor which 
also inhibits cathepsin B and α-chymotrypsin to a small degree (reviewed by Mehdi, 1991), 
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and is now more frequently used. The most specific inhibitor for calpain is the endogenous 
calpain inhibitor calpastatin which is thought to play a role in the regulation of calpain 
activity in vivo. Interestingly the binding of calpastatin to calpain requires calcium but at a 
lower concentration than that required for calpain activation (reviewed by Goll et al, 2003). 
 
Synthetic peptides used to assay calpain activity are usually poorly soluble in aqueous 
solutions and need to be used at concentrations of 1-2 mM but calpain activity is not 
optimal under these conditions. Calpain cleaves proteins at a limited number of sites 
specified by the structural conformation of the polypeptide chain rather than amino acid 
sequence, resulting in large proteolytic fragments. Another difficulty is that calpain rapidly 
loses proteolytic activity when assayed at temperatures above 25 °C (Goll et al 2003).  
Numerous proteins have been identified that can be cleaved by calpain, including α-
tropomyosin, EGF receptor kinase, p35, desmin, MAP1, MAP2, tubulin, vimentin, 
neurofilament proteins, tau, myosin  and αII-spectrin among others (Goll et al 2003).   
 
A frequently used assay to monitor calpain activity involves the detection of calpain 
specific cleavage products of the cytoskeletal protein αII-spectrin Cleavage of αII-spectrin 
by calpain results in 150 kD and 145 kD spectrin breakdown products (SBDPs) which can 
be detected by immunoprobing Western blots with an anti-α-spectrin antibody. αII-spectrin 
can also be cleaved by the caspase 3, a cysteinyl protease usually activated in apoptosis as 
part of the cell death cascade (reviewed in Wang, 2000), but cleavage by caspase 3 results 
in 150 kD and 120 kD SBDPs (Alvira et al, 2008, Chen et al, 2006, Dutta et al, 2002, Lewis 
et al, 2007, Nath et al, 1996, Tamada et al, 2005, Veeranna et al, 2004, Wang et al, 1996). 
Therefore it is possible by SDS-PAGE and Western blotting to distinguish between calpain 
and caspase 3 specific cleavage of αII-spectrin by monitoring the levels of the 145 kD and 
120 kD SBDPs relative to full-length αII-spectrin (reviewed by Wang, 2000). 
 
3.1.2.2. Autophagy-Lysosome Pathway 
3.1.2.3.1. Macroautophagy 
 
There are several compounds available that can either inhibit or activate macroautophagy. 
Rapamycin activates autophagy by inhibiting mTOR (mammalian target of rapamycin), a 
natural inhibitor of macroautophagy (Cuervo et al, 2004, reviewed by Martinez-Vicente & 
Cuervo, 2007). A widely used inhibitor of macroautophagy is Bafilomycin A1 (an antibiotic 
isolated from Streptomyces) which inhibits vacuolar-type H+ ATPase by binding to its 
membrane spanning pore domain (reviewed by Yamamoto et al, 1998, Yoshimori et al, 
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1991). Vacuolar H+ ATPase is found in organelles of the central vacuolar system such as 
lysosomes and endosomes where it plays an important role in maintaining the acidic 
environment of these compartments. To facilitate the fusion of autophagosomes and 
lysosomes, vacuolar H+ ATPase acidifies the lumenal space of autophagosomes or 
lysosomes. So by inhibiting vacuolar ATPase, Bafilomycin A1 inhibits the fusion of 
autophagosome and lysosome (reviewed by Yamamoto et al, 1998). Another inhibitor of 
autophagy is 3-methyl adenine (3-MA) which inhibits autophagy by inhibiting autophagic 
vesicle formation (Seglen & Gordon, 1982). 
 
Several methods can be used to monitor the number of autophagosomes in cells as a result 
of a treatment with a compound of interest and include electron microscopy, fluorescence 
microscopy using GFP-LC3 or anti-LC3 or monitoring LC3-II levels on immunoprobed 
Western blots. Electron microscopy is a widely used method to monitor macroautophagy 
but is prone to misinterpretation and requires expert analysis. The quantification of 
autophagy by counting GFP-LC3 or anti-LC3 puncta needs to be on a per cell basis, which 
may be difficult especially when dealing with a large number of cells.  Whichever method 
is used, it is essential to remember that the accumulation of autophagosomes may be due to 
either increased autophagosome synthesis or reduced macroautophagy in which the fusion 
of autophagosomes with lysosomes is reduced or lysosomal proteolysis is affected 
(reviewed by Klionsky et al, 2008). 
 
As shown in Figure 3.2, LC3-II is found on the lumenal and cytosolic surfaces of the 
autophagosome. When the autophagosome fuses with the lysosome, the lumenal pool of 
LC3-II is degraded by lysosomal proteases and the cytosolic pool of LC3-II is cleaved by 
Atg4B and recycled (reviewed by Ichimura et al, 2008, and Rubinsztein et al, 2007).  
 
In higher eukaryotes, the levels of LC3-II (when using a loading control such as actin rather 
than LC3-I levels) are said to be a measure of the number of autophagic vesicles in a cell at 
a particular time. Since increased levels of LC3-II can result from increased autophagic 
vesicle synthesis or a reduction in autophagy, it is essential when trying to determine the 
effect of a treatment on autophagy to also look at LC3-II levels in the presence of inhibitors 
of autophagy. Since lysosomal protease inhibitors are not very specific, Bafilomycin A1 is 
often used in such instances (reviewed by Rubinsztein et al, 2009). 
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Figure 3.2 A diagrammatic representation of the role of LC3-II in autophagic vesicle formation. 
The levels of LC3-II can be used as a reporter to monitor the number of autophagosomes at a particular 
time. The microtubule associated protein 1 light chain 3 (MAP-LC3/Atg8/LC3) is cleaved at its C-
terminus to form LC3-I which becomes covalently conjugated to phosphatidylethanolamine to form LC3-
II. LC3-II is targeted to the Atg12-Atg5-Atg16 complex of the phagophore and remains associated with 
the expanding membrane of the autophagosome as it matures. LC3-II can be found on the lumenal and 
cytosolic surfaces of the autophagic membrane. When the lysosome and autophagosome fuse the lumenal 
population of LC3-II is degraded by lysosomal proteases while the cytosolic population is recycled. An 
inhibitor of macroautophagy, Bafilomycin A1 inhibits the fusion of autophagosome and lysosome 
(adapted from Rubinsztein et al, 2009).  
 
According to Rubinsztein et al (2009), LC3-II levels in Bafilomycin treated cells expressed 
as a ratio of the levels in untreated cells gives an indication of the effect of a particular 
compound on autophagy. In their review of the use of LC3-II levels to measure autophagy, 
they describe three different scenarios in which treatments with compounds affect LC3-II 
levels either by increasing/decreasing autophagosome degradation or by increasing 
autophagosome synthesis. The three scenarios are represented in the cartoon in Figure 3.3. 
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Figure 3.3 A cartoon illustrating three theoretical scenarios in which a compound of interest may 
result in a change in the levels of LC3-II.  
To discern the effect of the compound on autophagy, samples are either untreated, treated with 
Bafilomycin A1 (BafA1), treated with the compound or treated with the compound and Bafilomycin A1. 
The levels of LC3-II (corrected for protein loading with actin, tubulin, etc) are compared to the levels of 
LC3-II in untreated samples (Rubinsztein et al, 2009). 
 
3.1.2.3.2. Lysosomal Proteases 
 
The most abundant lysosomal proteases are the cathepsins which include the aspartyl 
cathepsins (D and E), the cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, X) and the 
serine cathepsin G (reviewed by Pillay et al, 2002). Surprisingly, some cysteine cathepsin 
splice variants are apparently found outside the lysosome in other cellular compartments or 
extracellularly (reviewed by Vasiljeva & Turk, 2008). Pepstatin A is a potent inhibitor of 
the aspartyl cathepsins, D and E as well as pepsin and rennin but has no effect on the 
activity of neutral and alkaline proteases (Marciniszyn et al, 1976). Cathepsin inhibitor II 
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(Z-FG-NHO-BzMe) is a serine and cysteine protease inhibitor that inhibits the cysteine 
cathepsins B, L, S and papain (Demuth et al, 1996). 
 
3.1.2. Aims 
 
Despite the large volume of literature available on neurofilaments not much is known about 
the degradative pathways involved in their turnover in unstressed conditions. Cellular stress 
can lead to the activation of degradative pathways and the subsequent degradation of 
proteins (Iwasaki et al, 1987, Kunz et al, 2004, Schlaepfer et al, 1985, Stys & Jiang, 2002) 
which may or may not normally be degraded by these proteases when cells are not stressed. 
Exposure to some compounds may even lead to the inhibition of the activity of a particular 
pathway (Caneda-Ferron et al, 2008, Zeng et al, 2006), which will prevent the degradation 
of its particular protein substrates. This chapter aims to provide further insight to the 
degradative pathways involved in neurofilament turnover in Human SH-SY5Y 
neuroblastoma cells in unstressed conditions. The second aim of this chapter is to 
investigate the effect of mitochondrial dysfunction (as a consequence of MPP+ treatment) 
and dopamine induced oxidative stress on the modulation of degradative pathways in 
general and on neurofilament turnover in particular. 
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3.2. Results 
3.2.1. Optimal cycloheximide concentration of assessment for the 
determination of cytoskeletal protein half-life  
 
To estimate the half-lives of various cytoskeletal proteins, including NFs, in proliferating 
SH-SY5Y cells, cells were treated with cycloheximide (CHX) over a period of 72 hours. 
The concentration of CHX that gave the most consistent estimates of half-life was 
determined by comparing a range of CHX concentrations.  
 
The levels of NFs, α-tubulin and vimentin were monitored by probing Western blots of total 
cell extracts harvested every 24 hours over the 72 hour time-course, and time points 
compared by densitometric analysis. The arbitrary densitometry units (ADU) or signal at 
each time-point was expressed as a percentage of the signal or ADU at 0 hours. The natural 
logarithm of the percentage of the original signal [Ln(% original signal)]  was plotted 
against time. Half-lives were calculated from the gradient (k or decay rate constant) of the 
‘line of best fit’ obtained from these plots.  
The equation (equation 2) used to calculate half-life which was derived from equation 1 as 
illustrated below: 
 
  
 
 
 
 
CHX treated cells (2 – 20 µg/ml) had a shrunken morphology and with the exception of 
cells treated with 2 µg/ml cycloheximide, fewer cells were visible after 48 and 72  hours 
treatment (Figure 3.4 A). To monitor the effect of CHX on cell viability, the number of 
viable cells was determined by trypan blue exclusion and expressed as a percentage of the 
total number of cells (Figure 3.4 B). Data suggested that with 10 µg/ml and 20 µg/ml CHX 
there was slight toxicity at 48 hours and that by 72 hours only around half the cells survived 
compared to the control; 5 µg/ml CHX only became toxic at 96 hours 
 
    Ct =level at time t 
     Co = original level 
(1) Ct = Coe-kt  k = decay rate constant 
     t = time 
 
(2) → T(1/2) = Ln(2)/k 
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Figure 3.4 Assessment of the effect of cycloheximide (CHX) treatment of the viability of SH-SY5Y 
neuroblastoma cells. 
(A) Phase contrast images of human SH-SY5Y neuroblastoma cells treated with 2 to 20 µg/ml 
cycloheximide over a 72 hour time-course. Cells were viewed at 100 x magnification, scale bar 
represents 40 µm and n = 4. (B) The percentage of viable cells treated with 2 to 20 µg/ml cycloheximide 
was determined by trypan blue exclusion and expressed as a percentage of the total number of cells. 
Error bars represent range, n = 2. 
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The estimates of half-life for the three NF subunits, α-tubulin, vimentin and α-synuclein 
obtained from their decay rate constants, using concentrations of CHX ranging from 2 to 20 
µg/ml, are given in Table 3.2. An example of a typical Western blot and the resultant plots 
from which decay rate constants were determined is depicted in Figure 3.5 which details the 
half-life determination of NF-L.  To reliably estimate half-life from the decay rate constant, 
only estimates from ‘lines of best fit’ with high R2 values (0.8 and above) were considered. 
In general cells treated with 2 or 5 µg/ml CHX yielded fewer reliable estimates than cells 
treated with 10 and 20 µg/ml CHX. Due to the likely increased toxicity of 20 µg/ml CHX, a 
concentration of 10 µg/ml was selected for use in subsequent experiments.  
 
Table 3.2 Table summarizing the estimates of half-life for the neurofilament subunits, vimentin and 
α-tubulin using a range of cycloheximide concentrations. 
Estimates of half-life were obtained when plotting the natural logarithm of the percentage original signal 
[Ln(% original signal)] against time (h). The number of experiments with R2 values high enough (0.8 and 
above) to be included in the estimate of half-life are indicated in brackets. Half-life is expressed in hours 
± range (if only two experiments were included) or standard deviation (if three or more experiments were 
included). 
T(1/2), h 
Concentration of Cycloheximide (µg/ml) Protein 
2 µg/ml 5 µg/ml 10 µg/ml 20 µg/ml 
NF-H No estimate 58 ± 47 (2) 53.2 ± 28.3 (3) 40.2 ± 23.5 (2) 
NF-M No estimate 40.5 (1) 66.6 ± 7.8 (3) 40.5 ± 9.1 (3) 
NF-L 51.1 ± 11.4 (3) 37.6 ± 13.9 (3) 40 ± 8.8 (3) 34.1 ± 10.4 (4) 
Vimentin 28.9 (1) 44.2 ± 13 (3) 46.4 ± 26.6 (4) 27.3 ± 14.4 (4) 
α-Tubulin 29.8 ± 12.1 (3) 42.3 ± 18.3 (3) 31.1 ± 10.1 (3) 16.4 ± 13.1 (2) 
α-Synuclein 40.3 (1) 38.7 (1) 21.8 ± 9.1 (2) 23.3 (1) 
 
 
Chapter 3 Degradative Pathways involved in Neurofilament Turnover 
 89 
 
 
 
Figure 3.5 Example of Western blots and plots from which the half-life of proteins were calculated. 
Representative blots of total cell extracts of SH-SY5Y cells treated with 2 -20 µg/ml cycloheximide over 72 
hours, probed with anti-NF-L (DA2, from Zymed). Plots show estimates of NF-L half-life using 2 -20 µg/ml 
cycloheximide from Western blots from three or four (in the case of 20 µg/ml cycloheximide) individual 
experiments.  Briefly, immunoprobed blots were analysed using AIDA densitometry software and the signal 
for the NF-L band at each time-point was expressed as a percentage of the original signal at t = 0 h. The 
natural logarithm of the percentage original signal [Ln(% original signal)] was plotted against time and the 
gradient of the line of best fit (decay rate constant - k) was used to calculate half-life using the equation: 
T(1/2) = Ln(2)/k. The mean half-life [T(1/2)] ± standard deviation calculated from the decay rate constants 
from each experiment is quoted above each plot. 
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3.2.2. Degradative pathways involved in neurofilament turnover  
 
To establish which degradative pathways are involved in neurofilament turnover, 
proliferating SH-SY5Y cells were treated with 10 µg/ml CHX in the presence of 
Epoxomicin (proteasome inhibitor), Bafilomycin A1 (inhibitor of autophagy), MDL28170 
(calpain inhibitor)  or Pepstatin A (Cathepsin D inhibitor, aspartyl cathepsins) over a 72 
hour period. The half-lives estimated for the three NF subunits in the presence or absence of 
each of the inhibitors listed above are summarized in Table 3.3.  
 
The half-life of NF-H (Table 3.3) was estimated to be 48.6 ± 4.4 h (n =25). The half-life of 
NF-H was not significantly altered by epoxo or MDL28170 but inhibition of 
macroautophagy with BafA1 resulted in an increase in NF-H half-life to 134 ± 17.1 h, this 
increase in half-life was also observed in cells treated with PepA which inhibits cathepsin D 
[T(1/2) > 169.1 h] and in cells treated with epoxo, MDL28170 and BafA1 in combination 
(117 ± 11.7 h). The half-life of NF-H in the presence of Pepstatin A is quoted as greater 
than 169.1 h since levels of NF-H in two experiments did not drop, and the value is based 
on one experiment in which levels did decrease slightly over the 72 h time-course; it is clear 
however that pepstatin inhibited NF-H degradation. 
 
The half-life of NF-M (Table 3.3) was estimated to be 53.5 ± 3.6 h (n = 21). Inhibition of 
the proteasome (epoxo), calpain (MDL28170) and macroautophagy (BafA1) had no effect 
on this half-life.  
 
Compared to the half-life of the two larger NF subunits, the half-life of NF-L was 
significantly shorter (p < 0.05) at 37.2 ± 2.6 h (n = 27). As for NF-M, inhibition of the 
proteasome, macroautophagy, calpain and cathepsin D had no effect on the half-life of NF-
L. The half-life of NF-L in cells treated with epoxo, BafA1 and MDL28170 in combination 
was similar to that in control cells. 
 
The effects of inhibition of the proteasome, macroautophagy, calpain and cathepsin D on 
the half-lives of α-tubulin (a component of the microtubule network) and vimentin (an 
intermediate filament protein) were also determined (Table 3.3). The half-life of α-tubulin 
and vimentin were respectively estimated as 41.2 ± 4 h (n = 18) and 41.8 ± 4.1 9 h (n = 21), 
both significantly shorter than that of NF-M (p < 0.05). Inhibition of the proteasome, 
macroautophagy, calpain and cathepsin D had no significant effect on the half-lives of α-
tubulin and vimentin.  
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Table 3.3 Estimates of half-life (T(1/2), h) and the effect of inhibition of the proteasome, 
macroautophagy , calpain and cathepsin D on the half-life of α-tubulin, α-synuclein, vimentin, NF-
H, NF-M and NF-L.  
Half-life is quoted as T(1/2) ± SEM. In experiments for which T(1/2) could not be calculated because the 
slope of the line of best fit (k, rate constant) was positive, half-lives were quoted as greater than a value 
for that protein that could be calculated. The half-life if NF-L is significantly shorter than that of NF-H 
and NF-M (*Two-tailed T-Test, p < 0.05). The half-lives of α-tubulin, α-synuclein and vimentin are 
significantly shorter than that of NF-M (†Two-tailed T-Test, p < 0.05). The half-life of NF-H was 
increased following inhibition of macroautophagy and cathepsin D (§Two-tailed T-Test, p < 0.05). 
T(1/2) ± SEM, h 
Treatment 
NF-H NF-M NF-L α-tubulin vimentin 
α-
synuclein 
Untreated 
(Cycloheximide) 
48.6 ± 4.4 
(n = 25) 
53.5 ± 3.6 
(n = 21) 
37.2 ± 2.6* 
(n = 27) 
41.2 ± 4† 
(n = 18) 
39.4 ± 
3.7† 
(n = 24) 
31.4 ± 
6.7† 
(n = 4) 
Inhibition of 
proteasome 
(Epoxomicin) 
37 ± 11.4 
(n = 4) 
36.6 ± 8.7 
(n = 3) 
29.9 ± 7.3 
(n = 4) 
39.8 ± 8.7 
(n = 4) 
34.0 ± 1.0 
(n = 4) 
346.6 
Inhibition of 
macroautophagy 
(Bafilomycin 
A1) 
134 ± 
17.1§ 
(n = 4) 
57.9 ± 13.4 
(n = 4) 
40.9 ± 7.6 
(n = 4) 
38.7 ± 4.6 
(n = 3) 
44.7 ± 
17.3 
(n = 4) 
>346.6 
Inhibition of 
calpain 
(MDL28170) 
25.9 ±3.0 
(n = 4) 
50.3 ± 10.6 
(n = 4) 
31.7 ± 3.2 
(n = 4) 
21.0 ± 4.3 
(n = 4) 
43.3 ± 
12.9  (n = 
4) 
>346.6 
Inhibition of 
cathepsin D 
(Pepstatin A) 
> 169.1§ 
(n = 3) 
ND 
38.4 ± 2.6 
(n = 3) 
63.7 ± 29.0 
(n = 4) 
25.2 ± 2.6 
(n = 4) 
24.7 
Epoxomicin, 
Bafilomycin A1 
and MDL28170 
117 ± 
11.7§ 
(n = 3) 
53.8 ± 11.5 
(n = 3) 
30.4 ± 3.5 
(n = 2) 
ND 
32.2 ± 7.2 
(n = 3) 
ND 
 
To confirm that the inhibition of degradative pathways in the presence of CHX could 
elucidate pathways involved in the turnover of proteins of interest the effect of inhibition of 
the proteasome, macroautophagy, calpain and cathepsin D on the half-life of α-synuclein 
was investigated (Table 3.3). The half-life of α-synuclein was estimated to be 31.4 ± 6.7 h 
(n = 4) which is significantly shorter than that of NF-M (p < 0.05). Inhibition of cathepsin D 
with PepA had no effect on α-synuclein half-life but inhibition of the proteasome, 
macroautophagy and calpain all resulted in a large increase in α-synuclein half-life. In the 
case of Bafilomycin A1 and MDL28170, half-lives were quoted as greater that 346.6 h 
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because the levels of α-synuclein did not decrease over the 72 h time-course and as a result 
half-life could not be estimated using the decay rate constant and the equation for half-life.    
 
To confirm that NF-H is degraded by macroautophagy, cells were treated with 0.2 µg/ml 
Rapamycin (an inducer of autophagy) in the presence of 10 µg/ml CHX for 48 h. Cells were 
also treated with 10 nM BafA1 and 5 mM 3-methyl adenine (3-MA, another inhibitor of 
autophagy), both in the presence of CHX for 48 h. Western blots probed with anti-NF-H 
(n52) showed that an induction of autophagy by rapamycin resulted in a decrease in NF-H 
levels compared to levels in CHX treated controls (Figure 3.6). The levels of NF-H were 
maintained in cells treated with BafA1 and 3-MA. 
 
Figure 3.6 Effect of the activation of macroautophagy by Rapamycin on the levels of NF-H 
compared to levels in total cells extracts of cycloheximide treated control cells.  
(A) A representative Western blot of total cell extracts of SH-SY5Y cells treated with either 0.2 µg/ml 
Rapamycin (Rapa), 10 nM Bafilomycin A1 (BafA1) or 5 mM 3-methyl adenine (3-MA) in the presence 
of cycloheximide (CHX) probed with anti-NF-H (n52; 1:2000, Sigma). (B) Plot summarising the results 
of densitometric analysis of Western blots. The levels of NF-H were significantly lower in cells treated 
with Rapamycin than in CHX treated control cells (p < 0.05, One-way ANOVA, n = 5). 
 
3.2.3. Does inhibition of one pathway activate another? 
 
Since it has not been possible in most cases to clearly assign a pathway(s) involved in the 
turnover of all three NF subunits, the possibility that the inhibition of one proteolytic 
pathway resulted in a compensatory activation of one of the other pathways was 
investigated.  
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3.2.3.1. Effect of inhibiting various proteolytic pathways on proteasome activity 
 
Chymotrypsin-like activity (CLA), chosen to represent proteasome activity, was assessed 
for cells treated with CHX in the presence or absence of epoxo, BafA1 and MDL28170 
using a fluorogenic peptide assay as described in section 2.2.4. Interestingly, CLA was 
significantly reduced in cells treated with 10 µg/ml CHX for 72 hours compared to 
untreated cells (Figure 3.7 A). This decrease in CLA is likely to be due to decreased 
proteasome levels since new protein synthesis is inhibited rather than a direct effect on the 
proteasome. CLA was significantly reduced by epoxomicin (by up to 60% with 5 nM and 
75% by 10 nM epoxo), but the other inhibitors had no significant effect on CLA.  
 
 
Figure 3.7 The effects of treatment with various protease inhibitors on chymotrypsin-like activity 
(CLA) in SH-SY5Y cells  
(A) CLA was determined in extracts from untreated control cells compared to cells treated with 10 µg/ml 
cycloheximide (CHX) over a 72 h time-course. CLA was significantly reduced in CHX treated cells after 
72 h (p < 0.05, n = 3, Paired T-Test). (B) CLA in cells treated with either epoxomicin (5 nM or 10 nM), 5 
nM Bafilomycin A1 or 10 µM MDL28170 in the presence or absence of CHX. CLA was significantly 
reduced in cells treated with 5 and 10 nM epoxomicin after 48 and 72 hours (**p < 0.005; Two-way 
ANOVA, n = 3). Error bars represent standard deviation. 
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3.2.3.2. Effect of inhibiting proteolytic pathways on the cleavage of αII-spectrin 
 
To determine whether cycloheximide treatment results in the activation of calpain and/or 
caspase 3, the levels of the 145 kD calpain-specific spectrin breakdown product (SBDP) 
and the 120 kD caspase 3-specific SBDP relative to the full-length αII-spectrin were 
compared in cells treated with CHX for 48 h and untreated controls. The determination of 
the apparent molecular weights of the SBDPs by comparing their electrophoretic mobility 
to that of a set of molecular weight standards run on the same SDS-PAG is described in 
appendix I. Initial results suggest that after 48 h treatment with CHX no significant increase 
in the levels of the calpain and caspase 3 specific SBDPs of αII-spectrin was observed 
(Figure 3.8). 
 
 
Figure 3.8 The activation of caspase 3 and calpain after 48 h treatment of SH-SY5Y cells with µg/ml 
cycloheximide was assessed indirectly by monitoring the levels of αII-spectrin 145 kD and 120 kD 
cleavage products.  
(A) Representative Western blot of total cell extracts of SH-SY5Y neuroblastoma cells either untreated or 
treated with 10 µg/ml Cycloheximide for 48 h, probed with anti-αII-spectrin (Sigma, 1:1000). (B) Plot 
summarising the results of densitometric analysis of the Western blot. The arbitrary densitometry units 
(ADU) of the 145 kD and 120 kD spectrin breakdown products (SBDP) were expressed as a ratio of the 
full-length αII-spectrin for each sample. Error bars represent standard deviation (n = 3). 
 
 
Inhibition of macroautophagy by BafA1 resulted in an increase in the production of the 145 
kD and 120 kD SBDPs after 24 h compared to the control at the same time-point (Two-way 
ANOVA, Figure 3.9). However after 48 and 72 h, results were very variable making it 
difficult to come to any conclusion about the activation of calpain and/or caspase 3. No 
effect of the inhibition of calpain (with MDL28170), the proteasome (epoxo) or cathepsin D 
(PepA) was observed compared to the control at each time-point. When comparing the 
levels of the 145 kD and 120 kD SBDPs for each treatment with time by one-way ANOVA, 
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an increase in the 145 kD SBDP was observed after 72 h in controls and with proteasome 
inhibition and an increase in the 120 kD SBDP was observed in controls (after 48 and 72 h) 
and with proteasome and calpain inhibition for 72 h.  
 
Figure 3.9 Effect of inhibition of proteolytic pathways on the cleavage of αII-spectrin in SH-SY5Y 
neuroblastoma cells. 
Effect of the inhibition of calpain, the proteasome, macroautophagy and cathepsin D on the activation of 
caspase 3 and/or calpain was assessed indirectly by monitoring the levels of (A) 145 kD and (B) 120 kD 
αII-spectrin breakdown products (SBDPs). Plots summarise the results of densitometric analyses of 
Western blots of total cell extracts probed with anti-αII-spectrin (Sigma, 1:1000). The arbitrary 
densitometry units (ADU) of the 145 kD and 120 kD spectrin breakdown products (SBDP) were 
expressed as a ratio of the full-length αII-spectrin for each sample. The effect of each treatment on the 
levels of SBDPs was assessed over time (†One-way ANOVA, Bonferroni posthoc test). There was a 
significant increase in the cleavage of αII-spectrin after 48 and 72 h treatment with CHX. The effect of 
treatment with proteolytic inhibitors on the levels of SBDPs over time was compared to the levels of 
SBDPs in the CHX treated control over time (*Two-way ANOVA, Bonferroni posthoc test). Error bars 
represent standard deviation (n = 3). 
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3.2.3.3. Effect of inhibiting proteolytic pathways on macroautophagy 
 
 
Figure 3.10 Effect of inhibition of proteolytic pathways in SH-SY5Y neuroblastoma cells on the levels 
of LC3-II to monitor the inhibition or activation of macroautophagy. 
Western blots of total cell extracts from cells treated with 10 µg/ml Cycloheximide (CHX) with/without (A) 
10 µM MDL28170 inhibiting calpain, (B) 5 nM Epoxomicin inhibiting the proteasome, (C) 10 nM 
Bafilomycin A1 inhibiting macroautophagy or (D) 1 µM Pepstatin A inhibiting cathepsin D, immunoprobed 
with anti-LC3 (1:1000) and anti-actin (1:1000). Plots summarise the results of densitometric analyses of 
LC3-II levels (corrected for total protein with actin) expressed as a ratio of LC3-II levels in CHX treated 
controls. In cells treated with Bafilomycin A1, levels of LC3-II were increased compared to CHX treated 
controls (Two-tailed T-Test, p < 0.05). Error bars represent standard deviation (n = 3). 
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The levels of LC3-II in total cell extracts of cells treated with MDL28170, epoxomicin 
(epoxo), Bafilomycin A1 (BafA1) or Pepstatin A (PepA) in the presence of CHX were 
monitored (Figure 3.10). Inhibition of macroautophagy with BafA1 resulted in an increase 
in LC3-II levels (around four-fold) compared to the levels in CHX treated control cells but 
there was no effect on LC3-II levels with inhibition of calpain, the proteasome or cathepsin 
D. 
 
3.2.3.4. Effect of inhibiting proteolytic pathways on the activity of aspartyl and 
cysteine cathepsins 
 
The effect of the inhibition of calpain with MDL28170, the proteasome with Epoxomicin, 
macroautophagy with Bafilomycin A1 (BafA1), cathepsin D (aspartyl cathepsin) with 
Pepstatin A (PepA) or the cysteine cathepsins (L, B, C, F, H, K, O, S, V, W, X) with 
Cathepsin Inhibitor III on the activity of the aspartyl and cysteine cathepsins was 
investigated using fluorogenic peptide assays. Since all the half-life data were obtained in 
cells treated with CHX, the effects were investigated in the presence of CHX (Figure 3.11).  
 
Figure 3.11 Effect of inhibition of proteolytic pathways in SH-SY5Y cells on cathepsin activity. 
The influence of the inhibition of calpain (with MDL28170), the proteasome (with Epoxomicin), 
macroautophagy (with Bafilomycin A1), cathepsin D (with Pepstatin A) or the cysteine cathepsins (with 
Cathepsin inhibitor III) in the presence of cycloheximide (CHX) on the activity of (A) cysteine cathepsins and 
(B) cathepsin D was assessed using fluorogenic peptide assays. Activity (FL units/min/µg protein) was expressed 
as a percentage if the activity in CHX treated controls. Cysteine cathepsin activity was reduced with inhibition of 
macroautophagy and cysteine cathepsins but increased with calpain inhibition (two-tailed T-Test, p < 0.05). 
Cathepsin D activity was reduced following inhibition of cathepsin D but was unaffected by inhibition of 
proteolytic pathways (two tailed T-Test, p < 0.05). Error bars represent standard deviation (n = 3).  
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The inhibition of macroautophagy with BafA1 and calpain with MDL28170 altered cysteine 
cathepsin activity. BafA1 reduced cysteine cathepsin activity to 58.5 ± 17 % of the activity 
in CHX treated control cells whilst MDL28170 increased cysteine cathepsin activity to 
239.7 ± 45 % of activity in CHX treated control cells. Treatment with cathepsin inhibitor III 
resulted in complete inhibition of cysteine cathepsin, confirming that the activity measured 
is that of the cysteine cathepsins (Figure 3.11 A). However, with the exception of Pepstatin 
A (which resulted in complete inhibition of cathepsin D activity) treatment with the other 
inhibitors had no effect on cathepsin D activity (Figure 3.11 B). 
 
3.2.4. Effects of MPP+ and dopamine on neurofilament turnover and 
degradative pathways 
3.2.4.1. Effect of MPP+ and DA on the half-life of neurofilament proteins, α-
tubulin and vimentin 
 
To investigate whether MPP+ and/or dopamine has an effect on the half-life of 
neurofilament proteins, cells were treated with either 2 mM MPP+ or Dopamine (DA; 100 
µM or 500 µM) in the presence of 10 μg/ml CHX over a 72 hour time-course (Table 3.4). 
Significance tests were performed using a paired T-Test in which half-life estimates from 
total cell extracts of MPP+/CHX and DA/CHX treated cells were compared to estimates of 
half-life obtained from the CHX treated controls for each experiment. The values for half-
life quoted in Table 3.4 were calculated using the percentage change in half-life in cells 
treated with MPP+/CHX or DA/CHX compared to their own CHX controls, multiplied by 
the mean half-life estimated from all the experiments in which cells were treated with CHX 
alone. 
 
The half-life of NF-L in cells treated with 2 mM MPP+ in the presence of CHX was 
estimated to be shorter at 24.4 ± 2.1 h than that estimated in cells treated solely with CHX. 
2 mM MPP+ treatment reduced the estimated half-lives of NF-H, NF-M, α-tubulin and 
vimentin but the effect was not statistically significant. 
 
Treatment of cells with 100 µM DA had no significant effect on the half-lives of the five 
cytoskeletal elements but in all cases the mean values for half-life tended to be greater than 
half-lives estimated in cells treated only with CHX.  In cells treated with 500 µM DA 
however the half-lives of all five cytoskeletal elements were significantly lower than in cells 
treated only with CHX.  
 
Chapter 3 Degradative Pathways involved in Neurofilament Turnover 
 99 
Table 3.4 Estimates of half-life (T(1/2), h) and the effect MPP+ and dopamine (DA) treatment on 
the half-life of α-tubulin, vimentin, NF-H, NF-M and NF-L.  
Half-life is quoted as T(1/2) ± SEM and was calculated by multiplying the percentage change in half-life 
for MPP+/CHX and DA/CHX compared to CHX treated controls with the mean half-life estimated for all 
CHX treated control experiments (n ≥ 18). To test for significance, the half-life estimated in the presence 
of MPP+ or DA was compared to the half-life estimated for the cycloheximide treated controls for each 
experiment using a paired T-Test*. The half-life of NF-L was shorter than that of NF-H and NF-M under 
unstressed conditions (§ Two-tailed T-Test, p < 0.05). The half-lives of α-tubulin and vimentin were 
shorter than the half-life of NF-M († Two-tailed T-Test, p < 0.05). The half-life of NF-L was shorter in 
cells treated with MPP+/CHX than in CHX treated controls and in cells treated with 500 µM DA/CHX, 
the half-lives of NF-H, NF-L and α-tubulin were shorter than in CHX treated controls (paired T-Test, *p 
< 0.05, **p < 0.005).  
 
3.2.4.2. Effect of MPP+ and DA on the activity of proteolytic pathways 
 
Cells were treated with 2 mM MPP+ or DA (100 µM or 500 µM) in the presence or absence 
of 10 µg/ml cycloheximide and proteolytic activities estimated as described earlier (section 
3.2.3)  in order to assess the effect of complex 1 inhibition and oxidative stress on these 
activities. 
 
3.2.4.2.1. Effect of MPP+ and DA on proteasome activity 
 
CLA was significantly reduced in cells treated with 2 mM MPP+ alone for 48 h to around 
40 % of the activity in untreated control cells (Figure 3.12 A). Since all the half-life data 
was acquired in cells co-treated with CHX, the effect MPP+ on CLA in the presence of 
CHX was also assessed (Figure 3.12 B). In cells co-treated with 2 mM MPP+ and CHX for 
48 h, the effect of MPP+ was lost, ie there was no significant difference in CLA in 
MPP+/CHX treated cells compared to that in CHX treated control cells.  
 
T(1/2) ± SEM, h 
Treatment 
NF-H NF-M NF-L α-tubulin vimentin 
Untreated 
(cycloheximide) 
48.6 ± 4.4  
(n = 25) 
53.5 ± 3.6   
(n = 21) 
37.2 ± 2.6§  
(n = 27) 
41.2 ± 4†   
(n = 18) 
39.4 ± 3.7†    
(n = 24) 
2 mM MPP+ 
40.5 ± 17.6 
(n = 4) 
43.7 ± 6.7 
   (n = 3) 
24.4 ± 2.1** 
(n = 4) 
35.4 ± 10.3 
(n = 3) 
28.1 ± 8.4 
(n = 4) 
100 µM DA 
307.7 ± 125.7 
(n = 3) 
87.3 ± 50.7 
(n=3) 
71.1 ± 22.0 
(n = 4) 
105.1 ± 52.0 
(n = 3) 
56.3 ± 27.6 
(n = 3) 
500 µM DA 
21.4 ± 1.9* 
(n = 3) 
ND 
17.6 ± 2.4* 
(n = 3) 
17.6 ± 2.1* 
(n = 3) 
ND 
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Treatment with 100 µM DA for 48 h had no significant effect on CLA compared to CLA in 
untreated control cells (Figure 3.12 A), but in the presence of CHX 100 µM DA resulted in 
a small decrease in CLA to around 78 % of CLA in CHX treated control cells. In cells 
treated with 100 µM DA, CHX and 25 nM epoxo; CLA was reduced to 7 % of CLA in 
CHX treated control cells, indicating that the activity measured in CHX treated and 
CHX/100 µM DA treated cells was proteasomal. Treatment of SH-SY5Y cells with 
CHX/500 µM DA virtually abolished CLA. 
 
Co-treatment with 25 nM epoxo resulted in virtual abolishment of CLA (p < 0.001) for all 
treatments indicating that the activity measured was proteasomal (Figure 3.12 B). 
 
Figure 3.12 Effect of MPP+ and DA treatment on proteasome activity in SH-SY5Y cells. 
Chymotrypsin-like Activity (CLA) of the 20S proteasome in cell lysates of cells (A) treated for 48 hours with 
either 2 mM MPP+; 25 nM Epoxomicin (Epoxo) or 100 µM Dopamine (DA) expressed as a percentage of 
CLA in untreated control cells or (B) cells treated with 2 mM MPP+, 25 nM epoxo, 100 µM DA or 500 µM 
DA in the presence of 10 µg/ml cycloheximide (CHX) for 48 h. There was a significant reduction in CLA in 
cells treated with 2 mM MPP+ (One-way ANOVA, *p < 0.05, n = 5) and cells treated with 25 nM 
Epoxomicin (One-way ANOVA, **p < 0.005, n = 6) compared to CLA in untreated control cells. In the 
presence of CHX the effect of MPP+ on CLA was lost and treatment with 100 µM DA resulted in a small 
reduction in CLA (One-way ANOVA, p < 0.05, n = 6), while treatment with 500 µM DA resulted in a drastic 
reduction in CLA (One-way, ANOVA, **p < 0.005, n = 3) compared to CHX treated controls. The addition 
of 25 nM Epoxomicin to all treatments resulted in a reduction in proteasome activity (One-way ANOVA, p < 
0.001,) indicating that the measured activity was proteasomal.  
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3.2.4.2.2. Effect of MPP+ and DA on calpain and caspase 3 specific cleavage of αII-
spectrin 
 
A comparison of the morphology of cells treated with 500 µM DA, 100 µM DA or 2 mM 
MPP+ in the presence of 10 µg/ml CHX for 48 h suggests that treatment with 500 µM 
DA/CHX resulted in extensive cell death whereas cells treated with 100 µM DA/CHX and 2 
mM MPP+/CHX had a similar appearance to CHX treated controls (Figure 3.13).  
 
 
Figure 3.13 Assessment of the morphology of SH-SY5Y neuroblastoma cells treated with 500 µM 
Dopamine (DA) and 10 µg/ml cycloheximide (CHX). 
Phase contrast images of either treated with 10 µg/ml CHX or 500 µM or 100 µM DA plus CHX or 2 mM 
MPP+ plus CHX for 48 h. Treatment with 500 µM DA plus CHX resulted in extensive cell death. Scale 
bar represents 40 µm. 
 
Treatment with 2 mM MPP+ and CHX for 48 h had no effect on cleavage of αII-spectrin 
compared to CHX treated controls (Figure 3.14 A-C). However, the inclusion of the calpain 
inhibitor (MDL28170) resulted in an increase in the production of the 120 kD caspase 3 
specific SBDPs compared to CHX treated control (Figure 3.14 A and B).  
 
Cycloheximide (CHX)      500 µM Dopamine plus CHX 
2 mM MPP+ plus CHX       100 µM Dopamine plus CHX 
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Figure 3.14 The Effect of MPP+ and Dopamine (DA) treatment of SH-SY5Y cells on calpain and caspase 3 
activity was investigated indirectly by monitoring the cleavage of αII-spectrin.  
Cells were treated with 10 µg/ml cycloheximide (CHX) and 2 mM MPP+(n = 6), 100 µM DA (n = 3) or 500 µM 
DA (n = 3) in the presence or absence of 10 µM MDL28170  for 48 h. (A) Representative Western blot probed 
with anti-αII-spectrin (1:1000). Plots summarising the results of densitometric analyses of (B) the 145 kD  spectrin 
breakdown products (SBDP) relative to full length αII-spectrin and (C) the 120 kD SBDP relative to full-length 
αII-spectrin expressed as percent control. Treatment with 100 or 500 µM DA with/without MDL28170 and 
MPP+/MDL28170 resulted in an increase in the production of the 145 kD SBDP and treatment with 
MPP+/MDL28170, 100 µM DA/MDL28170 and 500 µM DA with/without MDL28170 resulted in an increase in 
the production of the 120 kD SBDP compared to CHX treated controls (Two-tailed T-Test, *p < 0.05, **p < 0.005; 
n = 3). Error bars represent SEM. 
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Compared to CHX treated controls, 100 µM DA/CHX treatment for 48 h (Figure 3.14 A 
and C) had no effect on the production of the 120 kD caspase 3 specific cleavage product, 
but increased the production of the 145 kD calpain-specific cleavage product (Figure 3.14 A 
and B). Surprisingly, the inclusion of the calpain inhibitor with 100 µM DA/CHX, 
increased the cleavage of αII-spectrin and the production of both the 145 and 120 kD 
SBDPs (Figure 3.14 B and C). In cells treated with 500 µM DA (Figure 3.14 A-C) there 
was a significant increase in the cleavage of αII-spectrin and the appearance of both the 145 
kD (calpain) and 120 kD (caspase 3) specific SBDPs. 
 
3.2.4.2.3. Effect of MPP+ and DA on macroautophagy 
 
The levels of LC3-II increased three-fold following treatment with either 2 mM MPP+ or 
10 nM Bafilomycin A1 and 2-fold following treatment with 100 µM DA  compared to CHX 
treated control cells. Co-treatment of cells treated with 2 mM MPP+ or 100 µM DA with 10 
nM Bafilomycin A1 resulted in a >4-fold increase in LC3-II levels compared to levels in 
CHX treated controls. However 500 µM DA (+/- Bafilomycin A1) had no effect on LC3-II 
levels (Figure 3.15).  
 
Figure 3.15 Effect of treatment of SH-SY5Y cells with 2 mM MPP+ or 100 or 500 µM Dopamine 
(DA) on the levels of LC3-II as a measure of macroautophagy. 
The plot represents the results of the densitometric analysis of the LC3-II band which was represented as 
a ratio of the LC3-II band in cycloheximide treated control cells. The levels of LC3-II increased 3-fold in 
total cell extracts of cells treated with BafA1 (T-Test, p < 0.005; n = 6) and MPP+ (T-Test, p < 0.005; n = 
6) and 2-fold in cells treated with 100 µM DA (T-Test, p < 0.05; n = 3). In cells treated with MPP+ or 
100 µM DA with BafA1, LC3-II levels increased 4 and 4.5-fold respectively (T-Test, p < 0.005, n = 3). 
In cells treated with 500 µM DA with/without BafA1 the levels of LC3-II were similar to levels in CHX 
treated control cells. Error bars represent standard deviation.  
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3.2.4.2.4. Effect of MPP+ and DA on cathepsin activity 
 
Treatment with 2 mM MPP+ resulted in a 30% reduction in cathepsin D activity whilst 100 
µM DA had no effect.  Culture of cells with pepstatin A virtually abolished cathepsin D 
activity (Figure 3.16 A). A comparison of cathepsin D activity in CHX treated cells with 
activity in untreated controls revealed that CHX resulted in a 50 % reduction in cathepsin D 
activity (Figure 3.16 B). In cells incubated with CHX, addition of 2 mM MPP+ or 100 µM 
DA had no effect on cathepsin D activity (Figure 3.16 C). In all cases cathepsin D activity 
was sensitive to Pepstatin A.  
 
Co-treatment of SH-SY5Y cells with an inhibitor of cysteine cathepsins (Cathepsin 
Inhibitor III, calbiochem) and 2 mM MPP+ resulted in cell death compared to treatment 
with either MPP+ or the cathepsin inhibitor on their own (Figure 3.17). This effect was not 
seen in cells treated with 100 µM DA and cathepsin inhibitor III.  
 
The effect of 2 mM MPP+ and 100 µM DA on the activity of the cysteine cathepsins 
was also investigated (Figure 3.18). Treatment with 2 mM MPP+ alone resulted in a 
marked increase (85%, Figure 3.18 A) in cysteine cathepsin activity, which exhibited a 
further increase when CHX was present (603.8 % of activity in CHX treated controls, 
Figure 3.18 B). Treatment of cells with the Cathepsin Inhibitor III was included as a 
control and in all cases resulted in a marked decrease in measured activity, indicating 
that the activity measured was that of the cysteine cathepsins. In cells treated with 100 
µM DA either in the presence or absence of CHX, no significant change in cysteine 
cathepsin activity was observed (Figure 3.18 A/B). Treatment with CHX resulted in a 
marked decrease in cysteine cathepsin activity which was similar to the activity 
observed in cells treated with Cathepsin Inhibitor III either in the absence or presence of 
CHX (Figure 13.18 C). 
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Figure 3.16 Effect of treatment of SH-SY5Y cells with 2 mM MPP+ or 100 µM Dopamine (DA) was 
assessed using a fluorogenic peptide assay for cathepsin D activity.  
(A) The activity of cathepsin D in cell lysates of SH-SY5Y cells treated with either 2 mM MPP+; or 100 
µM DA; or 1 µM Pepstatin A; or 2 mM MPP+ and 1 µM Pepstatin A; or 100 µM DA and 1 µM Pepstatin 
A. Activity was expressed as a percentage of the activity in untreated control cells. Treatment with MPP+ 
reduced cathepsin D activity to 71 % of the activity in untreated control cells (p < 0.05; T-Test, n = 3). 
Treatment with Pepstatin A either with or without MPP+ or DA reduced cathepsin D activity indicating 
that the activity measured is that of cathepsin D (p < 0.001; T-Test, n = 3). (B) The activity of cathepsin D 
in cell lysates of SH-SY5Y cells treated with 10 µg/ml cycloheximide (CHX) with either 2 m MPP+; or 
100 µM DA; or 1 µM Pepstatin A; or 2 mM MPP+ and Pepstatin A; or 100 µM DA and Pepstatin A. The 
activity of cathepsin D in cells treated with MPP+ and DA in the presence of CHX was similar to that in 
CHX treated control cells. Co-treatment with Pepstatin A resulted in a drastic reduction in cathepsin D 
activity indicating that the measured activity is that of cathepsin D. (C) The activity of cathepsin D in 
CHX treated controls expressed as a percentage of the activity in untreated controls. Treatment with CHX 
results in a significant reduction in measured cathepsin D activity (p < 0.05; T-Test, n = 3). Error bars 
represent standard deviation. 
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Figure 3.17  Effect of co-treatment of SH-SY5Y neuroblastoma cells with MPP+ or DA and a 
cysteine cathepsin inhibitor. 
Phase contrast images of cells either untreated or treated with either 2 mM MPP+, 10 µM Cathepsin 
Inhibitor III (Calbiochem), 2 mM MPP+ and 10 µM Cathepsin Inhibitor III, 100 µM Dopamine (DA) or 
100 µM DA and 10 µM Cathepsin Inhibitor for 48 hours. Treatment of SH-SY5Y cells with both MPP+ 
and Cathepsin Inhibitor III resulted in increased cell death compared to cells that were either untreated or 
treated with MPP+ or Cathepsin Inhibitor III alone. In cells treated with 100 µM DA and Cathepsin 
Inhibitor III, there was no visible additional effect on cell viability. Scale bar represents 40 µm 
 
Control Cathepsin Inhibitor III 
2 mM MPP+ 2 mM MPP+ and Cathepsin Inhibitor III 
100 µM DA 100 µM DA and Cathepsin Inhibitor III 
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Figure 3.18 Determination of the effect of treatment with 2 mM MPP+ and 100 µM Dopamine (DA) 
on the activity of the cysteine cathepsins in SH-SY5Y neuroblastoma cells.  
Cysteine cathepsin activity measured using a fluorogenic peptide assay in (A) untreated cells or cells 
treated with either 10 µM Cathepsin Inhibitor III (Cath Inh III), 2 mM MPP+, 2mM MPP/Cath Inh III, 
100 µM DA or 100 µM DA/10 µM Cath Inh III expressed as a percentage of the mean activity in 
controls. (B) Cysteine cathepsin activity in cells treated with 10 µg/ml Cycloheximide (CHX) with either 
10 µM Cath Inh III, 2 mM MPP+, 2 mM MPP+/Cath Inh III, 100 µM DA or 100 µM DA/Cath Inh III 
expressed as a percentage of the mean activity in CHX treated control cells. An increase in the activity of 
cysteine cathepsins following treatment with 2 mM MPP+, either in the presence or absence of CHX and 
a reduction in cysteine cathepsin activity with treatments involving Cath Inh  III was observed (*p < 0.05, 
**p < 0.005; T-Test, n = 3). (C) The cysteine cathepsin activity in CHX treated control cells expressed as 
a percentage of the mean activity in untreated control cells. Treatment with CHX results in a significant 
decrease in cysteine cathepsin activity (*p < 0.05; T-Test, n = 3). Error bars represent standard deviation. 
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3.2. Discussion 
3.2.1. The establishment of an experimental model for the determination 
of the half-life of proteins 
 
To establish the optimum CHX concentration for treating SH-SY5Y neuroblastoma cells 
that would give the most reliable estimates of NF half-life whilst not causing extensive cell 
death, the effects of a range of concentrations of CHX on cell viability and estimates of 
half-life were examined. The most toxic concentrations of CHX (10 and 20 µg/ml) yielded 
most consistent estimates for NF half-life than the less toxic concentrations (2 and 5 µg/ml), 
suggesting that with 2 and 5 µg/ml some protein synthesis was still occurring. Due to the 
dose dependent effects on cell viability, 10 µg/ml was selected for subsequent experiments.  
 
3.2.2. Degradative pathways involved in neurofilaments turnover 
3.3.2.1. Estimations of half-life 
 
The half-life of NF-L was found to be significantly shorter than that of the two larger 
subunits (NF-M and NF-H). This may be the result of the presence of extensive 
phosphorylation sites on the C-termini of NF-M and NF-H which when phosphorylated are 
known to increase the resistance of neurofilaments to degradation (Greenwood et al, 1993). 
The half-life of NF-L (37.2 ± 2.6 h) in this system was similar to that of the cytoskeletal 
proteins vimentin (39.4 ± 3.7) and α-tubulin (41.2 ± 4 h), and also that of α-synuclein (31.4 
± 6.7 h). The estimated α-synuclein half-life is similar to a previously reported 33.1 ± 6.3 h 
estimate in PC12 cells (Cuervo et al, 2004). An earlier estimate of the half-life of α-
synuclein suggested a half-life of 2.76 ± 0.24 h but in this case the α-synuclein was His-
tagged which may have increased it rate of degradation (Bennett et al, 1999). 
 
The estimates of the half-life of cytoskeletal proteins in SH-SY5Y cells are considerably 
shorter than estimates of the half-life of cytoskeletal proteins in vivo which are usually 
quoted in days or even weeks. In brain tissue from rats labelled intracranially with 
[35S]methionine for 10 days, cytoskeletal proteins were shown to exhibit biphasic decay 
rates. In total protein fractions; the fast-turnover rate for α-tubulin was around 5 days and 
the slow-turnover rate was around 15 days which was similar to that in a triton X-100 
insoluble fraction. For NF-H, the half-life in the triton X-100 insoluble fraction was around 
18 days (Safaei & Fischer, 1990). This estimate is similar to the half life of 21 days reported 
for NF-L in mice expressing human NF-L under doxycycline control (Millecamps et al, 
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2007). Nixon and Logvinenko (Nixon & Logvinenko, 1986) also reported a biphasic loss of 
radiolabelled NFs in mice for which fast-turnover rate was estimated as 20-22 days and the 
slow-turnover rate was estimated as 55 days.  
 
The discrepancy in half-life determination in cultured cells compared to in vivo has been 
attributed to the shorter duration of experiments involving cultured cells (Safaei & Fischer, 
1990), but may reflect the fact that cultured cells are usually mitotic. In fact, in HEK293 
cells treated with the protein synthesis inhibitor puromycin, the half-life of α-tubulin was 
reported to be around 22.5 h (Ren et al, 2003) which is considerably less than the 5 to 15 
day estimate in vivo (Safaei & Fischer, 1990) but is more in the range of the estimates 
reported herein. The half-life of vimentin has also previously been reported to be 32 h in 
mouse fibroblasts (Coleman & Lazarides, 1992). The shorter half-life of cytoskeletal 
proteins in cultured cells suggests that in these cells, cytoskeletal proteins are more labile. 
 
3.3.2.2. Pathways involved in turnover of cytoskeletal proteins 
 
 
An attempt to reveal the proteolytic pathways involved in the turnover of NF proteins was 
made by estimating half-life in cells treated with cycloheximide in the presence or absence 
of inhibitors to the major proteolytic pathways. 
 
3.3.2.2.1. The role of the proteasome 
 
 
In the case of α-synuclein, proteasome inhibition increased the half-life from 31.4 ± 6.7 h to 
346.6 h. Since a role for the proteasome in the degradation of α-synuclein has been 
extensively documented (Bennett et al, 1999, Kim et al, 2006, Tofaris et al, 2001, Webb et 
al, 2003), these results confirm that treatment of SH-SY5Y cells with 5 nM Epoxomicin in 
the presence of CHX is sufficient to inhibit the proteasome. However in the present work 
there was no evidence for the involvement of the proteasome in the degradation of NF 
proteins, α-tubulin or vimentin in unstressed conditions.  
 
Proteasome inhibition did not result in the activation of any of the other proteolytic 
pathways investigated. Therefore, the lack of evidence for proteasomal involvement in the 
degradation of NFs, α-tubulin or vimentin in this system is not due to the compensatory 
activation of any of other proteolytic pathways investigated. The only effect that was 
observed was a reduction the production of the 145 kD and 120 kD calpain and caspase 3 
specific SBDPs after 72 h epoxomicin treatment. This conflicts with the results reported by 
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Hamano et al (2009) in which proteasome inhibition resulted in increased cleavage of αII-
spectrin and activation of caspase 3.  
 
An alternative explanation for the lack of evidence for proteasomal involvement in NF, 
vimentin and α-tubulin degradation may be the incomplete inhibition of the proteasome 
with the concentration of epoxomicin used in this work. Although the concentration used 
was sufficient to prevent α-synuclein degradation, it may not be sufficient to prevent NF, α-
tubulin or vimentin degradation. CLA was used as a measure of proteasomal activity but the 
proteasome also contains TLA and PLA protease activities which are not affected by 
epoxomcin to the same degree as CLA. TLA and PLA may be more important in the 
degradation of some proteins than CLA (Kisselev et al, 2006), therefore lack of evidence 
for proteasomal involvement in NF degradation may be limited to that of CLA.  
 
The interaction of α-tubulin and parkin (an E3 which ubiquitinates tubulin) reported in 
literature, has led to the proposal of the involvement of the UPS in the degradation of α-
tubulin (Ren et al, 2003). However a reported accumulation of polyubiquitinated α-tubulin 
following proteasome inhibition with lactacystin was only evident in cells overexpressing 
parkin (Ren et al, 2003), suggesting that the role of parkin may not be limited to targeting α-
tubulin for degradation by the proteasome.  
 
Owing to the high affinity binding of parkin to microtubules, parkin has also been suggested 
to stabilize microtubules and to play a role in the transport of misfolded proteins along 
microtubules to the aggresome, which is apart from its E3 ligase activity. In fact the binding 
of parkin to microtubules is not mediated via its ubiquitin-like domain but instead via the 
Linker, RING1 and RING2 tubulin-binding domains. The microtubule destabilizing effect 
of colchicine was attenuated in cells overexpressing parkin, providing evidence for the role 
of parkin in microtubule stabilization (Yang et al, 2005). Therefore, the targeting of α-
tubulin for degradation by the proteasome via parkin-mediated polyubiquitination may be 
secondary to its function as a microtubule stabilizing agent.  
 
3.3.2.2.2. The role of calpain 
 
The inhibition of calpain by the inhibitor MDL28170 had no effect on the half-life of NF-
M, NF-L or vimentin but slightly reduced the half-lives of NF-H and α-tubulin (but not 
significantly, p = 0.08). The half-life of α-synuclein was increased when calpain was 
inhibited, which is not unexpected since calpain has also been implicated in the degradation 
of α-synuclein (Kim et al, 2006, Kim et al, 2003).  
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The possible decrease in the half-lives of α-tubulin and NF-H would suggest that there is 
some compensatory activation of proteolytic pathways in cells treated with MDL28170. 
There was a slight decrease in the levels of LC3-II (but again not statistically significant) 
suggesting increased autophagic vesicle degradation. The slight decrease in LC3-II levels 
may be explained by the compensatory activation of cysteine cathepsins (cathepsin B, C, F, 
H, K, L, O, S, V, W and X) in cells treated with MDL28170 and CHX, the activity of which 
was increased significantly to 240 % of activity in CHX treated controls. This suggests that 
the cysteine cathepsins may play a role in the degradation of NF-H and α-tubulin. Indeed, 
leupeptin – a serine and cysteine protease inhibitor which inhibits trypsin, plasmin, 
kallikrein, papain, thrombin and cathepsins A and B - has been reported to suppress the 
degradation of neurofilaments in an experimental model of spinal cord injury (Iwasaki et al, 
1987).  
 
As indicated in the introduction to this chapter, there is an extensive volume of literature 
that implicates calpain in neurofilament degradation (Kunz et al, 2004, Schlaepfer et al, 
1985, Shields et al, 1997, Stys & Jiang, 2002). In the study by Kunz et al (2004) calpain 
was activated following zymosan-induced inflammation leading to NF-L degradation. Stys 
and Jiang (2002) implicated calpain in NF-H and NF-M degradation following anoxia and 
reoxygenation of rat optic nerves.  Other studies that implicated a role for calpain in NF 
degradation were in vitro based, in which isolated neurofilament proteins were either added 
directly to calcium-activated calpain or calcium was added to whole cell homogenates 
(Greenwood et al, 1993, Kamakura et al, 1985, Schlaepfer et al, 1985, Shields et al, 1997). 
However, in this SH-SY5Y cell model there is no evidence for the role of calpain in basal 
neurofilament turnover.  
 
3.3.2.2.3. The role of macroautophagy 
 
Inhibition of macroautophagy in SH-SY5Y cells had no effect on the half-life of NF-M, 
NF-L, α-tubulin and vimentin. It did however result in an increase in the half-life of NF-H 
(increased to 117 ± 11.7 h from 48.6 ± 4.4 h) and α-synuclein, implicating macroautophagy 
in the degradation of both these proteins. Evidence of the role of macroautophagy in the 
degradation of α-synuclein has already been reported in PC12 cells in which inhibition of 
macroautophagy by Bafilomycin A1 and 3-methyl adenine (3-MA) resulted in increased α-
synclein levels and activation of macroautophagy by Rapamycin resulted in increased 
clearance of α-synuclein (Webb et al, 2003). The induction of macroautophagy by 
Rapamycin is via the inhibition of mTOR (reviewed in Klionsky et al, 2008). To further 
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confirm the role macroautophagy in NF-H degradation, SH-SY5Y cells were treated with 
Bafilomycin A1, 3-MA or Rapamycin in the presence of CHX for 48 hours. SDS-PAGE 
and Western blotting of total cell extracts revealed that the levels of NF-H protein were 
significantly decreased following treatment with Rapamycin.  
 
Since long-term inhibition of autophagy may cause nonspecific effects (reviewed in 
Rubinsztein et al, 2009), the effect of the inhibition of autophagy in the presence of CHX on 
the ativities of the proteasome, calpain, cathepsin D and the cysteine cathepsins was also 
investigated. Inhibition of macroautophagy for 72 h resulted in a 10 % increase in 
proteasomal activity compared to CHX treated controls. After 24 hours treatment with 
Bafilomycin A1 and CHX, levels of the 145 kD calpain-specific and the 120 kD caspase-3-
specific SBDPs were increased compared to CHX treated controls suggesting that treatment 
with Bafilomycin A1 resulted in calpain and caspase 3 activation. However, after 48 and 72 
hours treatment with Bafilomycin A1 αII-spectrin cleavage was similar to CHX treated 
controls. Treatment with Bafilomycin A1 and CHX for 48 hours also resulted in a 
significant reduction in the activity of the cysteine cathepsins to 58.5 % of the activity in 
CHX treated control cells.  
 
3.3.2.2.4. The role of cathepsins 
 
Inhibition of cathepsin D with Pepstatin A had no effect on the half-life of NF-L, α-tubulin, 
vimentin or α-synuclein but resulted in a significantly increased NF-H half life indicating 
that cathepsin D plays a role in NF-H turnover. This is supported by early in vitro 
experiments using purified cathepsin D (Nixon & Marotta, 1984, Suzuki et al, 1988). 
Suzuki et al (1988) reported that NF-L was the most susceptible subunit to degradation by 
cathepsin D and that the incorporation of NF-M and NF-H into the assembled neurofilament 
protected NF-L from degradation. Their conclusion about the greater susceptibility of NF-L 
contradicts Nixon and Marotta (1984) who reported that NF-M and NF-H were more 
susceptible than NF-L to cathepsin D but Suzuki et al (1988) argued that the degradation of 
NF-M resulted in a 68 kD cleavage product which could not be distinguished from NF-L by 
SDS-PAGE, thus artificially increasing levels of the 68 kD NF protein. In this work 
however, there was no evidence to support the in vivo role of cathepsin D in the degradation 
of NF-M and NF-L. 
 
Treatment with Pepstatin A plus CHX had no effect on the production of the 145 kD 
(calpain) and 120 kD (caspase-3) αII-spectrin products compared to CHX treated controls, 
suggesting that the inhibition of cathepsin D did not result in the activation of either calpain 
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or caspase 3. Furthermore treatment with Pepstatin A and CHX for 48 hours had no effect 
on the levels of LC3-II compared to CHX treated controls, suggesting that cathepsin D 
inhibition had no measurable effect on macroautophagy. When investigating the effect of 
Pepstatin A on the activity of cathepsin D and the cysteine cathepsins, the inhibition of 
cathepsin D by Pepstatin A was confirmed. Additionally, Pepstatin A was shown to have no 
effect on the activity of the cysteine cathepsins.   
 
3.3.2.2.5. Conclusion 
 
In conclusion; NF-H is degraded via macroautophagy and cathepsin D. Degradative 
pathways involved in the turnover of NF-M, NF-L vimentin and α-tubulin under basal 
conditions still remain elusive. However, there is some indication that the cysteine 
cathepsins may be involved in the degradation of α-tubulin and NF-H, due to the decrease 
in the half-lives of these proteins when cells are treated with MDL28170 and CHX, shown 
to result in an increase in the activity of the cysteine cathepsins. 
 
3.2.3. Effect of mitochondrial dysfunction and increased oxidative stress 
on neurofilament degradation 
3.3.3.1. Effects of mitochondrial dysfunction  
 
The half-life of NF-L in cells treated with 2 mM MPP+ and CHX decreased significantly 
compared to CHX treated controls, suggesting that complex 1 inhibition via MPP+ 
activated a degradative pathway(s) involved in NF-L degradation. 2 mM MPP+ treatment 
had no significant effect on the half-lives of NF-M, NF-H, α-tubulin and vimentin. However 
in all cases, the half-lives were slightly shorter than the half-lives in CHX treated controls.  
 
Previous work in this laboratory showed that 2 mM MPP+ treatment resulted in a decrease 
in proteasome activity (Caneda-Ferron et al, 2008); this was confirmed in the present study 
with 2 mM MPP+ treatment resulting in a 60% decrease in proteasome activity. However, 
in cells treated with MPP+ plus CHX, MPP+ did not reduce proteasomal activity, suggests 
that the effect of MPP+ on the proteasome may require new protein synthesis. However 
CHX itself resulted in a 50% reduction in proteasomal activity, possibly making additional 
effects more difficult to detect. The reduction in proteasome activity with CHX may be the 
result of the turnover of proteasomal subunits. 
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The effect of MPP+ on the activity of calpain and caspase 3 was monitored indirectly via 
the cleavage of αII-spectrin. Calpain specific cleavage of αII-spectrin results in 145 kD and 
150 kD spectrin breakdown products (SBDPs) while caspase 3 specific cleavage results in 
120 kD and 150 kD SBDPs. Treatment with MPP+ did not result in the appearance of 
additional 145 kD and 120 kD SBDPs compared to CHX treated controls, suggesting that 
MPP+ does not activate either calpain or caspase 3 after 48 h treatment. 
 
The addition of the calpain inhibitor (MDL28170) however unexpectedly resulted in an 
increase in the production of the 120 kD caspase 3 specific cleavage product of αII-spectrin 
compared to CHX treated controls, suggesting an activation of caspase 3. In cells treated 
with MDL28170/CHX and also in cells treated with MPP+ (with or without CHX) an 
activation of the cysteine cathepsins was observed. Cysteine cathepsins have previously 
been shown to lead to caspase-mediated cell death in a number of cell lines including SH-
SY5Y cells (Droga-Mazovec et al, 2008) and could be responsible for the cleavage of αII-
spectrin detected in the present study. Cysteine proteases often all cleave the same 
substrates but at slightly different positions resulting in protease specific cleavage patterns 
(reviewed in Wang, 2000), it is not inconceivable that the cysteine cathepsins can also 
cleave αII-spectrin. 
 
LC3-II levels in cells treated with 10 nM Bafilomycin A1 or 2 mM MPP+ in the presence of 
CHX increased about three-fold compared to levels in CHX treated controls. In cells treated 
with CHX, 2 mM MPP+ and 10 nM Bafilomycin A1 in combination there was a slight 
increase (four-fold of CHX treated controls) in LC3-II levels compared to levels in 
CHX/Bafilomycin A1 and CHX/MPP+ treated cells but this increase was not significant. 
According to the scenarios described by Rubinsztein et al (2009), an induction of 
autophagosome vesicle synthesis is indicated by an increase in LC3-II levels during BafA1 
and compound of interest (MPP+ in this case) co-treatment above that seen when cells are 
treated with BafA1 alone. In the present work however the additional increase in LC3-II 
upon co-treatment with BafA1 is not significant, suggesting a reduction in macroautophagy. 
 
Treatment with MPP+ in SH-SY5Y cells has previously been reported to result in increased 
levels of LC3-II as well as an increase in the number of autophagic vesicles (Zhu et al, 
2007). The authors suggested that MPP+ induced autophagy by increasing autophagic 
vesicle formation - since co-treatment with Bafilomycin A1 and MPP+ treatment resulted in 
an additional increase in LC3-II levels to that seen in cells treated with MPP+ or 
Bafilomycin A1 alone; this was confirmed by electron microscopy. The difference between 
the work by Zhu et al (2007) and the work presented here is the inclusion of CHX to inhibit 
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new protein synthesis. The inclusion of CHX therefore may be preventing cells from 
increasing the number of autophagic vesicles. However if MPP+ inhibits autophagic 
degradation, an increase in autophagic vesicle production may be a compensatory effect by 
the cell to increase the degradation of the substrates of autophagy.  
 
A reduction in the degradation of LC3-II can result from either a defect in the transport of 
autophagosomes to lysosomes, an inhibition of the fusion of autophagosome and lysosome 
or impaired lysosomal proteolytic activity (reviewed in Rubinsztein et al, 2009). 
Interference with dynein function has been shown to inhibit macroautophagy (Cai et al, 
2009, Ravikumar et al, 2005). MPP+ has been shown to alter the transport of membranous 
organelles in squid axoplasm by increasing the rate of retrograde transport by dynein and 
decreasing the rate of anterograde transport by kinesin (Morfini et al, 2007). One would 
therefore expect that MPP+ would result in increased transport of autophagosomes to 
lysosomes, thus decreasing the levels of LC3-II. In another study MPP+ treatment of PC12 
cells impaired the clearance of α-synuclein by macroautophagy by impairing the function of 
dynein (Cai et al, 2009).  
 
Treatment of SH-SY5Y cells with MPP+ resulted in a significant decrease in cathepsin D 
activity (71.6 % of control). However in the presence of CHX, the effect of MPP+ on 
Cathepsin D activity was lost. When comparing cathepsin D activity in cells treated with 
CHX, it was revealed that CHX treatment alone reduced cathepsin D activity by half. 
Therefore, the effect of MPP+ on cathepsin D activity may be masked by the much greater 
effect of CHX, which may be due to the turnover of cathepsin D itself which can not be 
replenished in the presence of CHX.  
 
What was more interesting was the effect of MPP+ on the activity of the cysteine 
cathepsins, here 2 mM MPP+ treatment resulted in a marked increase in cysteine cathepsin 
activity which was unaffected by the inclusion of CHX. In addition CHX treatment itself 
resulted in a massive reduction in cysteine cathepsin activity, suggesting that the cysteine 
cathepsins are turned over rapidly. Another interesting feature was that cells treated with 
both the cathepsin inhibitor and MPP+ exhibited extensive cell death. This suggests that 
cysteine cathepsin activity may be protective in SH-SY5Y cells treated with 2 mM MPP+. 
Microarray data has shown that the expression of cysteine cathepsins is elevated in response 
to MPP+ treatment in (Xu et al, 2005), however since the activity of the cysteine cathepsins 
remains elevated even in the presence of CHX, the effect of MPP+ in this case may not only 
be a result of increased expression.  
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There are a number of conflicting reports dealing with the role of the cysteine cathepsins in 
cell death. As mentioned earlier the cysteine cathepsins have been shown to induce caspase-
dependent cell death in a number of cell lines (including in SH-SY5Y cells) by the cleavage 
of Bcl-2, Bcl-xL, Mcl-1 and Bid (Droga-Mazovec et al, 2008). However in human cancer 
cell lines; the inhibition of cysteine cathepsins leads to the induction of apoptosis (Zhu & 
Uckun, 2000) suggesting that the induction of the cysteine cathesins is protective. In a 
highly invasive mitochondrial DNA depleted osteosarcoma cell line (with impaired 
mitochondrial respiration) cathepsin B expression is elevated (Hamer et al, 2009) and in 
human endocrine tumours increased cathepsin B and L expression is associated with 
invasion and metastasis (Gocheva et al, 2006). Zheng et al (2008) demonstrated that 
cathepsin L is able to degrade caspase 3 and cathepsin D but is itself not degraded by either 
cathepsin D or caspase 3.  
 
3.3.3.2. Effects of increased oxidative stress induced by dopamine 
 
The half-life of neurofilament proteins and α-tubulin in cells treated with 500 µM DA and 
CHX was significantly reduced compared to CHX treated control cells. The half-lives of 
NF-H, NF-L and α-tubulin were reduced to 21.4 ± 1.9, 17.6 ± 2.4 and 17.6 ± 2.1 h 
respectively. However in cells treated with the lower concentration of 100 µM, DA did not 
result in an increase in NF, vimentin or α-tubulin proteolysis. Instead, half-lives tended to 
be greater.  
 
Treatment with 100 µM DA had no significant effect on proteasome activity compared to 
the activity in untreated controls. However, in cells treated with 100 µM DA and CHX for 
48 h, there was a significant reduction (around 22 %) in proteasome activity compared to 
the activity in CHX treated controls. 500 µM DA treatment had a greater effect on 
proteasome activity, reducing proteasome activity to 3 % of the activity in CHX treated 
controls. 100 and 500 µM DA has previously been shown to reduce proteasome activity 
after 72 and 48 h respectively, the effect of which was due to DA-mediated oxidative 
damage (Caneda-Ferron et al, 2008), and it is likely that some of the effects in the present 
work are due to oxidative stress caused by dopamine. 
 
Exposure to 100 µM DA for 48 h resulted in an increase in the production of the 145 kD 
calpain specific SBDP compared to CHX treated controls, suggestive of calpain activation. 
The half-lives of the neurofilament in cells treated with 100 µM DA tended to be longer 
than in CHX treated controls. The activation of calpain has previously been shown to 
increase the phosphorylation of neurofilaments by the activation of Erk1,2 in rat primary 
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neuronal cultures treated with ionomycin resulting in calcium influx (Veeranna et al, 2004). 
In addition hypoxia treatment of rats results in calpain activation which leads to the 
cleavage of p35 to p25 and prolonged activation of cdk5 (Tamada et al, 2005) which has 
been implicated in the phosphorylation of neurofilaments (Pant et al, 1997, Sun et al, 1996). 
Calpain-induced activation of Cdk5 via p35 cleavage has also been reported in the brains of 
PD patients (Alvira et al, 2008). Increased phosphorylation of neurofilaments is associated 
with increased resistance to proteolysis (Greenwood et al, 1993). 
 
The cleavage of αII-spectrin, resulting in the appearance of the 145 kD and 120 kD SBDPs 
was elevated in cells treated with 500 µM DA for 48 h compared to CHX treated controls. 
This suggests that in these cells calpain and caspase 3 are activated. Phase contrast images 
indicated that 500 µM DA resulted in extensive cell death which suggests the activation of 
cell death proteases. The inclusion of MDL28170 did not decrease the levels of the 145 and 
120 kD SBDPs or ‘rescue’ the cells, most likely due to the high level of oxidative damage 
resulting from 500 µM DA treatment.  
 
In cells treated with 500 µM DA, the half-lives of NFs and α-tubulin were half that in CHX 
treated controls. Calpain has previously been implicated in the degradation of NFs 
following stress which induces calcium activated cysteine proteases such as calpain (Kunz 
et al 2004, Schlaepfer et al 1985, Stys and Jiang 2002) and caspase 3 and calpain also often 
share substrates, though usually they cleave at slightly different sites (reviewed in Wang, 
2000). It is therefore likely that in cells treated with 500 µM DA, caspase 3 is activated and 
cleaves NFs and α-tubulin. 
 
The effect of 100 and 500 µM DA on macroautophagy was assessed by monitoring the 
levels of LC3-II in DA/CHX treated cells compared to Bafilomycin A1/CHX and CHX 
treated controls. In cells treated with 500 µM DA/CHX, there was no change in the levels of 
LC3-II compared to CHX treated controls. However treatment with 500 µM DA/CHX and 
Bafilomycin A1 did not result in an increase in LC3-II levels compared to CHX treated 
controls. This suggests that inhibition of macroautophagy by Bafilomycin A1 in this case 
was not able to prevent LC3-II degradation. This may be due to the activation of cell death 
proteases evident with this toxic concentration of DA.  
 
In cells treated with 100 µM DA/CHX, LC3-II levels were increased two-fold compared to 
levels in CHX treated controls. The addition of Bafilomycin A1 to 100 µM DA/CHX 
resulted in a 4.5-fold increase in LC3-II compared to CHX treated controls, which was only 
slightly higher than the three-fold increase in Bafilomycin A1/CHX treated cells but not 
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significantly different. These results suggest that treatment with 100 µM DA/CHX reduces 
macroautophagy. Treatment with 100 µM DA had no effect on the activity of cathepsin D 
or the cysteine cathepsins in either the presence or absence of CHX. 
 
3.3.3.3. Conclusion 
 
The effects of MPP+ and DA treatment on protein degradative pathways and the half-life of 
cytoskeletal proteins is summarised in Figure 3.19. Briefly, MPP+ resulted in the activation 
of cysteine cathepsins and a reduction in the activity of cathepsin D and possibly 
macroautophagy (indicated by increased levels of LC3-II). The reduction in NF-L half-life 
and the overall decrease (although not significant) in half-life of the other NF proteins, α-
tubulin and vimentin in cells treated with MPP+, suggests and involvement of cysteine 
cathepsins in their turnover. Further investigation should concentrate on clarifying the 
effects of MPP+ on cysteine cathepsins and macroautophagy.  
 
500 µM DA resulted in calpain and caspase 3 activation leading to extensive cell death. 
Calpain and most likely caspase 3 (since calpain and caspase 3 often cleave the same 
substrates) are candidates for the degradation of the neurofilament proteins and α-tubulin in 
cells treated with 500 µM DA. 500 µM DA also greatly reduced proteasomal activity, 
possibly as a result of DA-mediated oxidative damage (Caneda-Ferron et al, 2008). 
 
In cells treated with 100 µM DA, the half-life of neurofilament proteins tended to be longer 
than in CHX treated controls (albeit not statistically significant). This apparent increase in 
half-life could be due to decreased proteasome activity and/or decreased macroautophagy. 
However there is some evidence that the activation of calpain which could lead to the 
phosphorylation of neurofilaments thus increasing their resistance to proteolysis. 
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Figure 3.19 Schematic summarising the effect of 48 h treatment of SH-SY5Y neuroblastoma cells with 
MPP+ (2 mM) with/without cycloheximide (CHX, 10 µg/ml) or Dopamine (DA, 100 µM or 500 µM) 
with CHX on proteolytic pathways and the degradation of neurofilaments and cytoskeletal proteins.  
MPP+ treatment resulted in an activation of cysteine cathepsins which may be responsible for the decrease 
in NF-L half-life suggesting a role for cysteine cathepsins in NF degradations that warrants further 
investigation. The activity of the 20S proteasome is reduced following treatment with MPP+ and DA. The 
levels of LC3-II were increased with 100 µM DA and MPP+ treatment suggesting an effect on 
macroautophagy, possibly inhibition of macroautophagy by preventing the fusion of autophagosome and 
lysosome but this effect needs further investigation. There is some indication of increased calpain activity 
with 100 μM DA and increased caspase 3 activity with 500 μM DA (by monitoring αII-spectrin cleavage 
products).  The half-lives of all cytoskeletal proteins looked at were decreased with 500 µM DA suggesting 
cleavage by caspase 3. Green arrows refer to increased protein levels and red arrows represent a decrease. 
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4.1. Introduction 
4.1.1. Differentiation of SH-SY5Y cells 
 
Retinoic acid (RA), traditionally used to differentiate SH-SY5Y neuroblastoma cells, is a 
metabolic derivative of vitamin A that has a crucial role in development and differentiation of 
the nervous system. Retinoid deficiency in the adult CNS has been observed in 
neurodegenerative conditions and RA and other neurotrophins play a role in neuronal repair 
following injury (reviewed by Malik et al, 2000). The differentiation of SH-SY5Y cells with 
RA was first described by Pahlman et al (1984) with optimal differentiation at concentrations 
ranging from 100 nM to 10 µM RA resulting in 40-50 % of cells exhibiting a differentiated 
morphology with processes longer than 50 µm.  
 
Changes in mRNA expression within the first 6 h of RA treatment detected using cDNA 
Microarrays included a number of genes either up or down regulated; many of which were 
cytoskeletal, transcription factors, receptors or proteins involved in cell signalling and cell 
cycle control. Upregulated mRNAs included amongst others; HSPA8 (heat shock protein 70), 
Dynein Light chain, Kinesin 2, the proteasome non-ATPase subunit PSMD4, ubiquitin 
carbonyl-terminal esterase L1 (UCHL1), the ribosomal proteins L28 and L27, vimentin, 
Mitogen-activated protein kinase 4 (MAPK4), protein kinase inhibitor, Cytochrome C 
oxidase subunit (COX6B) and caspase 9. The most down-regulated mRNAs included profilin 
1 and serine/threonine protein-kinase (Truckenmiller et al, 2001).  
 
The activity and protein expression of tissue transglutaminase (TG2) protein is increased 
following RA-induced differentiation (Singh et al, 2003, Zhang et al, 1998). TG2 is a 
multifunctional enzyme with three separate enzymatic activities; ATPase, GTPase and Ca2+-
dependent transamidating activity which cross-links proteins or incorporates polyamines into 
protein substrates. It is this transamidating activity of TG2 that has been suggested to play a 
role in differentiation (Tucholski et al, 2001). Singh et al (2003) reported that TG2 catalyses 
the activation of the small G-protein RhoA via transamidation which in turn results in 
increased stress fibre and focal adhesion complex formation and the activation of p38γ MAP 
kinase, which induces NF upregulation and neuritogenesis. In addition, TG2 was also shown 
to activate Erk1/2 and JNK via its transamidation activity as well as JNK-induced expression 
of growth associated protein-43 (GAP-43; Singh et al, 2003).  
 
Recently Cheung et al (2009) re-evaluated the effect of RA-induced differentiation on 
neuronal markers in SH-SY5Y cells. They reported an increase in protein expression of 
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neuron specific enolase (NSE) - which was also previously reported by Pahlman et al (1984) - 
synaptophysin, post-synaptic associated protein-97 (SAP97) and neuronal nuclei (NeuN) after 
7 days treatment. RA treatment however did not have a significant effect on protein 
expression of NF-H, dopamine transporter (DAT) and tyrosine hydroxylase (TH) (Cheung et 
al 2009). This lack of an effect on DAT and TH protein expression was previously reported 
by Presgraves et al (2004). In addition Encinas et al (2000) reported an increase in NF-M 
protein expression but no change in NF-L protein following RA treatment.  An increase in the 
activation of Akt, Erk1/2, JNK and c-jun and a decrease in phospho-PKC levels with RA 
treatment was also reported (Cheung et al, 2009). However no increase in JNK 
phosphorylation was observed by Jämsä et al (2004). Bcl-2 protein is also reportedly 
upregulated following RA treatment, facilitated by NF-κB activation (Feng & Porter, 1999) 
as is tau, p35 and CDK5 (Jämsä et al, 2004). 
 
Combining RA with 12-0-tetradecanoyl-phorbol-13-acetate (TPA) - previously shown to 
induce differentiation of SH-SY5Y cells (Påhlman et al, 1983) - resulted in a greater number 
of cells exhibiting a differentiated morphology and longer processes (Pahlman et al, 1984). 
Study of protein expression in RA/TPA differentiated cells revealed that protein expression of 
TH and DAT was upregulated (Presgraves et al, 2004). Insulin and insulin-like growth factors 
have also been used to differentiate SH-SY5Y cells and reportedly result in increased 
expression of NF-L, NF-M and α-tubulin mRNA (Wang et al, 1992). 
 
An additional method used to differentiate SH-SY5Y cells exploits the induced expression of 
the Neurotrophic Tyrosine kinase receptor B (NTrkB) during RA-induced differentiation, 
which enables the cells to be responsive to Brain Derived Neurotrophic Factor (BDNF) 
(Encinas et al, 1999, Fernandes et al, 2007, Kaplan et al, 1993, Ruiz-León & Pascual, 2001, 
Ruiz-León & Pascual, 2003). NTrkB belongs to a family of receptors which are responsive to 
neurotrophins such as Nerve Growth Factor (NGF), neurotrophin 3 (NT-3), NT-4/5, NT-6 
and BDNF. Four different types of neurotophin receptors have been identified and are 
classified according to their binding preferences; p75NTR (which does not show a preference), 
NTrkA (binds NGF), NTrkB (binds BDNF or NT-4/5) and NTrkC (binds NT-3, reviewed by 
Kaplan & Miller, 1997). BDNF binding to NTrkB promotes cell survival during neuronal 
development and modulates synaptic plasticity in the adult brain (reviewed by Hu & Russek, 
2008). BDNF is a neurotrophin which on binding NTrkB activates signal transduction 
pathways promoting cell survival and differentiation (Kaplan & Miller, 1997). In some 
neuroblastoma cell lines, RA treatment induces the expression of BDNF mRNA but in SH-
SY5Y cells, levels of BDNF mRNA are too low for the cells to be self-sufficient making it 
necessary to supplement them with recombinant human BDNF (Kaplan et al, 1993).  
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The binding of BDNF to TrkB results in receptor dimerisation and activation by 
autophosphorylation. In the central and peripheral nervous systems, BDNF promotes survival 
by inducing the expression of Bcl-2 via the activation of the transcription factor cAMP-
response element binding protein (CREB, Hu & Russek, 2008). Encinas et al (1999) reported 
that the BDNF induced the activation of the Ras/MAPK and phosphatidylinositol-3 kinase(PI 
3-K)/Akt pathways (Kaplan & Miller, 1997) in SH-SY5Y cells facilitated neuritogenesis and 
cell survival respectively. BDNF treatment also induced the expression of GAP-43 mRNA 
which depended on the activation of the Ras/MAPK pathway but protein levels were only 
transiently elevated (Encinas et al 1999, 2000). 
 
Encinas et al (2000) have described a protocol of RA/BDNF differentiation that yielded a 
nearly pure population of cells arrested in G1 with rounded cell bodies and an extensive 
network of interconnecting axon-like processes that exhibited strong NF-H staining in 
neuritic processes and the cell body. However Western blot analysis suggested a decrease in 
the levels of NF-L and NF-M during RA/BDNF induced differentiation (Encinas et al, 2000). 
RA/BDNF treatment also results in increased protein levels and phosphorylation of tau as 
well as increased levels of p35 and Cdk5 however no increase in JNK phosphorylation was 
observed (Jämsä et al, 2004). A diagrammatic representation summarising the effects of RA 
and RA/BDNF induced differentiation on signalling cascades in SH-SY5Y cells reviewed in 
this introduction can be found in Figure 4.1.  
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Figure 4.1 Schematic representation summarising the effect of RA and RA/BDNF induced 
differentiation of SH-SY5Y neuroblastoma cells on intracellular signalling cascades promoting cell 
survival and neuritogenesis. Arrows indicate protein upregulation. RA treatment results in the upregulation 
of protein expression and activity of tissue transglutaminase (TG2), which activates RhoA by transamidation 
which in turn results in increased stress fibre and focal adhesion complex formation, and the activation of 
p38γ MAP kinase resulting in increased neurofilament (NF) protein expression and neuritogenesis (Singh et 
al, 2003). TG2 also activates Erk1/2 and JNK, resulting in JNK-induced c-jun phosphorylation and GAP-43 
protein expression (Cheung et al, 2009, Singh et al, 2003). Additional proteins upregulated by RA treatment 
include Neuron Specific Enolase (NSE) (Cheung et al, 2009, Pahlman et al, 1984), Bcl-2 (Feng & Porter, 
1999), Tau, p35, Cdk5 (Jämsä et al 2004) and Neurotrophic Tyrosine Kinase Receptor B (NTrkB; Encinas et 
al 1999, 2000). Binding of BDNF to NTrkB facilitates receptor dimerization and activation by 
autophosphorylation (reviewed by Hu et al 2008) which in turn activates signalling cascades including Ras-
MAPK pathway and the phosphatidylinositol-3-OH kinase (PI3-K)-Akt pathway responsible for 
neuritogenesis and cell survival respectively (Encinas et al 1999, reviewed in Hu et al 2008). RA/BDNF 
treatment also results in increased levels and phosphorylation of Tau protein (Jämsä et al, 2004). 
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4.1.2. The role of complex I and the proteasome in protein conformation 
diseases 
 
Many neurodegenerative diseases are characterised by the presence of intra- and extra-
cellular proteinacious inclusions. Due to a general decline in the activity of protein 
degradative pathways, energy production and a build-up of oxidatively damaged proteins and 
organelles, ageing neurons may be particularly susceptible to problems with protein 
processing (reviewed by Robinson, 2008).  
 
Numerous studies have suggested that inclusions or aggresomes in neuronal cells may be a 
protective mechanism since the inhibition of aggresome or inclusion formation often leads to 
increased apoptotic cell death (Bjorkoy et al, 2005, Hasegawa et al, 2004, Rideout et al, 2005, 
Tanaka et al, 2004). Aggresomes were first described by Johnston et al (1998) in human 
embryonic kidney 293 (HEK293) cells expressing mutant forms of integral membrane 
proteins that do not fold correctly, aggregates of which accumulate following either 
proteasome inhibition or over-expression.  Aggregates of misfolded proteins were transported 
to the MTOC where they were surrounded by a “cage” of vimentin filaments. Ultra-structural 
analysis of aggresomes revealed that they contained a region of electron-dense particles 
surrounded by a fibrous region containing individual filaments of 8-10 nm in diameter. 
Frequently mitochondria and vesicular bodies appeared to be trapped in the filamentous 
region (Johnston et al, 1998). This description of aggresomes is reminiscent of LBs and has 
lead to the hypothesis that LBs and proteinacious inclusions in other neurodegenerative 
diseases may formed in an aggresome-like process (McNaught et al, 2002, reviewed by 
Olanow et al, 2004). 
 
Proteasome inhibition has previously been shown to result in the production of ubiquitinated 
protein aggregates in differentiated PC12 cells, some of which are also immunoreactive for α-
synuclein. It is noteworthy that despite an increase in α-synuclein aggregation with 
proteasome inhibition, the actual levels of α-synuclein detected by Western blotting were 
similar to those in untreated cells (Rideout et al, 2001). A number of other studies have also 
employed the use of proteasome inhibitors to induce inclusion formation providing evidence 
for a role of defects in the UPS in protein aggregation (Fornai et al, 2003, Ito et al, 2002, 
Rideout et al, 2005, Rideout & Stefanis, 2002). 
 
Mitochondrial Complex I inhibition by MPTP/MPP+ has been extensively used in 
experimental models of PD (Bezard et al, 1997, Caneda-Ferron et al, 2008, De Girolamo & 
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Billett, 2005, Gupta et al, 1986, Zeng et al, 2006).  Continuous infusion of MPTP and MPP+ 
in mouse and rat models respectively was able to produce proteinacious inclusions that 
resemble Lewy bodies (Fornai et al, 2005, Yazdani et al, 2006). Inclusions were also 
produced in a mouse model in which mice were treated chronically with MPTP and 
probenecid - which inhibits the clearance of MPTP (Meredith et al, 2002). Chronic exposure 
of rat mesencephalic cultures to MPP+ resulted in the occurrence of fine α-synuclein granules 
which when combined with lactacystin caused the formation of α-synuclein positive 
inclusions (Sawada et al, 2004). 
 
p62/SQSTM1 has been identified in the cytoplasmic inclusions of a number of human 
diseases in both the liver and brain including Lewy bodies in PD and neurofibrillary tangles 
in AD (Nakaso et al, 2004, Zatloukal et al, 2002). Inclusions containing p62 and ubiquitin 
were also produced in a mouse model of amyotrophic lateral sclerosis (Gal et al, 2007) and a 
cell model expressing mutant huntingtin (Bjorkoy et al, 2005).  
 
In NGF differentiated PC12 cells, proteasome inhibition lead to the formation of an 
aggresome-like structure located in the perinuclear region that was immunoreactive for p62, 
ubiquitin and γ-tubulin. Aggregate formation was dependent on the expression of p62 since 
downregulation of p62 expression with anti-sense oligonucleotides decreased the number of 
cells with p62-positive aggregates (Nakaso et al, 2004). Several studies have shown that 
proteasome inhibition leads to an upregulation in the expression of p62 at both the protein and 
mRNA level and as such in the number and size of p62 bodies (Bjorkoy et al, 2005, Nakaso 
et al, 2004). 
 
Recently it has been suggested that aggregate-containing cells may induce macroautophagy to 
clear aggregates (Rideout et al, 2004). The structure of p62 supports the hypothesis that it 
plays a role in targeting polyubiquitinated protein aggregates for degradation by 
macroautophagy as it contains an N-terminal LC3 binding domain and a C-terminal ubiquitin 
binding domain (Bjorkoy et al, 2005, Pankiv et al, 2007). Using a double tag strategy that 
enabled them to follow labelled LC3 and p62 through the acidification process during 
autophagosome and lysosome fusion in live cells, Pankiv et al (2007) were able to show that 
even large p62 bodies were degraded by autophagy and that this degradation was inhibited by 
treatment with Bafilomycin A1. Knockdown of p62 expression using siRNA reduced the 
amount of ubiquitinated proteins within autolysosomes suggesting that p62 is required for the 
degradation of ubiquitinated aggregates by autophagy (Pankiv et al, 2007).  
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4.1.3. Aims of this Chapter 
 
In this work the effects of RA and RA/BDNF induced differentiation of SH-SY5Y cells 
on the expression of cytoskeletal elements will be evaluated in more detail. Despite the 
large volume of literature available, some aspects of RA and RA/BDNF induced 
differentiation are still controversial, such as the effect of differentiation on the expression 
of NFs. Some studies suggest increased NF expression (Singh et al 2003) while others 
report either no change (Cheung et al, 2009, Encinas et al, 2000) or decreased expression 
(Encinas et al, 2000). In addition the effects of differentiation on the expression of 
markers of differentiation such as TG2, NTrkB and Bcl-2 will be revisited. 
 
The main aim of this chapter is to establish whether the inhibition of complex I and/or the 
proteasome could result in the formation of inclusions resembling aggresomes in SH-
SY5Y neuroblastoma cells. The inclusion-producing cell model could then be used to 
clarify whether neurofilaments play a role in aggresome or inclusion formation. 
Inclusions are produced more readily in differentiated SH-SY5Y cells than in 
proliferating cells (Hasegawa et al, 2004, Lee et al, 2004, reviewed by Robinson, 2008), 
since differentiated cells are not able to minimize inclusions by distributing protein 
aggregates between daughter cells. Terminally differentiated cells are also more prone to 
the accumulation of oxidatively damaged proteins and as such, protein degradation 
pathways such as the UPS play an essential role in the clearance of damaged proteins. 
Therefore, to establish an inclusion-producing cell model, SH-SY5Y neuroblastoma cells 
were differentiated using a modified differentiation protocol derived from the protocol 
described by Encinas et al (2000). 
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4.2. Results 
4.2.1. Differentiation of SH-SY5Y cells with Retinoic acid and Brain Derived 
Neurotrophic Factor 
4.2.1.1. Cellular morphology of RA/BDNF differentiated cells 
 
Phase contrast images of SH-SY5Y cells induced to differentiate with RA or BDNF following 
RA pre-treatment are shown in Figure 4.2. Proliferating cells have a flattened appearance with 
few cellular processes. On treatment with 10 µM RA, cells become more elongated with a 
greater number of cellular processes. There does not seem to be much difference in the 
appearance of cells treated with RA for 5 days or for 8 days. Cells treated with BDNF 
following RA pre-treatment have more compact cell bodies with longer cellular processes. For 
RA/BDNF differentiated cells, cellular processes are more numerous and appear to form an 
interconnecting network. 
 
Figure 4.2 Phase contrast images of SH-SY5Y cells differentiated using retinoic acid (RA) or RA 
followed by Brain Derived Neurotrophic Factor (BDNF). Cells were either (A) proliferating, (B) 
differentiated for 5 days with 10 µM RA, (C) differentiated for 8 days with 10 µM RA, (D) differentiated 
for 5 days with 10 µM RA followed by 3 days with 50 ng/ml BDNF or (E) differentiated for 5 days with 10 
µM RA followed by 8 days with 50 ng/ml BDNF. Scale bar represents 100 µm. 
 
A) Proliferating cells 
(D) 5 days Retinoic acid 3 days BDNF 
C) 8 days Retinoic acid  
E) 5 days Retinoic acid 8 days BDNF 
B) 5 days Retinoic acid 
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Morphological characteristics were quantified by measuring the length of axonal processes 
and the diameter of cell bodies and by counting the number of cells with axon-like processes 
(summarized in Table 4.1). Axon-like processes were defined as being at least 2.5 times 
longer than the diameter of the cell body. The figures were obtained from phase contrast 
images of SH-SY5Y cells grown in T25 flasks and taken on an inverted microscope coupled 
to a digital camera. Cells were viewed at 100 x magnification using the 10 x objective. 
Images were analysed using QWin software from Leica to measure axon and cell body 
length. From the same images the percentage of cells with axon-like processes was 
determined by counting the number of cells in the field of view and then counting the number 
of cells with processes that have a length of at least 2.5 times the diameter of the cell body.  
 
The cell body of cells differentiated with 10 µM RA for 8 days (38.8 ± 2.2 µm) is 
significantly larger (p < 0.012, T-Test) than that in proliferating SH-SY5Y cells (30.3 ± 2.6 
µm). In cells that are differentiated with RA followed by BDNF the cell bodies are 
significantly smaller (around 20 µm) than the cell bodies of proliferating cells (Table 6.1). 
The mean length of processes does not differ significantly between proliferating cells and 
cells induced to differentiate using RA. For cells induced to differentiate using BDNF 
following 5 days RA pre-treatment, the length of cell processes is significantly greater than in 
proliferating cells (58.9 ± 6.9 µm). For cells treated with BDNF for 3 days the mean length of 
processes was 106.1 ± 13.8 µm (p < 0.006, T-Test) and for cells treated with BDNF for 8 
days it was 108.4 ± 22.6 µm (p < 0.022, T-Test). 
 
In proliferating cells, the percentage of cells with processes long enough to be ‘axonal-like’ 
(Table 6.1) is 9.0 ± 3.2 % of cells. This percentage increased with cells induced to 
differentiate with RA but the increase was only significant in cells treated for 5 days with RA 
(20.1 ± 5 %; p < 0.031, T-Test). In cells treated with BDNF following RA pre-treatment the 
percentage of cells with axon-like processes increased dramatically; for cells treated with 
BDNF for 3 days, 62.5 ± 1.4 % of cells had axons (p < 0.0001, T-Test) and for cells treated 
for 8 days with BDNF, 56.8 ± 12.8 % of cells had axons (p < 0.003, T-Test). 
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Table 4.1 Assessment of morphological characteristics to compare the efficiency of differentiation using 10 µM Retinoic Acid (RA) or 50 ng/ml Brain Derived 
Neurotrophic Factor (BDNF) after 10 µM RA pre-treatment. Morphological characteristics compared include mean cell body diameter, mean length of cellular processes 
and the percentage of cells with processes long enough to be defined as axons1 (n = 3).  
 
Diameter of 
the Cell 
body (µm) 
SD 
P (T-test, 
compared 
to mitotic) 
Mean length 
of processes  
(µm) 
SD 
P (T-test, 
compared to 
mitotic) 
Number of 
cells 
Number of 
cells with 
axons1 
Percentage 
of cells with 
axons1  
(%) 
SD 
P (T-test, 
compared 
to mitotic) 
 
Proliferating cells 
 
30.3 2.6  58.9 6.9  178 ± 32 16 ± 6.1 9.0 3.2  
 
5 days RA 
 
29.7 0.6 0.698 75.7 9.3 0.066 147.7 ± 22.3 30 ± 10.5 20.1* 5 0.031 
 
8 days RA 
 
38.8* 2.2 0.012 71.2 16.3 0.295 84.3 ± 12.7 12 ± 6.6 14.1 6.9 0.308 
 
5 days RA/   
3 days BDNF 
 
22.1** 0.9 
 
 
0.006 
 
 
106.1** 13.8 
 
 
0.006 
 
 
143.7 ± 49.7 89.3 ± 21 62.5*** 1.4 0.0001 
 
5 days RA/   
8 days BDNF 
 
19.5*** 1.3 0.003 108.4* 22.6 0.022 138.7 ± 75.7 72.3 ± 27.1 56.8*** 12.8 0.003 
 
1Axons are defined as processes that are at least 2.5 times longer than the diameter of the cell body 
Two-sample T-test, compared to mitotic *p < 0.05, **p < 0.01, ***p < 0.005 (n = 3)
129  
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4.2.1.2. The effect of RA/BDNF-induced differentiation on mRNA copy number and 
protein levels 
4.2.1.2.1. The Validation of the use of GAPDH as a house-keeping gene for 
Quantitative Real-Time PCR results 
  
GAPDH was used as a loading control for quantitative real-time PCR experiments 
determining the effect of RA-induced and RA/BDNF-induced differentiation on the mRNA 
copy number of several genes including the neurofilament subunits, α-1 tubulin, the motor 
proteins (dynein light intermediate chain and kinesin 5C), tissue transglutaminase (TG2), Bcl-
2 and a proteasome ATPase subunit (PSMC1) knocked-down in a PD mouse model (Bedford 
et al, 2008).  
 
Figure 4.3 The effect of RA and RA/BDNF-induced differentiation of the expression of GAPDH in 
SH-SY5Y cells.  
(A) The copy number of GAPDH mRNA per reaction as determined by quantitative real-time PCR. There is 
no significant change in the levels of GAPDH mRNA (n = 3). (B) Representative Western blot of total cell 
extracts of SH-SY5Y cells, either proliferating or differentiated with RA or RA/BDNF probed with anti-
GAPDH (1:1000) and plot summarising the results of densitometric analysis of Western blots normalised 
for protein loading against total protein. There was no significant change in the levels of GAPDH in total 
cell extracts of RA and RA/BDNF differentiated cells compared to levels in total cell extracts from 
proliferating cells. Error bars represent standard deviation (n = 3). 
 
The copy number of GAPDH mRNA (Figure 4.3 A) decreased slightly after RA treatment 
(but this decrease is not significant) and was similar in RA/BDNF differentiated cells to that 
in proliferating cells. The levels of GAPDH protein (Figure 4.3 B and C) in total cell extracts 
of proliferating cells and cells differentiated with either RA or RA/BDNF, investigated by 
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Western blotting with anti-GAPDH (1:1000),  remained relatively similar in proliferating, RA 
differentiated and RA/BDNF differentiated cells. 
 
To validate the use of GAPDH as a loading control, the copy number of GAPDH mRNA was 
compared to mRNA copy number of two other house-keeping genes, β-actin and ribosomal 
L32 (Figure 4.4). All three show a similar pattern of expression with a lower copy number in 
cells treated with RA for 5 d but for L32 the decrease was statistically significant (p < 0.05).  
 
Figure 4.4. A comparison of the mRNA copy number of GAPDH, β-actin and L32.  
Plots displaying the results of qRT-PCR of (A) GAPDH, (B) β-actin and (C) ribosomal L32 from cDNA 
preparations from SH-SY5Y cells either proliferating or induced to treated the 10 µM retinoic acid (RA) for 
5 days or 50 ng/ml Brain Derived Neurotrophic Factor (BDNF) for 3 days following 5 days pre-treatment 
with 10 µM RA (RA/BDNF). There was a significant decrease in mRNA copy number of L32 compared to 
copy number in mitotic cells following 5 days RA treatment. Error bars represent standard deviation (* p < 
0.05, T-Test; n = 3).  
 
4.2.1.2.2. Effect of RA/BDNF-induced differentiation on the expression of NTrkB, TG2 
and Bcl-2 
 
Both NTrkB and TG2 mRNA expression was increased following RA and RA/BDNF induced 
differentiation but Bcl-2 mRNA copy number remained unchanged after differentiation 
(Figure 4.5 A-C).  
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Figure 4.5 The expression of Neurotrophic Tyrosine Kinase Receptor B (NTrkB), tissue 
transglutaminase (TG2) and Bcl-2 in SH-SY5Y cells following differentiation with 10 µM Retinoic 
acid (RA) or 10 µM RA and 50 ng/ml Brain Derived Neurotrophic Factor (BDNF).  
The copy number of (A) NTrkB, (B) TG2 and (C) Bcl-2 mRNA was determined by qRT-PCR and 
expressed per 1000 copies GAPDH. Representative Western blots of total cell extracts from proliferating 
cells, RA and RA/BDNF differentiated cells probed with (D) anti-TG2 (cub, 1:1000) and (E) anti-Bcl-2 
(1:1000) accompanied by plots summarising the results of densitometric analysis of Western blots for each 
protein. Error bars represent standard deviation (n = 3). There was a significant increase in NTrkB mRNA 
copy number and the levels of TG2 mRNA and protein (One-way ANOVA; *p < 0.05, **p < 0.005) with 
differentiation. There was a significant decrease in Bcl-2 protein following 5 d (two-tailed T-Test, p < 0.05; 
n = 3) and 8 d (one-tailed T-Test; p < 0.05, n = 3) RA treatment. 
 
 
Probing Western blots with specific antibodies provided discrete binding profiles for TG2 
(Figure 4.5 D) and Bcl-2 (Figure 4.5 F) but the signals for NTrkB were smeared (results not 
shown). All treatments resulted in an increase in TG2 protein levels but Bcl-2 protein levels 
were decreased with RA treatment and unchanged (compared to proliferating cells) in 
RA/BDNF treated cells. 
 
(A) NTrkB mRNA (B) TG2 mRNA 
(D) TG2 protein 
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4.2.1.2.3. Effect of RA/BDNF-induced differentiation on the expression of Cytoskeletal 
Proteins 
 
All differentiation treatments reduced the copy number of NF-H mRNA but only RA 
treatment reduced NF-M and NF-L mRNA levels (Figure 4.6 A, C, E). In contrast protein 
levels of NF-H (Figure 4.6 B), NF-M (Figure 4.6 D) and NF-L (Figure 4.6 F) were generally 
unaffected by differentiation, other than an increase in NF-H levels with 8 d RA treatment 
and a decrease in NF-M levels with 5d RA/3d BDNF treatment.  
 
The effect of the two differentiation protocols on the levels of phosphorylated NF-H and NF-
M was investigated by immunoprobing Western blots with phosphorylation-specific 
antibodies; RT97 which recognises hyper-phosphorylated NF-H (Figure 4.7 A), associated 
with a more mature phenotype (Shea et al, 1997), smi31 which recognises both pNF-H and 
pNF-M  (Figure 4.7 B) and RNF403 which recognises pNF-M (Figure 4.7 C). In general, the 
levels of phosphorylated NF-H and NF-M were reduced following differentiation, albeit not 
significantly. 
 
Although the copy number of α1-tubulin mRNA (Figure 4.8 A) was generally reduced with 
differentiation (but not significantly, with the exception of 8 d RA treatment), the levels of α-
tubulin protein (Figure 4.8 B) were unaffected by RA treatment and increased with 
RA/BDNF treatment. However, the levels of vimentin (Figure 4.8 C) and β-actin (Figure 4.8 
D) protein were unaffected by RA and RA/BDNF treatment. 
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Figure 4.6 The expression of the neurofilament (NF) subunits in SH-SY5Y cells following differentiation 
with 10 µM Retinoic Acid (RA) or 10 µM RA and 50 ng/ml Brain Derived Neurotrophic Factor (BDNF).  
The mRNA copy number for (A) NF-H, (C) NF-M and (E) NF-L was determined by qRT-PCR and expressed 
per 1000 copies GAPDH. Representative Western blots of total cell extracts probed with (B) anti-NF-H (n52, 
1:2000), (D) anti-NF-M (RMO270, 1:500) and (E) anti-NF-L (DA2, 1:1000) accompanied by plots 
summarising the results of densitometric analysis. There was significant reduction in the mRNA copy number 
of NF-H (two-tailed T-Test; *p<0.05, **p < 0.005) following RA and RA/BDNF induced differentiation. NF-M 
and NF-L copy number was reduced after 5 d (two-tailed T-Test; *p < 0.05) and 8 d (one-tailed T-Test; *p < 
0.05) RA treatment but was unaffected by RA/BDNF treatment. The levels of NF-H protein increased 
significantly after 8 d RA treatment compared to levels in proliferating cells. The levels of NF-M protein 
decreased significantly after 5 d RA/3d BDNF induced differentiation (Two-tailed T-Test; p < 0.05). Error bars 
represent standard deviation (n = 3). 
(A) NF-H mRNA (B) NF-H protein 
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Figure 4.7 Assessment of the effect of differentiation with 10 µM retinoic acid (RA) or 10 µM RA and 
50 ng/ml Brain Derived Neurotrophic Factor (BDNF) on the phosphorylation of neurofilament (NF) 
heavy (H) and medium (M) subunits.  
Representative Western blots of total cell extracts were probed with (A) anti-hyper phosphorylated NF-H 
(RT97, 1:50). Error bars represent range (n = 2), (B) smi31 (1:1000) recognising phosphorylated NF-H and 
NF-M and (C) RNF403 (1:500) recognising phosphorylated NF-M. Each Western blot is accompanied by a 
plot summarising the results of densitometric analyses of Western blots using AIDA software. Error bars 
represent standard deviation (n = 3).  
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Figure 4.8 The expression of α-tubulin, vimentin and actin in SH-SY5Y neuroblastoma cells 
differentiated with 10 µM retinoic acid (RA) or 10 µM RA and 50 ng/ml Brain Derived Neurotrophic 
Factor (BDNF).  
(A) The Copy number of α1-tubulin mRNA expressed per 1000 copies GAPDH was determined by 
quantitative Real-Time PCR. There is a significant decrease in the copy number of α1-tubulin mRNA 
following 8 days RA treatment (One-tailed T-Test; * p < 0.05). Representative Western blots of total cell 
extracts immunoprobed with (B) anti-α-tubulin (b512, 1:2000), (C) anti-vimentin (RV202, 1:5000) or (D) 
anti-actin (1:1000) accompanied with plots summarising the results of densitometric analysis of Western 
blots. There is a significant increase in the levels of α-tubulin protein following RA/BDNF induced 
differentiation (One-way ANOVA, Bonferonni’s posttest, *p < 0.05, **p < 0.005) but no significant 
change in the levels of vimentin or actin protein following RA and RA/BDNF induced differentiation. 
Error bars represent standard deviation (n = 3). 
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4.2.1.2.4. Effect of RA/BDNF-induced differentiation on Kinesin 5C, Dynein Light 
Intermediate Chain and the Proteasome ATPase PSMC1 
 
Although the copy number of kinesin 5C (KIF5C) mRNA (Figure 4.9 A) was unaffected by 
RA and RA/BDNF treatment, the levels of kinesin 5C protein (Figure 4.9 B) were increased 
following RA/BDNF treatment. A similar increase in protein levels (seen in two independent 
experiments) was observed for kinesin 5 A (Figure 4.9 C) - a possible NF motor (Xia et al, 
2003). Despite an increase in the mRNA copy number of Dynein Light Intermediate Chain 
(Figure 4.9 D) in cells treated with RA or BDNF for 8 d, the levels of dynein light 
intermediate chain protein were unaffected by differentiation (Figure 4.9 E). 
 
Due to the importance of efficient protein clearance systems in terminally differentiated cells 
(Ardley et al, 2003, reviewed in Robinson, 2008) and the establishment of a PD mouse model 
resulting from PSMC1 knockdown (Bedford et al, 2008), the effect of RA and RA/BDNF 
induced differentiation on PSMC1 expression was investigated. The copy number of PSMC1 
mRNA (Figure 4.10 A) and protein (Figure 4.10 B) was generally unaffected by 
differentiation, with the exception of increased mRNA levels in cells treated with BDNF for 8 
d. 
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Figure 4.9 The expression of Kinesin 5C, Kinesin 5A and Dynein Light Intermediate Chain in SH-
SY5Y cells differentiated with 10 µM retinoic acid (RA) or 10 µM RA and 50 ng/ml BDNF. 
Plots summarising the results of qRT-PCR of (A) Kinesin 5C mRNA and (D) Dynein Light Intermediate 
Chain mRNA expressed per 1000 copies of GAPDH. Representative Western blots of total cell extracts 
probed with (B) anti-Kinesin 5C (1:1000), (C) anti-Kinesin 5A (1:1000) and (E) anti-dynein intermediate 
chain (Dyn70.1, 1:1000) and plots summarising the results of densitometric analysis of Western blots. 
There was no significant change in mRNA copy number of Kinesin 5C but for dynein light intermediate 
chain there was a significant increase in copy number following 8 d RA treatment and 5d RA/8d BDNF 
treatment (T-Test, p < 0.05; n = 3). There was a significant increase in Kinesin 5C protein (T-Test, p < 
0.05; n = 3) and an increasing trend in kinesin 5A protein (n = 2) following RA/BDNF induced 
differentiation compared to proliferating cells. There appeared to be no effect of RA and RA/BDNF 
induced differentiation on levels of dynein intermediate chain in total cell extracts (n = 2). Error bars 
represent SEM (n = 3) or range (n = 2).  
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Figure 4.10 The expression of the Proteasome ATPase subunit, PSMC1, in SH-SY5Y cells following 
differentiation with 10 µM retinoic acid (RA) or 10 µM RA and 50 ng/ml Brain Derived Neurotrophic 
Factor (BDNF).  
 (A) Plot summarising the results of qRT-PCR of PSMC1 expressed per 1000 copies of GAPDH revealed a 
significant increase in the mRNA copy number in cells treated with BDNF for 8 days (*p < 0.05, T-Test). 
(B) Representative Western blot of total cell extracts probed with anti-PSMC1 (Sigma, 1:1000) and plot 
summarising the results of densitometric analyses of Western blots which revealed no significant change in 
the levels of PSMC1 protein with RA and RA/BDNF induced differentiation. Error bars represent standard 
deviation (n = 3). 
 
4.2.2. Inhibition of Complex I and the Proteasome in RA/BDNF differentiated 
SH-SY5Y cells 
4.2.2.1. Effect of complex I inhibition on the viability of RA/BDNF differentiated 
SH-SY5Y cells  
 
The effect of a range of MPP+ concentrations on the viability of RA/BDNF differentiated 
SH-SY5Y neuroblastoma cells was assessed morphologically and by MTT reduction after 24, 
48 and 72 hours of treatment. Phase contrast images following 72 h treatment (Figure 4.11 A) 
revealed that 500 µM MPP+ resulted in a marked reduction in the number of viable cells seen 
in a field of view.  Similarly the results of the MTT reduction assay (Figure 4.11 B) suggested 
a significant concentration and time dependent reduction in cell viability (*Two-way 
ANOVA, p > 0.0001; n = 4), with the greatest reduction in viability occurring at the higher 
concentrations (1 and 2 mM) of MPP+ at all times and 500 µM MPP+ resulting in reduced 
MTT reduction (58.5 ± 13.8 % of control) by 72 h.  
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Figure 4.11 The effect of a range of MPP+ concentrations on the viability of cells differentiated with 
10 µM Retinoic Acid (RA) and 50 ng/ml Brain Derived Neurotrophic Factor (BDNF) assessed by 
MTT reduction assay.  
(A) Phase contrast images of RA/BDNF differentiated cells treated with a range of MPP+ concentrations 
for 72 h. Images were taken at 100 x magnification and the scale bar represents 40 µm. (B) Plot 
summarising the results of the MTT reduction assay. Mean corrected absorbance at 570 nm was expressed 
as a percentage of absorbance of control (untreated RA/BDNF differentiated cells). *A significant decrease 
in MTT reduction was observed with increasing MPP+ concentration and time (2-way ANOVA, ***p < 
0.0001). † MTT reduction in treated cells compared to MTT reduction in control cells using Two-tailed T-
Test (†p < 0.05, ††p < 0.005). Error bars represent SEM (n = 4). 
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4.2.2.2. Effect of Complex I Inhibition and Inhibition of Proteasome on Protein 
Expression 
 
The effect of complex I inhibition and the inhibition of the proteasome in RA/BDNF 
differentiated SH-SY5Y cells was investigated by treating cells with 500 µM MPP+ or 10 nM 
epoxomicin for 24 h. In addition the importance of the proteasome during complex I 
inhibition was investigated by combining epoxomicin and MPP+ treatments. The effect of 
these treatments on the expression of a number of proteins including the cytoskeletal proteins, 
motor proteins, TG2, PSMC1, Bcl-2 and α-synuclein was investigated. 
 
The copy number of NF-L mRNA was unaffected by MPP+ and epoxomicin treatment but 
was reduced following MPP+/epoxo treatment, whereas NF-L protein levels were unaffected 
by treatment (Figure 4.12 A and B). None of the treatments had an effect on the expression of 
NF-H mRNA and protein (Figure 4.12 C and D) whereas NF-M protein was elevated 
following epoxomicin and MPP+/epoxomicin treatment although mRNA expression was 
unaffected (Figure 4.12 E and F). Other than a slight increase in the levels of phosphorylated 
NF-M with MPP+ treatment seen with smi31, the levels of phosphorylated NF-M and NF-H 
were largely unaffected by treatment (Figure 4.13). 
 
Treatment did not have a significant effect on the mRNA copy number of α1-tubulin but α-
tubulin protein levels were reduced following MPP+/epoxo treatment (Figure 4.14 A and B). 
Actin protein and β-actin mRNA levels were reduced with MPP+ treatment but unaffected by 
epoxo and MPP+/epoxo treatment (Figure 4.14 C and D). Similarly, the levels of γ-tubulin 
protein were reduced with MPP+ treatment but unaffected by epoxomicin and 
MPP+/epoxomicin treatment (Figure 4.14 E). The levels of vimentin protein were reduced 
with all treatments (Figure 4.14 F).  
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Figure 4.12 Effect of 24 h treatment with 500 µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM 
MPP+ and 10 nM epoxo on the expression of the three neurofilament subunits in RA/BDNF 
differentiated SH-SY5Y neuroblastoma cells.  
Plots summarising the results of qRT-PCR of (A) NF-L, (C) NF-M and (E) NF-H mRNA expressed per 
1000 copies GAPDH. In general, treatment had no effect on the mRNA expression of the three NF subunits 
with the exception of a reduction in NF-L mRNA with MPP+/Epoxo treatment (One-tailed T-Test, *p < 
0.05; n = 3). Error bars represent standard deviation. Representative Western blots of total cell extracts 
probed with (B) anti-NF-L (DA2, 1:1000), (D) anti-NF-M (RMO270, 1:500) and (F) anti-NF-H (n52, 
1:2000) accompanied by plots summarising the results of densitometric analyses of Western blots. 
Treatments had no effect on the expression of NF-H (n = 4) and NF-L (n = 5) protein but an increase in NF-
M protein levels was observed with epoxomicin treatment (Two-tailed T-Test, *p < 0.05; n =5) and 
MPP+/epoxo treatment (One-tailed T-Test, *p < 0.05; n = 5). Error bars represent SEM. 
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Figure 4.13 Effect of treatment of RA/BDNF differentiated SH-SY5Y neuroblastoma cells with 500 
µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo for 24 h on the 
phosphorylation status of NF-H and NF-M. 
 Each panel contains a representative Western blot and a plot summarising the results of densitometric 
analyses of Western blots. (A) Densitometric analyses of Western blots probed with smi31 (1:1000) 
revealed that generally there was no effect of treatment on the levels of pNF-M and pNF-H except for a 
slight increase in levels of pNF-M with MPP+ treatment (One-tailed T-Test, p < 0.05; n = 4). Error bars 
represent standard deviation. (B) However, densitometric analyses of Western blots probed with RNF403 
(1:1000) revealed no significant change in the levels of pNF-M in total cell extracts with treatment 
compared to control. Error bars represent SEM (n = 5). 
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Figure 4.14 Assessment of the expression of α-tubulin, actin, vimentin and γ-tubulin following 
treatment of RA/BDNF differentiated SH-SY5Y cells with 500 µM MPP+, 10 nM epoxomicin (epoxo) 
or 500 µM MPP+/10 nM Epoxo for 24 h. 
The mRNA copy number of (A) α1-tubulin and (C) β-actin assessed by qRT-PCR expressed per 100 copies 
or per copy of GAPDH respectively. β-Actin and α1-tubulin mRNA expression was generally unaffected by 
treatment except for a decrease in β-actin mRNA with MPP+ treatment (One-tailed T-Test, *p < 0.05; n = 
3). Representative Western blots of total cell extracts immunoprobed with (B) anti-α-tubulin (b512, 
1:2000), (C) anti-actin (1:1000), (D) anti-γ-tubulin (1:1000) and (E) anti-vimentin  (RV202, 1:5000) 
accompanied by plots summarising the results of densitometric analyses of Western blots. A reduction in α-
tubulin protein was observed following MPP+/epoxo treatment (Two-tailed T-Test, *p < 0.05, n = 5) but 
actin levels were largely unaffected (n = 5). The levels of γ-tubulin protein were reduced following MPP+ 
treatment (Two-tailed T-Test, *p < 0.05; n = 3) and vimentin levels were reduced with MPP+, MPP+/epoxo 
(Two-tailed T-Test, *p < 0.05; n = 5) and epoxo (One-tailed T-Test, *p < 0.05; n = 5) treatment. Error bars 
represent SEM when n =5 and standard deviation when n = 3. 
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Kinesin 5C mRNA (Figure 4.15 A) expression was unaffected by treatment as were protein 
levels (Figure 4.15 B, monitored in two independent experiments), in addition kinesin 5A 
protein levels were also unchanged (Figure 4.15 C, n = 5).  However the levels of dynein 
intermediate chain protein were reduced with all treatments (Figure 4.15 E), although mRNA 
copy number with treatment remained unchanged (Figure 4.15 D). 
 
Figure 4.15 Assessment of the expression of kinesin 5C and 5A dynein light intermediate chain in 
RA/BDNF differentiated SH-SY5Y cells treated with 500 µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM 
MPP+/10 nM epoxo for 24 h. 
The mRNA copy number of (A) kinesin 5C and (D) dynein light intermediate chain assessed by qRT-PCR and 
expressed per 1000 copies GAPDH revealed no effect of treatment on mRNA expression. Error bars represent 
standard deviation (n = 3). Representative Western blots of total cell extracts probed with (B) anti-Kinesin 5C 
(1:1000), (C) anti-Kinesin 5A (1:1000) and (E) anti-dynein intermediate chain (Dyn 70.1, 1:1000) and plots 
summarising the results of densitometric analyses of Western blots. The protein levels of kinesin 5C (n =2, error 
bars represent range) and kinesin 5A (n = 5, error bars represent SEM) appeared to be unaffected by treatment but 
dynein intermediate chain protein levels were reduced with all treatments (Two-tailed T-Test, *p< 0.05; n = 5, 
error bars represent SEM). 
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Protein and mRNA expression of the proteasome ATPase subunit, PSMC1, was largely 
unaffected by treatment with MPP+, epoxo or MPP+/epoxo (Figure 4.16).  
 
 
Figure 4.16 Effect of 500 µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo 
treatment of RA/BDNF differentiated SH-SY5Y neuroblastoma cells on the expression of PSMC1  
(A) mRNA copy number assessed by qRT-PCR expressed per 1000 copies GAPDH and (B) protein by 
probing Western blots of total cell extracts with anti-PSMC1 (1:1000) and plot summarising the results of 
densitometric analyses of Western blots. There was no of treatment on the PSMC1 mRNA or protein levels. 
Error bars represent standard deviation (n = 3). 
 
MPP+ treatment had no effect on the expression of TG2 mRNA and protein whereas 
treatment with epoxomicin reduced mRNA levels while leaving protein levels unchanged and 
visa versa with MPP+/epoxo treatment (Figure 4.17).  
 
Figure 4.17 Expression of tissue transglutaminase (TG2) in RA/BDNF differentiated cells treated with 500 
µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo for 24 h. 
(A) Plot summarising the results of qRT-PCR which revealed that treatment resulted in a reduction in TG2 
mRNA copy number per 10,000 copies GAPDH with epoxomicin treatment (One-tailed T-Test, *p < 0.05; n = 3). 
Error bars represent standard deviation. (B) Representative Western blot and plot summarising the results of 
densitometric analyses of Western blots probed with anti-TG2 (cub, 1:1000). A reduction in TG2 protein levels 
was observed with MPP+/epoxo treatment (One-tailed T-Test, p < 0.05; n = 5). Error bars represent SEM. 
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Although treatment did not appear to effect Bcl-2 mRNA expression, the general trend in 
protein levels from two independent experiments suggested an increase in Bcl-2 levels with 
epoxomicin and MPP+/epoxo treatment (Figure 4.18).  
 
Figure 4.18 Expression of Bcl-2 in RA/BDNF differentiated SH-SY5Y cells treated with 500 µM 
MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo for 24 h.  
(A) Plot summarising the results of qRT-PCR which revealed that treatment had no significant effect on 
Bcl-2 mRNA copy number per 10,000 copies GAPDH (n = 3). (B) Representative Western blot and plot 
summarising the results of densitometric analyses of Western blots probed with anti-Bcl-2 (1:1000). Error 
bars represent range (n = 2).  
 
Treatment also had no effect on the levels of α-synuclein protein (Figure 4.19). 
 
Figure 4.19 Effect of 24 h treatment of RA/BDNF differentiated SH-SY5Y cells with 500 µM MPP+, 
10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo on the expression of α-synuclein.  
A representative Western blot and plot summarising the results of densitometric analyses of Western blots 
probed with anti-α-synuclein (1:1000) revealed that treatment had no effect on α-synuclein levels. Error 
bars represent SEM (n = 5). 
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4.2.2.3. Effect of Inhibition of Complex I and the Proteasome on the Distribution of 
Cytoskeletal proteins  
 
To assess the effect of treatment with MPP+, epoxo or MPP+/epoxo on the solubility of 
cytoskeletal proteins; cell lysates were prepared in 50 mM Tris-HCl (pH 8) buffer containing 
1 % (v/v) Igepal CA-630 and centrifuged (10 000 x g, 10 min). The resultant cell debris pellet 
was boiled in 100 µl total extraction buffer [50 mM Tris-HCl pH 6.8, 5 mM EDTA, 1 % 
(w/v) SDS, 1 mM Sodium orthovanadate, 1 % (v/v) HALT protease and phosphatase 
inhibitor cocktail]. The Lysate supernatant and the cell debris pellet are hereafter referred to 
as the Igepal soluble fraction and the Igepal insoluble fraction respectively.  
 
The levels of NF-M in the igepal soluble and insoluble cell fractions were not affected by 
treatment with MPP+, epoxo or MPP+/epoxo (Figure 4.20 A). Although the levels of pNF-M 
in the igepal soluble cell fraction were generally unaffected by treatment, levels in the igepal 
insoluble fraction were elevated with epoxomicin treatment (Figure 4.20 B). Expressing the 
insoluble and soluble cell fractions as a ratio (insoluble/soluble) revealed that with treatment 
the levels of pNF-M were greater in the insoluble fraction than the soluble fraction.  
 
The levels of NF-H in the igepal soluble and insoluble cell fractions were generally 
unaffected by treatment with the exception of the igepal insoluble fraction from cells treated 
with epoxomicin in which levels were elevated (Figure 4.21 A). In addition, expressing the 
signal (as % control) from the igepal soluble and insoluble fractions as a ratio revealed an 
increase in the insoluble fraction compared to the soluble with MPP+ and epoxomicin 
treatments but not with MPP+/epoxo treatment. 
 
Other than a reduction in levels of NF-L in the soluble fraction with MPP+ treatment, NF-L 
levels in the igepal soluble and insoluble cell fractions were generally unchanged with 
treatment (Figure 4.21 B). Similarly, the insoluble/soluble ratios of fractions from treated 
cells were similar to the ratio from controls.  
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Figure 4.20 The Levels of NF-M and phosphorylated NF-M in Igepal soluble and insoluble cell 
fractions of RA/BDNF differentiated SH-SY5Y cells treated with 500 µM MPP+, 10 nM epoxomicin 
(epoxo) or 500 µM MPP+/10 nM epoxo for 24 h. 
 Representative Western blots of Igepal soluble and insoluble cell fractions probed with (A) anti-NF-M 
(RMO270, 1:500) or (B) anti-pNF-M (RNF403, 1:1000). Plots summarise the densitometric analyses of 
Western blots with signal expressed as % of mean control. The levels of NF-M in the igepal soluble and 
isoluble fractions were unaffected by treatment but the levels of pNF-M were greater in the igepal insoluble 
fraction with epoxomicin treatment (T-Test, *p < 0.05; n = 3). Error bars represent standard deviation. The 
mean ratio of the signal (as % control) of the igepal insoluble versus soluble fraction ± standard deviation, 
quoted in the box below the Western blots, was greater for pNF-M with MPP+ (One-tailed T-Test, *p < 
0.05; n = 3), epoxo and MPP+/epoxo treatment (Two-tailed T-Test, *p < 0.05; n = 3). 
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Figure 4.21 Effect of 24 h treatment of RA/BDNF differentiated SH-SY5Y cells with 500 µM MPP+, 
10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo on the levels NF-H and NF-L in igepal 
soluble and insoluble cell fractions.  
Representative Western blots probed with (A) anti-NF-H (n52, 1:2000) and (B) anti-NF-L (DA2, 1:1000) 
accompanied by plots summarising the results of densitometric analyses of Western blots. The levels of NF-
H in the igepal insoluble fraction were increased with epoxomicin treatment (Two-tailed T-Test, *p < 0.05; 
n = 3) and the levels of NF-L were reduced in the soluble fraction with MPP+ treatment (One-tailed T-Test, 
*p < 0.05; n = 3). The mean ratio of the signal (as % control) of igepal insoluble versus soluble fractions ± 
standard deviation is quoted in the box below the Western blots. The ratio of insoluble/soluble for NF-H 
was greater than controls with MPP+ and epoxo treatment (One-tailed T-Test, *p < 0.05; n = 3) but not with 
MPP+/epoxo treatment.  
 
Treatment had no significant effect on the levels α-tubulin in the igepal soluble and insoluble 
cell fractions compared to control (Figure 4.22 A) but the insoluble/soluble ratio with MPP+ 
and MPP+/epoxo suggested that levels in the insoluble fraction were increased with respect to 
levels in the soluble fraction. The levels of vimentin were reduced in the soluble fraction but 
unchanged in the insoluble fraction with MPP+ treatment; levels were also unchanged in both 
fractions with epoxomicin and MPP+/epoxo treatment (Figure 4.22 B). Other than a reduction 
in levels in both fractions with epoxomicin treatment, there was no effect of treatment on the 
levels of actin in either fraction (Figure 4.22 C). 
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Figure 4.22 Effect of 24 h treatment of RA/BDNF differentiated cells with 500 µM MPP+, 10 nM 
epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo on the levels of α-tubulin, vimentin and actin in 
the igepal soluble and igepal insoluble cell fractions.  
Representative Western blots probed with (A) anti-α-tubulin (b512, 1:2000), (B) anti-vimentin (RV202, 
1:5000) and (C) anti-actin (1:1000). The plots summarise the results of densitometric analyses of Western 
blots. The levels of vimentin were reduced in the soluble fraction compared to control with MPP+ treatment 
(Two-tailed T-Test, **p < 0.005; n = 3) as were the levels of actin in both fractions with epoxomicin 
treatment (One-tailed T-Test, *p < 0.05; n = 3). The mean ratio of the signal (as % control) of igepal 
insoluble versus soluble fractions ± standard deviation is quoted in the box below the Western blots. The 
ratio of insoluble/soluble of α-tubulin is greater with MPP+ and MPP+/epoxo treatment (One-tailed T-Test, 
p < 0.05; n = 3). Error bars represent SEM (n = 3). 
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in some cells areas of intense NF staining are visible (indicated by the arrows). In MPP+ 
treated cells, regions of intense NF-H staining are also accompanied by some swelling of the 
axonal processes in that region. These swellings were not observed in epoxomicin treated 
cells and were not as clearly visible in MPP+/epoxo treated cells. 
 
Figure 4.23 The distribution of NF-H in RA/BDNF differentiated SH-SY5Y cells treated with 500 µM 
MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo for 24 h. 
Figure shows fluorescence and fluorescence/phase contrast composite images of cells stained with anti-NF-
H (green; n52, 1:200), nuclei were counterstained with dapi (blue). Images were taken with a fluorescence 
microscope using a 40 x objective, scale bars represent 20 µm. Areas of intense NF-H staining in or near the 
cell body are indicated by arrows. In MPP+ treated cells regions of concentrated NF-H staining are 
accompanied by axonal swelling as seen in the phase contrast images (red arrow). Regions of axonal 
swelling were not observed in cells treated with epoxomicin. 
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Aggresomes are surrounded by a “cage” of intermediate filaments of which vimentin has 
previously been shown to be a component (Johnston et al, 1998). With this in mind, the effect 
of treatment on the distribution of vimentin was investigated by immunofluorescence staining 
(Figure 4.24).  
 
Figure 4.24 The distribution of vimentin in RA/BDNF differentiated SH-SY5Y cells treated with 500 µM MPP+, 10 
nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo for 24 h, 
Figure shows immunofluorescence images of cells stained with anti-vimentin (green; RV202, 1:500) taken with a 
fluorescence microscope using a 40 x objective (scale bar represents 20 µm). Nuclei were counterstained with dapi (blue). 
Areas of intense vimentin staining in the cell body (indicated by arrows) are visible in control and treated cells. 
Control 
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10 nM Epoxomicin/500 µM MPP+ 
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In control cells, strong vimentin staining was evident in both the cell body and the axonal 
processes. The axonal processes in cells treated with MPP+ were not as strongly stained as in 
control cells, with most of the staining concentrated in the cell body. Cells treated with 
epoxomicin or MPP+/epoxo stained strongly in both the cell body and the axonal processes. 
Regions of intense vimentin staining in the cell body are visible in both control and treated 
cells making it difficult to see a concentration of vimentin in the perinuclear region which 
may indicate aggresome formation. 
4.2.2.4. Effect of Inhibition of Complex I and the Proteasome on Macroautophagy 
 
The effect of MPP+, epoxo and MPP+/epoxo treatment on macroautophagy was investigated 
by monitoring the levels of LC3-II in treated cells compared to the levels in controls and in 
the presence of Bafilomycin A1 (BafA1, inhibitor of macroautophagy). Preliminary results 
(from two independent experiments) revealed that the levels of LC3-II with MPP+, epoxo and 
MPP+/epoxo treated cells were barely detectable and similar to the control whereas with 
BafA1, MPP+/BafA1 or MPP+/epoxo/BafA1 treatment, levels were 20-fold, 10-fold and 5-
fold higher than in the control respectively (Figure 5.25). 
 
 
Figure 4.25 Indirect measurement of macroautophagy by monitoring the levels of the autophagic 
vesicle marker, LC3-II, in RA/BDNF differentiated SH-SY5Y cells treated for 24 h with 500 µM 
MPP+, 10 nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo with or without 10 nM Bafilomycin 
A1 (BafA1) 
Representative Western blot probed with anti-LC3B (1:1000) and anti-actin (1:1000). The plot summarises 
the results of densitometric analysis of the LC3-II band from two independent experiments corrected for 
protein loading by actin. Levels of LC3-II in control cells and MPP+, epoxo and MPP+/epoxo treated cells 
were barely detectable but levels of LC3-II in BafA1, MPP+/BafA1 and MPP+/epoxo/BafA1 treated cells 
were increased 20-, 10- and 5-fold respectively. Error bars represent range (n = 2). 
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In addition to LC3-II, the effect of MPP+, epoxo and MPP+/epoxo treatment on the levels of 
p62/SQSTM1 was also determined (Figure 4.26). Preliminary results from two independent 
experiments suggest that p62 levels in MPP+ and epoxo treated cells treated are similar to 
control levels whereas levels in MPP+/epoxo treated cells are slightly higher. In BafA1, 
MPP+/BafA1 and MPP+/epoxo/BafA1 treated cells levels were 10-15 fold higher (n = 2). 
 
Figure 4.26 The levels of p62 in RA/BDNF differentiated cells treated for 24 h with 500 µM MPP+, 10 
nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo with or without Bafilomycin A1 (BafA1). 
Representative Western blot probed with anti-p62 (1:1000) and plot summarising the results of 
densitometric analysis of Western blots from two independent experiments. The levels of 62 in MPP+ and 
epoxo treated cells were similar to control levels while levels with MPP+/epoxo treatment seemed to be 
slightly higher. Levels of p62 with BafA1, MPP+/BafA1 or MPP+/BafA1/epoxo treatment were increased 
10- to 15-fold of levels in the control. Error bars represent range (n = 2). 
 
p62 is often associated with inclusions and protein aggregates, an association that is thought 
to be indicative of the attempted removal of aggregated proteins by macroautophagy (Pankiv 
et al, 2007). As such, the effect treatment with MPP+, epoxo and MPP+/epoxo on the 
solubility in of p62 was assessed by immunoprobing Western blots of igepal soluble and 
insoluble cell fractions (Figure 4.27). With the exception of MPP+/epoxo treatment in which 
levels were increased, the levels of p62 in the igepal soluble fraction following MPP+ and 
epoxo treatments were unchanged. In the igepal insoluble fraction, p62 levels were increased 
with epoxo and MPP+/epoxo treatment. Following MPP+ treatment, no significant change in 
p62 levels in the igepal insoluble fraction was observed. An increase in the ratio of 
insoluble:soluble protein was observed with epoxo treatment but not with MPP+ or 
MPP+/epoxo. 
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Figure 4.27 Effect of 24 h treatment of RA/BDNF differentiated cells treated with 500 µM MPP+, 10 
nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo on the solubility of p62/SQSTM1 in igepal-
containing cell lysis buffer. 
Representative Western blots of igepal soluble and insoluble cell fractions probed with anti-p62 (1:1000). 
Plot summarising the results of densitometric analyses of Western blots that revealed an increase in the 
levels of p62 in the igepal soluble fraction with MPP+/epoxo treatment (One-tailed T-Test, *p < 0.05; n = 
3) and in the igepal insoluble cell fraction with epoxo and MPP+/epoxo treatment (Two-tailed T-Test, *p < 
0.05, **p < 0.005; n = 3). Error bars represent standard deviation (n = 3). The mean ratio of the signal (as % 
control) of igepal insoluble versus soluble fractions ± standard deviation is quoted in the box below the 
Western blots and revealed that the level of p62 in the insoluble fraction was greater than in the soluble 
fraction with MPP+/epoxo treatment (Two-tailed T-Test, *p < 0.05; n = 3). 
 
Double-immunofluorescence staining of p62 (red) with α-tubulin (green, Figure 4.28) and 
NF-H (green, Figure 4.30) revealed that p62 did not generally co-localise with α-tubulin but 
there was some evidence of co-localisation (indicated by the yellow colour of overlapping red 
and green signals) with NF-H. In control cells a small degree of apparent NF-H and p62 
colocalisation is visible but the majority of the staining for NF-H and p62 remains distinctly 
individual. However, in treated cells (but not that obviously in epoxo treated cells), NF-H 
staining is mainly localized in the perinuclear region where it often co-localized with p62, 
resulting in strong yellow staining. In all treated cells an accumulation of either NF-H and/or 
p62 in the perinuclear region (indicated by arrows) was observed. 
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Figure 4.28 Immunofluorescence staining of α-tubulin and p62/SQSTM1 in RA/BDNF 
differentiated SH-SY5Y cells treated for 24 h with 500 µM MPP+, 10 nM epoxomicin (epoxo) or 
500 µM MPP+/10 nM epoxo. 
Fluorescence microscope images of cells stained with anti-α-tubulin (green; b512, 1:200) and anti-p62 
(red; 1:100). p62 bodies appeared more numerous in MPP+ and MPP+/Epoxomicin treated cells 
(indicated by yellow arrows) than in control cells. Images were taken using a fluorescence microscope 
with a 100x oil objective, scale bars represent 8 µm. Two independent fields are shown. 
 
Control 
500 µM MPP+ 
10 nM Epoxomicin 
500 µM MPP+ and 10 nM Epoxomicin 
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Figure 4.29 Immunofluorescence staining of NF-H and p62/SQSTM1 in RA/BDNF differentiated SH-
SY5Y cells either treated for 24 h with 500 µM MPP+, 10 nM epoxomicin (epoxo) or 500 µM 
MPP+/10 nM epoxo. 
Fluorescence microscope images of cells stained with anti-NF-H (green; n52, 1:100) and anti-p62 (red, 
1:100). Co-localization of NF-H and p62 (yellow) appeared to be more prevalent in MPP+ and 
MPP+/Epoxomicin treated cells as did p62 bodies in treated cells. Images were taken using a fluorescence 
microscope with  a 100 x oil objective. Scale bars represent 8 µm. Three independent fields are shown in 
each case. 
 
Control 
500 µM MPP+ 
10 nM Epoxomicin 
500 µM MPP+ /10 nM Epoxomicin 
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As indicated earlier, p62/SQSTM1 has been shown to interact with LC3-II and ubiquitinated 
proteins and has as such been hypothesized to function in the targeting of aggregated proteins 
and/or organelles for destruction by macroautophagy. Due to the possible role of 
macroautophagy in the removal of protein aggregates, treated cells were double 
immunostained with anti-NF-H and anti-LC3B which recognises LC3-I and LC3-II (Figure 
4.30). The majority of LC3 and NF-H appeared to co-localize in control and treated cells 
(yellow). LC3 staining was distributed between the cell body and the axonal processes in 
control and MPP+ treated cells. In epoxo and MPP+/epoxo treated cells LC3 was mainly was 
concentrated in a localized region of intense staining within the cell body. Similarly, regions 
of intense NF-H staining (which co-localized with LC3) were visible in the cell body of 
MPP+, epoxo and MPP+/epoxo treated cells.   
 
In addition the effect of treatment on cathepsin D levels and activity was determined by 
immunoprobing Western blots of total cell extracts with anti-cathepsin D (CTD19) which 
recognises the 52 kD pro-form of cathepsin D and the 34 kD cleaved form (Figure 4.31). 
Preliminary results from two independent experiments revealed a marked increase in the 
levels of the 34 kD cleaved form of with epoxomicin treatment and a decrease with MPP+ 
treatment. Combining treatments with BafA1 resulted in a 4-5 fold increase in the cleaved 
cathepsin D. 
 
Figure 4.30 Effect of 24 h treatment of RA/BDNF differentiated SH-SY5Y cells with 500 µM MPP+, 10 
nM epoxomicin (epoxo) or 500 µM MPP+/10 nM epoxo with or without 10 nM Bafilomycin A1 (BafA1) on 
the levels and activity of Cathepsin D. 
Representative Western blot of total cell extracts probed with anti-cathepsin D (CTD19, 1:1000). Plot 
summarising the results of densitometric analyses of the 52 kD pro-form and 34 kD cleaved forms of Cathepsin 
D from two independent experiments. The levels of the 34 kD cleaved form were increased in cells treated with 
epoxo, BafA1, MPP+/BafA1 and MPP+/epoxo/BafA1 but decreased in cells treated with MPP+. Error bars 
represent range (n = 2). 
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Figure 4.31 Immunofluorescence staining of LC3 and NF-H in RA/BDNF differentiated SH-SY5Y cells treated 
with MPP+, epoxomicin (epoxo) or MPP+/epoxo. 
Immunofluorescence images of RA/BDNF differentiated SH-SY5Y neuroblastoma cells either untreated or treated 
with 500 µM MPP+, 10 nM Epoxomicin or 500 µM MPP+/10 nM Epoxomicin for 24 h imaged by laser confocal 
micrsocopy. Cells were stained with anti-NF-H (green; n52, 1:200) and anti-LC3B (red; 1:100). LC3B staining in 
Epoxomicin and MPP+/Epoxomicin treated cells was mainly concentrated in the cell body where some of it appeared 
to co-localize with NF-H staining (yellow). Whereas in control and MPP+ treated cells, LC3B staining was found in 
the axonal processes and cell body where it appeared to co-localize with NF-H staining (yellow). In MPP+, 
Epoxomicin and MPP+/Epoxomicin treated cells some protein aggregates (indicated by arrows) where found in the 
perinuclear region.   
Control 500 µM MPP+ 
10 nM Epoxomicin 
500 µM MPP+ and 10 nM Epoxomicin  
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4.3 Discussion 
4.3.1. The Differentiation of SH-SY5Y neuroblastoma cells 
4.3.1.1. Morphological Characteristics of RA and RA/BDNF differentiated SH-SY5Y 
neuroblastoma cells 
 
The morphological features of proliferating, RA and RA/BDNF differentiated SH- cells were 
compared to assess the efficiency of RA/BDNF induced differentiation. In phase contrast 
images, the cell bodies with RA/BDNF treatment were smaller and more rounded in 
appearance than the cell bodies of proliferating and RA-differentiated cells. RA/BDNF 
differentiation also resulted in a larger percentage of cells with long axon-like processes that 
formed an interconnecting network of fibres. These results are similar to those reported by 
Encinas et al (2000) in their comparison of RA and RA/BDNF induced differentiation of SH-
SY5Y cells. Therefore, morphologically RA/BDNF treatment yielded a population of cells 
with a differentiated phenotype that was more homogeneous than obtained with RA-induced 
differentiation. 
 
4.3.1.2. The Effect of RA and RA/BDNF induced differentiation of SH-SY5Y 
neuroblastoma cells on mRNA and protein expression 
 
Comparing the mRNA copy number of GAPDH and two other house-keeping genes (β-actin 
and the ribosomal subunit L32) in proliferating, RA or RA/BDNF treated cells revealed that 
all 3 mRNAs showed the same trend but that GAPDH mRNA copy number was more similar 
across the treatments than β-actin and L32 mRNAs, thus validating the use of GAPDH as a 
loading control in this work.  
 
The expression of NTrkB mRNA was induced with RA and RA/BDNF treatment (Table 4.2) 
which agrees with published reports of the induction of NTrkB mRNA and protein expression 
by RA (Encinas et al, 1999, 2000; Hasegawa et al, 2004).  
 
The expression of TG2 mRNA and protein increased following RA and RA/BDNF induced 
differentiation (Table 4.2). Again, increased TG2 protein expression following RA-induced 
differentiation has already been documented (Singh et al, 2003, Tucholski et al, 2001, Zhang 
et al, 1998). Therefore sequential treatment with BDNF following RA pre-treatment 
maintains the high level of TG2 expression induced by RA.  
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There was no evidence of RA and RA/BDNF induced expression of Bcl-2; in fact the level of 
Bcl-2 protein was lower in RA differentiated cells than in proliferating cells (Table 4.2). This 
effect was unexpected since differentiation is usually associated with increased levels of Bcl-
2 protein to promote cell survival (Zhang et al, 1996) and increased expression of Bcl-2 in 
SH-SY5Y cells differentiated with RA (Feng & Porter, 1999, Itano et al, 1996, López-
Carballo et al, 2002) and TPA (Feng & Porter, 1999, Hanada et al, 1993) has previously been 
reported. However it has been reported that a decrease in Bcl-2 levels following RA-induced 
differentiation occurs in the clone used in the present work (Beck, PhD thesis; 2004).  
 
Another marker of neuronal differentiation is the expression of neurofilament proteins 
(Hoffman et al, 1987, reviewed by Perrot et al, 2008). In PC12 cells induced to differentiate 
with nerve growth factor (NGF) the expression of NF-L and NF-M was increased 
(Lindenbaum et al, 1987, Zentrich et al, 2002), a similar finding was also previously reported 
in SH-SY5Y cells treated with insulin (Wang et al, 1992). However, in the present work 
instead of an increase in mRNA expression, decreased expression was observed for all three 
NF subunits with RA treatment and for NF-H with RA/BDNF treatment (Table 4.2).  
 
The overall pattern of NF-L and NF-M mRNA expression is similar which is not unexpected 
since during neuronal development and differentiation the expression of the neurofilament 
subunits is coordinated, with NF-M and NF-L expression occurring first, followed by NF-H 
expression at the latter stages of development. This differential expression pattern suggests 
that the element controlling the expression of NF-L and NF-M differs from that controlling 
NF-H expression (Carden et al, 1987, Paterno et al, 1997). Indeed in humans, the NF-M and 
NF-L genes are closely linked on chromosome 8 while the NF-H gene is on chromosome 22 
(reviewed by Perrot et al, 2008).  
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Table 4.2 Effect of differentiation of SH-SY5Y cells with 10 µM retinoic acid (RA) or 10 µM RA and 50 ng/ml Brain Derived Neurotrophic Factor (BDNF) on protein and 
mRNA expression. 
The mRNA copy number (determined by qRT-PCR) is expressed per 1000 copies GAPDH and protein levels (determined from immunoprobed Western blots of total cell extracts) 
are expressed as a mean percentage of control (level in proliferating cells). For all experiments values are quoted ± standard deviation (n = 3)1. Increasing expression is highlighted in 
yellow (light yellow refers to a trend - from 2 independent experiments) and decreasing expression is highlighted in green. RA and RA/BDNF treatments were compared to 
proliferating cells and statistical analyses were performed using two-tailed and one-tailed T-Tests, *p > 0.05 and **p < 0.005. 
Proliferating Cells 5 d RA 8 d RA 5 d RA/3 d BDNF 5d RA/8 d BDNF Target 
Protein mRNA Protein mRNA Protein mRNA Protein mRNA Protein mRNA Protein 
NTrkB 0.08 ± 0.04 - 2.9 ± 0.5* - 3.7 ± 0.7* - 6.3 ± 3.1* - 3.1 ± 1.7* - 
TG2 0.7 ± 0.3 98.6 ± 26.4 9.2 ± 3.8** 2563 ± 1416* 10.1 ± 3.3** 6604 ± 4319* 11.1 ± 1.8** 5283 ± 2350* 5.0 ± 3.6 3606 ± 2787* 
Bcl-2 2.0 ± 0.5 100.0 ± 19.1 1.9 ± 0.4 64.3 ± 5.0* 2.4 ± 0.9 56.0 ± 21.3* 2.1 ± 0.4 88.7 ± 11.9 2.6 ± 1.1 100.7 ± 5.0 
NF-L 38.7 ± 6.4 99.8 ± 2.3 17.7 ± 4.7* 85.1 ± 33.8 20.0 ± 6.5* 136.2 ± 73.0 39.4 ± 2.6 104.9 ± 58.9 46.5 ± 6.0 64.9 ± 47.1 
NF-M 5.9 ± 1.3 100.0 ± 34.6 2.6 ± 1.0* 86.2 ± 23.5 3.0 ± 1.4* 56.53 ± 29.4 2.9 ± 2.2 44.8 ± 8.7* 5.2 ± 1.2 61.4 ± 15.0 
NF-H 16.9 ± 3.2 100.0 ± 15.8 6.4 ± 1.1** 102.8 ± 19.1 8.3 ± 0.9* 170.2 ± 22.1* 8.7 ± 3.3* 118.3 ± 43.0 6.7 ± 2.4* 104.3 ± 25.6 
Vimentin - 100 ± 23.4 - 84.7 ± 2.9 - 89.7 ± 4.7 - 115.0 ± 40.0 - 81.7 ± 16.5 
α-Tubulin 627.6 ± 289.6 100.0 ± 10.4 285.5 ± 96.6 108.5 ± 18.7 270.1 ± 9.0* 107.8 ± 25.3 601.1 ± 110.0 152.7 ± 11.5* 
330.8 ± 
41.1 
192.3 ± 
11.4** 
Actin - 100.3 ± 38.2 - 109.3 ± 27.0 - 109.3 ± 26.6 - 150.3 ± 48.8 - 128.0 ± 14.2 
Kinesin 5C 6.7 ± 3.4 100.0 ± 26.8 3.5 ± 1.4 132.5 ± 28.3 3.6 ± 1.6 144.4 ± 59.0 5.1 ± 0.8 164.4 ± 8.6* 6.0 ± 1.4 192.5 ± 27.7* 
Kinesin 5A - 100.0 ± 24.0 - 109.5 ± 31.8 - 164.0 ± 55.2 - 157.0 ± 11.3 - 170.5 ± 36.1 
Dynein Light 
Intermediate 
Chain 
2.1 ± 0.5 100.0 ± 24.0 3.1 ± 1.1 77.0 ± 12.7 4.4 ± 1.0* 58.0 ± 24.0 4.2 ± 2.3 94.5 ± 3.5 3.3 ± 0.6* 78.5 ± 5.0 
PSMC1 46.1 ± 9.3 100.0 ± 12.9 47.6 ± 8.1 98.7 ± 17.9 82.8 ± 53.5 111.6 ± 9.7 76.4 ± 24.1 120.4 ± 29.8 65.8 ± 6.1* 92.1 ± 18.5 
1. Dynein Intermediate Chain and Kinesin 5A protein are the result of two independent experiments, so % ADU of proliferating cells for protein is expressed ± range 
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In general no change in the protein levels of the three NF subunits was observed with RA and 
RA/BDNF treatment, other than an increase in NF-H levels after 8 d RA treatment and a 
decrease in NF-M levels after 3 d in BDNF (Table 4.2). Truckenmiller et al (2001) reported 
an increase in NF-M and NF-L protein levels in SH-SY5Y cells after just 6 h RA treatment 
but a recent study found no significant effect of RA on the levels and distribution of NF-H 
(Cheung et al, 2009). The decrease in NF-M expression following RA/BDNF induced 
differentiation supports the work of Encinas et al (2000) in which RA/BDNF-induced 
differentiation of SH-SY5Y cells resulted in a decrease in NF-M and NF-L protein levels.  
 
Phosphorylation is thought to stabilize the neurofilament network since phosphorylated 
neurofilaments are more resistant to degradation by proteases (Greenwood et al, 1993). 
During postnatal brain development NF-M phosphorylation is preceded by its incorporation 
into the triton-insoluble NF network (Shea et al, 1997) and the differentiation of PC12 cells 
with NGF has previously been shown to lead to increased NF-M and NF-H phosphorylation 
(Lindenbaum et al, 1987). However in the present work no evidence of increased NF 
phosphorylation was observed following RA or RA/BDNF treatment. 
 
Vimentin is the intermediate filament found in cells of mesenchymal origin and is widely 
expressed in embryos (reviewed by Kim & Coulombe, 2007) and in human foetal brain 
(Levin et al, 2009). Vimentin expression is associated with an immature phenotype and in 
neuronal cells is usually superseded by the expression of neurofilament proteins as the cell 
matures (reviewed by Grant & Pant, 2000, Yabe et al, 2003) although extensive vimentin 
expression has been reported in Alzheimer’s disease brain and in adult mouse brain neurons 
in response to injury (Levin et al, 2009). RA and RA/BDNF induced differentiation had no 
effect on the levels of vimentin protein (Table 4.2) and immunofluorescence staining revealed 
an extensive network of vimentin filaments in differentiated SH-SY5Y cells.  
 
The expression of the human α1-tubulin gene is limited to cells of neurological origin (Hall & 
Cowan, 1985) and is associated with neuronal growth and response to axonal injury (Gloster 
et al, 1994). Following birth the expression of α1-tubulin initially increases but then decreases 
during the latter stages of development to the levels observed in adult brain (Moskowitz & 
Oblinger, 1995). In PC12 cells differentiated with NGF, an increase in α-tubulin expression 
was observed (Miller et al, 1987), and a transient increase in α-tubulin expression has been 
reported in SH-SY5Y cells treated with insulin (Wang et al, 1992). In the present work RA 
induced differentiation reduced α-tubulin mRNA expression but had no effect on α-tubulin 
protein levels, whilst RA/BDNF treatment resulted in increased α-tubulin protein levels, 
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which may be involved in the establishment of the extensive network of long axonal 
processes seen in RA/BDNF differentiated cells.  
 
Axonal transport of proteins and organelles such as mitochondria in cells with long axonal 
processes is essential for the maintenance of cell health and function. An increase in the 
expression of kinesin 2 and dynein light chain mRNA has been observed after 6 h RA 
treatment (Truckenmiller et al, 2001). Although kinesin mRNA levels were largely unaffected 
by RA and RA/BDNF treatment, an increase in kinesin 5A and 5C protein was observed 
following RA/BDNF treatment suggesting either an increased rate of protein translation or 
protein stability. The increase in kinesin 5A and 5C protein levels may be linked to the 
extension of axonal processes which is dependent on axonal transport. In the case of dynein 
intermediate chain and PSMC1, protein levels were unaffected by RA or RA/BDNF induced 
differentiation but after 8 d RA treatment, dynein mRNA levels were increased, and after 8 d 
BDNF treatment both dynein and PSMC1 mRNA levels were increased. The lack of an 
increase in protein despite increased transcription suggests that after treatment, either the 
mRNA is unstable or the protein is more prone to degradation. An increase in the mRNA 
expression of a proteasome subunit during the first 6 h of RA treatment has previously been 
reported (Truckenmiller et al, 2001). 
 
It is clear that RA and RA/BDNF induced differentiation did not always affect protein and 
mRNA expression in a similar manner, suggesting that during differentiation protein 
expression is also controlled at the post-transcriptional or translational level or that protein 
stability is altered. This is similar to results obtained in mice with targeted disruption of the 
NF-L gene in which loss of NF-L resulted in decreased NF-M and NF-H protein levels but no 
apparent change in mRNA levels (Zhu et al, 1997). 
 
5.3.1.3. Conclusion 
 
An overview of the effect of RA and RA/BDNF induced differentiation on protein expression 
in the present work is shown in Figure 4.32. Morphologically RA/BDNF differentiated SH-
SY5Y cells exhibited a neuronal phenotype with numerous long axonal processes that formed 
an intricate interconnecting network of fibres. In agreement with other published work, RA 
and RA/BDNF induced differentiation increased the expression of TG2 and NTrkB. 
RA/BDNF induced differentiation did result in increased expression of α-tubulin and Kinesin 
5A and 5C which may be involved in establishment and maintenance of axonal processes. 
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However, no increase in the expression of Bcl-2 was observed, instead with RA treatment 
Bcl-2 protein levels were reduced.  
 
Figure 4.32 Diagrammatic representation summarising of the effect of RA and RA/BDNF induced 
differentiation on protein expression in SH-SY5Y neuroblastoma cells.  
RA treatment induces the expression of Neurotrophic Tyrosine Kinase Receptor B (NTrkB, which allows 
cells to become responsive to BDNF). RA treatment also induces the expression of Tissue 
Transglutaminase (TG2) previously shown to be essential for neuritogenesis and cell survival. TG2 
expression was maintained at the high level induced by RA during BDNF treatment. Bcl-2 levels were 
reduced following RA treatment which may have serious implications on the maintenance of cell survival. 
Bcl-2 levels returned to levels observed in proliferating cells with BDNF treatment. An increase in NF-H 
levels which may be essential for neuritogenesis was observed with RA treatment. With BDNF treatment 
NF-H levels were maintained at the levels in proliferating cells but NF-M levels remained lower. The 
increase in α-tubulin levels with BDNF treatment may be important in the establishment of long axonal 
processes. BDNF treatment also resulted in increased levels of kinesin 5A and 5C which are essential for 
transport of proteins and organelles into the axonal processes. 
 
In general, no change in the protein expression and phosphorylation of neurofilament subunits 
was observed with RA or RA/BDNF induced differentiation, other than an increase in NF-H 
levels after 8 d RA treatment and a decrease in NF-M levels after 3 d BDNF treatment. 
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4.3.2. Effect of Inhibition of Complex I and the Proteasome  
4.3.2.1. Effects on proteins  
 
The effects of 24 h treatment with MPP+ and/or Epoxomicin on mRNA and protein levels 
and protein distribution is summarised in Table 4.3. Statistically significant increased and 
decreased levels are highlighted in yellow and green respectively. Trends are also indicated 
on the table however these observations are not statistically significant and are the result of 
two independent experiments. 
 
Despite changes in certain proteins, mRNA levels were mostly unaffected by treatment, 
possibly due to the short time course. The only changes in mRNA expression observed were 
decreases in NF-L mRNA with MPP+/epoxo treatment, actin mRNA with MPP+ treatment 
and TG2 mRNA with epoxo treatment. Therefore it would be interesting to investigate the 
effects of longer treatment periods on mRNA expression.  
 
With epoxo and MPP+/epoxo treatment, NF-M protein levels increased (Table 4.3). In 
proliferating SH-SY5Y cells, treatment with epoxo did not result in an accumulation of NF-M 
(refer to Chapter 3) even in the absence of cycloheximide (results not shown). This suggests 
that the proteasome has a more important role in neurofilament degradation in differentiated 
cells than in proliferating cells. In addition, all three treatments resulted in an increase in the 
ratio of pNF-M in igepal insoluble/soluble fractions which suggests a redistribution of pNF-
M into the igepal insoluble fraction with treatment. The increase in the igepal 
insoluble/soluble ratio of NF-H observed with MPP+ or epoxo treatment (in the absence of 
any effect on NF-H in total protein) also suggests a redistribution of NF-H into the insoluble 
fraction (Table 4.3). Rideout et al (2001) previously reported the production of α-synuclein-
positive inclusions that was not accompanied by an overall increase in α-synuclein levels. An 
increase in the levels of NF-M but not NF-H has previously been reported in a rat model of α-
synucleinopathy before the loss of dopaminergic neurons (Chung et al, 2009).  
 
 
 
Chapter 4 Inhibition of Complex I and the Proteasome in RA/BDNF differentiated cells 
 
 168 
Table 4.3 Table summarising the effects of 24 h treatment of RA/BDNF differentiated SH-SY5Y cells with 500 µM MPP+, 10 nM epoxomicin (epoxo) or MPP+/epoxo on protein 
and mRNA expression and the distribution of protein 
Increased levels are highlighted in yellow, decreased levels in green and trends are also indicated (result of two independent experiments). Changes in mRNA copy number determined by 
qRT-PCR, protein expression in total cell extracts, distribution of protein between Igepal-CA630 soluble and insoluble fractions. Statistical analyses were performed using one- and two-
tailed T-Tests. n/a = not applicable. Values quoted as fold change ± standard deviation. 
mRNA Total Protein Ratio of Igepal Insoluble/Soluble  Protein 
Protein 
MPP+ Epoxo MPP+/Epoxo MPP+ Epoxo MPP+/Epoxo MPP+ Epoxo MPP+/Epoxo 
NF-L NC NC 1.4 ± 0.2* fold ↓ NC NC NC NC NC NC 
NF-M NC NC NC NC 2.7 ± 0.6* fold ↑  2.2 ± 0.8* fold ↑  NC NC NC 
pNF-M n/a n/a n/a NC NC NC 2.3 ± 1.0* fold ↑ 2.0 ± 0.4* fold ↑ 2.4 ± 0.8*fold↑  
NF-H NC NC NC NC NC NC 2.1 ± 0.6* fold ↑ 2.9 ± 1.1* fold ↑ NC 
pNF-H n/a n/a n/a NC NC  NC - - - 
α-tubulin NC NC NC NC NC 2.4 ± 0.2* fold ↓  3.4 ± 1.5* fold ↑ NC 2.2 ± 0.7*fold↑ 
γ-tubulin - - - 1.5 ± 0.2* fold ↓  NC NC - - - 
Actin 1.9 ± 0.3*fold↓ NC NC 1.8 ± 0.2** fold↓ NC NC NC NC NC 
Vimentin - - - 1.7 ± 0.3* fold ↓  1.7 ± 0.2* fold ↓  1.9 ± 0.3* fold ↓ NC NC NC 
KIF5C NC NC NC NC NC NC - - - 
KIF5A - - - NC NC NC - - - 
Dynein NC NC NC 1.7 ± 0.3* fold ↓ 1.5 ± 0.2* fold ↓ 2.3 ± 0.3* fold ↓   - - - 
TG2 NC 1.6 ± 0.05* fold↓  NC NC NC 1.8 ± 0.4* fold ↓  - - - 
PSMC1 NC NC NC NC NC NC - - - 
Bcl-2 NC NC NC NC ↑ Trend (ns) ↑ Trend (ns) - - - 
α-
synuclein - - - NC NC NC - - - 
p62 - - - NC NC ↑ Trend (ns) NC 2.3 ± 0.6* fold ↑ NC 
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The enrichment of NF-H and pNF-M in the insoluble fraction may be indicative of protein 
aggregation. Indeed immunofluorescence staining of NF-H showed some accumulation of 
NF-H immunofluorescence in the perinuclear region of cell body following MPP+, epoxo and 
MPP+/epoxo treatment. In MPP+ treated cells accumulations of NF-H staining were 
accompanied by some swelling of the axonal process in that region, this swelling was not 
observed in epoxo treated cells and not as clearly visible in MPP+/epoxo treated cells. 
Neurofilaments have previously been found in inclusion bodies in differentiated and 
undifferentiated SH-SY5Y cells treated with acrylamide and 2,5-hexanedione (Hartley et al, 
1997). Proteasome inhibition with lactacystin has previously been shown to result in 
increased levels of phosphorylated NF-M and NF-H in PC12 cells resulting from JNK 
activation (Masaki et al, 2000). Numerous experimental models resulting in the formation of 
inclusions or aggresomes have employed proteasome inhibition to induce protein aggregation 
(Bedford et al, 2008, Bolhuis & Richter-Landsberg, 2010, Miwa et al, 2006, Rideout et al, 
2001, Rideout & Stefanis, 2002).  
 
Vimentin staining was also investigated because accumulation of vimentin in the perinuclear 
region has been described in many experimental models of inclusion or aggresome formation 
(Fu et al, 2005, Kawaguchi et al, 2003, Muqit et al, 2006, Zaarur et al, 2008). Since vimentin 
staining was extensive in the axonal processes and the cell body following RA/BDNF 
induced differentiation, it was not possible to detect vimentin accumulation in the perinuclear 
region. 
 
Actin and γ-tubulin levels were reduced following MPP+ treatment and α-tubulin levels were 
reduced following MPP+/epoxo treatment. An enrichment of α-tubulin in the insoluble pool 
which may be indicative of protein aggregation following MPP+ and MPP+/epoxo treatment 
is suggested by the observed increase in the insoluble/soluble ratio (Table 4.3). 
 
A reduction in the levels of dynein intermediate chain was observed with all three treatments 
but the levels of kinesin 5C and 5A were unaffected (Table 4.3). Previous studies such as the 
MPP+ treatment of PC12 cells reported a decrease in dynein protein expression (Cai et al, 
2009) accompanied by a decrease in the co-localisation of dynein and LAMP1 (Cai et al, 
2009). In a rat model of α-synucleinopathy an initial decrease in dynein protein expression 
was followed by an increase in expression. In this model there was no effect at the timepoints 
investigated on the expression of kinesin 5 protein, although there was a decrease in 
expression of most of the other kinesin motors at the latter timepoint (Chung et al, 2009).  
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The importance of efficient axonal transport in neuronal health is highlighted by the 
implication of defects in axonal transport in neurodegenerative conditions (Ebbing et al, 
2008). In a mouse model of frontotemporal dementia progressive loss of dopaminergic 
neurons of the substantia nigra was preceded by defects in anterograde vesicular and 
mitochondrial transport (Ittner et al, 2008). MPP+ treatment has also previously been reported 
to result in defects in axonal transport of membranous organelles (Morfini et al, 2007). 
Inhibition of dynein has also been shown to result in the accumulation of GFP tagged NF-M 
in the cell body and in the proximal axons (Motil et al, 2007) and GFP tagged NF-H in the 
distal axons (He et al, 2005). Dynein has also been shown to co-localize with perinuclear 
inclusions formed in FeCl2 treated RA/BDNF differentiated cells over-expressing α-synuclein 
(Hasegawa et al, 2004). 
 
As the retrograde transport motor, dynein is involved in the transport of autophagosomes to 
lysosomes which are located around the perinuclear region (reviewed by Cai et al, 2009, and 
Rubinsztein et al, 2009). The importance of the role of dynein in macroautophagy was 
highlighted by the decrease in both macroautophagy and the clearance of aggregate-prone 
proteins in PC12 cells expressing mutated dynein or in which dynein activity was chemically 
impaired (Ravikumar et al, 2005).  
 
Other than a reduction in TG2 levels with MPP+/epoxo treatment, no change in the levels of 
α-synuclein, PSMC1 or TG2 in total protein was observed with treatment. Preliminary results 
suggest a possible increase in the levels of Bcl-2 with epoxo and MPP+/epoxo treatment 
suggesting a possible adaptive mechanism for survival that needs to be explored (Table 4.3). 
 
Preliminary results from two independent experiments suggest a possible increase in p62 
levels following MPP+/epoxo treatment. The igepal insoluble/soluble ratio for p62 was 
increased with epoxo treatment, suggesting an enrichment of p62 into the insoluble pool. No 
increase was observed in the insoluble/soluble ratio with MPP+/epoxo treatment but in this 
case, an increase in p62 was observed in both the soluble and the insoluble fractions. The 
increase in p62 in the igepal insoluble fraction may be the result of p62 associating with 
insoluble aggregated proteins thus targeting them for degradation by macroautophagy via its 
ability to interact with both ubiquitin and LC3-II (Bjorkoy et al, 2005, Pankiv et al, 2007). 
The levels of p62 in cell treated with the autophagy inhibitor, Bafilomycin A1 (BafA1), either 
on its own or with MPP+ or MPP+/epoxo were 10-15 fold greater than in control cells. 
Inhibition of macroautophagy with BafA1 has previously been shown to result in increased 
levels of p62 determined by Western blotting (Bjorkoy et al, 2005).  
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Immunofluorescence staining revealed that α-tubulin and p62 did not co-localise. However 
immunofluorescence staining revealed regions of NF-H and p62 co-localization that 
coincided with the intense regions of concentrated NF-H staining in or near the cell body, 
suggesting an association of p62 with aggregated NF-H that would be interesting to 
investigate further. In addition double immunofluorescence of NF-H and LC3 also revealed 
NF-H and LC3 co-localisation especially in the regions of intense NF-H staining that are 
suggestive of aggregates.  
 
Defects in the ubiquitin proteasome system and lysosomal pathway have been implicated in 
the pathogenesis of neurodegenerative conditions characterised by the accumulation of 
aggregated proteins (reviewed by Keller et al, 2004, and Martinez-Vicente & Cuervo, 2007, 
Rubinsztein, 2006). In a mouse model producing Lewy body-like inclusions with chronic 
MPTP treatment, inclusions contained large amounts of lipofuscin which are the products of 
lipid peroxidation and accumulate in secondary lysosomes; accumulation of which is 
indicative of lysosomal malfunction (Meredith et al, 2002). Aggregates formed during 
rotenone treatment of COS-7 cells were eliminated after rotenone was washed out of the 
system and mitochondrial ATP production was recovered. The removal of the aggregates was 
partially blocked by proteasome inhibition (Lee et al, 2002). Rideout et al (2004) also 
reported the elimination of neuronal inclusions formed by proteasome inhibition in rat cortical 
neurons via the induction of macroautophagy. 
 
Preliminary work investigating the effect of MPP+, epoxo and MPP+/epoxo treatment on 
macroautophagy was performed by monitoring LC3-II levels. There was no obvious effect of 
the treatment on the levels of LC3-II. Inhibiting macroautophagy with BafA1 revealed that 
MPP+/BafA1 and MPP+/epoxo/BafA1 treatment for 24 h lead to a smaller increase in LC3-II 
levels than BafA1 alone which may suggest that MPP+ and MPP+/epoxo treatments resulted 
in decreased autophagosome synthesis (Rubinsztein et al, 2009). This is contrary to previous 
reports in which MPP+ treatment of SH-SY5Y cells (Zhu et al, 2007) and proteasome 
inhibition in rat cortical neurons (Rideout et al, 2004) resulted in increased autophagosome 
synthesis. 
 
Preliminary results using Western blotting revealed that MPP+ treatment decreased the levels 
of active cathepsin D (a lysosomal protease). This is similar to results in chapter 3, in which 
MPP+ treatment was also shown to result in a decrease in cathepsin D activity using a 
fluorogenic cathepsin D activity assay. With epoxo treatment however increased levels of 
active cathepsin D were observed, suggesting increased cathepsin D activity. Proteasome 
inhibition has previously been shown to result in an increase in cathepsin D 
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immunofluorescence staining (Rideout et al, 2004). The increase in active cathepsin D 
observed with treatments that included BafA1 may be a result of an accumulation of 
lysosomes following impaired fusion of autophagosomes and lysosomes.  
 
4.3.2.2. Conclusion  
 
The effect of 24 hour treatment with MPP+, epoxo and MPP+/epoxo on the levels and 
distribution of neurofilaments, vimentin, dynein intermediate chain, p62 and LC3 is 
summarised in Figure 4.33. All three treatments resulted in a reduction in the levels of dynein 
intermediate chain and vimentin. The reduction in dynein intermediate chain levels may have 
serious implication for the axonal transport system, defects which have been associated with 
protein aggregation as mentioned earlier. Enrichment of pNF-M, NF-H, p62 and α-tubulin in 
the igepal insoluble were also observed, suggestive of protein aggregation. 
 
Treatment of RA/BDNF differentiated cells with MPP+, epoxo and MPP+/epoxo may be 
promising inclusion-producing models since NF-H with p62 and LC3 co-localizes and 
accumulates in the perinuclear region. Further work could involve extended treatment 
regimes since in COS-7 cells expressing human α-synuclein, longer treatments with rotenone 
resulted in increased inclusion formation that became more resistant to clearance (Lee et al, 
2004). Confirmation of inclusion formation and characterisation of inclusions could be 
accomplished with immunofluorescence staining for other markers of aggresomes and 
scanning electron microscopy. 
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Figure 4.33 Diagrammatic representation of the effects of 24 h treatment of RA/BDNF differentiated 
SH-SY5Y neuroblastoma cells with 500 µM MPP+, 10 nM epoxomicin (epoxo) and 500 µM MPP+/10 
nM epoxo on protein levels and distribution.  
All three treatments resulted in a reduction (red arrows) in the levels of dynein intermediate chain and 
vimentin in total cell extracts, an increase (green arrows) in pNF-M and p62 in the igepal insoluble pool and 
an accumulation of NF-H, p62 and LC3B immunofluorescence in the perinuclear region. Co-localisation of 
NF-H with p62 and LC3B in the perinuclear region was also observed. MPP+ treatment also resulted in a 
decrease in actin and γ-tubulin in total protein and an increase in NF-H and α-tubulin in the igepal insoluble 
pool. Epoxo treatment resulted in an increase in NF-M in total protein and NF-H in the igepal insoluble pool. 
With MPP+/epoxo treatment a decrease in α-tubulin and TG2 total protein and an increase in NF-M in total 
protein, α-tubulin in the igepal insoluble pool and p62 in the igepal soluble pool was observed. 
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5.1. Introduction 
5.1.1. Green Fluorescent Protein 
 
Green Fluorescent Protein (GFP) exhibits bright green fluorescence when exposed to blue 
light. It is composed of 11 β-pleated sheets arranged as a β-barrel with the chromophore 
located in the centre of the barrel structure (Figure 5.1 A). The chromophore is formed by the 
amino acid triplet Ser-Tyr-Gly at positions 65-66-67 (Figure 5.1 B); the amide nitrogen of 
Gly67 and the carbonyl of Ser65 react to form a cyclic ring structure and the tyrosine side 
chain is then oxidized and its hydroxyl group is deprotonated (Heim et al, 1994). The position 
of the chromophore in the β-barrel protects it from solvent quenching effects and explains 
why attempts to truncate GFP to decrease its size have not been successful. Since GFP has no 
cofactor requirement for fluorescence it can be used to track gene expression and protein 
dynamics by fusing GFP to a protein of interest (reviewed by Miyawaki et al, 2003, Straight, 
2007, and Tsien, 1998).  
 
GFP and GFP-like proteins are quite large (25-30 kD) and as such fusion of GFP to a protein 
may alter its structure and function. To be confident that the GFP fusion protein can be used 
to study a protein of interest it is necessary to determine whether its presence alters the 
localization or behaviour of the protein. There are three categories that GFP fusion proteins 
should ideally fulfil (Straight 2007): 
1. The distribution of the GFP fusion protein should be similar to the distribution of the 
endogenous protein. This can be accomplished with antibody staining  
2. If the protein has some kind of enzymatic activity, the GFP fusion protein should 
retain the same activity and kinetics of the endogenous enzyme.  
3. The fusion protein should be produced at levels comparable to the endogenous protein 
and have a similar half-life.  
 
5.1.2. GFP-tagged Neurofilaments 
 
The tagging of intermediate filaments (IFs) with GFP has revolutionized the study of IF 
behaviour. In a review of fluorescence-based methods used to study IFs, Flitney and Goldman 
(2004) suggest that although GFP can be attached to either the N- or C-termini of IF proteins, 
targeting to the N-terminus best retains IF function. The vast majority of studies employing 
GFP tagged NFs tend to have the NF proteins tagged with GFP on their N-terminus, of which 
a few are discussed below. 
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Figure 5.1 The structure of GFP and its chromophore. 
 (A) The barrel shaped structure of Green fluorescent protein formed by the 11 β-pleated sheets with the 
chromophore situated in the centre of the barrel (Figure from Tsien 1998). (B) The chromophore is produced by 
the cyclization of Ser65, Tyr66 and Gly67 and the oxidation of the tyrosine side-chain. The initial step in 
chromophore formation is folding of the GFP protein, then cyclization is achieved by nucleophilic attack of the 
carbonyl group of Ser65 by the amide N of Gly67, then dehydration followed by oxidation. The chromophore is 
shown in green (reviewed by Miyawaki et al, 2003, Straight, 2007, and Tsien, 1998). 
 
The use of GFP tagged NFs has advanced our understanding of NF proteins, due to the 
opportunity to investigate their behaviour using time-lapse imaging on live cells. The use of 
GFP/NF-H provided evidence that NFs are transported rapidly but also intermittently, so that 
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their transport is interrupted by long periods in which NFs are stationary, resulting in an 
overall slow transport rate (Roy et al, 2000). The rapid and intermittent transport of NFs was 
confirmed with GFP/NF-M using Fluorescence Recovery After Photobleaching (FRAP) and 
time-lapse imaging (Wang & Brown, 2001). NFs were also shown to be transported as 
polymers that contain NF-M, NF-L and two other neuronal IF proteins called α-internexin and 
peripherin in cultured sympathetic neurons using GFP/NF-M and GFP/NF-L (Yan et al, 2007, 
Yan & Brown, 2005). Work with GFP/NF-M has also lead to the discovery that when 
neurofilaments enter the growth cone in the distal axon, they quickly reverse direction; 
resulting in a high proportion of NFs undergoing retrograde transport in the distal axon 
(Uchida & Brown, 2004). 
 
GFP/NF-M has also been used to investigate the role of the motor proteins, kinesin and 
dynein in the anterograde and retrograde transport of NFs (Motil et al, 2006, Theiss et al, 
2005). The importance of phosphorylation of NF-H and NF-M tail domains by Cdk5 in the 
regulation of neurofilament transport was investigated using GFP/NF-H (Ackerley et al, 
2003) and GFP/NF-M (Moran et al, 2005).  
 
In studies of neurodegeneration, NF-M tagged with GFP on its N-terminus has been used to 
study the effect of glutamate (Ackerley et al, 2000), arsenic (DeFuria & Shea, 2007), the 
overexpression of peripherin (Millecamps et al, 2006) and the expression of Charcot-Marie-
Tooth disease (CMT) associated NF-L mutations  (Brownlees et al, 2002) on neurofilament 
transport and distribution.  
 
5.1.3. Aims 
 
This chapter describes the development and characterization of GFP tagged NF proteins 
transiently transfected into SH-SY5Y cells. In addition, the use of GFP tagged NFs was 
assessed as (a) bait to identify NF-associating proteins by co-immunoprecipitation of GFP 
and (b) to track changes in NF distribution in real-time following MPP+ treatment. 
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5.2. Results  
5.2.1. Development and characterisation of GFP-tagged neurofilament 
medium chain 
5.2.1.1. Cloning of human NF-M into pEGFP-C3 
 
NF-M was amplified from an SH-SY5Y cDNA preparation. Figure 5.2 is a schematic 
representation describing the cloning of GFP/NF-M. To ensure that the DNA insert is always 
inserted into the GFP plasmid in the correct orientation, the forward and reverse primers 
(given below) used to amplify NF-M were designed with EcoRI (highlighted in yellow) and 
SalI (highlighted in teal) restriction endonuclease recognition sequences on their 5’ ends 
respectively. The sequence complementary to the sequence of human NF-M is underlined 
below, the transcription start site is highlighted in green and the transcription stop site is 
highlighted in red.  
 Fwd: 5’-GAATTCAGATGAGCTACACGTTGGACTC-3’ 
 Rev: 5’-GTCGACTTAGTCACTCTGGGTGACTTCCTTT-3’ 
 
The PCR product was analysed by agarose gel electrophoresis (Figure 5.2 A) and determined 
to be the expected 2.8 kb for NF-M. The 2.8 kb band was excised from the gel, purified and 
cloned into pCR-XL TOPO for sequencing. Sequence analysis of the cloned DNA and 
comparison with the database entry for human NF-M (NM_005382) confirmed that it was 
NF-M, but also that it contained a PCR derived point mutation resulting in a G→A 
substitution (Figure 5.2 C). This mutation resulted in a glutamate to lysine amino acid 
substitution and was reversed by site directed mutagenesis which is described in more detail 
in section 2.2.12.8. The GFP expression vector used was kindly donated by Carl Miller 
(Kings College London) and contained a rat NF-M insert (pEGFP-C3 rNF-M). To clone 
human NF-M into the GFP expression vector (pEGFP-C3), pEGFP-C3 rNF-M and pCR-XL 
TOPO hNF-M were digested by quantitative double digest (described in section 2.2.12.7.2) 
with the restriction endonucleases SalI and EcoRI. The digests were analysed by agarose gel 
electrophoresis (Figure 5.2 D) and the bands corresponding to pEGFP-C3 and hNF-M were 
excised, purified from the gel and ligated by T4 DNA ligase. pEGFP-C3 hNF-M (GFP/NF-
M) clones were analysed by restriction endonuclease digestion with SalI and EcoRI and 
agarose gel electrophoresis. Clone 3 was selected and sequenced to confirm the sequence was 
that of NF-M and that GFP and NF-M were in-frame. 
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Figure 5.2 A schematic of the cloning procedure used to clone NF-M into pEGFP-C3.  
NF-M was amplified by PCR from a preparation of SH-SY5Y cDNA using forward and reverse primers 
containing the EcoRI and SalI recognition sequences respectively. (A) The PCR product was excised and 
purified from the gel and cloned into the cloning vector pCR-XL-TOPO. From a restriction endonuclease 
digest with EcoRI (B) plasmids containing the NF-M insert were selected and sent for sequencing. (C) The 
clone selected for cloning into pEGFP-C3 (clone 2) had a point mutation (highlighted in red) at position 
427 bp which results in a Glutamic acid (Glu) to Lysine (Lys) amino acid substitution which was removed 
by site-directed mutagenesis (shown in teal). NF-M was isolated from pCR-XL-TOPO by restriction 
endonuclease digestion with EcoRI and SalI and the rNF-M insert in the pEGFP-C3 vector was removed by 
restriction endonuclease digestion of pEGFP-C3 rNF-M with EcoRI and SalI. (D)The bands corresponding 
to pEGFP-C3 (4.7 kb) and NF-M (2.8 kb) were excised (indicated in red) and purified from the gel. NF-M 
and pEGFP-C3 were ligated by T4 DNA ligase and plasmid preparations were analysed by restriction 
endonuclease digests with EcoRI and SalI (E). 
 
5.2.1.2. Characterisation of GFP/NF-M expression in SH-SY5Y cells 
 
Western blots of total cell extracts from GFP/NF-M expressing cells probed with anti-GFP, 
anti-NF-M and anti-pNF-M can be found in Figure 5.3 A. On blots probed with anti-GFP 
(Figure 5.3 A i), a 30 kD band corresponding to GFP was found in extracts from GFP 
expressing cells, and a 180 kD band corresponding to the predicted molecular weight of 180 
kD for GFP/NF-M was found in extracts from GFP/NF-M expressing cells. The apparent 
molecular weights of GFP/NF-M and GFP were determined using their Rf values to compare 
their electrophoretic mobility to that of molecular weight standards run on the same gel 
(Appendix II). On blots probed with anti-NF-M (Fig 5.3 A ii) and anti-pNF-M (Fig 5.3 A iii), 
GFP expressing cells contained endogenous NF-M (150 kD) whilst GFP/NF-M expressing 
cells contained both endogenous NF-M (150 kD) and GFP/NF-M (180 kD). Again, the 
apparent molecular weights of endogenous NF-M and GFP/NF-M were confirmed using Rf 
values (Appendix II). 
 
Laser confocal microscopy  confirmed that the pattern of GFP/NF-M expression in GFP/NF-
M expressing cells (Figure 5.3 B ii) was similar to NF-M expression in wild-type cells 
visualised by immunofluorescence staining of NF-M with anti-NF-M (RMO270, Figure 5.3 B 
i).  
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Figure 5.3 The Characterisation of GFP/NF-M expression in SH-SY5Y cells. 
(A) Western blots of total cell extracts of SH-SY5Y neuroblastoma cells transfected with (1) GFP and (2) 
GFP-tagged NF-M probed with anti-GFP and anti-NF-M antibodies.; (i) the anti-GFP blot shows a 180 kDa 
band corresponding to the GFP/NF-M fusion protein and (ii) the anti-NF-M and (iii) anti-pNF-M blots both 
have a band corresponding with the endogenous NF-M and a band corresponding to the GFP/NF-M fusion 
protein. (B) Confocal microscope images of (i) wild-type SH-SY5Y cells stained with anti-NF-M (green) 
and (ii) GFP/NF-M expressing cells showing GFP/NF-M expression (green). Nuclei were counterstained 
with propidium iodide. Cells were viewed using the 63 x objective. Scale bar represents 20 µm. 
 
To further characterize GFP/NF-M expression, its co-localization with the other NF subunits 
was investigated by laser confocal microscopy and immunofluorescence staining with anti-
NF antibodies (Figure 5.4). Immunofluorescence staining with anti-NF-H (n52, Figure 5.4 
A), anti-pNF-M/pNF-H (smi31, Figure 5.4 B) and anti-NF-L (DA2, Figure 5.4 C) and anti-
NF-M (RMO270, Figure 5.4 D) revealed that GFP/NF-M colocalised with all three NF 
subunits. 
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Figure 5.4 Assessment of GFP/NF-M co-localisation with endogenous neurofilaments (NFs). 
Confocal microscope images of SH-SY5Y neuroblastoma cells expressing GFP/NF-M showing the co-
localization of GFP/NF-M with each of the NF subunits. GFP/NF-M expressing cells were stained with (A) 
anti-NF-H (n52, 1:200), (B) anti-phosphoryated NF-H and NF-M (smi31, 1:100), (C) anti-NF-L (DA2, 
1:100) and (D) anti-NF-M (RMO270, 1:50). The antibody staining - detected using a goat anti-mouse 
alexafluor 568 conjugated secondary antibodies - is shown in red on the left hand side of each panel and 
GFP fluorescence of the GFP-tagged NF-M is shown in green in the centre of each panel. As the red and 
green images are overlaid as seen on the right of each panel, areas of co-localization are highlighted yellow. 
Cells were viewed with a 63 x oil objective, scale bar represents 20 µm.  
 
NF-H staining GFP/NF-M Overlay 
GFP/NF-M pNF-H and pNF-M staining Overlay 
NF-L staining GFP/NF-M Overlay (C) 
NF-M staining GFP/NF-M Overlay (D) 
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The transfection efficiency of the LipofectAMINE™2000 transfection with GFP/NF-M was 
estimated from the mean number of propidium iodide stained nuclei and the mean number of 
cells with GFP fluorescence in laser confocal microscope images from 5 different 
experiments (the number of images analysed per experiment are indicated in brackets in 
Table 5.1). The mean percentage of GFP/NF-M expressing cells was 19.2 ± 2.0 % of the total 
number of cells. 
 
Table 5.1 The transfection efficiency of GFP/NF-M in Human SH-SY5Y neuroblastoma cells using 
LipofectAMINE™2000.  
The mean numbers of cells expressing GFP/NF-M fluorescence were expressed as a percentage of the mean 
number of total cells (determined from the number of propidium iodide stained nuclei). The numbers of cells 
were counted in laser confocal microscope images from 5 different experiments, the number of images of 
different fields of view that were analysed are indicated in the brackets.  
Experiment 
Mean number of 
Propidium iodide 
stained nuclei 
Mean number of cells 
with GFP fluorescence 
Transfected cells (%) 
1 (3) 48.3  8.3 17.2 
2 (6) 14.7  3.8 26.1 
3 (7) 20.3 3.9 19.0 
4 (4) 12.3 2.0 16.3 
5 (3) 19.3 3.3 17.2 
mean ± SEM 23.0 ± 7.3 4.3 ± 1.2 19.2 ± 2.0 
 
To assess whether attachment of GFP altered the degradation of GFP/NF-M, the half-life of 
GFP/NF-M was determined by treating GFP/NF-M expressing cells with CHX over a 72 hour 
time course and immunoprobing Western blots of total cell extracts with anti-GFP or anti-
NF-M. The half-lives of GFP/NF-M calculated from the anti-GFP (Figure 5.5 B) and anti-
NF-M blots (Figure 5.5 C) were similar at 13.8 ± 2.2 h and 17.4 ± 0.8 h respectively. When 
looking at the lower band on the anti-NF-M blot thought to correspond with endogenous NF-
M (figure 5.5 A and D), the signal peaks at 24 hours and then decreases again after 48 hours. 
Figure 5.5 E was produced from the sum of both bands of the anti-NF-M Western blot. The 
half-life calculated from the ‘line of best fit’ in this case was 20.2 ± 1.4 h, which is slightly 
longer than that calculated from the anti-GFP Western blot.  
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Figure 5.5  Assessment of the half-life of GFP/NF-M using Western blots of total cell extracts from SH-SY5Y neuroblastoma cells expressing GFP/NF-M and treated with 10 µg/ml cycloheximide 
over a 72 hour time-course. (A) Western blots were probed with anti-GFP antibody (1:5000; abcam) or anti-NF-M (1:500; RMO270, Zymed). (B) and (C) Half-life of GFP/NF-M from three experiments was 
calculated from the slope of the ‘line of best fit’ obtained when plotting the natural logarithm of the percentage original signal for each experiment (ie signal at 0 h) against time (h). (D) Plot of the natural 
logarithm of percentage original signal for the lower band on the anti-NF-M blot which corresponds with endogenous NF-M shows an peak in the signal at 24 h. (E) Half-life of NF-M calculated using both 
bands on the anti-NF-M blot was significantly greater than half-life calculated from the anti-GFP blot (* T-Test, p < 0.05; n = 3). Half-lives quoted are mean half-lives from 3 independent experimens ± SEM.  
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5.2.2. Development and characterisation of GFP-tagged neurofilament light 
chain 
5.2.2.1. Cloning of human NF-L into pEGFP-C3 
 
Again, to ensure that NF-L (amplified from SH-SY5Y cDNA) was inserted into the GFP 
expression vector in the correct orientation, the forward and reverse primers (given below) 
were designed with EcoRI (highlighted in yellow) and SalI (highlighted in teal) restriction 
endonuclease recognition sequences on their 5’ ends respectively. The start codon is 
highlighted in green, the stop codon is highlighted in red and the part of the primer sequence 
homologous to human NF-L is underlined:  
 Fwd: 5’-GAATTCCCATGAGTTCCTTCAGCTACGAG-3’ 
 Rev: 5’-GTCGACGGGGGTTCAATCTTTCTTCTTAGC-3’  
 
The PCR product was analysed by agarose gel electrophoresis (Figure 5.6 A) and determined 
to be the expected 1.6 kb for NF-L. This band was excised from the gel, purified and cloned 
into pCR-2.1 TOPO for sequencing. Sequence analysis of the cloned DNA with the database 
entry for human NF-L (NM_006158) confirmed that it was NF-L, but also that it contained a 
PCR derived point mutation resulting in an A→G substitution (Figure 5.6 C). This mutation 
which results which in an arginine to lysine amino acid substitution was reversed by site 
directed mutagenesis (described in more detail in section 2.2.12.8.).  
 
Human NF-L was cloned into the GFP expression vector (pEGFP-C3) by preparing 
quantitative double digests (described in section 2.2.12.7.2) of pEGFP-C3 rNF-M and pCR-
2.1 hNF-L with the restriction endonucleases SalI and EcoRI. The digests were analysed by 
agarose gel electrophoresis (figure 5.6 D) and the bands corresponding to pEGFP-C3 and 
hNF-L were excised, purified from the gel and ligated by T4 DNA ligase. pEGFP-C3 hNF-L 
clones were analysed by restriction endonuclease digestion with SalI and EcoRI and agarose 
gel electrophoresis (figure 5.6 E). Clone 11 was selected and sequenced to confirm hNF-L 
identity and that GFP and NF-L were in-frame.  
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Figure 5.6 A schematic of the cloning procedure used to clone NF-L into pEGFP-C3.  
NF-L was amplified by PCR from a preparation of SH-SY5Y cDNA using forward and reverse primers 
containing the EcoRI and SalI recognition sequences respectively (A) and cloned into the cloning vector 
pCR-2.1-TOPO. From a restriction endonuclease digest with EcoRI (B) plasmids containing the NF-L insert 
were selected and sent for sequencing. (C) The clone selected for cloning into pEGFP-C3 (clone 12) had a 
point mutation (highlighted in red) at position 1616 bp which results in an Argenine (Arg) to Lysine (Lys) 
amino acid substitution which was removed by site-directed mutagenesis (shown in blue). NF-L was 
isolated from pCR-2.1-TOPO by digestion with EcoRI and SalI and the rNF-M insert in the pEGFP-C3 
vector was removed by restriction endonuclease digestion of pEGFP-C3 rNF-M with EcoRI and SalI. (D). 
The bands corresponding to pEGFP-C3 (4.7 kb) and NF-L (1.6 kb) were excised (indicated in red) and 
purified from the gel. NF-L and pEGFP-C3 were ligated by T4 DNA ligase and plasmid preparations were 
analysed by restriction endonuclease digests with EcoRI and SalI (E). 
 
5.2.2.2. Characterisation of GFP/NF-L expression in SH-SY5Y cells 
 
Western blots of total cell extracts of GFP and GFP/NF-L expressing cells probed with anti-
GFP (Figure 5.7 A i) confirmed the presence of a 30 kDa  band corresponding to GFP in 
extracts from GFP expressing cells and a 100 kDa band in extracts from GFP/NF-L 
expressing cells. In blots probed with anti-NFL (Figure 5.7 A ii), a 70 kDa band 
corresponding to endogenous NF-L was found in extracts of GFP expressing and GFP/NF-L 
expressing cells as well as an additional band of 100 kDa corresponding to the predicted 
apparent molecular weight of GFP/NF-L. The apparent molecular weights of GFP, GFP/NF-L 
and NF-L were all determined by using Rf values to compare their electrophoretic mobility to 
those of molecular weight standards run on the same gel (Appendix II). 
 
The expression of GFP/NF-L was compared to NF-L expression in wild-type cells by 
immunofluorescence staining of NF-L (Figure 5.7 B). In GFP/NF-L expressing cells, clumps 
or aggregates of GFP fluorescence were found in the perinuclear region (Figure 5.7 B ii). 
Transfection of GFP/NF-L into SH-SY5Y cells produced a mixed population (Figure 5.8) 
with some cells exhibiting normal NF-L expression pattern (compared to wild-type – Figure 
5.7 B i) and others in which aggregations of GFP/NF-L were found. 
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Figure 5.7 Characterisation of GFP/NF-L expression in SH-SY5Y neuroblastoma cells. 
(A) Western blots of total cell extracts of SH-SY5Y neuroblastoma cells transfected with (1) GFP and (2) GFP-
tagged NF-L probed with anti-GFP and anti-NF-L (DA2).  For cell extracts of GFP/NF-L expressing cells, (i) the 
anti-GFP blot shows a 100 kDa band corresponding to the GFP/NF-L fusion protein and (ii) the anti-NF-L blot 
shows a 70 kDa band for endogenous NF-L and a 100 kDa band corresponding to the GFP/NF-L fusion protein. 
(B)  Confocal microscope images of (i) wild-type SH-SY5Y stained with anti-NF-L (green) and (ii) GFP/NF-L 
expressing cells showing GFP/NF-expression (green) results in a clump of GFP fluorescence in the perinuclear 
region. Nuclei were counterstained with propidium iodide (red) and cells were viewed using the 63 x objective. 
Scale bar represents 20 µm. 
 
 
Figure 5.8 GFP/NF-L aggregates were found in SH-SY5Y cells with high GFP/NF-L expression. 
Confocal microscope images of GFP/NF-L revealed that most GFP/NF-L expressing cells contain regions of 
accumulated GFP/NF-L in the perinuclear region (indicated by yellow arrows) but some cells with lower levels 
of GFP/NF-L expression do not show GFP/NF-L accumulation (indicated by blue arrows).  Cells were viewed 
with the 63 x objective, scale bar represents 20 µm. 
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5.2.3. Development and characterisation of GFP-tagged neurofilament 
heavy chain 
5.2.3.1. Cloning of human NF-H into pEGFP-C3 
 
Initial attempts to amplify the entire sequence of NF-H did not yield a full-length NF-H 
cDNA sequence (results not shown) which may be due to the high GC content of the first 
1000 bp of the NF-H sequence (as can be seen in the CpG plot in Figure 5.9 A). The GC-rich 
region would be prone to the formation of secondary structures which could interfere with 
primer elongation. As a result of this region of high GC content, a different strategy which 
involved cloning NF-H in two separate parts (the so-called N-terminal part containing this 
GC-rich region and the C-terminal part) was adopted. A unique XmnI endonuclease 
recognition sequence located within the first 1000 bp of wild-type NF-H cDNA was selected 
as the region of overlap between the N- and C-terminal parts of NF-H. To accomplish this, 
the reverse primer of the N-terminal part and the forward primer of the C-terminal part were 
complementary to each other and contained contained the XmnI endonuclease recognition 
sequence (Figure 5.9 B). 
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Figure 5.9 CpG plot showing GC content of NF-H cDNA and scheme depicting the cloning strategy 
adopted to clone the GC-rich N-terminus and the C-terminus of NF-H separately. 
(A) The GC content of NF-H cDNA (NM_021076) as determined by CpG plot using EMBOSS/CpG plot 
tool on EMBL-EBI. The CpG plot shows a high GC content in the first 1000 bp of the NF-H sequence 
which may result in the formation of secondary structures which interfere with the PCR reaction by not 
allowing the primers to bind. (B) In order to clone NF-H in two parts, primers were designed around a 
unique XmnI restriction endonuclease recognition sequence in the NF-H sequence that divides the NF-H 
cDNA into roughly two halves. The primers were designed so that the N- and C-terminal parts overlapped 
at this point. PCR amplification of the two parts will result in an 1110 bp N-terminal part and a 1984 bp C-
terminal part.  
 
The cloning procedure of the N-terminal part of NF-H into pCR-2.1-TOPO is depicted in the 
top panel of Figure 5.10. The N-terminal part of NF-H was amplified using a genomic PCR 
kit optimized for amplifying GC rich sequences and the forward and reverse primers listed 
NF-H_N-fwd NF-H_C-fwd 
NF-H_N-rev NF-H_N-fwd 
CpG Island 
XmnI (B) 
 
(A) 
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below (translational start codon highlighted in green, sequence homologous to NF-H is 
underlined, XmnI recognition sequence highlighted in pink): 
  Fwd: 5’-TGCTCAGGCCATGATGAGCTTCG-3’ 
  Rev: 5’-TGGTCCTTCGGTAAGTCGTCGAC-3’ 
 
The genomic PCR kit contains a GC melt solution (5 M) which melts any secondary stem-
loop structures in GC rich regions, allowing primer elongation. The best results were 
obtained when using 5 µl of GC melt solution in the PCR mix. The lack of a PCR product in 
the PCR reaction containing no GC melt is noteworthy since it supports the hypothesis that 
secondary structures formed in the GC rich region prevented primer elongation.  
 
Plasmids containing the 1110 bp insert were sequenced and clones that best matched the 
data-base sequence for NF-H (NM_021076) were selected. The selected clone had one PCR 
derived C→T mutation at position 164 introducing a Ser→Phe amino-acid substitution 
which was removed by site-directed mutagenesis described in more detail in section 2.2.12.8 
(Figure 5.10 C). The transformation of the mutagenesis reaction yielded a single NF-H clone 
which was sequenced and confirmed to be correct. 
 
The primers designed for the amplification of the C-terminal part of NF-H from a SH-SY5Y 
cDNA preparation are listed below (translational stop codon is highlighted in red, the 
sequence homologous to NF-H is underlined and the XmnI recognition sequence is 
highlighted in pink): 
  Fwd: 5’-ACCAGGAAGCCATTCAGCAGCTG-3’ 
  Rev: 5’-TGTTCCGGCGGTTCCCCTTCATT-3’ 
 
The C-terminal part of NF-H was amplified using five different PCR reactions with different 
polymerases and buffers (Figure 5.10 D). Of the five reactions, three yielded PCR products 
of the expected 1.98 kb for the C-terminal part of NF-H. The 1.98 kb bands for the Platinum 
Taq DNA polymerase and the Platinum PCR SuperMix reactions were excised and purified 
from the gel and cloned into pCR-XL-TOPO. The results of EcoRI restriction endonuclease 
digests of plasmid DNA are shown in Figure 5.10 E. Two clones, originally from the 
Platinum Taq DNA polymerase reaction and three from the Platinum PCR SuperMix reaction 
were selected for sequencing. Clone 4 of the Platinum PCR SuperMix was selected because 
its sequence matched the database entry for NF-H (NM_021076). 
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Figure 5.10 A schematic of the cloning procedure used to clone NF-H in two parts.  
The N-terminal of NF-H was amplified by PCR from SH-SY5Y cDNA (A) and cloned into pCR-2.1-TOPO. From a 
restriction endonuclease digest with EcoRI (B) plasmids containing the 1110 bp insert were selected and sent for 
sequencing. (C) The clone selected for cloning into pEGFP-C3 (clone 7) had a point mutation (highlighted in red) at 
position 164 bp which results in a Serine (Ser) to Phenylalanine (Phe) amino acid substitution which was removed by 
site-directed mutagenesis (shown in blue). The C-terminal part of NF-H was amplified using five different PCR 
reactions (1, Platinum Taq DNA polymerase; 2, Platinum Taq DNA polymerase High Fidelity; 3, AccuPrime DNA 
polymerase using polymerase buffer I; 4, AccuPrime DNA polymerase using polymerase buffer II and 5, Platinum 
PCR SuperMix) and run a 1% (w/v) agarose gel at 80 mA (D). 1.98 kb bands from reaction 1 and 5 were excised 
(shown in red), purified from the gel and cloned into pCR-XL-TOPO. (E) An EcoRI restriction endonuclease digest 
allowed the selection of plasmids containing the 1.98 kb insert for sequencing.                                                                                                              
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The separately cloned N- and C-terminal parts of NF-H were isolated from their respective 
cloning vectors by EcoRI and XmnI double digests and agarose gel electrophoresis (Figure 
5.11 A). The N- and C-termini were ligated into pCR-XL TOPO by T4 DNA Ligase. The 
insertion of the full length NF-H into pCR-XL TOPO was confirmed by restriction 
endonuclease digestion with EcoRI followed by agarose gel electrophoresis (Figure 5.11 B). 
Four plasmids containing an insert were sequenced, three of which were found to contain an 
NF-H insert, the sequence of which matched the data-base entry for NF-H (NM_021076). 
 
Attempts to add the SalI and EcoRI restriction endonuclease recognition sequences to the 
NF-H insert to ensure correct orientation when cloning it into pEGFP-C3 were unsuccessful. 
Therefore NF-H was sub-cloned directly into pEGFP-C3 using the EcoRI recognition site. 
To ensure that when NF-H was cloned into pEGFP-C3 in frame with GFP it was necessary 
to clone a short piece of linker DNA containing a new EcoRI recognition sequence flanked 
by two BglII recognition sequences into pEGFP-C3.  
 
Figure 5.12 describes the addition of the short piece of linker DNA into the GFP expression 
vector, the presence of which was confirmed by sequence analysis. pEGFP-C3 rNF-M was 
linearised with BglII and ligated with the oligonucleotide linker. To insert NF-H into the GFP 
vector, pEGFP-C3 rNF-M (now containing the EcoRI linker) and pCR-XL TOPO-hNF-H 
were digested with EcoRI. The pEGFP-C3 vector and NF-H were isolated by agarose gel 
electrophoreses and ligated by T4 DNA Ligase (Figure 5.12 and 5.13).  
 
The presence of the NF-H insert was confirmed by restriction endonuclease digestion with 
EcoRI and agarose gel electrophoresis (Figure 5.13 B). To determine which plasmid 
contained the insert in the correct orientation, plasmids containing the inserts were analysed 
by restriction endonuclease digestion using either XhoI or SacI followed by agarose gel 
electrophoresis (Figure 5.13 C). Of all the plasmids, 4 and 12 were found to be in the 
incorrect orientation. The plasmid from clone 6 was selected for sequencing and GFP and 
NF-H were confirmed to be in-frame. 
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Figure 5.11 A Schematic describing the process by which N- and C-terminal parts of NF-H were 
ligated into the cloning vector (pCR-XL-TOPO).  
The N- and C-terminal parts of NF-H were isolated from their cloning vectors, pCR-2.1-TOPO NF-H_N 
and pCR-XL-TOPO NF-H_C respectively by quantitative restriction endonuclease digest with XmnI and 
EcoRI. (A) The products of the digests run on a 1% agarose gel, the bands corresponding to the N- and C-
terminal parts of NF-H and the cloning vector pCR-XL-TOPO were excised (indicated in red) and purified 
from the gel before being ligated together by T4 DNA ligase. (B) Restriction endonuclease digests with 
EcoRI were used to confirm the insertion of the 3.1 kb full-length NF-H into pCR-XL-TOPO. Plasmids 
containing the insert were sequenced and a clone was selected for subcloning into pEGFP-C3.           
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Figure 5.12 The cloning strategy adopted to clone NF-H into the pEGFP-C3 expression vector using 
an EcoRI recognition sequence cloned into pEGFP-C3.  
The new EcoRI recognition sequence was cloned into the vector using a small double-stranded 
oligonucleotide linker so that the GFP sequence and the NF-H sequence once cloned into the EcoRI site are 
in frame. The sequence of the double stranded oligonucleotide is in the pink box, the BglII recognition 
sequence is highlighted in red and the EcoRI recognition sequence is highlighted in blue. 
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Figure 5.13 A schematic describing the subcloning of NF-H into pEGFP-C3.  
pCR-XL-TOPO hNF-H and pEGFP-C3 rNF-M containing the EcoRI linker (pEGFP + EcoRI) were digested with the 
restriction endonuclease EcoRI and run on agarose gels (A), bands corresponding to NF-H and pEGFP-C3 + EcoRI 
bands were excised (indicated in red). NF-H was subcloned into the EcoRI recognition site of pEGFP-C3. Plasmid 
mini-preps of pEGFP-C3 NF-H were analysed by restriction endonuclease digestion with EcoRI and (B) agarose gel 
electrophoresis to confirm the presence of the NF-H insert. The orientation of inserts was confirmed with XhoI and SacI 
restriction endonuclease digestion (C), selected clone was sent for sequencing. Further sequencing confirmed that GFP 
and NF-H was in-frame. 
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Western blots of total cell extracts probed with anti-GFP revealed that GFP/NF-H was 
expressed as a truncated protein of approximately 70 kDa (Figure 5.14 A i). This protein also 
did not react with anti-NF-H (Figure 5.14 A ii) which is raised to the C-terminal tail of NF-H 
suggesting only the N-terminal part of GFP/NF-H was expressed. The pattern of GFP/NF-H 
expression was investigated by laser confocal microscopy (Figure 5.14 B ii) and revealed 
abnormal, speckled GFP/NF-H expression along the axonal processes.  
 
Figure 5.14 Characterisation of truncated GFP/NF-H in SH-SY5Y neuroblastoma cells. 
(A) Western blots of total cell extracts of cells transfected with (1) GFP and (2) GFP-tagged NF-H (trunc.) 
probed with anti-GFP (1:500) and anti-NF-H (n52, 1:200) revealed that the GFP/NF-H is expressed as a  70 
kDa truncated protein that did not react with n52. (B) Confocal microscope images of (i) wild-type SH-
SY5Y cells stained with anti-NF-H (green). Nuclei were counterstained with propidium iodide, (ii) 
GFP/NF-H(trunc.) expressing cells showing GFP/NF-H expression (green). For (i) and (ii) Cells were 
viewed using the 40 x objective and the scale bar represents 40 µm. 
 
The expression of a 70 kDa truncated GFP/NF-H suggested interrupted translation, possibly 
in the region of the XmnI recognition sequence. As such, sequence analysis of the GFP/NF-H 
plasmid revealed that the region around the XmnI recognition sequence (Figure 5.15) 
contained a single base deletion which results in a premature stop codon. The resultant 
protein most likely terminates within the rod domain of NF-H. 
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    1           2 
 70 kDa 
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  1     2 
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(ii) GFP/NF-H(trunc.) expression (B) (i) Anti-NF-H staining (WT cells) 
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Figure 5.15 Sequence analysis of GFP/NF-H plasmid DNA revealed a single base deletion that 
resulted in a premature stop codon. 
(A) Sequence analysis of GFP/NF-H DNA in the area including the XmnI restriction endonuclease 
recognition sequence (in bold) revealed a single base deletion resulting in a premature stop codon. (B) 
Schematic illustrating the structure of human NF-H (reviewed by Perrot et al, 2008) and a proposed 
structure for the truncated NF-H resulting from the premature stop codon introduced by the single base 
deletion in the XmnI restruction endonuclease recognition sequence in human NF-H. The number of amino 
acids was calculated from the average molecular weight of amino acids in Daltons. 
 
To correct the single base deletion the missing base was inserted by site-directed mutagenesis, 
which is described in more detail in section 2.2.12.8. As depicted in Figure 5.16 a primer set 
containing the missing base was designed around the region of the single-base deletion. 
Agarose gel electrophoresis of pEGFP-C3 and the mutagenesis plasmid pEGFP-C3 hNF-H 
confirmed the presence of the 3.1 kb hNF-H insert in the mutagenesis plasmid. 
Head domain Rod domain Tail domain 
1 101 414 1026 
Head domain Rod domain (trunc.) 
1 101 347 Premature stop codon results in 
expression of first 40 kD of NF-H 
Average amino acid = 115 Da 
:. 40 kD ~ 347 amino acids 
(B) 
taccaggaagccattcagcag 
TACCAGGAAG-CATTCAGCAG 
 
Sequencing of NF-H 
around the XmnI 
restriction site revealed a 
single base deletion 
  1        10        20        30        40        50 
  |        |         |         |         |         | 
  APSRPRAPAQAMMSFGGADALLGAPFAPLHGGGSLHYALARKGGAGGTRS 
  AAGSSSGFHSWTRTSVSSVSASPSRFRGAGAASSTDSLDTLSNGPEGCMV 
  AVATSRSEKEQLQALNDRFAGYIDKVRQLEAHNRSLEGEAAALRQQQAGR 
  SAMGELYEREVREMRGAVLRLGAARGQLRLEQEHLLEDIAHVRQRLDDEA 
  RQREEAEAAARALARFAQEAEAARVDLQKKAQALQEECGYLRRHHQEEVG 
  ELLGQIQGSGAAQAQMQAETRDALKCDVTSALREIRAQLEGHAVQSTLQS 
  EEWFRVRLDRLSEAAKVNTDAMRSAQEEITEYRRQLQARTTELEALKSTK 
  DSLERQRSELEDRHQADIASYQEAFSSWTLS* 
 
Single base deletion results in a premature stop codon 
(A) 
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Figure 5.16 A Schematic describing the insertion of the base missing from the XmnI recognition 
sequence.  
A Schematic representation of the strategy used to replace the deleted base in the XmnI recognition 
sequence of GFP/NF-H, the resultant mutagenesis plasmid was analysed by agarose gel electrophoresis. 
The base that was inserted is highlighted in yellow in the mutagenesis primers and the XmnI recognition 
sequence is in bold. 
 
5.2.3.2. Characterisation of GFP/NF-H expression in SH-SY5Y cells 
 
Western blots of total cell extracts probed with anti-GFP (Figure 5.17 A i) confirmed the 
presence of a 30 kDa band consistent with the molecular weight of GFP in GFP expressing 
cells and a band of approximately 230 kDa consistent with the predicted molecular weight of 
GFP/NF-H in GFP/NF-H expressing cells. Probing Western blots with anti-NF-H (Figure 
5.17 A ii) and anti-pNF-H/pNF-M (Figure 5.17 A iii) revealed that extracts from GFP/NF-H 
expressing cells contained bands corresponding to endogenous untagged NF-H and the GFP 
tagged NF-H. The apparent molecular weights of GFP and GFP/NF-H were determined from 
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pEGFP-C3 hNF-H 
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have an insert of the size expected 
for hNF-H.  
4.7 kb pEGFP-C3 
          1     2 
3.1 kb hNF-H 
Chapter 5 Development and Characterisation of GFP-tagged Neurofilaments 
 199 
their Rf values by comparing their electrophoretic mobility to that of molecular weight 
standards (Appendix II). GFP/NF-H expression was similar to that of NF-H in wild-type cells 
(Figure 5.17 B). 
 
Figure 5.17 Characterisation of GFP/NF-H expression in SH-SY5Y neuroblastoma cells. 
(A) Western blots of total cell extracts of SH-SY5Y neuroblastoma cells transfected with (1) GFP and (2) 
GFP-tagged NF-H probed with anti-GFP and anti-NF-H antibodies; (i) the anti-GFP blot shows a 230 kDa 
band corresponding to the GFP/NF-H fusion protein. The (ii) anti-NF-H and the (iii) anti-pNF-M/pNF-H 
both have a band corresponding with the endogenous NF-H band and a band corresponding with the 
GFP/NF-H fusion protein. (B) Confocal microscope images of (i) wild-type SH-SY5Y cells stained with 
anti-NF-H (green), nuclei were counterstained with propidium iodide and cells are viewed using the 40 x 
objective and the scale bar represents 40 µm. (ii) Cells expressing GFP/NF-H (green) after insertion of the 
base lost from the XmnI recognition site during the ligation of the N and C termini. Cells were viewed 
using the 63x oil objective and the scale bar represents 20 µm. (a) Fixed cells and (b) live cells. 
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 Co-localization studies of GFP/NF-H expressing cells with the other NF subunits (Figure 
5.18) revealed a clear co-localization of GFP/NF-H with NF-H, NF-M, and pNF-M/pNF-H. 
 
Figure 5.18 Co-localisation of GFP/NF-H with NF-M, NF-H and phosphorylated NF-M and NF-H in 
SH-SY5Y neuroblastoma cells. 
The co-localization of GFP/NF-H with each of the NF subunits. GFP/NF-H expressing cells were stained 
with (A) anti-NF-H (n52), (B) anti-NF-M (RMO270) and (C) anti-phosphoryated NF-H and NF-M (smi31). 
The antibody staining - detected using a goat anti-mouse alexafluor 568 conjugated secondary antibodies - 
is shown in red on the left hand side of each panel and GFP fluorescence of the GFP-tagged NF-M is shown 
in green in the centre of each panel. As the red and green images are overlaid as seen on the right of each 
panel, areas of co-localization are highlighted yellow. Cells were viewed with a 63 x oil objective, scale bar 
represents 20 µm. 
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The efficiency of transfection of GFP/NF-H with LipofectAMINE™2000 was estimated to be 
17.9 ± 6.3 % (Table 5.2).  
 
Table 5.2 The transfection efficiency of GFP/NF-H in Human SH-SY5Y neuroblastoma cells using 
LipofectAMINE™2000.  
The mean numbers of cells expressing GFP/NF-H fluorescence in experiments 1 and 2 were expressed as a 
percentage of the mean number of total cells (determined from the number of propidium iodide stained nuclei 
for experiments 1 and 2). The individual number of fields of view analysed for each experiment are given in 
brackets. For experiment 3 the number of GFP/NF-H expressing cells in live cultures was determined by 
counting the number of cells with GFP/NF-H fluorescence and the total number of cells visible in bright field 
images taken concurrently with fluorescence images. The number of individual dishes examined are indicated 
in brackets. 
Experiment 
Mean number of Total 
cells in each field of view 
Mean number of cells 
with GFP fluorescence 
Transfected cells (%) 
1 (3) 24.3 6.3 26.0 
2 (1) 12 1 8.3 
3 (5) 21.6 4.2 19.4 
mean ± SEM 19.3 ± 4.6 3.8 ± 1.9 17.9 ± 6.3 
 
The half-life of GFP/NF-H (Figure 5.19) estimated from the anti-GFP blot was 13.1 ± 1.6 h 
whereas the half-life estimated from the anti-NF-H blot was longer at 25.5 ± 1.6 h. 
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Figure 5.19 Determination of the half-life of GFP/NF-H. 
Western blots probed with (A) anti-GFP (1:10000) and (B) anti-NF-H (n52, 1:2000). Plot of the natural 
logarithm of the percentage of original signal (obtained from densitometric analysis of Western blots) 
against time (h), from which half-life [T(/2)] was calculated using the decay rate constant (k) from the 
equation of the line best of fit. T(1/2) quoted is the mean T(1/2) from 3 independent experiments ± SEM. 
T(1/2) obtained from the anti-GFP blot is significantly shorter than the T(1/2) obtained from the anti-NF-H 
blot (**T-Test, p < 0.005; n = 3). 
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5.2.4.    Immunoprecipitation of GFP tagged neurofilaments 
5.2.4.1. Assessment of the solubility of GFP tagged neurofilaments in the 
immunoprecipitation lysis buffer  
 
The immunoprecipitation procedure using the anti-GFP isolation kit from Miltenyi Biotec 
(described in more detail in sections 2.2.2.4 and 2.2.5) is outlined in Figure 5.20. The Lysate 
Supernatant (LS) was obtained from the cell lysate following centrifugation at 10,000 x g for 
10 minutes at 4 °C; the resultant cell debris pellet (P), was solubilised in 1 ml of total 
extraction buffer containing 1 % SDS, followed by heating at 100 °C for 5 minutes. The GFP 
tagged NFs were isolated from LS using anti-GFP µbeads. The excluded supernatant (ES) 
refers to the flow-through from the µ-column after application of LS labelled with anti-GFP 
µbeads to the column.  
 
Figure 5.20 An illustration of the protocol used for the immunoprecipitation of GFP-tagged 
neurofilaments from cell lysates of SH-SY5Y cells.  
The provenance of the Lysate Supernatant (LS), the cell debris pellet (P) and the excluded supernatant (ES) 
is also indicated in points 6 and 9 (yellow boxes).  
 
1. Seed 1.5 x 106 cells 2. Transfect with GFP/NF
3. Treat with toxin
5. Using cell scraper collect cell lysate
4. Add 1 ml of cell lysis buffer
7. Add anti-GFP microbeads to LS
6. Centrifuge at 10,000 xg for 10  
min at 4 ºC and collect supernatant 
= Lysate Supernatant (LS)
Keep Cell Debris Pellet (P) and 
solubilize in 1 ml 1 % SDS and heat 
for 5 min at 100 °C 8. Apply to column and allow 
to empty under gravity
10. Rinse 4x with wash buffer 1
11. Rinse 1x with wash buffer 2
12. Elute with 0.1 M Triethylamine
9. Collect flow-through = 
Excluded Supernatant (ES)
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In the work presented below, a comparison of four transfections was made: mock, GFP, 
GFP/NF-M and GFP/NF-H:  
The solubility of proteins in the igepal-containing lysis buffer was initially assessed by 
copper-staining Western blots of gels to which equal volumes of LS, ES and P for all four 
transfections were applied  (Figure 5.21). Irrespective of transfection, the majority of the total 
protein was soluble in the igepal-containing lysis buffer and a small amount was left in P for 
all four samples. 
 
Figure 5.21 Copperstained Western blot of Lysate supernatant (LS), excluded supernatant (ES) and 
cell debris pellet (P). 
Copperstained Western blot of the Lysate Supernatant (LS), excluded supernatant (ES) and cell debris pellet 
(P) resulting from a 10 000 x g centrifugation of the cell lysate of GFP, GFP-NF-M and GFP/NF-H 
expressing cells that were harvested in 1 ml of the low salt lysis buffer. The cell debris pellet was 
solubilised in 1 ml 8 M urea. 20 µl of each sample was loaded per well.   
 
To establish (a) whether GFP and GFP/NFs are solubilised by the lysis buffer, and (b) 
whether GFP and GFP/NFs are retained in the column, Western blots of the LS, ES and P 
were probed with anti-GFP (Figure 5.22). Firstly, no reaction with anti-GFP was observed in 
any of the fractions from mock transfected cells. Secondly, in fractions from GFP and 
GFP/NF expressing cells, the majority of GFP and GFP/NFs were located in LS with very 
little in P, indicating that GFP and GFP/NFs are soluble in the igepal lysis buffer used. 
Comparison of LS and ES from GFP and GFP/NF transfectants revealed that the majority of 
the GFP and GFP/NF is depleted from ES confirming that GFP and GFP/NFs are retained in 
the column.   
 
 
          Mock          GFP      GFP/NF-M   GFP/NF-H 
      LS  ES   P  LS   ES  P   LS  ES   P   LS  ES   P  Std   
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Figure 5.22 Analysis of the levels of GFP or GFP/NF in the lysate supernatant (LS), excluded 
supernatant (ES) and cell debris pellet (P) from untransfected cells (mock) or cells expressing either 
GFP, GFP/NF-M or GFP/NF-H.  
(A) Representative Western blot of equal volumes of the LS, ES and P probed with anti-GFP (1:7500). (B) 
Plot comparing the mean corrected ADU expressed as a percentage of total protein (ES + LS) obtained 
following densitometric analysis of the anti-GFP immunoreactive bands on Western blots for LS, ES and P 
fractions from GFP, GFP/NF-M and GFP/NF-H expressing cells. Error bars represent standard deviation (n 
= 3). The different fractions for each transfection were compared by one-way ANOVA (** p < 0.001). The 
majority of the GFP and GFP/NF-M /H were found in LS with very little in P. GFP and GFP/NF is depleted 
in ES indicating that it is retained in the column. (n = 3) 
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Next Western blots of LS, ES and P were probed with antibodies to NFs, vimentin, α-tubulin 
and actin to establish whether NFs and other cytoskeletal proteins (a) are soluble in the igepal 
lysis buffer, (b) differ with respect to their distribution in LS, ES and P depending on the 
transfection and (c) are retained in the column by association with the anti-GFP µbeads.  
 
For all the cytoskeletal proteins, levels were greater in the LS than in P (Figure 5.23 and 
5.24). The most soluble protein was α-tubulin (with around 99 % of total protein in the igepal 
soluble pool), followed by actin (with 85-90 % of total protein in the igepal soluble pool). 
The intermediate filaments (NFs and vimentin) were less soluble but in general the solubility 
ranged between 70 – 90 % of total protein. NF-L in mock transfected and GFP expressing 
cells was least soluble (50 – 60 % of total protein in the soluble pool). 
 
Based on the ES content, there was no indication of depletion of NFs, α-tubulin, vimentin and 
actin from LS of mock and GFP transfected cells, indicating no binding to the column (Figure 
5.23 and 5.24). When extracts from GFP/NF-M and GFP/NF-H expressing cells are 
fractionated on the anti-GFP column, there is evidence of a depletion of NF-M and NF-H 
from LS (Figure 5.23 A and B), indicative of the retention of GFP/NFs in the column. For 
extracts from GFP/NF-M expressing cells, NF-H (Figure 5.23 A) and NF-L (Figure 5.23 C) 
levels in ES were lower than in LS, suggesting retention of these subunits in the column 
together with GFP/NF-M. Depletion of NF-M (Figure 5.23 B) and NF-L (Figure 5.23 C) from 
LS is not as evident in GFP/NF-H extracts as is depletion of NF-L and NF-H from GFP/NF-
M extracts, suggesting that a proportion of GFP/NF-H is not assembled into hetero-oligomers 
with NF-M and NF-L. 
 
There was no evidence of depletion of α-tubulin (Figure 5.24 B) or actin (Figure 5.24 C) from 
LS of either GFP/NF-M or GFP/NF-H expressing cells following passage through the anti-
GFP beads indicating that neither of these proteins is retained in the column together with 
GFP/NF-M and GFP/NF-H. There is evidence of depletion of vimentin (Figure 5.24 A) from 
LS of GFP/NF-M and from LS of GFP/NF-H (although to a lesser degree) expressing cells, 
indicating retention of vimentin in the column together with GFP/NF-M and GFP/NF-H. 
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Figure 5.23 The distribution of neurofilaments (NFs) in the lysate supernatant (LS), excluded supernatant (ES) and cell 
debris pellet (P) from SH-SY5Y neuroblastoma cells. 
Analysis of the levels of (A) NF-H, (B) NF-M and (C) NF-L in the cell debris pellet (P), lysate supernatant (LS or Lys Sup) and 
excluded supernatant (ES or Excl Sup) from mock transfected or GFP, GFP/NF-M or GFP/NF-H expressing cells. 
Representative Western blots of equal volumes of the LS, ES and P were probed with anti-NF-H (n52, 1:2000), anti-NF-M 
(RMO270, 1:500) and anti-NF-L (DA2, 1:1000). Plots of mean corrected ADU (arbitrary densitometry units) expressed as 
percentage of total protein (LS + P) obtained from densitometric analyses of Western blots. There was a significant difference in 
the levels of NF-H in LS, ES and P in extracts from GFP/NF-H expressing cells (one-way ANOVA; p < 0.005). The levels of 
NF-H in LS were greater than in P in extracts from mock transfected and GFP expressing cells (one-way ANOVA, *p < 0.05) 
and in extracts from GFP/NF-M expressing cells (two-tailed T-test, †p < 0.05). The was some indication of a decrease in levels 
of NF-H, NF-M and NF-L in ES compared to LS in GFP/NF-M and GFP/NF-H expressing cells. In extracts from mock and GFP 
expressing cells there was no indication of a decrease in the levels of NF-H, NF-M and NF-L in ES compared to LS. Error bars 
represent standard deviation for NF-H (n = 3) and range for NF-M (n = 2) and NF-L (n = 2).  
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Figure 5.24 The Distribution of vimentin, α-tubulin and actin in the lysate supernatant (LS), excluded supernatant 
(ES) and pellet (P) from SH-SY5Y neuroblastoma cells. 
Representative Western blots of equal volumes of the LS, ES and P probed with (A) anti-vimentin (RV202, 1:5000), (B) 
anti-α-tubulin (b512, 1:2000) and (C) anti-actin (1:1000) in the P, LS and ES from untransfected cells (mock) or cells 
transfected with GFP, GFP/NF-M or GFP/NF-H. Plots summarise the results of densitometric analyses of Western blots; 
mean corrected ADU (arbitrary densitometry units) was expressed as a percentage of ADU of total protein (LS + P). The 
levels of vimentin, α-tubulin and actin were greater in LS than P in extracts from mock transfected and GFP, GFP/NF-M 
and GFP/NF-H expressing cells (**p < 0.005; One-way ANOVA, Bonferroni post-hoc tests). There was no evidence of a 
decrease in the levels of α-tubulin or actin in the ES compared LS for all four transfection, or vimentin in the ES of mock 
transfected and GFP expressing cells. The levels of vimentin in ES were lower than the levels in LS in extracts from 
GFP/NF-M expressing cells (†p < 0.05; One-tailed T-Test) and to some degree in GFP/NF-H expressing cells.  Error bars 
represent standard deviation (n = 3). 
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5.2.4.2. Identification of neurofilament-associating proteins by co-
immunoprecipitation with GFP tagged neurofilaments 
 
Two approaches were used to identify neurofilament associating proteins which were co-
immunoprecipitated with GFP-tagged neurofilaments; a general proteomic approach using 
1D/2D-PAGE/peptide mass fingerprinting (PMF) and a more targeted approach using 
Western blotting combined with immunoprobing. 
 
5.2.4.2.1. Determination of associated proteins by electrophoresis plus PMF 
 
Immunoprecipitated eluates from mock transfected and GFP, GFP/NF-M and GFP/NF-H 
expressing cells were separated by one-dimensional SDS-PAGE and the protein profiles of 
the different immunoprecipitates were compared by silver-staining (Figure 5.25). Bands were 
excised from the gel (indicated by blue and green boxes) and subjected to in-gel trypsin 
digestion followed by MS analysis. No identification was made for bands 3 and 6, which are 
represented by green boxes in Figure 5.25. GFP was identified in the immunoprecipitate from 
GFP expressing cells, while in immunoprecipitates from GFP/NF-M and GFP/NF-H 
expressing cells, GFP/NF-M and GFP/NF-H were identified, respectively, together with 
vimentin. The spectra from which identifications were made can be found in Appendix III.  
 
 
Figure 5.25 SDS-PAGE and silver-staining of immunprecipitated eluates from cell lysates of mock transfected 
cells and cells expressing GFP, GFP/NF-M or GFP/NF-H.  
In-gel trypsin digestion and mass spectrometry of excised bands (indicated by the blue and green boxes) resulted in the 
identifaction of GFP in GFP immunoprecipitate, GFP/NF-M and vimentin in the GFP/NF-M immunoprecipitate and 
GFP/NF-H and vimentin in the GFP/NF-H immunoprecipitate. The green boxes represent bands for which no 
identification could be made. 
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Silver-stained two-dimensional SDS-PAGs of immunoprecipitates from GFP and GFP/NF-M 
expressing cells can be found in Figure 5.26. The protein profiles of each of the 
immunoprecipitates were compared using SameSpot software. The spots that were excised 
are indicated by the green and blue rings which were then subjected to in-gel trypsin 
digestion. Trypsin digests were analysed by MS (Peptide mass fingerprints are in Appendix 
III). GFP was identified in the immunoprecipitate from GFP expressing cells. In the 
immunoprecpitate from GFP/NF-M expressing cells, GFP/NF-M, NF-L, vimentin and Hsc70 
(identification confirmed by MSMS) were identified.  
 
Figure 5.26 Two-dimensional SDS-PAGE of immunoprecipitates from cells expressing GFP or 
GFP/NF-M.  
Gels were silver-stained and protein profiles were compared using SameSpot software. Spots indicated by 
the green and blue rings were picked and identified by mass spectrometry. Spots for which no identification 
could be made are indicated by the green rings whereas positive identifications are indicated by the blue 
rings. Positive identifications are listed in the coloured boxes nest to the gels. 
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5.2.4.2.2. Determination of associated proteins using a targeted approach 
 
Western blots of immunoprecipitates from mock transfected cells or from cells expressing 
GFP, GFP/NF-M or GFP/NF-H were probed with antibodies to NFs and phosphorylated NFs. 
Blots revealed that all three NF subunits and pNF-M/pNF-H  are co-immunoprecipitated with 
GFP/NF-M and GFP/NF-H  (Figure 5.27 A and B). In addition blots probed with anti-
vimentin antibody revealed that vimentin co-immunprecipitated with GFP/NF-M and 
GFP/NF-H (Figure 5.27 C). Western blots of immunoprecipitates were probed with anti-
Hsc70 antibody to confirm the association of neurofilaments with Hsc70 which was identified 
by MSMS with GFP/NF-M (Figure 5.27 C); however the reaction of anti-Hsc70 with 
immunoprecipitates from GFP/NF-M and GFP/NF-H expressing cells was very weak and 
some reaction was also observed with the immunoprecipitates from mock transfected and 
GFP expressing cells. 
 
Figure 5.27 Co-immunoprecipitation of GFP/NF-M and GFP/NF-H with all three neurofilament 
subunits, phosphorylated NF-M and NF-H and vimentin. 
 Representative Western blots of immunoprecipitates (E1) from SH-SY5Y cells that were either mock 
transfected (Mo, ie. no plasmid) or transfected with GFP, GFP/NF-M or GFP/NF-H (n = 3). (A) Western 
blots were probed with either anti-NF-L (DA2, 1:1000, top), anti-NF-M (RMO270, 1:500, middle) or anti-
NF-H (n52, 1:2000, bottom). (B) Western blots were probed with antibodies to phosphorylated 
neurofilaments; anti-pNF-M (RNF403, 1:1000, top) and anti-pNF-H/pNF-M (smi31, 1:1000, bottom). (C) 
Western blots probed with either anti-vimentin (RV202, 1:5000, left) or anti-Hsc70 (1:5000, right). 
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To identify other possible neurofilament associating proteins, Western blots of GFP/NF-M or 
GFP/NF-H were probed with antibodies to a number of candidate proteins. The motor 
proteins Dynein, Kinesin 5A and Kinesin 5C were not detected on Western blots of 
immunoprecipitates (Figure 5.28 A). Western blots were also probed with antibodies to other 
cytoskeletal proteins; α-tubulin, actin and αII-spectrin (Figure 5.28 B) which were detected in 
all immunoprecipitates and therefore were not specifically co-immunoprecipitated with 
GFP/NF-M and GFP/NF-H. Cdk5 (kinase), PSMC1 (proteasomal subunit) and Tissue 
Transglutaminase (TG2) were not detected on Western blots of immunopreciptates (Figure 
5.28 C.) 
  
Figure 5.28 Assessment of the presence/absence of a number of target proteins in immunoprecipitates 
from GFP/NF-M and GFP/NF-H expressing cells. 
 Western blots of immunoprecipitates from SH-SY5Y neuroblastoma cells that were either mock 
transfected or transfected with GFP, GFP/NF-M or GFP/NF-H probed with antibodies to a number of 
candidate proteins. (A) Western blots probed with anti-Dynein (Dyn 70.1, 1:1000), anti-kinesin 5A (1:1000) 
and anti-kinesin 5C (1:1000). (B) Western blots probed with anti-α-tubulin (b512, 1:2000), anti-actin 
(1:1000) and anti-αII-spectrin (1:5000). (C) Western blots probed with anti-Cdk5 (1:100), anti-PSMC1 
(1:1000) and anti-TG2 (CUB, 1:1000). 
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5.2.5. The effect of an acute dose of MPP+ treatment on neurofilament 
dynamics in SH-SY5Y cells 
 
Time-lapse fluorescence and bright field images of SH-SY5Y neuroblastoma cells expressing 
GFP/NF-M or GFP/NF-H either untreated or treated with 5 mM MPP+ were taken every 5 
minutes. Cells were maintained at 37 °C in media containing NaHCO3 during the duration of 
the imaging experiment. To minimise the risk of photobleaching and the production of free 
radicals the shutters were closed in the intermittent periods during which images were not 
being taken.  
 
The effect of 5 mM MPP+ treatment on the length of axonal processes in GFP/NF-M (Figure 
5.29) and GFP/NF-H (Figure 5.30) expressing cells was assessed by comparing the length of 
axonal processes (measured using ImageJ software) at the start of the time-lapse experiment 
(t = 0 min) to the length of the axonal processes in the same cells at each time-point during 
the course of the experiment. For each experiment a mean change in length was determined 
by measuring process length for all the cells in a field of view. Changes in the length of 
processes were then expressed as a ratio of the length at the start of the experiment. 
 
There was a significant effect of time on the length of axonal processes in GFP/NF-M and 
GFP/NF-H expressing cells in both treated and untreated cells (Figure 5.29 A and 5.30 A). To 
estimate the rate at which axonal processes retract in treated cells compared to controls a 
linear regression analysis was performed (Figures 5.29 B and 5.30 B). Using Bonferroni post-
hoc tests to compare the changes in axonal process length at each time-point, axonal 
processes were significantly reduced in length after 40 minutes in GFP/NF-H expressing cells 
and after 20 minutes of exposure in GFP/NF-M expressing cells. In GFP/NF-M and GFP/NF-
H expressing control cells, axonal processes retracted at a rate of 0.3 % per minute; in MPP+ 
treated cells the rate of retraction was respectively 0.9 % and 0.7 % per minute. Time-lapse 
movies can be found in the CD included with this work.  
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Figure 5.29 Analysis of the mean change in the length of axonal processes in GFP/NF-M expressing cells 
over time.  
Cells were either untreated or treated with 5 mM MPP+ and imaged every 5 minutes over a period of 50 
minutes. Scale bar represents 20 µm. (A) Representative images of GFP/NF-M expressing cells showing 
reduction in axonal process length in 5 mM MPP+ treated cells. (B) Plot displaying the rate of change in 
axonal process length in treated and untreated (control) cells determined by linear regression analysis. The 
dotted lines refer to the 95 % confidence interval for the linear regression. The rate of the reduction in axonal 
process length is greater in treated cells than in controls. (C) Plot summarising the mean change in axonal 
process length in treated and untreated cells at each time-point. The reduction in axonal process length is 
significantly greater in treated cells than in control cells as early as 20 minutes into the time-course (*p > 0.05; 
Two-Way ANOVA and Bonferroni posttest). Error bars represent SEM (n = 3). 
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Figure 5.30 Mean change in the length of axonal processes of GFP/NF-H expressing cells  during the 
first 45 minutes treatment with 5 mM MPP+.  
Cells were either untreated (control) or treated with 5 mM MPP+ and imaged every 5 minutes. Scale bar 
represents 20 µm. (B) Plot displaying the rate of change in axonal process length in untreated and treated 
cells determined by linear regression analysis. The dotted lines indicate the 95 % confidence interval for the 
linear regression analysis. The rate of reduction in axonal process length is greater in treated cells than in 
controls. (C) Plot summarising the change in axonal process length in treated and untreated cells at each 
time-point. The lengths of axonal processes in treated cells were significantly reduced after 40 and 45 
minutes of treatment compared to the axonal processes of controls at the same time-point (*p > 0.05; Two-
Way ANOVA and Bonferroni posttest). Error bars represent SEM (n = 3). 
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To establish whether NFs retract at the same rate as the axonal process, GFP/NF-M 
fluorescence and bright field (BF) images of cells treated with 5 mM MPP+ were compared 
over the time-course in one experiment (Figure 5.31 A). Linear regression analysis (Figure 
5.31 B) revealed that in this particular experiment the mean rate of GFP/NF-M retraction was 
0.7 % of original length per minute while the rate of retraction of the axonal process obtained 
from the bright field image was 0.6 % of the original length per minute.  
 
Figure 5.31 Assessment of whether neurofilaments retract at a faster rate than the rest of the axonal 
process in GFP/NF-M expressing cells treated with 5 mM MPP+ for a period of 1 h. 
Time-lapse fluorescence and bright field images were taken every 5 minutes during the course of the experiment. 
(A) Composite fluorescence and bright field images of GFP/NF-M expressing cells treated with 5 mM MPP+ 
produced in ImageJ. Scale bar represents 20 µm. (B) Linear regression analysis of change in axonal length over 
time revealed no significant difference in the rate of retraction of GFP/NF-M fluorescence and the axonal 
structure.  
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5.3. Discussion 
5.3.1 GFP tagged neurofilaments 
5.3.1.1. Development and characterisation of GFP/NF-M 
 
Western blotting of total cell extracts from GFP/NF-M expressing cells confirmed the 
expression of a 180 kDa protein consistent with the molecular weight predicted for the 
GFP/NF-M fusion protein that reacted with both anti-GFP and anti-NF-M. The detection of 
the phopho-epitopes revealed that GFP/NF-M is also phosphorylated.  
 
GFP/NF-M appeared to be incorporated into the NF network based on the expression pattern 
(which was similar to NF-M in wild-type cells) and its co-localization with with NF-M, NF-
L, pNF-M and pNF-H. It is noteworthy that in the case of NF-H staining, some GFP/NF-M 
expressing cells did not seem to stain very strongly for NF-H. Additional evidence for the 
association of GFP/NF-M with endogenous NF-M, NF-L and NF-H resulted from their co-
immunoprecipitation with GFP/NF-M.  
 
Studies with mice lacking either NF-H or NF-M have provided evidence that there is some 
redundancy in the functioning of these two subunits, such that if one subunit is missing, the 
expression of the other subunit is increased (Nakagawa et al, 1995, Rao et al, 2002).  
 
Half-life determinations of GFP/NF-M revealed that the half-life of GFP/NF-M (13.8 ± 2.2 h 
to 20.2 ± 1.4 h) is shorter than that of NF-M which was previously calculated to be 53.5 ± 3.6 
h (Table 3.2-2), suggesting that GFP/NF-M is more labile than the endogenous NF-M. The 
peak in 150 kD NF-M levels after 24h was unexpected and suggests that the levels of NF-M 
have increased after 24 hours; an explanation of this phenomenon may be that the GFP 
portion of the GFP/NF-M fusion protein is preferentially cleaved off leaving the NF-M 
portion of the fusion protein free to join the pool of endogenous NF-M. 
5.3.1.2. Development and characterisation of GFP/NF-L 
 
Western blotting of total cell extracts from GFP/NF-L expressing cells confirmed the 
presence of a 100 kDa protein that reacted with both antibodies to both NF-L and GFP 
consistent with the predicted apparent molecular weight of GFP/NF-L. However, confocal 
microscopy revealed aggregates of GFP fluorescence in the cell body, suggesting that 
GFP/NF-L failed to be incorporated into the NF network.  
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Since the head and rod domains of NF-L are critical for NF-L self-assembly into 
homopolymers in vitro (Kim et al, 2007); the position of the GFP tag on the N-terminus of 
GFP/NF-L may be preventing its incorporation into the NF network. However NF-L tagged 
N-terminally with GFP has been used successfully in other studies without abberrant 
aggregation (Kim et al, 2007, Lin et al, 2004, Yan et al, 2007, Yuan et al, 2009).  
 
Alternatively, the aggregation of GFP/NF-L may be caused by the disruption in the 
stoichiometry of NF-L to NF-M/H which is important during neuronal development 
(reviewed by Julien, 1999, Kong et al, 1998). Support for this explanation comes from the 
presence of a small minority of GFP/NF-L expressing cells that have an expression pattern 
that resembles the typical NF staining, suggesting that in these cells the expression of 
GFP/NF-L was low enough not to disrupt NF subunit stoichiometry. A similar observation in 
which the expression of GFP/NF-L resulted in aggregates was reported by Yuan et al (2009) 
who also attributed aggregation to be the result of a disruption in subunit stoichiometry since 
co-expression with NF-M or NF-H prevented aggregation.  
 
5.3.1.3. Development and characterisation of GF/NF-H 
 
Initially the expression of GFP-tagged NF-H did not yield a GFP/NF-H fusion protein of the 
expected molecular weight of 230 kDa, but instead resulted in a 70 kDa truncated protein that 
was detectable by anti-GFP but was not detectable by the anti-NF-H antibody used. The anti-
NF-H antibody used (n52) is specific for the C-terminal domain KSP motifs of NF-H (Harris, 
Ayyub & Shaw, 1991), suggesting that the C-terminal domain is missing from the GFP fusion 
protein. Reanalysis of the GFP/NF-H nucleotide sequence revealed a single base deletion in 
the XmnI restriction endonuclease recognition sequence that resulted in a premature stop 
codon which interrupted translation giving rise to a truncated GFP/NF-H protein. This 
GFP/NF-H plasmid was renamed GFP/NF-H(trunc). 
 
Confocal microscopy also revealed that the truncated GFP/NF-H did not exhibit the typical 
staining pattern observed for NF, suggesting that it is not incorporated into the NF network. 
The truncated GFP/NF-H is in itself interesting since it appears to have a punctate staining 
pattern all along axonal processes suggesting that the truncated protein is transported into the 
axon but is unable to incorporate into the NF network.  
 
The single base deletion was corrected by re-inserting the missing base by site-directed 
mutagenesis. Analysis of total cell extracts from cells expressing the corrected GFP/NF-H by 
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Western blotting  revealed expression of a 230 kDa protein (consistent with the predicted 
apparent molecular weight for the GFP/NF-H fusion protein) that was not only detected by 
anti-GFP and anti-NF-H but also by smi31 which recognises pNF-H, indicating that GFP/NF-
H can also be phosphorylated. 
 
GFP/NF-H expression exhibited a similar pattern to NF-H expression in wild-type cells albeit 
at a greater level than seen in wild-type cells. GFP/NF-H was colocalised with all three NF 
subunits suggesting that it is incorporated into the NF network. In addition, co-
immunoprecipitation of GFP/NF-H with all three NF subunits reaffirmed its association with 
endogenous NFs. 
 
Half-life determinations of GFP/NF-H (13.1 ± 1.6 h to 25.5 ± 1.6 h) estimated using Western 
blots probed with anti-GFP and anti-NF-H revealed that the half-life of GFP/NF-H is shorter 
than that of NF-H which was previously calculated to be 48.6 ± 4.4 h (Table 3.2-2). 
Therefore, as with NF-M, GFP labelling of NF-H has made the protein more labile. 
 
5.3.1.4. Conclusion 
 
The selection of GFP tagged neurofilaments for this work was dependent on their ability to 
exhibit a phenotype that closely resembles that of the endogenous neurofilaments. Since 
GFP/NF-L expression resulted in the aggregation of GFP fluorescence in the perinuclear 
region, its use as a tool to study neurofilament dynamics was discounted. Both GFP/NF-M 
and GFP/NF-H exhibited an expression pattern that closely resembles that of endogenous 
neurofilaments. They were also shown to associate with the neurofilament subunits 
suggesting that they are incorporated into the neurofilament structure. As such, both GFP/NF-
M and GFP/NF-H were selected for use as tools to study the effects of mitochondrial 
dysfunction (resulting from treatment with MPP+) on neurofilament distribution and their 
association with other proteins. A limitation of both GFP/NF-M and GFP/NF-H is their 
shorter half-lives which suggest that tagging NFs with GFP increases their rate of 
degradation, perhaps by targeting them for degradation by pathways that may not ordinarily 
be involved in their turnover. 
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5.3.2. Neurofilament associating proteins identified by co-
immunoprecipitation 
 
Analysis of the composition of the lysate supernatant and the pellet confirmed that α-tubulin 
and actin were highly soluble in the lysis buffer and that in general around 80 % of IF protein 
was also soluble. Reduced levels of GFP and GFP tagged NFs in the excluded supernatants 
confirmed that they were retained in the µ-column, binding to the anti-GFP µ-beads. In 
addition, reduced levels of non-labelled NF subunits and vimentin in the excluded supernatant 
suggested that they were also retained in the µ-column via their interaction with the GFP 
tagged NFs. There was no loss of actin and α-tubulin which suggests that they do not interact 
with NFs directly.  
 
Mass spectrometry and Western blotting of immunoprecipitates of GFP/NF-M and GFP/NF-
H expressing cells has identified vimentin as a neurofilament-associating protein in SH-SY5Y 
neuroblastoma cells. The association of vimentin with neurofilaments has previously been 
described in radially orientated filaments of early bipolar neuroblasts during development 
(Cochard & Paulin, 1984), early differentiating neurons in rat embryos (Bignami et al, 1982) 
and by double immuno-fluorescence and immuno-electron microscopy of vimentin and NFs 
in differentiated PC12 cells which revealed that vimentin and NFs did co-localise in some 
filaments (Yabe et al, 2003). Immunofluorescence and immunoprecipitation studies 
confirmed that vimentin is preferentially associated with the more motile hypophosphorylated 
population of NFs. In fact, using pulse chase metabolic labelling of NF-H and live cell 
imaging of GFP/NF-M Yabe et al (2003) were able to show that newly synthesized NF-M 
and NF-H are transiently associated with vimentin.  
 
A combination of mass spectrometry and Western blotting confirmed that GFP tagged NFs 
were also associated with all three NF subunits (NF-H, NF-M and NF-L). In addition 
immunoprobing with antibodies to phospho-epitopes of NF-M and NF-H confirmed not only 
the presence of endogenous phosphorylated NF-M and NF-H but also phosphorylated forms 
of the GFP tagged NFs in immunoproecipitates. Although phosphorylated NFs are usually 
associated with the more insoluble stationary NF network, their presence in the more motile 
fraction from which the immunoprecipitates were prepared is not entirely unexpected. Shea et 
al (1997) reported the presence of phosphorylated NF-H in triton-soluble fraction of 
developing brains from mice which only declined 120 days after birth. Table 5.3 summarises 
the results of mass spectrometry and Western blotting of immunoprecipitates SH-SY5Y 
expressing either GFP/NF-M or GFP/NF-H. 
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Table 5.3 Summary of the results of immunoprobed Western blots of GFP/NF-M and GFP/NF-H 
immunoprecipitates used to identify NF-associating proteins. 
Western blots of immunoprecipitates from Human SH-SY5Y neuroblastoma cells that were either mock 
transfected or transfected with GFP, GFP/NF-M or GFP/NF-H, immunoprobed with antibodies to a number 
of candidate proteins to identify proteins that may co-immunoprecipitate with GFP/NF-M or GFP/NF-H. 
Protein Type Result of Western blot 
Dynein Motor protein Not detected 
Kinesin 5C Motor protein Not detected 
Kinesin 5A Motor protein Not detected 
α-tubulin Cytoskeletal, MTs Not specific to GFP/NF-M and GFP/NF-H 
actin Cytoskeletal, MFs Not specific to GFP/NF-M and GFP/NF-H 
NF-L Cytoskeletal, IF Associates with GFP/NF-M and GFP/NF-H 
NF-M and pNF-M Cytoskeletal, IF Associates with GFP/NF-M and GFP/NF-H 
NF-H andpNF-H Cytoskeletal, IF Associates with GFP/NF-M and GFP/NF-H 
vimentin Cytoskeletal, IF Associates with GFP/NF-M and GFP/NF-H 
α-II-spectrin Cytoskeletal Not specific to GFP/NF-M and GFP/NF-H 
Cdk5 Kinase Not detected 
PSMC1 Proteasome subunit Not detected 
TG2 Cross-linking enzyme Not detected 
Hsc70 Chaperone Not specific to GFP/NF-M and GFP/NF-H 
 
5.3.2. Acute MPP+ treatment results in axonal retraction 
 
Some retraction of axonal processes occurred in control cells with time during the time-lapse 
experiment which may suggest that exposure to fluorescent light is having some effect on 
cellular health. However, in general the structure of control cells was more static than that of 
cells treated with 5 mM MPP+ in which extensive reorganisation of the cytoskeleton was 
evident in most cells. Indeed in some MPP+ treated cells axonal processes projecting one way 
retracted completely and extended in the opposite direction, suggesting that cells were trying 
to search out a more suitable environment. In general, the rate of retraction of processes in 
GFP/NF-M and GFP/NF-H expressing cells treated with MPP+ was greater than that of 
control cells. A comparison of the rate of retraction of GFP fluorescence in the axonal process 
and the axonal process itself seen with in bright field suggested that the retraction of NFs 
following treatment occurred simultaneously with the rest of the axonal structure. 
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5.3.4. Conclusion 
 
GFP tagged neurofilaments are associated with all three NF subunits as well as vimentin. The 
lack of identification of NF associated proteins other than NF subunits and vimentin is most 
likely due to limitations in detection. Future work involving the immunoprecipitation of 
GFP/NFs would concentrate on increasing the yield of GFP/NF immunoprecipitate. This 
could be achieved by improving the transfection efficiency of the GFP/NF transfection, using 
more cells or pooling samples.  
 
Time-lapse imaging of 5 mM MPP+ treated cells revealed that an acute dose of MPP+ 
treatment results in a general retraction of axonal processes with neurofilaments and the rest 
of the axonal structural elements moving simultaneously. Future work involving time-lapse 
and live cell imaging could involve longer treatment regimes with lower doses of MPP+. In 
addition, organelle stains such as mitotracker and lysotracker could be used to monitor 
changes in their distribution with treatment and how these changes relate to changes in 
neurofilament distribution. 
 
 
- 
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6.1. Degradative pathways involved in the turnover of cytoskeletal 
proteins 
6.1.1. The half-lives and degradative pathways involved in the turnover of 
cytoskeletal proteins in SH-SY5Y cells 
 
The half-lives of NF-L, α-tubulin and vimentin estimated in this work were all similar to the 
half-life of α-tubulin estimated by Ren et al (2003) in HEK293 cells. The half-lives of NF-M 
and NF-H were longer than that of NF-L which may be due to their increased 
phosphorylation status which increases their resistance to proteolysis (Greenwood et al, 
1993). In vivo the half-lives of cytoskeletal proteins are usually quoted in days (Millecamps et 
al, 2007, Nixon & Logvinenko, 1986, Safaei & Fischer, 1990) and often exhibit biphasic 
decay rates with the soluble pool being degraded at a faster rate than the insoluble pool 
(Nixon & Logvinenko, 1986, Safaei & Fischer, 1990). The shorter half-life estimated in this 
work may be due to the use of proliferating cultured cells in which (due to their quick 
doubling time) proteins may be turned over more quickly than in vivo. Also, no evidence for 
biphasic decay rates was observed in this work. Whether this would also be true in 
differentiated cells is not known and could form the basis of future work. 
 
Use of specific protease inhibitors in the presence of CHX established that α-synuclein is 
degraded by the UPS, macroautophagy and calpain. The role of cysteine cathepsins could not 
be ruled out since CHX resulted in a huge reduction in cysteine cathepsin activity; suggesting 
very rapid turnover of this protease. The same approach failed to establish the degradative 
pathways for any of the other cytoskeletal proteins, except NF-H which appeared to be 
degraded by macroautophagy and the lysosomal protease cathepsin D. A role for cathepsin D 
in NF turnover has previously been suggested (Nixon & Marotta, 1984, Suzuki et al, 1988), 
but in these studies cathepsin D was also shown to degrade NF-L and NF-M in vitro 
(although there was some discrepancy over which NF subunit was most susceptible to 
cathepsin D proteolysis). One is therefore uncertain as to why a pathway can not be ascribed 
to NF-L, α-tubulin and vimentin, given that they have a similar half-life to α-synuclein and 
that there is little evidence of the compensatory activation of other proteolytic pathways in the 
presence of specific inhibitors. It is possible that the cysteine cathepsins may be involved and 
in future attempts could be made to test this by monitoring protein levels in the absence of 
CHX. 
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6.1.2. Effects of complex I inhibition on cytoskeletal protein turnover 
 
Following complex I inhibition with MPP+, the half-lives of all the cytoskeletal proteins were 
shorter (although not significantly) than the half-lives in CHX-treated controls. In the absence 
of CHX, MPP+ reduced the activity of the proteasome and cathepsin D; this reduction was 
not evident in the presence of CHX, probably because CHX itself resulted in a reduction in 
proteasome and cathepsin D activity. MPP+ has previously been reported to reduce 
proteasome activity in SH-SY5Y cells and to directly reduce the activity of purified 20S 
proteasome (Caneda-Ferron et al, 2008). Whilst MPTP treatment in marmosets results in 
reduced expression of the α-subunits and components of the regulatory caps (Zeng et al, 
2006).  
 
The activity of the cysteine cathepsins was elevated in MPP+ and MPP+/CHX treated cells; 
this increase can not solely be attributed to increased expression since increased cysteine 
cathepsin activity was also observed in the absence of new protein synthesis. Increased 
cysteine cathepsin levels have also been observed in mitochondrial DNA depleted 
osteosarcoma cells with impaired mitochondrial respiration (Hamer et al, 2009) and cathepsin 
L mRNA expression was elevated in MPP+ treated PC12 cells (Xu et al, 2005). The increase 
in cysteine cathepsin activity may account for the lack of decreased cytoskeletal protein 
turnover in MPP+ treated cells, suggesting a role for the cysteine cathepsins in the 
degradation of cytoskeletal proteins. 
 
Of particular interest in this work is the apparent protective effect of cysteine cathepsins in 
MPP+ treated cells as cysteine cathepsin inhibition resulted in increased cell death. Cysteine 
cathepsins appear to have contradictory roles in cell survival and cell death since their 
activation is ordinarily associated with apoptotic and necrotic cell death (Droga-Mazovec et 
al, 2008, Stoka et al, 2001, Turk & Stoka, 2007, Vasiljeva & Turk, 2008, Wang et al, 2006) 
whilst in cancer cells increased cysteine cathepsin activity promotes cell survival (Colella et 
al, 2010, Gocheva et al, 2006, Zhu & Uckun, 2000). In addition, cathepsin L and B double 
deficient mutant mice die soon after birth and exhibit features of early onset 
neurodegeneration (Stahl et al, 2007), a condition which can be rescued with the expression 
of human cathepsin L (Sevenich et al, 2006). So, a fuller understanding of why mitochondrial 
dysfunction is resulting in increased cysteine cathepsin activity in SH-SY5Y cells is required.  
 
MPP+ treatment in the presence of CHX also resulted in an increase in LC3-II levels, 
indicative of the number of autophagic vesicles. In this work, comparison of LC3-II levels in 
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MPP+, BafA1 and MPP+/BafA1 treated cells suggested a reduction of autophagic 
degradation with MPP+ treatment. This result contradicts Zhu et al (2007) who observed that 
MPP+ induces macroautophagy in SH-SY5Y cells (but in the absence of a protein synthesis 
inhibitor) but is supported by another study in which MPP+ reduced dynein function and 
impaired clearance of α-synuclein by macroautophagy (Cai et al, 2009). A recent report has 
suggested that MPP+ inhibits LC3-II phosphorylation and as such induces autophagosome 
vesicle synthesis (Cherra et al 2010). However induction of autophagosome synthesis does 
not preclude an inhibition of macroautophagy since for macroautophagy to proceed to 
completion, autophagosomes and lysosomes need to fuse. It is this fusion of autophagosome 
and lysosome that may be inhibited by MPP+.  
 
Figure 6.1 summarises the findings in the present work and proposed consequences of these 
observations. 
 
 
Figure 6.1 Flow diagram illustrating the effects of complex I inhibition on the activity of proteolytic 
pathways.  
Treatment of SH-SY5Y neuroblastoma cells with MPP+ (2 mM) for 48 h in the presence or absence of 10 µg/ml 
cycloheximide (CHX). MPP+ treatment resulted in a reduction in proteasome and cathepsin D activity. No effect 
on proteasome and cathepsin D activity was observed in MPP+/CHX treated cells compared to CHX treated 
controls. MPP+ treatment also resulted in an increase in cysteine cathepsin activity and the levels of LC3-II 
which suggests the inhibition of macroautophagy. Due to the inhibition of cathepsin D and macroautophagy and 
the increase in cysteine cathepsin activity, it may be cysteine cathepsins that are involved in the turnover of 
cytoskeletal proteins in MPP+ treated proliferating SH-SY5Y cells. Clear boxes and dotted lines represent 
proposed consequences/significance of observations. 
Complex I Inhibition 
 Proteasome Activity 
(only in absence of CHX) 
 Cathepsin D Activity 
(only in absence of CHX) 
 macroautophagy 
↑ LC3-II levels 
↑ Cysteine 
Cathepsin 
Activity 
Degradation of cytoskeletal 
proteins including NFs 
↑ Cell Survival ? 
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6.1.3. DA-mediated oxidative stress and cytoskeletal protein turnover 
 
In cells treated with 100 µM DA, estimations of the half-lives of cytoskeletal proteins were 
problematic due to a large degree of experimental variation but in general half-life appeared 
to be increased. Treatment with 100 µM DA resulted in a reduction in proteasome activity but 
only in the presence of CHX. As mentioned before, the effects of 100 and 500 µM DA on the 
proteasome was established to be the result of DA mediated oxidative damage (Caneda-
Ferron et al, 2008). In the present work the reduction in proteasome activity with 100 µM DA 
in the presence of CHX may be due to oxidative damage of proteasome subunits which can 
not be replaced due to the inhibition of protein synthesis. 100 µM DA also resulted in an 
increase in LC3-II levels which when comparing LC3-II levels of cells treated with DA, 
BafA1 or DA/BafA1 suggested an inhibition of macroautophagy may be responsible for 
increased LC3-II levels. Interestingly, by monitoring αII-spectrin cleavage, an increase in the 
appearance of the calpain specific cleavage product was observed with 100 µM DA treatment, 
suggesting an activation of calpain. Calpain activation has previously been shown to induce 
Cdk5 activity by p35 cleavage (Tamada et al, 2005) which in turn is known to phosphorylate 
NFs (Pant et al, 1997, Sun et al, 1996) increasing their resistance to proteolysis (Greenwood 
et al, 1993). 
 
Treatment with 500 µM DA resulted in extensive cell death, a reduction in the half-lives of 
cytoskeletal proteins and the apparent activation of caspase 3, suggested by the production of 
the 120 kD caspase 3-specific cleavage product of αII-spectrin (reviewed in Wang, 2000). 
Proteasome activity was virtually abolished with 500 µM DA and LC3-II levels could not be 
elevated by BafA1 co-treatment. Due to the extensive degree of cell death observed in 
cultures treated with 500 µM, these effects are most likely due to the activation of cell death 
proteases. 
 
Figure 6.2 summarizes the findings of the present work and the proposed consequences of 
these observations. 
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Figure 6.2 Flow diagram illustrating the effects of dopamine (DA)-mediated oxidative stress on the activity 
of proteolytic pathways.  
Treatment of SH-SY5Y neuroblastoma cells with 100 µM DA in the presence of 10 µg/ml cycloheximide (CHX) 
resulted in an increase in LC3-II levels which suggested an inhibition of macroautophagy. 100 µM DA treatment 
also resulted in reduced proteasome activity (monitored by measuring chymotrypsin-like activity, CLA) and an 
apparent activation of calpain1. Treatment of SH-SY5Y with 500 µM DA/CHX virtually abolished proteasome 
activity (monitores by measuring CLA) and resulted in an apparent activation of caspase 31. 
1The effect on calpain and caspase 3 activation was determined indirectly by monitoring the levels of αII-spectrin 
calpain-specific and caspase 3-specific cleavage products on Western blots probed with anti-αII-spectrin (Sigma). 
 
6.2. Assessment of protein aggregation in RA/BDNF differentiated SH-
SY5Y cells following mitochondrial dysfunction and proteasome 
inhibition 
6.2.1. Effects of mitochondrial dysfunction  
 
MPP+ treatment resulted in an accumulation of NF-H in the cell body that was accompanied 
by a local swelling of the axonal structure in that region. Enrichment of NF-H, pNF-M and α-
tubulin in the insoluble fraction and the co-localization of NF-H in the perinuclear region with 
p62 and LC3 is suggestive of aggregate formation and the attempted clearance of aggregates 
by macroautophagy (Bjorkoy et al, 2005, Pankiv et al, 2007).  
 
The decrease in the levels of dynein intermediate chain observed with MPP+ treatment may 
interfere with dynein function and subsequently impair macroautophagy (Cai et al, 2009) 
since dynein function is required for autophagosome and lysosome fusion (Ravikumar et al, 
2005). Impaired dynein function also inhibits the entry of NFs from the cell body to axonal 
DA-mediated oxidative stress 
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processes (Motil et al, 2006) which could also result in a local accumulation of NFs in the cell 
body.  
 
Preliminary results also suggested a decrease in the levels of active cathepsin D which may 
impair cathepsin D-dependent lysosomal degradation. Work with proliferating cells suggested 
an increase in cysteine cathepsin activity with MPP+ treatment (section 3.2.4.2.4) and since 
cathepsin L is able to degrade cathepsin D (Zheng et al, 2008), the decrease in active 
cathepsin D observed in this work may be the result of cleavage by cathepsin L. A schematic 
summarising the effects of MPP+ treatment is given below in Figure 6.3, together with some 
proposed mechanisms. 
 
Figure 6.3 Scheme representing the effects of 24 h treatment of RA/BDNF differentiated SH-SY5Y neuroblastoma 
cells with 500 µM MPP+.  
Treatment with 500 µM MPP+ resulted in an increased distribution of NF-H in the cell body that concentrated in the 
perinuclear region accompanied with a swelling of the processes in these regions. These accumulations of NF-H also co-
localized with p62 and LC3 suggesting the attempted degradation of NF-H accumulations by macroautophagy. Increased 
levels of pNF-M, NF-H, α-tubulin and p62 in the insoluble cell fraction with MPP+ treatment suggests aggregate 
formation. The increased presence of p62 in the insoluble fraction may be indicative of its function to target aggregated 
proteins for degradation by macroautophagy. Decreased levels of actin, vimentin, γ-tubulin and dynein light intermediate 
chain were observed with MPP+ treatment. Decreased levels of dynein may impair dynein function resulting in impaired 
macroautophagy which may prevent the clearance of aggregated proteins. Preliminary results also suggested decreased 
levels of active cathepsin D which may result in decreased cathepsin D-dependent lysosomal degradation. Proposed 
consequences/significance of observations are given in clear boxes. 
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6.2.2. Effects of proteasome inhibition 
 
Treatment of RA/BDNF differentiated cells with epoxomicin also resulted in a local 
accumulation of NF-H in the cell body but in this case NF-H accumulation did not coincide 
with regions of axonal swelling as seen in MPP+ treated cells. These regions of NF-H 
accumulation also co-localized with p62 and LC3. The increased appearance of p62, pNF-M 
and NF-H in the igepal insoluble cell fraction with epoxo treatment suggests a decrease in 
their solubility which is suggestive of aggregation. The presence of p62 and the co-
localization of LC3 is suggestive of the attempted degradation of protein aggregates by 
macroautophagy (Bjorkoy et al, 2005, Pankiv et al, 2007).  
 
Epoxo treatment also resulted in increased levels of NF-M protein which may be the result of 
decreased turnover and aggregation in the insoluble pool. Decreased levels of vimentin and 
dynein intermediate chain protein were also observed. As mentioned earlier decreased levels 
of dynein may interfere with dynein function which could impair macroautophagy (Cai et al, 
2009, Ravikumar et al, 2005) and/or the delivery of NFs from the cell body into the axonal 
processes (Motil et al, 2006). The levels of active cathepsin D were increased with epoxo 
treatment, a compensatory activation of cathepsin D has previously been reported with 
proteasome inhibition (Rideout et al, 2004). 
 
 
A schematic summarizing the effects of epoxo treatment is given below in Figure 6.4, 
together with some proposed mechanisms. 
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Figure 6.4 Scheme representing the effects of 24 h treatment of RA/BDNF differentiated SH-SY5Y 
neuroblastoma cells with 10 nM Epoxomicin (epoxo).  
Treatment with epoxo resulted in an increased distribution of NF-H in the cell body that concentrated in the 
perinuclear region. These accumulations of NF-H also co-localized with p62 and LC3 suggesting the 
attempted degradation of NF-H accumulations by macroautophagy. Increased levels of pNF-M, NF-H and 
p62 in the insoluble cell fraction are suggestive of aggregate formation. The increased presence of p62 in 
the insoluble fraction may be indicative of its function to target aggregated proteins for degradation by 
macroautophagy. Decreased levels of vimentin and dynein light intermediate chain and increased levels of 
NF-M were observed in total cell extracts. Increased levels of NF-M may be the result of decreased 
turnover. Decreased levels of dynein may impair dynein function resulting in impaired macroautophagy 
which may prevent the clearance of aggregated proteins. Preliminary results also suggested an increase in 
the levels of active cathepsin D which suggests a compensatory activation of cathepsin D. Proposed 
consequences/significance of observations are indicated by the clear boxes and dotted lines. 
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6.2.3. Effects of a combination of mitochondrial dysfunction and 
proteasome inhibition 
 
As observed in MPP+ and epoxo treated cells, MPP+/epoxo treated cells also exhibited local 
accumulations of NF-H in the cell body that co-localized with p62 and LC3. Again, the 
enrichment of pNF-M, α-tubulin and p62 in the igepal insoluble fraction suggests protein 
aggregation and co-localization of p62 and LC3 is suggestive of the induction of 
macroautophagy to clear aggregated proteins.   
 
Increased levels of NF-M and decreased levels of TG2, vimentin, α-tubulin and dynein 
intermediate chain were observed following MPP+/epoxo treatment. Increased levels of NF-
M may be the result of decreased NF-M proteolysis resulting in or from protein aggregation 
in the insoluble fraction. In RA differentiated SH-SY5Y cells, MPP+ treatment resulted in the 
activation of TG2 induced cross-linking activity (Beck et al, 2006) and TG2 had been shown 
to be involved in α-synuclein aggregation in COS-7 and HEK293 cells expressing human α-
synuclein (Junn et al, 2003). The decreased TG2 levels observed with MPP+/epoxo treatment 
may be an adaptive response to prevent cross-linking of aggregated proteins which may 
prevent the effective clearance of protein aggregates in these cells. The decreased levels of 
dynein intermediate chain in total protein may have implications for dynein motor function 
and macroautophagy (Cai et al, 2009, Ravikumar et al, 2005) and the delivery of NFs into the 
axonal processes (Motil et al, 2006), ultimately resulting in protein aggregation in the cell 
body. A schematic summarising the effects of MPP+/epoxo treatment is given below in 
Figure 6.5, together with some proposed mechanisms.  
Chapter 6 Conclusions and Future Directions 
 232 
 
Figure 6.5 Scheme representing the effects of 24 h treatment of RA/BDNF differentiated SH-SY5Y 
neuroblastoma cells with 500 µM MPP+ and 10 nM Epoxomicin.  
Treatment with MPP+/epoxo resulted in an increased distribution of NF-H in the cell body that 
concentrated in the perinuclear region. These accumulations of NF-H also co-localized with p62 and LC3 
suggesting the attempted degradation of NF-H accumulations by macroautophagy. Increased levels of pNF-
M, α-tubulin and p62 in the insoluble cell fraction are suggestive of aggregate formation. The increased 
presence of p62 in the insoluble fraction may be indicative of its function to target aggregated proteins for 
degradation by macroautophagy. Increased levels of p62 were also observed in the igepal soluble cell 
fraction. Decreased levels of TG2, vimentin, α-tubulin and dynein light intermediate chain and increased 
levels of NF-M were observed in total cell extracts. Increased levels of NF-M may be the result of 
decreased turnover. Decreased levels of dynein may impair dynein function resulting in impaired 
macroautophagy which may prevent the clearance of aggregated proteins. Preliminary results also 
suggested no change in the levels of active cathepsin D. Proposed consequences/significance of 
observations are indicated by the clear boxes and the dotted lines. 
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6.3. Future directions 
 
Further validation of the effects of 100 µM DA on the activation calpain is required. Although 
most of the synthetic peptides to assay calpain activity are not very specific (reviewed in Goll 
et al, 2003), the inclusion of the endogenous calpain inhibitor (calpastatin) may provide 
additional evidence for the role of calpain. In addition, methods to monitor intracellular 
calcium levels following DA treatment may provide further information.   
 
Future work could concentrate on investigating the effects of MPP+ treatment on protein 
degradative pathways by monitoring its effects on protein and mRNA expression of the 
proteins involved in degradative pathways. The effects of MPP+ on protein degradative 
pathways in proliferating and RA/BDNF differentiated cells could also be compared. To 
clarify the effect of MPP+ on macroautophagy additional methods that can be used to 
measure macroautophagy are required. Methods which monitor autophagosome content such 
as electron microscopy, fluorescence labelling of autophagosomes and Western blot detection 
of LC3-II levels measure the induction of macroautophagy but do not establish whether these 
autophagosomes fuse with lysosomes (Klionsky et al, 2008). The measurement of autophagic 
flux by monitoring the turnover of autophagic protein substrates such as p62 would enable 
one to establish whether macroautophagy proceeds to completion (Klionsky et al, 2008).  
 
Further investigation of the apparent protective effects of the cysteine cathepsins in MPP+ 
toxicity is required. To establish whether the effect is limited to proliferating neuroblastoma 
cells and a characteristic of the original neuroblastoma or whether it may be of relevance to 
neurodegeneration, the role of cysteine cathepsins in MPP+ toxicity in RA/BDNF 
differentiated cells should be investigated. Although Mantle et al (1995) did not show a 
significant increase in the activity of cathepsin L in grey and white matter of the frontal cortex 
from post-mortem PD brain, the mean activity values suggested a slight increase in activity 
but due to a large degree of deviation, no statistical significance was found. They also 
concentrated on the frontal cortex and did not look at cathepsin activity in the substantia nigra 
which may have been more relevant for PD. It would therefore be interesting to compare 
cathepsin activities and expression (in particular that of cysteine cathepsins such as cathepsin 
L and B) in human PD substantia nigra and in the substantia nigra of PD animal models.  
 
In this work RA/BDNF differentiated cells were treated for 24 h with MPP+, epoxo or 
MPP+/epoxo; future work could concentrate on characterising the effects of treatment over 
longer treatment periods and to establish what other proteins co-localize with the NF-H, p62 
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and LC3 accumulated in the cell body. It would also be interesting to establish whether in 
these cells aggregated proteins are cleared either at a later time-point in treatment or when the 
treatment is removed. The clearance of aggregates after removal of treatment has been 
described for COS-7 cells treated with rotenone (Lee et al, 2002), but in COS-7 cells 
overexpressing parkin, inclusions induced by proteasome inhibition were not cleared 
following removal of the proteasome inhibitor (Ackerley et al, 2003).  
 
All three treatment regimes resulted in decreased dynein intermediate chain levels which may 
have implications for dynein function and as such the delivery of NFs into the axonal 
processes from the cell body, the retrograde transport of NFs and organelles in axonal 
processes and macroautophagy (Cai et al, 2009, He et al, 2005, Hirokawa et al, 1998, Motil et 
al, 2006, Motil et al, 2007, Ravikumar et al, 2005, Theiss et al, 2005, Webb et al, 2004). It 
would therefore be beneficial to investigate the effects of all three treatments on the 
functioning of motor proteins and the consequences thereof. 
 
According to Encinas et al (2000) RA/BDNF differentiated cells are stable for at least 3 
weeks as long as they have access to BDNF, it would therefore be possible to produce chronic 
models investigating the effects of mitochondrial dysfunction and proteasome inhibition on 
NFs and other proteins. 
 
Further work using siRNA technology to knockdown the expression of the NF subunits may 
provide additional information regarding the role of NFs in inclusion formation following 
complex I and/or proteasome inhibition of differentiated cells. Due the changes in the 
distribution of p62 following complex I and/or proteasome inhibition presented in this work, 
future work could concentrate on clarifying the role of p62 in inclusion formation and 
whether p62 interacts with NFs directly or whether NFs are ubiquitinated before p62 
association. Recently p62 and parkin have been implicated in the regulation of mitophagy 
(Geisler et al 2010a); it may therefore be interesting to evaluate whether NFs are involved in 
this process due to their reported association with active mitochondria (Wagner, 2003). 
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6.4. The use of GFP tagged NFs to monitor NF dynamics  
6.4.1. Development and characterisation of GFP/NFs  
 
All three neurofilament subunits (NF-H, NF-M and NF-L) were amplified from cDNA 
preparations of SH-SY5Y cells and cloned into the GFP expression vector (pEGFP-C3). 
Characterisation of the expression of all three GF/NF subunits in SH-SY5Y cells revealed 
that all three constructs were of the predicted molecular weight and immunoreactive with 
antibodies to GFP and antibodies to both phosphorylation dependent and phosphorylation 
independent epitopes of the respective NF subunits. Immunofluorescence and confocal 
imaging of GFP/NF-M and GFP/NF-H expressing cells revealed that the distribution pattern 
of both of these GFP/NF subunits was similar to that of endogenous NFs and that they co-
localized with the other NF subunits.  
 
However in most GFP/NF-L expressing cells, GFP fluorescence was confined to a localized 
region in the cell body that resembled an inclusion, suggesting either that GFP/NF-L is not 
assembled into the NF network or that the over-expression of NF-L resulting from the 
GFP/NF-L expression disrupts NF assembly. The importance of NF subunit stoichiometry 
during neuronal development has previously been suggested (Kong et al, 1998, Xu et al, 
1996, Zhu et al, 1997). 
 
The possibility of using GFP/NF-M and GFP/NF-H expressing cells for time-lapse imaging 
of live cultures treated with MPP+ was assessed by treating cells with 5 mM MPP+ and 
imaging cells every 5 minutes over the course of an hour. Time-lapse imaging of MPP+ 
treated cells revealed extensive reorganisation and retraction of the axonal cytoskeleton 
within the first 30-40 minutes of treatment.  
 
6.4.2. Assessment of GFP/NF co-immunoprecipitation 
 
GFP/NFs were successfully immunoprecipitated using anti-GFP µbeads from Miltenyi 
Biotec. As mentioned earlier the GFP/NFs immunoprecipiated in this work constituted the 
more motile soluble pool of NFs rather than the more insoluble less motile component (Yabe 
et al, 2001). Mass spectrometry and immunoprobing of Western blots identified the presence 
of all three NF subunits and vimentin in immunoprecipitates. As mentioned earlier vimentin 
association with NFs has previously been reported in the developing nervous system 
(Bignami et al, 1982, Cochard & Paulin, 1984) and in PC12 cells, vimentin was shown to 
associate with the more dispersed population of NF which constitute the more motile soluble 
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component (Yabe et al, 2003). However due to the low levels of immunoprecipitated proteins 
it was not possible to identify any other NF associating proteins during the project. 
 
6.4.3. Further recommendations for the use of GFP/NF subunits 
 
Future work with GFP/NF-L could involve the characterisation of the GFP/NF-L ‘inclusions’ 
in the cell body. Defective axonal transport and aggregation of NFs in inclusions has been 
observed in CMT disease resulting from mutations in the head and rod domains of NF-L 
(Brownlees et al, 2002, Pérez-Ollé et al, 2005, Zhai et al, 2007). It would be interesting to 
establish whether the other NF subunits are also trapped in the GFP/NF-L aggregations and 
whether these aggregates have some of the features of aggresomes. 
 
Further work involving time-lapse imaging of live cells expressing GFP/NF-M or GFP/NF-H 
could concentrate on the effects of lower doses of MPP+ on the transport rate of NFs and the 
distribution of GFP/NFs in relation to other axonally transported proteins and organelles such 
as mitochondria and lysosomes. Defective axonal transport has been implicated in a number 
of neurodegenerative conditions (reviewed by De Vos et al, 2008, Ittner et al, 2008, and Roy 
et al, 2005) and the effects of MPP+ treatment on the motor proteins and on the axonal 
transport of neurofilaments and mitochondria have not been fully explored although there is 
some evidence that MPP+ results in altered axonal transport (Morfini et al, 2007) and affects 
dynein level and function (Cai et al, 2009).  
 
Due to the low yield of immunoprecipitates from cell lysates of GFP/NF expressing cells, 
future work using co-immunoprecipitation needs to concentrate on improving yield. The main 
short coming of the transient GFP/NF transfection has been the low transfection efficiency 
which would need to be improved either by comparing some of the newer transfection 
reagents available which claim to be more efficient that the LipofectAMINE transfection 
reagent used in this work. An alternative approach (which may be more beneficial) could be 
to produce stably transfected cell lines, the advantage of which would also be a more 
homogenous population of cells all expressing a similar level of GFP tagged NFs.  
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6.5. Summary 
 
In conclusion, using a number of different biochemical approaches and methods in 
proliferating cells: 
 The half-lives of NF-H and NF-M were determined to be 48-53 h whilst the half-lives 
of NF-L, α-tubulin, vimentin and α-synuclein were shorter at 31-41 h. 
 A role for cathepsin D and macroautophagy in NF-H turnover in unstressed cells was 
established. 
 Some evidence for the activation of cysteine cathepsins with MPP+ treatment and 
their involvement in ensuring cell survival was obtained. 
 MPP+ treatment led to a reduction in cathepsin D activity, macroautophagy and the 
proteasomal activity but no reduction in the turnover of cytoskeletal proteins was 
observed.  
 Some evidence for the reduced degradation of all cytoskeletal elements in cells 
treated with 100 µM DA, accompanied by calpain activation and the inhibition of the 
proteasome and macroautophagy. Notably, with 100 µM DA treatment, no effect on 
cysteine cathepsins was observed and inhibition of cysteine cathepsins in 100 µM DA 
treated cells did not result in increased cell death. 
 
Using RA/BDNF differentiated cells a role for mitochondrial dysfunction (induced by 
MPP+) and/or proteasome inhibition (epoxomicin) in the accumulation and aggregation of 
neurofilaments was suggested due to: 
 the enrichment of NFs in the igepal insoluble fraction 
 the localized accumulation of NF-H in the cell body 
A role for macroautophagy in this experimental model was also suggested due to: 
 the enrichment of p62 in the igepal insoluble fraction 
 co-localization of NF-H accumulations with both p62 and LC3 
 
Further characterisation of the effects of mitochondrial dysfunction and/or proteasome 
inhibition on protein aggregation and protein degradative pathways could further our 
understanding of the pathogenesis of neurodegenerative conditions.  
 
A schematic attempting to integrate the observations made in the present work within the 
current understanding and hypotheses as reviewed in Chapter 1 can be found in appendix VI. 
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I. Determination of the molecular weights of αII-spectrin breakdown 
products (SBDP) 
 
The molecular weights of αII-spectrin breakdown products of were confirmed by 
comparing the Rf values (calculated by dividing the distance travelled by the band with the 
distance to the bottom of the blot) of molecular weight standards to that of the SBDPs. For 
standards, Rf values were plotted against the logarithm of the molecular weight and the 
‘line of best fit’ was used to determine the molecular weight SBDPs (Figure i).  
 
Band 1 is the full-length αII-spectrin and has a molecular weight of 280 kD but the 
molecular weight calculated is much greater than expected at 387.9 ± 3.78 kDa. When 
determining molecular weights from Rf values, molecular weight determinations are more 
accurate in the middle of the blot than at the top where separation is slower therefore the 
high molecular weight determined for full-length αII-spectrin is most likely an artefact.  
 
Band 2 was proposed as the 150 kD SBDP which is the result of cleavage by both calpain 
and caspase 3. The molecular weight of this band, estimated from two blots was 160.5 ± 
4.96 kD. The molecular weight of this band was slightly greater than expected but since it 
was a very prominent band in the lane with the prominent 120 kD band (indicating more 
caspase 3 cleavage); it is most likely the 150 kD caspase 3 SBDP and the higher molecular 
weight is an artefact. 
 
Band 3 was proposed as the 145 kD calpain specific SBDP. The molecular weight of this 
band, estimated from two blots was 138.3 ± 4.11 kD. 
 
Band 4 was proposed as the 120 kD caspase 3 specific SBDP. The molecular weight of this 
band, estimated from two blots was 121.7 ± 3.42 kD.  
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Figure i The calculation of the apparent molecular weights of αII-spectrin breakdown products 
(SBDPs). 
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αII-spectrin blot 
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distance 
(mm) 
to dye front 
(mm) Rf value Log MW 
200 14 69 0.203 2.301 
150 21  0.304 2.176 
100 28.5  0.413 2.000 
80 38  0.551 1.903 
60 51.5  0.746 1.778 
 
 
distance 
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to dye front 
(mm) 
Rf 
value Log(MW) MW 
band 1 7 68 0.103 2.592 390.6 
band 2 17.5  0.257 2.215 164.0 
band 3  20.5  0.301 2.150 141.2 
band 4  23.5  0.346 2.094 124.1 
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Blot 2 
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distance 
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to dye front 
(mm) 
Rf 
value Log MW 
200 12 57.5 0.209 2.301 
150 19  0.330 2.176 
100 27.5  0.478 2.000 
80 31.5  0.548 1.903 
60 50  0.870 1.778 
 
 
distance 
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to dye front 
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Rf 
value Log(MW) MW 
band 1 6 58 0.103 2.586 385.2 
band 2 16.5  0.284 2.196 157.0 
band 3  19.5  0.336 2.132 135.4 
band 4  22.5  0.388 2.076 119.2 
 
y = -0.3853Ln(x) + 1.7116
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 MW (kD) MW (kD) mean (kD) range (kD) 
band 1 390.6 385.2 387.9 3.78 
band 2 164.0 157.0 160.5 4.96 
band 3  141.2 135.4 138.3 4.11 
band 4  124.1 119.2 121.7 3.42 
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II. Optimization of transfection with LipofectAMINE™2000 
 
Previous work in our laboratory has suggested that chemical transfection with 
LipofectAMINE™ is milder and more efficient than electroporation on SH-SY5Y cells (Dr 
C Ufer, personal communication). Initial experiments were concerned with the optimization 
of the parameters for transfection using LipofectAMINE™2000. The transfection efficiency 
was determined by measuring the level of GFP fluorescence with a fluorometer (FLUOstar 
OPTIMA, BMG LABTECH) with 485 nm excitation and 520 nm emission filters, cells 
were also imaged by laser confocal microscopy. Cell viability was monitored by measuring 
MTT reduction.   
 
To determine the optimum cell density that resulted in high transfection efficiency while 
minimizing cellular toxicity, cells were seeded at varying cell densities in a 6-well plate and 
transfecting cells with 1 µg pGFPmax to 3 µl LipofectAMINE™2000. Phase contrast of 
transfected cells (Figure II.1 A) support MTT reduction data since cells seeded at a cell 
density > 250 000 cells/well were morphologically similar to untransfected controls. GFP 
expression in cells seeded at a density of 250 000 cells per well in a 6-well plate is shown in 
Figure II.1 B. A comparison of the level of GFP fluorescence and MTT reduction at various 
cell densities (Figure II.1 C) showed a maximum GFP fluorescence and MTT reduction 
when cells were seeded at a density of 250 000 cells/well.  
 
The optimum ratio of LipofectAMINE™2000 to plasmid DNA with which to transfect cells 
was determined by seeding cells at a density of 200 000 cells/well in a 6-well plate and 
transfecting them with 1 µg pGFPmax using 1-6 µl LipofectAMINE. Phase contrast images 
(Figure II.2 A) revealed that morphologically there were no apparent differences in the 
appearance of cells transfected using 1-4 µl LipofectAMINE but when using volumes ≥ 5 
µl, cells appeared to be in a poorer condition. GFP expression in cells transfected with 1 µl 
or 4 µl of LipofectAMINE (Figure II.2 B) revealed that more cells exhibit GFP 
fluorescence when the LipofectAMINE (µl):DNA (µg) ratio was 4:1 rather than 1:1.  A 
comparison of GFP fluorescence and MTT reduction (Figure II.2 C) revealed, the highest 
levels of GFP fluorescence were observed when the LipofectAMINE:DNA ratios were 2:1, 
3:1 or 4:1. MTT reduction revealed that cell viability was similar when using 1-4 µl 
LipofectAMINE™2000 but this decreased dramatically when using more than 4 µl.  
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From these experiments the ratio of LipofectAMINE™2000 (µl):DNA (µg) used for the 
transfection of SH-SY5Y cells was chosen to be 2:1 with an optimum cell density of 250 
000 cells/well in a 6-well plate.  
 
Figure ii Determination of the optimum cell density required for transfection of SH-SY5Y neuroblastoma cells 
with LipofectAMINE™2000.  
Optimum cell density that resulted in the highest transfection efficiency while maintaining cell viability was determined 
by comparing of the level of GFP fluorescence and MTT reduction. (A) Phase contrast images of cells transfected with 1 
µg pGFPmax using 3 µl LipofectAMINE™2000 and seeded at different cell densities in 6-well plates compared to 
untransfected controls. (B) Laser confocal microscope images of cells transfected with 1 µg pGFPmax using 3 µl 
LipofectAMINE™2000 seeded a cell density of 250 000 cells/well in 6-well plates. (C) Plot comparing the GFP 
fluorescence of cells seeded in 6-well plates at different cell densities and transfected with 1 µg pGFPmax using 3 µl 
LipofectAMINE™2000 with cell viability determined by MTT reduction. Scale bar represents 40 µm. 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50 100 150 200 250 300
Cell number (x1000)
FL
 u
ni
ts
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
A
bs
or
ba
nc
e 
(5
70
nm
)
GFP fluorescence
MTT viability
(A)  
(C) (B)  
300 000 cells 250 000 cells 
150 000 cells 100 000 cells 200 000 cells 
untransfected control 
Appendix 
 v 
 
Figure iii Determination of the optimum ratio of LipofectAMINE™2000 to DNA that resulted in 
the highest transfection efficiency while maintaining cell viability.  
The transfection efficiency was assessed by the level of GFP fluorescence and cell viability by MTT 
reduction. (A) Phase contrast images of cells transfected with 1 µg pGFPmax with different volumes of 
LipofectAMINE™2000 ranging from 1-6 µl. (B) Laser confocal microscope images of SH-SY5Y 
neuroblastoma cells transfected with 1 µg pGFPmax with 1 µl or 4 µl of LipofectAMINE™2000. (C) Plot 
comparing the level of GFP fluorescence of SH-SY5Y neuroblastoma cells transfected with 1 µg 
pGFPmax with different volumes of LipofectAMINE™2000 ranging from 1 µl to 6 µl with MTT 
reduction as a measure of cell viability. Scale bar represents 40 µm. 
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III. Restriction Map and Multiple Cloning Site of pEGFP-
C3
 
Figure iv Restriction Map and Multiple Cloning Site (MCS) of pEGFP-C3 (Clontech)  
 
IV. Determination of the molecular weight of GFP and GFP-tagged 
neurofilaments 
 
To confirm the molecular weights of GFP and GFP tagged NFs, total cell extracts were 
analysed by SDS-PAGE and Western blotting. The Rf values (calculated by dividing the 
distance travelled by the protein with the distance to the dye front) of molecular weight 
standards were plotted against the logarithm of molecular weight. The equation of the ‘line 
of best fit’ was used to determine the molecular weight of GFP and GFP/NFs from their Rf 
values (Figures iv-vii).  
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Figure v Determination of the molecular weights of GFP and GFP tagged neurofilaments of total cell 
extracts of SH-SY5Y cells expressing GFP, GFP/NF-M, GFP/NF-L or GFP/NF-H (truncated).  
Total cell extracts were analysed by SDS-PAGE and Western blotting followed by immunoprobing with anti-
GFP (abcam, 1:10 000). A standard curve of the logarithm of the molecular weights of molecular weight 
standards run on the same gel as the cell extracts versus the Rf values for each molecular weight standard 
(distance travelled divided by the distance to the dye front) was used to determine the molecular weights of 
GFP and GFP/NFs from their Rf values. 
MW (Da) 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value 
Log 
MW 
200 7 57 0.123 2.301 
150 11  0.193 2.176 
100 16  0.281 2.000 
75 20  0.351 1.875 
50 32  0.561 1.699 
37 41  0.719 1.568 
25 54  0.947 1.398 
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distance 
(mm) 
to dye front 
(mm) 
Rf 
value Log(MW) 
MW 
(Da) 
GFP 48.5 56.5 0.858 1.483 30.4 
GFP/NFL 16 56.5 0.283 1.974 94.3 
GFP/NFH(trunc) 22.5 57.5 0.391 1.831 67.8 
GFP/NFM 8.5 57 0.149 2.259 181.5 
 
Anti-GFP Blot 
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Figure vi Determination of the molecular weight of GFP/NF-M and endogenous NF-M  
The apparent molecular weights of GFP/NF-M and NF-M in a total cell extract of cells expressing 
GFP/NF-M were determined by SDS-PAGE and Western blotting. Western blots were immunoprobed 
with anti-NF-M (RMO270, 1:500; Invitrogen). A standard curve of the logarithm of the molecular 
weights of molecular weight standards run on the same gel as the cell extracts versus the Rf values for 
each molecular weight standard (distance travelled divided by the distance to the dye front), the equation 
of the line was used to determine the molecular weights of GFP/NF-M and NF-M from their Rf values. 
 
 
 
 
 
 
MW 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value 
Log 
MW 
200 7 57 0.123 2.301 
150 11  0.193 2.176 
100 16.5  0.289 2.000 
75 20.5  0.360 1.875 
50 32  0.561 1.699 
37 42  0.737 1.568 
25 55  0.965 1.398 
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value Log(MW) MW 
GFP/NFM 8.5 56.8 0.150 2.260 182.0 
NFM 10.2 56.8 0.180 2.180 151.3 
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Figure vii Determination of the molecular weight of GFP/NF-L and endogenous NF-L  
The apparent molecular weight of GFP/NF-L and endogenous NF-L in a total cell extract of cells 
expressing GFP/NF-L was determined by SDS-PAGE and Western blotting. Western blots were 
immunoprobed with anti-NF-L (DA2, 1:2000; Invitrogen). A standard curve of the logarithm of the 
molecular weights of molecular weight standards run on the same gel as the cell extracts versus the Rf 
values for each molecular weight standard (distance travelled divided by the distance to the dye front), the 
equation of the line was used to determine the molecular weights of GFP/NF-L and NF-L from their Rf 
values. 
 
 
 
 
MW 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value 
Log 
MW 
200 9.5 57 0.167 2.301 
150 13  0.228 2.176 
100 17  0.298 2.000 
75 21  0.368 1.875 
50 31.5  0.553 1.699 
37 39.5  0.693 1.568 
25 53.5  0.939 1.398 
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to dye front 
(mm) 
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value Log(MW) 
MW 
(Da) 
GFP/NFL 17 57 0.298 2.007 101.7 
NFL 22.8 57 0.400 1.853 71.3 
 
Appendix 
 x 
 
Figure viii Determination of the molecular weight of GFP and GFP/NF-H  
The apparent molecular weights of GFP and GFP/NF-H were determined by SDS-PAGE and Western 
blotting of total cell extracts of cells expressing GFP or GFP/NF-H. Western blots were immunoprobed 
with anti-GFP (abcam, 1:10 000) and molecular weights were determined from the Rf values (distance 
travelled divided by distance to the dye front) of GFP and GFP/NF-H. A standard curve was produced in 
which the Rf values of molecular weight standards was plotted against the logarithm of molecular weight. 
The equation of the line was used to determine the molecular weight. 
 
 
 
 
 
 
Anti-GFP 
MW 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value 
Log 
MW 
200 7 52 0.135 2.301 
150 11  0.212 2.176 
100 15  0.288 2.000 
75 19  0.365 1.875 
50 28.5  0.548 1.699 
37 36  0.692 1.568 
25 49.5  0.952 1.398 
 
y = -0.4729Ln(x) + 1.3984
R2 = 0.9922
0.000
0.250
0.500
0.750
1.000
1.250
1.500
1.750
2.000
2.250
2.500
0.000 0.100 0.200 0.300 0.400 0.500 0.600 0.700 0.800 0.900 1.000
Rf value
Lo
g 
(M
W
)
 
 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value Log(MW) MW 
GFP 44 52 0.846 1.477 30.0 
GFP/NFH 6 52 0.115 2.420 262.8 
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Figure ix Determination of the molecular weight of endogenous NF-H and GFP/NF-H  
The apparent molecular weight of GFP/NF-H and NF-H from total cell extracts of SH-SY5Y cells 
expressing GFP/NF-H. Total cell extracts analysed by SDS-PAGE and Western blotting were 
immunoprobed with anti-NF-H (n52, 1:2000; Sigma). The molecular weights of the proteins were 
determined from their Rf values (distance travelled divided by the distance to the dye front). A standard 
curve was produced in which the Rf values of molecular weight standards were plotted against the 
logarithm of molecular weight. Molecular weight of endogenous NF-H and GFP/NF-H was determined 
from the equation of the line. 
 
MW 
distance 
(mm) 
to dye front 
(mm) 
Rf 
value 
Log 
MW 
200 7.5 50.5 0.149 2.301 
150 11  0.218 2.176 
100 15.5  0.307 2.000 
75 19  0.376 1.875 
50 28  0.554 1.699 
37 36  0.713 1.568 
25 48  0.950 1.398 
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distance 
(mm) 
to dye front 
(mm) 
Rf 
value Log(MW) MW 
NF-H 8 50.5 0.158 2.306 202.2 
GFP/NFH 7 50.5 0.139 2.372 235.3 
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V. Peptide Mass Fingerprints 
 
Figure x Identification of GFP by mass spectrometry.  
Example of a Peptide mass fingerprint and result of mascot search which identified GFP in 
immunoprecipitate from GFP expressing cells. 
 
 
Figure xi Identification of GFP/NF-H by mass spectrometry. 
Peptide mass fingerprint and result of mascot search which identified GFP/NF-H in the 
immunoprecipitate from GFP/NF-H expressing cells from a band excised from a one-dimensional SDS-
PAGE gel. The peak circled in green is from GFP. 
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Figure xii Identification of (A) GFP/NF-M and (B) NF-M in by mass spectrometry.  
Example of a Peptide mass fingerprint and result of mascot search which identified GFP/NF-M and NF-
M in immunoprecipitate from GFP/NF-M expressing cells. The peak circled in green is from GFP. 
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GFP 
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Figure xiii Identifcation of vimentin by mass spectrometry. 
Example of a peptide mass fingerprint and the result of the mascot search which identified vimentin from 
a spot excised from a two-dimensional SDS-PAGE gel of the immunoprecipitate from GFP/NF-M 
expressing cells. 
 
Vimentin 
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Figure xiv Identification of Hsc70 by mass spectrometry. 
Peptide mass fingerprint and the result of the mascot search which identified Hsc70 from a spot excised 
from a two-dimensional SDS-PAGE gel of the immunoprecipitate from GFP/NF-M expressing cells. 
Peak 1487.753 (circled in orange) was subjected to MSMS to confirm the identification of Hsc70. 
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VI. Proposed effects of complex I inhibition and DA-mediated oxidative stress on degradative 
pathways and turnover of cytoskeletal proteins 
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Figure xv Summary of the proposed mechanisms of mitochondrial dysfunction and DA-mediated oxidative stress presented in this thesis integrated with current literature 
reviewed in chapter 1.   
The yellow boxes represent treatments, green boxes and red line represent the findings reported in the present work, the pink boxes and solid black lines represent information from 
current literature reviewed in chapter 1 of this thesis. The clear boxes and broken lines represent the proposed consequences/significance of the findings in the present work in 
relation to current literature. 
Mitochondrial dysfunction induced by the inhibition of complex I with MPP+ results in a reduction in cellular ATP levels and the production of mitochondrial derived oxidative 
stress. Exogenous addition of DA results in DA-mediated oxidative stress which results in the activation of calpain which activates Cdk5 via the cleavage of p35 to p25. Activation 
of Cdk5 results in the phosphorylation of NFs, which could lead to the accumulation of hyperphosphorylated NFs. Phosphorylation of NFs are increases their resistance to 
proteolysis resulting in accumulation and reduces their association with motor proteins such as kinesin and dynein, aberrant resulting in impaired NF transport. Both DA and MPP+ 
treatment reduced proteasome activity which has implications for the clearance of oxidatively damaged proteins thus promoting the formation of protein aggregates. A reduction in 
cathepsin D activity was also observed with MPP+ treatment which may result in reduced clearance of cathepsin D protein substrates such as NF-H. Cysteine cathepsins have been 
implicated in both cell death (apoptotic and necrotic) and cell survival, possibly via the degradation of caspase 3. There was some evidence for the role of cysteine cathepsins in 
ensuring cell survival in proliferating cells treated with MPP+ in the present work but the mechanism is not known. Cysteine cathepsins may also be involved in the turnover of 
cytoskeletal proteins during complex I inhibition but the significance of this with respect to cell survival is not certain. Perhaps cysteine cathepsin activity is elevated to promote the 
clearance of aggregated proteins to compensate for reduced cathepsin D activity and macroautophagy which may suggest that the clearance of aggregated proteins is cytoprotective.  
Dynein levels are reduced with MPP+ treatment which has previously been shown to result in impaired dynein function which may reduce NF transport from the cell body to axonal 
processes resulting in cell body accumulation of NFs and/or transport of NFs in axonal processes resulting in NF accumulation in neurites. Dynein function is also important for the 
fusion of autophagosome and lysosome in macroautophagy, therefore the observed reduction in macroautophagy with MPP+ treatment may be the result of impaired dynein function 
and/or a direct effect of mitochondrial dysfunction on macroautophagy. Impaired macroautophagy results in impaired clearance of protein aggregates targeted for degradation by 
p62/SQSTM1 resulting in inclusion formation. Reduced macroautophagy was also observed with the addition of exogenous DA which could reduce the clearance of aggregated 
proteins. 
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